


ACADEMIC PRESS SERIES IN BIOMEDICAL ENGINEERING



INTRODUCTION TO  
MODELING IN  
PHYSIOLOGY  
AND MEDICINE

CLAUDIO COBELLI  
EWART CARSON



# INTRODUCTION TO MODELING IN PHYSIOLOGY AND MEDICINE

*A volume in the*

ACADEMIC PRESS SERIES IN BIOMEDICAL ENGINEERING

JOSEPH BRONZINO, Ph.D., SERIES EDITOR

The Vernon Roosa Professor of Applied Science, Trinity College – Hartford,  
Connecticut

President of the Biomedical Engineering Alliance and Consortium

**Titles in the series**

*Modelling Methodology for Physiology and Medicine*, Carson & Cobelli,  
ISBN 9780121602451, 2000

*Handbook of Medical Imaging*, Bankman, ISBN 9780120777907, 2000

*Clinical Engineering Handbook*, Dyro, ISBN 9780122265709, 2004

*Diagnostic Ultrasound Imaging: Inside Out*, Szabo, ISBN 9780126801453, 2004

*Introduction to Biomedical Engineering*, Second Edition, Enderle, Blanchard &  
Bronzino, ISBN 9780122386626, 2005

*Circuits, Signals, and Systems for Bioengineers*, Semmlow, ISBN 9780120884933,  
2005

*Numerical Methods in Biomedical Engineering*, Dunn, Constantinides & Moghe,  
ISBN 9780121860318, 2005

*Hospital Preparation for Bioterror*, McIsaac, ISBN 9780120884407, 2006

*Introduction to Applied Statistical Signal Analysis*, Third Edition, Shiavi,  
ISBN 9780120885817, 2006

*Biomedical Information Technology*, Feng, ISBN 9780123735836, 2007

*Introduction to Modeling in Physiology and Medicine*, Cobelli & Carson,  
ISBN 9780121602406, 2007

# INTRODUCTION TO MODELING IN PHYSIOLOGY AND MEDICINE

Claudio Cobelli  
and  
Ewart Carson



AMSTERDAM • BOSTON • HEIDELBERG • LONDON • NEW YORK • OXFORD  
PARIS • SAN DIEGO • SAN FRANCISCO • SINGAPORE • SYDNEY • TOKYO

Academic Press is an imprint of Elsevier



Academic Press is an imprint of Elsevier  
84 Theobald's Road, London WC1X 8RR, UK  
30 Corporate Drive, Suite 400, Burlington, MA 01803, USA  
525 B Street, Suite 1900, San Diego, CA 92101-4495, USA

First edition 2008

Copyright © 2008, Elsevier Inc. All rights reserved

No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means electronic, mechanical, photocopying, recording or otherwise without the prior written permission of the publisher

Permissions may be sought directly from Elsevier's Science & Technology Rights Department in Oxford, UK: phone (+44) (0) 1865 843830; fax (+44) (0) 1865 853333; email: [permissions@elsevier.com](mailto:permissions@elsevier.com). Alternatively you can submit your request online by visiting the Elsevier web site at <http://elsevier.com/locate/permissions>, and selecting *Obtaining permission to use Elsevier material*

#### Notice

No responsibility is assumed by the publisher for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made

#### British Library Cataloguing in Publication Data

A catalogue record for this book is available from the British Library

#### Library of Congress Cataloguing in Publication Data

A catalogue record for this book is available from the Library of Congress

ISBN: 978-0-12-160240-6

For information on all Academic Press publications  
visit our web site at <http://books.elsevier.com>

Printed and bound in The Netherlands

08 09 10 11 12    10 9 8 7 6 5 4 3 2 1

Working together to grow  
libraries in developing countries

[www.elsevier.com](http://www.elsevier.com) | [www.bookaid.org](http://www.bookaid.org) | [www.sabre.org](http://www.sabre.org)

ELSEVIER

BOOK AID  
International

Sabre Foundation

# CONTENTS

PREFACE xi

## 1 INTRODUCTION 1

- 1.1 Introduction 1
- 1.2 The Book in Context 2
- 1.3 The Major Ingredients 3
- 1.4 Readership 4
- 1.5 Organization of the Book 4

## 2 PHYSIOLOGICAL COMPLEXITY AND THE NEED FOR MODELS 7

- 2.1 Introduction 7
- 2.2 Complexity 9
- 2.3 Feedback 10
  - 2.3.1 Negative Feedback 10
  - 2.3.2 Positive Feedback 10
  - 2.3.3 Inherent Feedback 11
  - 2.3.4 Combining Negative and Positive Feedback 11
  - 2.3.5 Derivative and Integral Feedback 13
  - 2.3.6 Effects of Feedback on the Complexity of System Dynamics 13
- 2.4 Control in Physiological Systems 13
  - 2.4.1 General Features 13
  - 2.4.2 Enzymes 15
  - 2.4.3 Hormones 17
- 2.5 Hierarchy 19
- 2.6 Redundancy 20
- 2.7 Function and Behavior and their Measurement 21

- 2.8 Challenges to Understanding 21
- 2.9 Exercises and Assignment Questions 22

## 3 MODELS AND THE MODELING PROCESS 23

- 3.1 Introduction 23
- 3.2 What is a Model? 23
- 3.3 Why Model? The Purpose of Modeling 25
- 3.4 How Do We Model? The Modeling Process 27
- 3.5 Model Formulation 27
- 3.6 Model Identification 29
- 3.7 Model Validation 30
- 3.8 Model Simulation 32
- 3.9 Summary 33
- 3.10 Exercises and Assignment Questions 34

## 4 MODELING THE DATA 35

- 4.1 Introduction 35
- 4.2 The Basis of Data Modeling 36
- 4.3 The Why and When of Data Models 36
- 4.4 Approaches to Data Modeling 36
- 4.5 Modeling a Single Variable Occurring Spontaneously 38
  - 4.5.1 Temperature 38
  - 4.5.2 Urine Potassium 41
  - 4.5.3 Gastro-intestinal Rhythms 43
  - 4.5.4 Hormonal Time Series 45
- 4.6 Modeling a Single Variable in Response to a Perturbation 52
  - 4.6.1 Glucose Home Monitoring Data 53
  - 4.6.2 Response to Drug Therapy – Prediction of Bronchodilator Response 54
- 4.7 Two Variables Causally Related 56
  - 4.7.1 Hormone/hormone and Substrate/hormone Series 56
  - 4.7.2 Urine Sodium Response to Water Loading 58
- 4.8 Input/output Modeling for Control 61
  - 4.8.1 Pupil Control 62
  - 4.8.2 Control of Blood Glucose by Insulin 63
  - 4.8.3 Control of Blood Pressure by Sodium Nitroprusside 66
- 4.9 Input/output Modeling: Impulse Response and Deconvolution 67
  - 4.9.1 Impulse Response Estimation 67
  - 4.9.2 The Convolution Integral 69

- 4.9.3 Reconstructing the Input 70
- 4.10 Summary 74
- 4.11 Exercises and Assignment Questions 74

## 5 MODELING THE SYSTEM 75

- 5.1 Introduction 76
- 5.2 Static Models 76
- 5.3 Linear Modeling 79
  - 5.3.1 The Windkessel Circulatory Model 80
  - 5.3.2 Elimination from a Single Compartment 81
  - 5.3.3 Gas Exchange 82
  - 5.3.4 The Dynamics of a Swinging Limb 83
  - 5.3.5 A Model of Glucose Regulation 87
- 5.4 Distributed Modeling 90
  - 5.4.1 Blood-tissue Exchange 91
  - 5.4.2 Hepatic Removal of Materials 101
  - 5.4.3 Renal Medulla 105
- 5.5 Nonlinear Modeling 110
  - 5.5.1 The Action Potential Model 110
  - 5.5.2 Enzyme Dynamics 120
  - 5.5.3 Baroreceptors 122
  - 5.5.4 Central Nervous Control of Heart Rate 124
  - 5.5.5 Compartmental Modeling 125
  - 5.5.6 Insulin Receptor Regulation 133
  - 5.5.7 Insulin Action Modeling 135
  - 5.5.8 Thyroid Hormone Regulation 138
  - 5.5.9 Modeling the Chemical Control of Breathing 141
- 5.6 Time-varying Modeling 145
  - 5.6.1 An Example in Cardiac Modeling 145
- 5.7 Stochastic Modeling 150
  - 5.7.1 Cellular Modeling 150
  - 5.7.2 Insulin Secretion 154
  - 5.7.3 Markov Model 155
- 5.8 Summary 156
- 5.9 Exercises and Assignment Questions 157

## 6 MODEL IDENTIFICATION 159

- 6.1 Introduction 159
- 6.2 Data for Identification 160
  - 6.2.1 Selection of Test Signals 160



- 6.2.2 Transient Test Signals 161
- 6.2.3 Harmonic Test Signals 162
- 6.2.4 Random Signal Testing 163
- 6.3 Errors 164
- 6.4 The Way Forward 166
  - 6.4.1 Parameter Estimation 166
  - 6.4.2 Signal Estimation 167
- 6.5 Summary 167
- 6.6 Exercises and Assignment Questions 168

## 7 PARAMETRIC MODELING – THE IDENTIFIABILITY PROBLEM 169

- 7.1 Introduction 169
- 7.2 Some Examples 173
- 7.3 Definitions 179
- 7.4 Linear Models: The Transfer Function Method 181
- 7.5 Nonlinear Models: The Taylor Series Expansion Method 184
- 7.6 Qualitative Experimental Design 187
  - 7.6.1 Fundamentals 187
  - 7.6.2 An Amino Acid Model 188
- 7.7 Summary 192
- 7.8 Exercises and Assignment Questions 193

## 8 PARAMETRIC MODELS – THE ESTIMATION PROBLEM 195

- 8.1 Introduction 196
- 8.2 Linear and Nonlinear Parameters 197
- 8.3 Regression: Basic Concepts 198
  - 8.3.1 The Residual 199
  - 8.3.2 The Residual Sum of Squares 200
  - 8.3.3 The Weighted Residual Sum of Squares 200
  - 8.3.4 Weights and Error in the Data 201
- 8.4 Linear Regression 203
  - 8.4.1 The Problem 204
  - 8.4.2 Test on Residuals 205
  - 8.4.3 An Example 207
  - 8.4.4 Extension to the Vector Case 208
- 8.5 Nonlinear Regression 212
  - 8.5.1 The Scalar Case 212
  - 8.5.2 Extension to the Vector Case 216
  - 8.5.3 Algorithms 220
  - 8.5.4 An Example 221

- 8.6 Tests for Model Order 221
- 8.7 Maximum Likelihood Estimation 225
- 8.8 Bayesian Estimation 227
- 8.9 Optimal Experimental Design 231
- 8.10 Summary 233
- 8.11 Exercises and Assignment Questions 233

## 9 NON-PARAMETRIC MODELS – SIGNAL ESTIMATION 235

- 9.1 Introduction 235
- 9.2 Why is Deconvolution Important? 236
- 9.3 The Problem 236
- 9.4 Difficulty of the Deconvolution Problem 238
- 9.5 The Regularization Method 244
  - 9.5.1 Fundamentals 244
  - 9.5.2 Choice of the Regularization Parameter 246
  - 9.5.3 The Virtual Grid 251
- 9.6 Summary 254
- 9.7 Exercises and Assignment Questions 255

## 10 MODEL VALIDATION 257

- 10.1 Introduction 257
- 10.2 Model Validation and the Domain of Validity 258
  - 10.2.1 Validation During Model Formulation 258
  - 10.2.2 Validation of the Completed Model 259
- 10.3 Validation Strategies 261
  - 10.3.1 Validation of a Single Model – Basic Approach 261
  - 10.3.2 Validation of a Single Model – Additional Quantitative Tools for Numerically Identified Models 262
  - 10.3.3 Validation of Competing Models 264
- 10.4 Good Practice in Good Modeling 265
- 10.5 Summary 266
- 10.6 Exercises and Assignment Questions 266

## 11 CASE STUDIES 269

- 11.1 Case Study 1: A Sum of Exponentials Tracer Disappearance Model 269
- 11.2 Case Study 2: Blood Flow Modeling 273

11.3	Case Study 3: Cerebral Glucose Modeling	274
11.4	Case Study 4: Models of the Ligand-Receptor System	276
11.5	Case Study 5: A Simulation Model of the Glucose-Insulin System	280
11.5.1	Model Formulation	280
11.5.2	Results	288
11.6	Case Study 6: A Model of Insulin Control	292
11.7	Case Study 7: Illustrations of Bayesian Estimation	297
11.8	Postscript	308

REFERENCES	309
------------	-----

INDEX	319
-------	-----

# PREFACE

Mathematical modeling is now widely applied in physiology and medicine to support the life scientist and clinical worker. Our aim in writing this book is to provide an introduction to this topic, presenting the underlying principles of good modeling methodology together with numerous examples indicating the way in which such modeling is finding application in physiology and medicine.

Mathematical modeling finds application in medical research, in education and in supporting clinical practice. In the research context, the use of models can, for example, yield quantitative insights into the manner in which physiological systems are controlled. In the educational setting, medical students can use computer model simulation to explore the dynamic effects of pathophysiological processes or of drug therapy. In the clinical arena, mathematical models can enable estimates to be made of physiological parameters that are not directly measurable – useful for example in diagnosis, as well as enabling predictions to be made as to how changes in drug therapy will impact on variables of clinical importance such as blood pressure or blood glucose concentration.

This book is directed at a broad readership across a wide range of student and practitioner backgrounds. In terms of the student readership, it is designed to appeal to biomedical engineers and to others studying physical and engineering sciences, and biological and life sciences. It should also appeal to medical students who wish to enhance their quantitative understanding of the physical and chemical processes that underpin physiology and medicine. Further, the book should be of interest to practitioners of all professions who have an interest in quantitative aspects of physiology and medicine.

The book begins by exploring some of the complexities of physiology that lend themselves to modeling in order that their quantitative features may be better understood. The concepts of mathematical modeling are then introduced, showing that models can be used for a wide range of purposes: to gain insights, to support processes of measurement, to make predictions of future behavior and in a variety of ways assist in enhancing clinical research and practice. A number of approaches to developing mathematical models are then considered, with each being illustrated by a range of examples. Much of the remainder of the text then focuses on issues associated with making estimates of model parameters and addressing the problem of

ensuring that a mathematical model is valid; that is to say fit for its intended purpose. The final chapter comprises a number of case studies which demonstrate, in detail, how the modeling concepts, methods and techniques that have been described and discussed earlier can be applied to real-world problems in physiology and medicine.

In writing this book, we wish to express our thanks to a number of our colleagues who have worked with us in developing the examples and case studies, including: Alessandra Bertoldo, Chiara Dalla Man, Giovanni Sparacino, Gianna Toffolo and Peter Weller; and to Andy Morrison for his assistance in the preparation of the figures. We are also indebted to those who over many years have offered us encouragement and support in our modeling ventures, including Riccardo Bonadonna, Derek Cramp, Ludwik Finkelstein, Roman Hovorka, David Kelley, Antonio Lepschy, Robert Rizza, Abdul Roudsari and Peter Sönksen. Finally, we should like to express our gratitude to Jonathan Simpson and all his colleagues at Academic Press/Elsevier for their encouragement, support and tolerance during the lengthy gestation of this book.

Claudio Cobelli and Ewart Carson

A full Solutions Manual is available for downloading by teachers and lecturers who adopt or recommend this text for class use. For further details and access please visit  
<<http://textbooks.elsevier.com/>>

# 1 INTRODUCTION

## Chapter Contents

- 1.1 Introduction**
- 1.2 The Book in Context**
- 1.3 The Major Ingredients**
- 1.4 Readership**
- 1.5 Organization of the Book**

## 1.1 INTRODUCTION

Over the past few decades there has been a considerable increase in the application of quantitative methods to the study of physiological systems. New techniques for making physiological measurements are being constantly developed and applied and there has been a corresponding increase in the methods available for the analysis and interpretation of such experimental data.

Improvements have occurred in both the quality and quantity of experimental data that are now available from studies in the intact organism and on the isolated organ. Advances in instrument technology and biochemical laboratory methods have contributed significantly to these improvements.

In parallel, there have been substantial advances in terms of concepts, methods and techniques for the study of dynamic systems; advances that have originated in the control and systems theory. These are increasingly finding their way into physiological investigations, and in associated investigations in the clinical sciences and medicine. An additional driver for all of this is, of course, the availability of more and more computing power. Harnessing all of these together is resulting in an increase in the use of mathematical modeling techniques in physiological investigations.

The increasing application of modeling and dynamic systems analysis offers benefits for the physiology, control and systems science, and biomedical engineering. For the control and systems science there is the opportunity to examine the structure and behavior of complex physiological systems which function effectively. Moreover, such systems provide a test bed for examining the merits and limitations of

techniques of modeling and dynamic systems analysis, originally developed largely for technological applications.

For the physiologist, the appropriate use of mathematical models offers many potential benefits. They provide a concise description of complex dynamic processes, indicate ways in which improved experimental design could be achieved, and enable hypotheses concerning physiological structure to be tested. Furthermore, they allow estimates to be made of parameters (physiological quantities) that are otherwise not directly accessible to measurement. Although initially most modeling applications have been in the areas of physiological and medical research, they are now increasingly being used as aids in the diagnosis and treatment of disease.

If these benefits are to be realized, there is clearly a need for a greater awareness and understanding of modeling methodology and techniques, together with their strengths and limitations. It is to address these issues that this book has been devised. Its aim is to provide insight into the why and how of modeling; the need for models, what they can do, how to build them, and how to use them.

The concepts, problems and approaches are illustrated with examples and case studies drawn both from literature within the field and from our own very extensive experiences gained over many years of endeavor. The illustrations cover a very wide range of physiological topics, demonstrating the wide applicability of the approaches being described.

## 1.2 THE BOOK IN CONTEXT

This book forms a part of the series of volumes in Biomedical Engineering. However, physiological modeling is very much an interdisciplinary subject. Hence the topic is also central to a range of related disciplines including biomathematics, medical and health informatics and systems physiology.

Significant activity in the field of mathematical modeling of physiological systems certainly stretches back more than a hundred years. Texts in the field have been produced over the best part of 40 years. Amongst the first were those of Milsum (1966) and Milhorn (1966). An early classic having a biomathematics flavor was that of Riggs (1963), whilst Talbot and Gessner (1973) produced a definitive text having a systems physiology focus. Since then dynamic modeling of physiological systems has been a major component of many biomedical engineering texts. Examples include Bronzino (2000) and Enderle *et al.* (2000). For a more advanced treatment of modeling methodology, the reader should consult Carson and Cobelli (2001).

Other volumes have focused on particular approaches to modeling or on specific areas of physiology. For example, volumes on compartmental modeling have been produced by Atkins (1969) and Godfrey (1983), amongst others. The analysis of data yielded by dynamic tracer experiments has been the subject of volumes by Jacquez (1972; 1996) and Cobelli *et al.* (2000). The modeling of metabolic and endocrine systems has been described by McIntosh and McIntosh (1980) and by Carson *et al.* (1983). The related subject of physiological modeling and control has been dealt

with extensively by authors such as Carson and Cramp (1985), Khoo (2000) and Northrop (2000).

In addition to textbooks on the subject, there is a number of modeling software packages that are now readily available. Some such as MATLAB<sup>®</sup> and SIMULINK<sup>®</sup> are generic modeling packages for dynamic systems. Others have been designed for a specific physiological application. Examples include SAAM (SAAM User Guide, 1998) and NONMEM (Beal and Sheiner, 1998).

However, there has been remarkably few attempts to produce what are essentially entry-level texts to the topic of modeling of physiological systems; the earlier volume by Finkelstein and Carson (1985) being one of the few. This is the focus of this present volume. Its aim is to provide a comprehensive introduction to the modeling of dynamic, physiological systems. The emphasis is placed firmly on developing sound modeling methodology, with numerous examples and case studies being included as illustrations.

### 1.3 THE MAJOR INGREDIENTS

In general terms, a model is a representation of reality. However, it is also an approximation of that reality since not all the ingredients of that reality can be incorporated into any model. Hence the models that we are concerned with in the chapters that follow will all, in their various ways, provide approximate representations of the particular physiological systems under consideration. What is crucial is that the form of model developed is appropriate for its purpose. As already hinted at, there can be a wide range of possible purposes for modeling. For instance, the form of a model adopted for the purpose of understanding some of the complexities of the control of breathing might well be quite different to that adopted as an aid to weaning the patient in an intensive care unit off a ventilator. This is the case even though in both examples the physiological focus is the respiratory system.

The way in which we develop a model will be dependent on our knowledge of the relevant physiology and the availability of relevant experimental data. So in essence the process of building a model can be regarded as a mapping of physiological knowledge and experimental data into the model. In the case of a model that is essentially a representation of the experimental data available, it is those data that dominate in this mapping process. On the other hand, if the model is one designed to provide a representation of the physiology more explicitly, then it will be the physical and chemical knowledge of that physiological system which dominates in the building of the model.

The overall process of modeling involves a number of inter-related ingredients. These are model building, model identification, simulation and model validation. Used appropriately in conjunction with each other, they provide a methodology for developing a model which will be fit for its intended purpose.

Model building involves formulating equations that provide an adequate representation of either the experimental data (in the case of a data-driven model) or the underlying physiology (in the case of a model that explicitly represents the underlying



physiology). Once the model has been built, identification can take place that includes making estimates of those parameters (physiological quantities) in the model that cannot be measured directly, using the available input/output experimental data.

Simulation involves solving the model equations to predict output behavior. Such computer simulation might, for instance, be used to predict the time course of a patient's blood glucose concentration, in the case of a model designed to explore relationships between insulin dosage and blood glucose in a diabetic patient. The fourth ingredient is that of model validation; this involves examining (in the case of two or more competing models) which is the best in relation to the modeling purpose. In the case of a single model it involves examining whether that model is good enough in relation to its purpose. This validation process involves the use of statistical tests as well as examining other features of the behavior of the model.

All are vital ingredients of the modeling exercise and are very much inter-related. One point that will be stressed in the chapters that follow is the iterative nature of the modeling process. Just as any design process is very much iterative in nature – only very rarely will it be right first time - so the same applies with modeling. Usually, several iterations through the cycle of ingredients will be needed before an acceptable end product is produced!

## **1.4 READERSHIP**

This book describes the development of models of physiological systems; models which can be used in a variety of ways, including as aids to understanding, as means of supporting clinical processes and for educational purposes amongst others. Given that the level of this text is essentially that of an introductory guidebook, it is aimed first at students of biomedical engineering and related disciplines. Such students may be undergraduates, or may be following more specialized Masters' programs in the subject.

However, one of the fascinations of the subject of physiological modeling is its very interdisciplinary nature. As such, it is an activity undertaken not only by those with technical backgrounds in biomedical engineering and health informatics, but also by many in the clinical and life sciences. Thus this text will also be relevant to the needs of physiologists, biologists and clinical scientists and practitioners interested in quantitative approaches and results.

## **1.5 ORGANIZATION OF THE BOOK**

As indicated above, the aim of this book is to provide an introduction to the modeling of physiological systems. However, before proceeding to the actual modeling process, it is worth spending a little effort in understanding something of the fundamentals of physiology itself. This is important if modeling is to be undertaken successfully. In the normal healthy individual, the physiological systems provide an almost incredible array of functions necessary for the maintenance of life. In doing so, they exhibit a

variety of forms of complexity. Chapter 2 thus provides some insights into the nature of physiological complexity.

Physiological complexity is discussed in terms of function and behavior (which we wish to access) and measurements (which are available). Complexity manifests itself in terms of concepts such as hierarchy and feedback, and each is considered in the physiological context. As a result of complexity it is often not possible to measure directly (*in vivo*) the quantities of interest. Only indirect measures of such quantities may be possible. This complexity of physiological systems, coupled with limitations in measurement means that models have to be adopted as a means to aid understanding.

Chapter 3 introduces the concepts of model and modeling process. It describes what is meant by a model, the variety of models, why modeling (i.e. modeling purpose) and the nature of the modeling process. There are many possible purposes for modeling. These can range from investigating the physical or chemical structure and associated parameters of the physiological system in question to the development of clinical models for either diagnosis or patient management. This is followed by a description of the modeling process, stressing the need for good modeling methodology. The basic ingredients of model formulation, model identification, model validation and model simulation are described.

Following on from the first three introductory chapters, Chapter 4 starts the detailed examination of approaches to modeling. Here the focus is modeling the data. The aim of this chapter is to describe data modeling approaches as representations of physiological dynamics. The chapter describes what we mean by modeling the data, when such approaches are applicable and how it should be done (i.e. a description of the principal types of data driven (black box) models. Approaches include modeling both continuous and discrete time signals, adopting both time domain and frequency domain methods.

In contrast, Chapter 5 focuses on modeling the system. The aim of the chapter is to describe approaches to modeling the physiology, showing that it can be done at different levels and that the approach adopted depends on available *a priori* knowledge and assumptions made. The approaches adopted compare and contrast the following cases: static v. dynamic, deterministic v. stochastic, time-invariant v. time-varying, lumped v. distributed, linear v. nonlinear and continuous v. discrete. As with the previous chapter, extensive examples are included as illustrations of the approaches available, demonstrating how modeling can be carried out for a wide range of physiological processes and situations.

We need a complete model of the physiological system under consideration. This may not be the case. By this stage we shall have at least one candidate model, but possibly more than one with the need to choose between them. Focusing on a single model, if it is incomplete this will be due to some of the parameter values being unknown. This is true whether the modeling approach has been data driven or driven by the physiology of the system. We may be dealing with the whole model or just part of it. Chapter 6 aims to provide a framework for dealing with this situation (whether the model is data driven or physiologically based). To solve this problem we need data. Data sometimes occur from the intrinsic dynamics of the system (e.g. spontaneous

oscillations or noise), but more usually we must design experiments. The chapter discusses what experiments need to be designed to yield appropriate data.

Chapters 7 and 8 address the problem of identifying models which include parameters, whether these are input/output models or models that explicitly correspond to the physiology of the system under investigation. Chapter 7 considers the problem of identifiability. That is, whether it is theoretically possible to make unique estimates of all the unknown parameters of the model on the basis of those input/output experiments that it is proposed to perform as a means of acquiring experimental data. Having addressed this problem of identifiability, techniques for estimating the unknown parameters are then discussed in Chapter 8. Emphasis is placed upon linear least squares and nonlinear least squares techniques, though brief reference is made to maximum likelihood and Bayesian estimation.

The focus of Chapter 9 is non-parametric models. These are defined and methods outlined for estimating functions, rather than parameters. Available techniques include raw deconvolution and deterministic regularization.

Chapter 10 considers the issue of model validation, that is to say whether a particular model is good enough for its intended purpose, or in the case of a number of competing models, which of them is best. Having defined what is meant by model validity, an overall framework, together with associated methods, for the validation process is presented. The chapter ends with some recommendations for good modeling practice. Finally Chapter 11 illustrates the methods and techniques that have been discussed in relation to validation through a series of case studies.

Throughout the text, numerous illustrations, examples and case studies are included, demonstrating how the methodology and techniques described can be applied across a wide range of physiological examples. All of these illustrations are appropriately referenced. With regard to the basic methodology described in this book, only essential references are included. The reader who wishes to engage in a deeper study of modeling methodology is encouraged to consult our companion volume (Carson and Cobelli, 2001), which includes extensive referencing to all methodological issues and detail.

# 2 PHYSIOLOGICAL COMPLEXITY AND THE NEED FOR MODELS

## Chapter Contents

### 2.1 Introduction

### 2.2 Complexity

### 2.3 Feedback

2.3.1 Negative Feedback

2.3.2 Positive Feedback

2.3.3 Inherent Feedback

2.3.4 Combining Negative and Positive Feedback

2.3.5 Derivative and Integral Feedback

2.3.6 Effects of Feedback on the Complexity of System Dynamics

### 2.4 Control in Physiological Systems

2.4.1 General Features

2.4.2 Enzymes

2.4.3 Hormones

### 2.5 Hierarchy

### 2.6 Redundancy

### 2.7 Function and Behavior and their Measurement

### 2.8 Challenges to Understanding


### 2.9 Exercises and Assignment Questions

## 2.1 INTRODUCTION

Before moving on to the modeling activity that forms the bulk of this book, it is worth devoting a little attention to the nature of the physiological systems that we shall be modeling. In various ways all physiological systems are characterized by their

complexity. So in this chapter we shall examine the nature of this complexity in physiology. It is important that we should understand this complexity, since by definition any model that we create will be a simplification, an approximation of that complex reality. By understanding something of this complexity we shall be in a better position to make the simplifying assumptions that correspond to the particular model formulation that we shall adopt. In essence, the model that we develop needs to have taken into account both this inherent complexity that we have simplified and the availability of measurement data which will be used in estimating the parameters of our model.

Figure 2.1 shows a schematic representation of the human organism. In effect, this is a conceptual model that gives a flavor of the complexity of human physiology.



**Figure 2.1** The human organism as a complex system (adapted from Janes and Carson, 1971).

Although quite a complex figure, it is clearly a very simplified and approximate representation of all the physiological detail. Nevertheless, it does capture the essence of much of the dynamic processes that are present within the living organism. It depicts the human organism as a complex multi-input, multi-output system, with linkages involving an array of physico-chemical processes. Finally, it includes many of the standard functions to be found in any complex control system; that is sensing, decision making and control, actuating or effecting, and the feeding back of information. Some of the ingredients of complexity in this physiological context are considered in later sections of this chapter. However, let us first examine some of the attributes of complexity in a more general sense.

## 2.2 COMPLEXITY

Complexity manifests itself in a number of ways. First, in general, the greater the number of components or elements there are in a system, the greater will be its complexity. So the greater the number of neurons in a central nervous system or the larger the number of intermediate substances in a metabolic pathway, the greater will be the complexity. However, complexity is associated not only with the number of elements, but also with their interconnectivity (Flood and Carson, 1993). In the case of the central nervous system this would correspond to the number of interconnections between neurons.

These concepts of numbers of elements and interactions form part of a framework for complexity that has been proposed by Yates (1978). Yates suggested that complexity arises when one or more of five attributes are found which, in addition to the two already referred to, include *nonlinearity*, *asymmetry* and *nonholonomic constraints*.

Nonlinear systems occur when at least one element in the system relates to and varies in a nonlinear way with another. It would be represented graphically by a curved rather than a straight line. Nonlinear systems are, in general, much more difficult to analyse and comprehend than linear systems; that is, they are more complex. Almost all physiological systems are inherently nonlinear, even if from a modeling perspective it may be possible, and indeed reasonable, to treat them as if they were linear under specific conditions. This is a concept that will be considered in some detail later in the book.

Asymmetry occurs when symmetry in a system's relationships no longer holds. Consider the following example. A single cell after fertilization multiplies to become two cells, and then four, and then eight, and so on. Eventually, this produces an organism in the mould of its parents. During the developmental process, the single cell becomes a distinct organism or creature due to organization and differential growth. Differential growth is a type of asymmetry, and without it the process of growth described above would result in nothing more than a very large number of cells. It is such differential growth that results in the specialization that gives rise to the emergence of specific organs within the overall organism, such as the liver.

Holonomics relate to the integrity of systems, so that holonomic constraints are constraints that relate to laws affecting an entire organism. The obverse of this is nonholonomic constraints. These relate to parts of a system that are temporarily outside central control and which, in essence, 'go off and do their own thing.' This applies in a major way in the physiological context. The central nervous system would not be able to cope with the myriad of regulatory functions that take place within the human organism, for instance. So the human organism has evolved and adapted in such a manner that there is very considerable local regulation and control. For example, large numbers of metabolic processes are regulated at the local level (as will be described later), without recourse to centralized neural control. Complexity arises in situations where there is a high degree of freedom in parts of a system. In other words, the behavior and control of the parts cannot easily be predicted just on the basis of knowledge of the overall system characteristics.

Complexity also arises as a consequence of stochastic and time-varying dynamic effects. These will be considered in later chapters. Three key concepts that will aid our understanding of physiological complexity are feedback, control and hierarchy. These will now be discussed in the following three sections.

## **2.3 FEEDBACK**

Feedback is a fundamental feature of all physiological systems. It is vital in terms of ensuring physiological regulation and control. It is very much an ingredient of the complexity that characterizes physiological systems.

At its simplest, feedback can be regarded as a mutual causality, whereby variable X has an affect on variable Y, and in turn variable Y has an affect on variable X. If an increase in variable X brings about an increase in variable Y, and that increase in variable Y brings about a decrease in variable X, the process is referred to as negative feedback.

### **2.3.1 Negative Feedback**

Glucose metabolism provides us with examples of such negative feedback. For instance, in a normal individual, an increase in blood glucose concentration (variable X), brought about by the ingestion of the carbohydrate component of a meal, causes an increase in the secretion of insulin (variable Y). The effect of this increased insulin level is to bring about a reduction in the blood glucose concentration towards a normal value. So this negative feedback process is inherently regulatory, seeking to enhance the control of blood glucose concentration. Physiologically the effects of insulin on glucose are achieved by processes that include the chemical conversion of glucose into glycogen that is stored in the liver.

### **2.3.2 Positive Feedback**

On the other hand, positive feedback corresponds to the situation in which variable X causes an increase in variable Y, where in turn, that increase in Y brings about

a further increase in X. An example outside the physiological domain is the so-called wage-price spiral. An increase in wages causes price increases that in turn act as a catalyst for further wage increases. This is clearly a destabilizing phenomenon.


### 2.3.3 Inherent Feedback

The examples of feedback considered above relate to control systems in which the feedback link takes the form of a flow of material or information. There is, however, a further form of feedback that needs to be considered, namely inherent feedback.

Consider the case of a metabolic system. Suppose that in a simple chemical reaction, it can be assumed that the rate of decrease of concentration of chemical A taking part in the reaction is directly proportional to its concentration. Mathematically this can be expressed as:

$$\frac{dC_A}{dt} = -k C_A \quad (2.1)$$

where  $C_A$  is the concentration of chemical A, and  $k$  is the rate constant for the reaction. Expressing (2.1) in the form of a signal flow diagram (see Figure 2.2), it can be seen that there is effectively a negative feedback connection. In other words, there is an *inherent* regulatory effect exhibited in this chemical reaction despite the fact that there is no *physical* feedback link. This phenomenon of inherent feedback that has been revealed is contained in any dynamic process that can be described mathematically in this way in differential equation form.



**Figure 2.2** Signal flow diagram illustrating inherent negative feedback.

### 2.3.4 Combining Negative and Positive Feedback

Both positive and negative feedback can be seen in a simple model of population dynamics. This is a model which could apply, for instance, in relation to the number of humans or animals in a particular location, or equally in the context of cell populations within an organism.

Suppose that the birth rate in a population is assumed to be directly proportional to the number of individuals in the population and let  $k_b$  be the rate constant that defines this relationship. Mathematically we can represent this by the following differential



equation that indicates that the rate of change of population occurs in a positive manner at a rate proportional to the number of individuals making up the population (P):

$$\frac{dP}{dt} = k_b P \quad (2.2)$$

In a similar way we could assume that the death rate in this population (P) is directly proportional to P, being characterized by a rate constant  $k_d$ . Mathematically this could be represented as:


$$\frac{dP}{dt} = -k_d P \quad (2.3)$$

where the negative sign indicates that this is a processes causing a negative rate of change in the population (in contrast to the birth effect).

Combining (2.2) and (2.3) gives us an overall model for the dynamics of this population:

$$\frac{dP}{dt} = k_b P - k_d P \quad (2.4)$$

Graphically we can describe this by the signal flow diagram shown in Figure 2.3. This clearly indicates the presence of both positive and negative feedback loops, providing another illustration of inherent feedback.



**Figure 2.3** Signal flow diagram of population growth model.

The death rate is negative feedback regulating population growth. The birth rate is positive inherent feedback; it tends to lead to population instability that is explosive exponential population growth. The relative strengths of these opposing feedback processes (for example, due to disease, medical intervention, famine, etc.) will determine the overall complexity of the patterns of population dynamics that are observed.

### 2.3.5 Derivative and Integral Feedback

In the examples considered so far, it has been assumed that the feedback effect has been directly proportional to the variable that brings about this effect. Other forms of feedback are possible, however. It can be shown that reliance on proportional feedback and control alone can result in delay in achieving the desired regulatory effect, often with oscillations being apparent before the desired steady state is achieved.

One way of improving dynamic response is to incorporate feedback whereby not only is there a sensing of change in variable  $X$ , but also a sensing of its rate of change ( $dX/dt$ ). There is some evidence that this occurs in the case of carbohydrate metabolism, for instance. In other words insulin is being secreted not only in response to elevation of glucose concentration, but also to positive rate of change of glucose concentration. The incorporation of such derivative (rate of change) feedback and control brings about a more speedy response within the control loop and a more rapid achievement of the desired regulation.

In addition to proportional and derivative feedback, there are systems in which there appears to be integral feedback. One of the problems with control based on proportional and derivative feedback is that there can be an error in the final steady state that is achieved once the correcting feedback has taken its effect. A means of overcoming this problem is to include control action whereby there is a feedback signal employed that is proportional to the integral between the desired value of the variable being controlled and its actual value. A number of studies have suggested that a number of physiological systems behave as if such integral feedback was in operation. For instance, Saratchandran *et al.* (1976) proposed that regulation of the thyroid hormones is achieved through a combination of proportional and integral feedback.

### 2.3.6 Effects of Feedback on the Complexity of System Dynamics

The sections above outline some of the principal modes of feedback action that are to be found in the complexity of physiology. In practice many of the instances of feedback are even more complicated. Moreover, feedback can result in a wide range.

Changes occurring with feedback processes are also closely associated with the transition from the healthy state to that of disease. For example, type I diabetes is the result of a total failure of the glucose/insulin feedback loop described in section 2.4.1. Equally, type II diabetes is at least in part the consequence of a partial failure of such a feedback loop, with the parameters involved changing from their normal values.

Feedback is intimately related not only to the manner in which physiological systems are regulated, but also the patterns of dynamic behavior that they exhibit. It can affect stability and speed of response. Some of the behavioral features will be examined in examples that will be considered in later chapters.

## 2.4 CONTROL IN PHYSIOLOGICAL SYSTEMS


### 2.4.1 General Features

The study of control in physiological systems reveals a range of manifestations of complexity. A central feature is homeostasis at various levels in the hierarchy from

intracellular mechanisms to mechanisms operating at the level of the whole organism. Much of the major focus is related to the internal environment of the intact physiological organism, but control systems also feature prominently in relation to the way we deal with externally sensed information (via the eyes, ears, etc.).

The patterns of regulation and control occurring within physiological systems are many and varied. Static and dynamic equilibrium, linear and nonlinear regulation, weak and highly stable rhythmicity (oscillating systems) – all are instrumental in the maintenance of the living state. In most engineering applications of feedback control, the focus is temporal control, studying and seeking to minimize transient errors in the approach to a goal value. In the physiological state, however, in addition to such temporal aspects, control also involves geometric or functional patterns (in the context of neural control) and the minimization of their deviations from normal resting values (Talbot and Gessner, 1973). This involves control action. For example, in the visual system, color and contrast involve spatial rather than time integrals and time derivatives. Equally the maintenance of the set of steady-state operating points for flows and concentrations in the circulatory or respiratory systems provide examples of functional pattern control.

Let us return now to chemical regulation and control within the physiological system and examine some of its dynamic features. A range of regulatory mechanisms is involved, both in the maintenance of the environment within the individual cell



**Figure 2.4** Major processes occurring within the cell and their integration into total system behavior.

and in their aggregation into the behavioral patterns of the entire organism. Some of the major processes occurring within the cell are shown in Figure 2.4.

Control is evident at each level. For example, at the lowest level there is both transcriptional and translational control involved in protein synthesis, incorporating genetic effects transmitted via RNA. Feedback features in all these control mechanisms. Proteins may either be incorporated into the cellular structure or may, as enzymes, be involved in subsequent chemical reactions occurring within the cell.

### 2.4.2 Enzymes

The rate of chemical changes in physiological systems is generally controlled by such enzymes, which act as biological catalysts. In the simplest enzyme controlled reaction, an enzyme E and chemical substrate S form an enzyme-substrate complex X which in turn decomposes into the original enzyme E and the product of the reaction P. This system of reactions can be represented by the equation:



Assuming first order reactions, such that rate of change is directly proportional to the concentration of the ingredients of the reaction, the mass transfer equations for the system are given by:

$$\frac{dE}{dt} = -k_{EX} E S + k_{XE} X \quad (2.6)$$

$$\frac{dS}{dt} = -k_{SX} E S + k_{XS} X \quad (2.7)$$


$$\frac{dX}{dt} = (k_{EX} + k_{SX}) E S - (k_{XS} + k_{XE}) X - k_{XP} X \quad (2.8)$$

$$\frac{dP}{dt} = k_{XP} X \quad (2.9)$$


where E, S, X and P are the quantities of free enzyme, substrate, complex and product respectively. The k values are the rate constants for the appropriate reactions, so that for instance  $k_{XP}$  is the rate constant relating rate of production of product to the quantity of complex.

A signal flow diagram for this system is shown in Figure 2.5. It can be seen that the dynamics resulting even from this very simple process are complex and nonlinear. For instance, the reversible reaction  $E + S \leftrightarrow X$  gives rise to two negative feedback loops tending to regulate E and S. On the other hand the regenerative cycle  $E \rightarrow X \rightarrow E$  leads to a positive feedback loop which has a potentially destabilizing effect.

This simplistic treatment has neglected many of the features which occur in more realistic enzymic reactions. For example, reaction rates frequently depend upon the presence of a substance other than enzyme or substrate to activate or inhibit the process. A typical reaction involving the enzyme phosphofructokinase which occurs in glucose metabolism is shown in Figure 2.6. The many pathways available give rise to even more complex patterns of regulatory behavior.



**Figure 2.5** Signal flow diagram for a simple enzymic reaction.




**Figure 2.6** Phosphofructokinase (PFK) reactions. The nomenclature adopted is: A = ATP; AM = Mg-ATP; C = citrate; CM = ATP-citrate; D = ADP; DM = Mg-ADP; E = enzyme (PFK); EAM = complex; EF = complex; EP = complex; F = substrate (fructose-6-phosphate); M = Mg (magnesium); P = product (fructose 1,6 diphosphate); and X = complex.

### 2.4.3 Hormones


Control in such chemical reactions, however, is not confined to the action of enzyme systems. For example, there is a large number of chemical reactions that form a part of glucose metabolism taking place in the liver that are under enzyme control. However, this set of reactions is also controlled by a range of hormones, including insulin, glucagon, adrenalin, cortico-steroids, growth hormone and the thyroid hormones. Hormones are powerful chemical agents secreted by endocrine glands such as the pancreas and the thyroid gland.

Three types of hormonal action are evident from a control perspective. The first type of action is associated with hormones that act on smooth muscle or other cells to stimulate an effect such as muscle contraction (Figure 2.7). These are sometimes referred to as kinetic hormones. The consequence of this action is perceived by a neural detector. For example, arterial baroreceptors monitor changes in blood pressure following the secretion of adrenalin from the adrenal medulla. The fact that neural transmission is involved in the feedback pathway from the site of the kinetic action to the particular endocrine gland ensures that within seconds the appropriate changes in hormonal output can occur.



**Figure 2.7** Hormonal action on smooth muscle or other cells to stimulate an effect such as muscle contraction.


The second type of hormonal action manifests itself in the change in blood concentration of a particular chemical (see Figure 2.8). Hormones bringing about such action are sometimes referred to as metabolic hormones. For example, insulin secreted in the pancreas brings about a decrease in the level of blood glucose. This may be due either to its direct allosteric effect in an enzyme system or to its mediation of a transport process. The feedback in this case is chemical, the lower level of blood



**Figure 2.8** Hormonal action manifesting itself in the change in blood concentration of a particular chemical.

glucose in the blood perfusing the pancreas being recognized and inhibiting further insulin secretion. The limitation of this type of control stems from the fact that this local chemical feedback has an effective time constant which is typically of the order of tens of minutes.


The third type of hormonal control involves endocrino-kinetic or trophic hormones (sometimes also known as endocrine-kinetic hormones). These are produced by one gland which, in turn, controls the activity of another (see Figure 2.9). For example, ACTH is a trophic hormone secreted by the anterior pituitary which, in turn, acts upon the adrenal cortex in controlling the rate of secretion of cortico-steroids. The actions of such target gland hormones are complex, multiple and slow. The effects of cortico-steroids, for instance, are such that their actions on peripheral tissues cannot be monitored by changes in a single blood constituent. It is therefore the concentration of the steroid itself that is used as the feedback signal. Also it can be seen that the feedback effects are more complex for this type of hormone. Pathways to both hypothalamus and pituitary may be present, affording greater flexibility in the system's response to a particular perturbation. Moreover, target gland activity can change very rapidly in response to a changed external environment. Disturbances such as stress or seasonal changes are detected and fed into the hypothalamus via the central nervous system.



**Figure 2.9** Trophic (endocrino-kinetic) hormone.

From a system's perspective, a number of interesting features are apparent if we consider a portion of the liver glucose system. The reactions by which glucose is converted into glucose-6-phosphate and glycogen involve complex enzyme systems. Some of these, in turn, are under hormonal control (see Figure 2.10). For example, if blood glucose level is high, insulin is secreted, thus facilitating the conversion of glucose-6-phosphate into glycogen and hence bringing about a decrease in the glucose level. The hormone glucagon, however, is also secreted in response to the same stimuli as applied to insulin. Yet its metabolic effect is in direct opposition to that of insulin in that it tends to raise glucose levels. Glucagon, however, is more sensitive than insulin and so modulates reactions promoted by insulin thereby bringing about better control action.

Here we have an antagonist pair of metabolic hormones acting in a manner parallel to that occurring in locomotion, where muscle extension is achieved by active contraction of an antagonist.



**Figure 2.10** Hormonal control of chemical reactions.

The overall control of the chemical processes of physiology involves the nervous system as well as hormones. Many of these are still not very well understood, though considerable advances in understanding have taken place in some areas; for instance, relating to the vagal control of breathing.

Nevertheless, it is clear that a complex array of control actions is involved in the totality of chemical processes to be found in the intact physiological organism. At a simple level there is strong local control action. This enables many of the chemical processes to be regulated without recourse to higher levels of control. This is due to the fact that chemical reaction rates are generally concentration-dependent, giving rise to inherent negative feedback. This, together with the sophisticated array of enzymic, hormonal and nervous system mechanisms involving both chemical and neural transmission, provides a degree of flexibility and adaptability that constitutes an excellent example of effectively functioning control.

## 2.5 HIERARCHY

From the foregoing descriptions it is clear that feedback and control in physiological systems offer many examples of functioning complexity. However, in our treatment of feedback and control a further feature of system complexity has become apparent. This is hierarchy.

The structure of the overall human organism offers itself to analysis in hierarchical terms; from genes, through cellular subsystems, cells, organelles, organs to the intact physiological organism. At each level there is feedback and control action of a variety of modes. Equally each level of organization is aggregated into the next level up in this organizational hierarchy (e.g. cellular subsystems aggregate into cells and organs into the intact organism).



Examining the control of organ systems a number of mechanisms are evident. As we have already seen, in many processes there is strong, local low level chemical control. This is particularly appropriate for the situation in which disturbances to the metabolic process are unlikely to be large in magnitude. On the other hand, for the likes of carbohydrate metabolism where gross perturbations occur daily, through the feeding process, hormonal mechanisms form an integral component of the regulatory process.

We can define a hierarchy of regulatory mechanisms in terms of intrinsic chemical, enzymic, hormonal and neural control. This multitude of controllers ensures that the organ systems and the organism as a whole are able to withstand disturbances normal and abnormal both in terms of magnitude and time scale.

## 2.6 REDUNDANCY

One more feature that characterizes the complexity of human physiology is redundancy. The most obvious examples of redundancy relate to the provision of pairs of organs: two eyes, ears, lungs and kidneys. In the case of the sensory organs, this permits an increased sophistication in sensory perception, such as binocular vision. The duplication of lung and kidney function provides the ability to cope with extremes of operating conditions that would tax the single organ. Moreover, the kidney, whilst of prime importance in the regulation of the body's water balance, also has a limited capacity to act as a chemical plant and can therefore provide a limited degree of back-up for the major chemical plant – the liver.

A degree of redundancy is also apparent in the organ control systems. For example, a number of hormonal control loops are involved in the maintenance of blood glucose levels. Glucagon, adrenalin, growth hormone and the cortico-steroids are all capable in their several ways of remedying low glucose levels. This is not to say that all these hormones are specific in their action, for many hormones mediate a variety of metabolic effects. Nevertheless, a high level of reliability is afforded in the correction of a deficiency in blood glucose. On the other hand there is only a single control loop capable of lowering elevated glucose levels – the insulin controller. This is, however, a robust controller in the healthy individual, thus offsetting to a degree the absence of any back-up system from a system design perspective.

Redundancy is also apparent in the nervous system. In many instances a small fraction of the available information needing to be transmitted is carried by each of a large number of units. In this way immunity to large scale loss of information is provided, even though small numbers of the central neurons are dying each and every day.

Organisms with a higher nervous system are capable of responding selectively to a vast number of specific combinations of sensory stimuli. This ability has led to the hypothesis that information from the dense organs is progressively re-coded to higher levels in a less redundant form. Since the transmission lines – the number of fibers in a sensory pathway – is fairly constant, this reduction process would occur in terms of reduced average activity in the sensory centers, that is economy of pulses. Great

economy can be achieved by this recoding, providing of course that it occurs with the minimum sacrifice of information.

## 2.7 FUNCTION AND BEHAVIOR AND THEIR MEASUREMENT

From the foregoing sections it is clear that physiological systems exhibit complexity in a variety of forms. The integration of the system components, the manner in which they are inter-connected and the mechanisms by means of which they are regulated and controlled gives rise to the functional and behavioral patterns that are to be found in the functioning physiological organism. Figure 2.1 provided us with one simplified representation of some of this overall physiological complexity. It is these functional and behavioral patterns which are of interest to us as physiological modelers.

However, in order to be able to quantify the dynamic processes and effects that are occurring within the complexity of our physiological systems, we must be able to make measurements. This is where many challenges lay; there are limits as to what can be measured in living organisms. There are constraints, both practical and ethical.

For example, it is generally not possible to make invasive measurements on the organs, nor in the tissues, nor of the secretion of the glands of the intact physiological organism. This has traditionally meant that, in terms of chemical variables in the body, measurements have been limited to those that could be derived from blood, urine or breath samples. More is now possible, however, due to technological advance. Making use of advanced imaging modalities it is now possible to derive measurements of say glucose in the brain, assuming that the organ in question, brain, liver or kidneys for example, can be precisely identified from the images in question.

So, at an experimental level, our ability to access and hence potentially understand physiological complexity is limited. We are constrained by measurement technology and methodology as to what may be measured directly (*in vivo*). As far as accessing information regarding other quantities is concerned, the only way forward is by using indirect or inferential methods. This means using models as will be explained below.

## 2.8 CHALLENGES TO UNDERSTANDING

So what is clear is that physiology is complex and that the availability of measurements to access the dynamics of this complexity is limited. It is this tension between complexity and measurement that is one of the major drivers for modeling activity and the manner in which it should be undertaken. As we shall see in the chapters that follow, modeling enables us to maximize the information that can be gained from measurements. It also aids our understanding of complexity. For quantitative models in essence are vehicles for relating our quantitative measurements to features of physiological behavior.

For instance, in the circulatory system we can measure blood pressure and flow rate. If we postulate, in the form of a mathematical model, that pressure is equal to the product of flow and compliance, then measurements of pressure and flow will enable

us to make estimates of compliance in the blood vessel under consideration. The measurements may enable us to assume that compliance is constant over a specified range of pressures and flow rates. We could then use this model to explore how changes in vessel compliance, due say to disease processes of arteriosclerosis, would alter these pressure/flow relationships. In this way models can aid our understanding.

This particular example illustrates the idea of a model as a means of indirect or inferential measurement. We cannot directly measure the compliance of a blood vessel. However, we can estimate its value, by inference, from the available measures of pressure and flow and the mathematical relationship between them that we have postulated in terms of the parameter that is compliance. So models can increase our understanding of physiological complexity. This is one reason why we might wish to develop a model of some aspect of physiology. The following chapter will explore the idea of why we might wish to formulate and use mathematical models, outlining a range of possible purposes for such physiological modeling.

## 2.9 EXERCISES AND ASSIGNMENT QUESTIONS

1. Give a summary of some of the main ways in which complexity manifests itself in physiological systems.
2. Feedback is an essential ingredient of functioning physiological systems. Using appropriate diagrammatic representations, illustrate some of the different modalities in which feedback may occur.
3. Describe briefly the ways in which hormones can exert a controlling action in the regulation of physiological systems.
4. List some of the different ways in which the concept of redundancy can be observed in functioning physiological systems.

# 3 MODELS AND THE MODELING PROCESS

## Chapter Contents

- 3.1 Introduction**
- 3.2 What is a Model?**
- 3.3 Why Model? The Purpose of Modeling**
- 3.4 How Do We Model the Modeling Process?**
- 3.5 Model Formulation**
- 3.6 Model Identification**
- 3.7 Model Validation**
- 3.8 Model Simulation**
- 3.9 Summary**
- 3.10 Exercises and Assignment Questions**

## 3.1 INTRODUCTION

The aim of this chapter is to show what is meant by a model, the variety of models, why modeling (i.e. modeling purpose), and the nature of the modeling process. A number of examples are included to illustrate these fundamental modeling concepts; concepts which constitute the building blocks for the more detailed treatment that will follow in later chapters.

## 3.2 WHAT IS A MODEL?

What do we mean by the term *model*? In essence, a model is a representation of reality involving some degree of approximation. Models can take many forms. For the most


part, however, this book will focus on mathematical models; that is, representations of physiological reality that are expressed in the form of mathematical equations.

However, our mathematical model will only be an approximation to reality. For instance, we can formulate equations that represent the way in which blood is pumped around the circulatory system by the heart. A completely realistic model would require us to represent mathematically every molecule of the heart muscle. This would clearly result in a totally intractably large set of equations. So in practice we are likely to adopt a simpler formulation that might include the four heart chambers (ventricles and atria) as entities in our model, but exclude detail at the molecular level. In this way our model is an approximation of the true situation, but one which is still likely to be of sufficient detail for the purpose for which we are building the model (see below).

There are, though, other forms of model. We can have conceptual, mental, verbal, physical, statistical, logical, graphical models, etc. For instance, a standard textbook of physiology may typically include a description of the inhalation of air that results in oxygen entering the bloodstream via the lungs, and the corresponding removal of carbon dioxide that is exhaled back into the atmosphere. This description may well extend to a sizeable word count, and is known as a verbal model of part of the respiratory system. Much of these physiological processes could equally well be captured by an appropriate set of differential and algebraic equations. So we see here how the true reality can be represented by two different modeling modalities; a verbal description and a mathematical one. Each though will just be an approximation of the full complexities of the respiratory dynamics and their controlling mechanisms.

In another modality, we can use a graph to represent the way in which a drug is cleared from the bloodstream. Suppose that the process can be approximated as a first order one; that is, the rate of clearance of the drug is directly proportional to the concentration of the drug in the bloodstream. We could represent this process by plotting graphically the concentration of the drug on the y-axis against time, plotted on the x-axis. The result would be an exponentially decaying curve (one which if plotted semi-logarithmically would yield a straight line). So this exponential plot of drug concentration versus time can be regarded as a graphical model of the drug clearance process.

Thus, in essence, a model is a representation of the physiological system of interest. Deriving the model is a transformation process, as depicted in Figure 3.1, where this



**Figure 3.1** Modeling methodology: a means of transforming a system into a model (adapted from Carson and Cobelli, 2001).

transformation is brought about using an appropriate modeling methodology as will be described later.

### 3.3 WHY MODEL? THE PURPOSE OF MODELING

The way in which we formulate a model, and the degree of detail that is incorporated into it, are determined principally by its intended purpose. From a basic scientific perspective, the four general types of purpose for which models are developed correspond to the four classical categories of descriptive, interpretive, predictive and explanatory models.

The descriptive use of mathematical models is the expression of quantitative relationships in terms of equations. These equations provide a concise and economic description of the system under consideration and facilitate ease of analysis and handling of data. For example, if a variable in a system is directly proportional to another (say a relationship between pressure and volume), then a linear equation relating the two is more concise and easy to handle than a graphical or verbal description.

Models can also be used for interpreting experimental results. For example, a single exponential decay, as a mathematical expression, provides a compact representation of data that approximate to a first order process. By a first order process we mean one in which, for instance, the rate of loss of a substance is directly proportional to the quantity or concentration of that substance in the pool or compartment from which it is being lost. This could apply to the rate of clearance of drug from the bloodstream. In other words, if a sequence of blood samples were analyzed for the concentration of a particular drug, the changing drug concentration of drug over time could be approximated as an exponential decay, the rate constant of which provided information regarding the rate of clearance of that drug. In a similar fashion, a mathematical model can be used to interpret data collected as part of a lung function test.


A third general category of purpose is that of prediction. Here we are addressing the question as to how a system would respond to a stimulus or to a change in the system. An example would be predicting how the human organism, or a specific physiological organ system, might respond to the injection or infusion of a drug. Suppose that a mathematical model has been formulated which includes the processes that are affected by a particular drug. The model can then be used, in simulation mode, by applying a stimulus to it corresponding to the drug injection or infusion. In the model, one can observe how the concentration of drug in the body changes with time, or how blood pressure changes over time following the administration of a drug that is designed to reduce blood pressure.

In another situation, one might use a model to simulate the way in which the time course of urea and creatinine in the bloodstream changes as a result of a change in kidney function. This change of kidney function would typically be simulated by changing the value of an appropriate parameter in the model.

Finally, models can be used for explanatory purposes. For example, if the parameters of the model correspond to explicit physiological processes or effects, then changes in observed behavior can be interpreted in terms of changing parameter

values. This means that the model can be used to help provide a physiological explanation for observed dynamic effects. In this way a model can, for instance, be used to help understand how changes in physiological parameters can bring about changes in the uptake of substances, including drugs, by various organs of the body.

The purpose of the modeling process is a key driver of good modeling methodology, as shown in Figure 3.2. Whilst descriptive, interpretive, predictive and explanatory are the four classical categories of model purpose, a number of more specific purposes can be identified in the context of physiological systems. These include: aiding understanding, hypothesis testing, inferential measurement, teaching, simulation and experimental design.



**Figure 3.2** The purpose of the model: driving the modeling process (adapted from Carson and Cobelli, 2001).

For example, competing models, constituting alternative hypotheses as to the nature of the physiological processes taking place, can be examined to determine which are compatible with physiological or clinical observation. Moreover, a model of the relevant metabolic processes, when taken together with measurements of a metabolite made in the bloodstream, can be used to infer the value of the metabolite in the liver. This use of models as a means of indirect measurement can avoid the need to resort to invasive techniques that might be difficult or ethically problematic.

Models can also assist in the educational process. By means of simulation of a model, the student can be exposed to a wider range of physiological and pathophysiological situations than would be possible in the conventional laboratory setting. Models can also play an important role in relation to experimental design. For example, if the number of blood samples that can be taken from a patient in a given period of time is limited, models can be used to determine the times at which blood samples should be extracted in order to obtain the maximum information from the experiment. This is particularly relevant in the context of pharmacokinetic or pharmacodynamic effects.

Models can also play key roles in relation to diagnosis and patient management. For instance, if a model includes a parameter that corresponds to the rate of uptake of a substance by the liver, then estimation of that parameter can provide a diagnostic indicator of the effectiveness of that uptake process, and for example whether there might clinically be some degree of obstruction. Equally, model simulation can be

used to compare the likely dynamic effects resulting from different routes of drug administration or of different dosage levels in terms of their expected effects on key clinical variables.

### 3.4 HOW DO WE MODEL? THE MODELING PROCESS

In developing a mathematical model, two fundamentally distinct approaches are possible.

The first is based on experimental data and is essentially a data-driven or black-box modeling approach. In essence, this means seeking quantitative descriptions of physiological systems based on input/output descriptions that are derived from experimental data collected on the system. So these are mathematical descriptions of data that only correspond implicitly to the underlying physiology.

These data-driven models are particularly appropriate where there is a lack of knowledge concerning the underlying physiology. Also, they are appropriate where an overall input/output representation of the system's dynamics is all that is needed; that is, there is not the need to know specifically how the physiological mechanisms gave rise to such input/output behavior.


The second approach, modeling the system, provides a clear contrast, inasmuch as there is an attempt to explicitly represent the underlying physiology. However, as has already been indicated, any model is by definition an approximation of reality, so any model of a physiological system will involve a greater or lesser degree of approximation to the underlying physical and chemical processes. These models offer the advantage that features of dynamic behavior that are observed can be directly related to physiological parameters and variables that are explicitly incorporated into the model.

Whichever approach to modeling is adopted, however, there is one common feature. A good model is dependent upon a clear and appropriate methodology being adopted for the modeling process. This provides the means by which the physiological system of interest is transformed into the model, as outlined in Figure 3.1. The nature of this methodology in relation to the model building or formulation process is shown below.

### 3.5 MODEL FORMULATION

In the case of a data-driven or black-box model, the methodology adopted in the model building process is summarized in Figure 3.3. A full account is given in Chapter 4. In essence, however, some model structure is chosen to provide an input/output description of the data obtained from the physiological system. There are several methods for formulating such models including time series analysis, transfer function analysis, etc. The degree of complexity of the mathematical formalism is chosen to be consistent with the intended purpose for the model. The parameters






**Figure 3.3** A methodological framework for modeling the data (adapted from Carson and Cobelli, 2001).

of this mathematical expression are then determined in the identification process as outlined in section 3.6.

The modeling methodology for the situation where the model seeks to provide an explicit representation of the underlying physiology is depicted in Figure 3.4. Here there are essentially three distinct components of the modeling process. These are formulation of a conceptual model, the mathematical realization of that conceptual model and then the solution of the model to give the required relations between the variables of interest (this last component being achieved once the model identification process is complete). This approach to modeling is considered in detail in Chapter 5.

The conceptual model is based on the physiological knowledge that it is proposed to have been represented by the model. However, since any model is an



**Figure 3.4** A methodological framework for modeling the system (adapted from Carson and Cobelli, 2001).

approximation of the underlying reality, a number of simplifying assumptions will need to be made. These can typically be categorized under the headings of aggregation, abstraction and idealization.

Aggregation is typified by lumping together all of the extravascular space of the human organism and treating it as a single lumped compartment. Another example would be treating the kidney as a single lumped entity as opposed to providing distinct model representation of the different types of nephron in the kidney.

Abstraction is the degree to which only certain aspects of a system are considered in a model. For example, in modeling blood glucose regulation, the bloodstream is regarded as containing only glucose and the hormones involved in its regulation. In such abstraction other features that are important but do not relate directly to glucose regulation are neglected.


For the purpose of formulating a model, structures or behavior that are difficult to describe or treat can be approximated by simple idealized ones. For example, in a metabolic system the injection of a metabolite can be regarded as being instantaneously distributed throughout the system although, in fact, the distribution takes a finite time.

Having produced the conceptual model, equations are then constructed to provide a mathematical description of the components of the conceptual model. In a dynamic model, these equations will typically describe the manner in which one or more physiological variable varies as a function of time. The constants in the mathematical models are the parameters that specify the relationships between variables.

In general, we shall want to be able to obtain explicit relationships between variables and/or parameters in the model – in other words to solve the model. Within the model the relevant variables are commonly connected through complex mathematical relations such as differential equations. Obtaining the required explicit relations is commonly done by computer implementation of the model. In some cases the structure and parameter values of the model may be known *a priori*. The model can therefore be solved and its validity further assessed as discussed in section 3.7. Often, however, there is uncertainty in the structure of the model and/or its parameters. In this situation, the solution is not possible directly, and identification of the model from input/output data must be carried out as described below.

## 3.6 MODEL IDENTIFICATION

In order to complete the transformation from system to model as shown in Figure 3.1, we need to have specified the structure of the model and to have fully determined all the parameters corresponding to that structure. In other words the model needs to be complete so that it can be solved. In practice our model may not be complete because some of the parameter values are unknown. This may be the case regardless of whether our model is data-driven or an explicit model of the underlying physiology. So at this stage an integrated identification framework is needed as shown schematically in Figure 3.5.



**Figure 3.5** Model identification (adapted from Carson and Cobelli, 2001).

Solving this identification problem requires data. Sometimes data may be obtained from the intrinsic dynamics of the physiological system. Examples include electrophysiological signals relating to brain, muscle or cardiac function. Such situations tend to be the exception, however, so in practice experiments usually need to be designed. These experiments involve applying some stimulus to the system and observing the dynamic response of one or more of the variables. Clearly, the input/output data from the experiment must contain that part of the model with the unknown parameter values. Typical input stimuli might involve the application of a trace quantity of a metabolite in the case of a metabolic system or a step change in the fraction of an inspired gas in the case of the respiratory system.

In the identification process, the first issue to be addressed is whether the experimental data are sufficiently rich to enable unique estimates to be made of all the unknown parameters. This is known as the identifiability problem. Problems of identifiability arise where there is a mismatch between the complexity of the model and the richness of the data. That is, the model is too complex (too many unknown parameters) for the experimental data, or the data are not sufficient for the model provided. In such cases, there is the need to explore whether the model might, in a manner that retains validity, be reduced (simplified), or whether the experimental design might be enriched. This could be achieved, for example, by making measurements of an additional variable.

If the model is uniquely identifiable, assuming perfect data, it is possible to proceed directly to estimating the unknown parameters. A range of techniques exist as will be discussed in detail in later chapters. Those that are most widely adopted use an approach based on linear or nonlinear least squares estimation.

### 3.7 MODEL VALIDATION


Validating a model is in essence examining whether it is good enough in relation to its intended purpose. This assumes of course that it has been developed in such a way

that it can reasonably be tested. A model is by definition an approximation of reality. As such, it will not be able to reproduce all the features of behavior that would be found in the real system. The question is can it reproduce those that matter in terms of how it is to be used in practice?

When working with a number of competing, candidate models, the validation process consists of determining which of these models is best in relation to its intended purpose. We can therefore define a valid model as one that has successfully passed through all the tests that form the validation process.

An important point to stress at the outset is that the validation process is very much an integral component of the modeling process overall. It is an activity which takes place whilst the model is being built as well as once the completed model is available. The issue of validity testing during the process of model formulation involves considering issues, such as whether the various ways in which the model is an approximation of reality are reasonable (given the intended purpose of the model).

Once the model is complete and all its parameters have been specified, the validation process can be summarized as shown in Figure 3.6. Again it is important to emphasize that the validity issue is intimately related to model purpose. In other words, it is specific to the particular problem being dealt with. So we are examining whether all the necessary ingredients are included in our model. For example, we might want to use our model to test the hypothesis that particular changes in vascular blood flow were linked to particular changes in the elastic properties of certain arteries. Suppose these changes in blood flow corresponded to the change from a healthy state to one of disease. We would then expect that by changing the elasticity parameters in a way which we knew corresponded to the disease process, we



**Figure 3.6** Validation of the complete model (adapted from Carson and Cobelli, 2001).

would see dynamic patterns of blood flow that were those observed in that disease state. In other words the model would be reproducing the changes in blood flow pattern that we were expecting. This test provides evidence to support the validity of the model.

More generally we can say that, dependent upon purpose, some features of the model and the system output (i.e. experimental output data) must correspond sufficiently for the same input (an acceptably small difference between them). So in relation to the domain of intended validity, we are testing whether our model is credible.

The basic approach when validating a single model is to compare the behavior of the model and the system, based upon appropriate output features of response. Any discrepancy between the system and model output should be analyzed for plausibility of behavior.

In some situations, as previously discussed, formal parameter estimation techniques will have been employed in developing the model. In such cases there are additional quantitative tools available for use in the validation process. These include examining the residuals of the mismatch between model and system response, and also examining the plausibility of the estimates of the parameters, where the parameters have a clear physiological meaning (e.g. elasticity of arteries).

When choosing between a number of competing models, the choice can be aided by examining the parsimony of the models. In other words, if two models are equally acceptable in terms of their features of response, and are also both plausible, then the preferred model would be that which had the smaller number of parameters or was of the lowest order. Further details of such testing, and of the validation process overall, are to be found in Chapter 10.

As we have seen, there are many comparatively simple cases of structured, dynamic physiological processes that can be modeled with sets of first order differential equations. In some situations it is possible to solve these equations analytically. However, there are many situations in which this is either not possible or not practicable. Hence an alternative approach is required.

The first difficulty is the particular problem of obtaining solutions for equations that are of a nonlinear form. The second difficulty relates to the tedious task of solving large sets of equations, corresponding to physiological processes where a large number of variables need to be incorporated into the model. Both of these factors may substantially hinder progress. In such situations it may be desirable to use digital computer simulation methods, given their widespread availability and ever-increasing computing power/cost ratio. The aim of the next section is to examine this arena of computer simulation and to provide an account of the what, when, why and how of simulation.

### 3.8 MODEL SIMULATION

Having derived a complete model, including estimating all unknown parameters and checking its validity in relation to its intended domain of application, it is now possible

to use it as a simulation tool. Computer simulation involves solving the model (i.e. the equations that are the realization of the model) in order to examine its output behavior. This might typically be the time course of one or more of the system variables. In other words we are performing computer experiments on the model.

In fact simulation can be used either during the process of model building or with a complete model. During model building, simulation can be performed in order to clarify some aspects of behavior of the system or part of it in order to determine whether a proposed model representation seems to be appropriate. This would be done by comparison of the model response with experimental data from the same situation. Simulation, when performed on a complete, validated model, yields output responses that provide information regarding system behavior; information which, depending on the modeling purpose, assists in describing the system, predicting behavior, or yielding additional insights (i.e. explanation).

Why carry out computer simulation? The answer is that it might not be either possible, appropriate, convenient or desirable to perform particular experiments on the system (e.g. it cannot be done at all, it is too difficult, too expensive or too dangerous, it is not ethical or it would take too long to obtain results). Therefore, we need an alternative way of experimenting with the system. Simulation offers such an alternative that overcomes the above limitations. Such experimenting can provide information that is useful in relation to our modeling purpose.

In order to perform computer simulation we first need a mathematical model that is complete in terms of all its parameters being noted and with initial conditions specified for all the variables. If the model is not complete in the sense of there being unspecified parameter values, then formal parameter estimation techniques must be employed to obtain such estimates (this estimation process will be described in Chapter 7). The model is then implemented on the computer. This assumes that the model equations cannot be, or are not being, solved analytically and that a numerical solution of the system is needed.

Therefore, the model is solved on the computer, this solution process producing the time course of the system variables. In technical terms, the computer implementation is done either by using a standard programming language (e.g. FORTRAN, C) or by using a specialist simulation package (e.g. MATLAB®). A number of practical issues arise in order to achieve successful simulation. These will be considered in some detail in Chapter 11, where one of the case studies gives particular emphasis to the practical aspects of computer simulation.

### 3.9 SUMMARY

This chapter has provided an outline of the nature of models and of the processes by means of which they are formulated, identified and validated. The manner in which computer simulation can be performed has also been briefly discussed. All these ingredients form the basis of the modeling processes that will be described in greater detail in the chapters which follow. It is worth re-iterating that this book is designed to describe and promote the essence of modeling methodology. The reader who wishes

to pursue particular aspects in greater detail should refer to our companion volume (Carson and Cobelli, 2001). Some of this additional detail was also to be found in our earlier work (Carson *et al.*, 1983). Having now outlined the principles of the modeling process, the next two chapters will provide a wide range of examples of model building. Chapter 4 starts this process, focusing on models that are designed to provide descriptions of experimental data.

### 3.10 EXERCISES AND ASSIGNMENT QUESTIONS

1. Describe what is meant by the concept of a model of a physiological system and discuss the various forms that a model might take. Give an illustration of some of these forms in the context of physiology.
2. Discuss the range of possible purposes for which a model of a physiological system might be formulated. Give an example in each case.
3. Describe the process of formulating a model of a physiological system, discussing the way in which the particular formulation might be influenced by the availability of physiological knowledge.
4. Using appropriate examples, discuss how the processes of model formulation, model identification and model validation are inter-related.
5. How might the process of simulation be useful in the physiological or clinical context?

# 4 MODELING THE DATA

## Chapter Contents

- 4.1 Introduction**
- 4.2 The Basis of Data Modeling**
- 4.3 The Why and When of Data Models**
- 4.4 Approaches to Data Modeling**
- 4.5 Modeling a Single Variable Occurring Spontaneously**
  - 4.5.1 Temperature
  - 4.5.2 Urine Potassium
  - 4.5.3 Gastro-intestinal Rhythms
  - 4.5.4 Hormonal Time Series
- 4.6 Modeling a Single Variable in Response to a Perturbation**
  - 4.6.1 Glucose Home Monitoring Data
  - 4.6.2 Response to Drug Therapy – Prediction of Bronchodilator Response
- 4.7 Two Variables Causally Related**
  - 4.7.1 Hormone/hormone and Substrate/hormone Series
  - 4.7.2 Urine Sodium Response to Water Loading
- 4.8 Input/output Modeling for Control**
  - 4.8.1 Pupil Control
  - 4.8.2 Control of Blood Glucose by Insulin
  - 4.8.3 Control of Blood Pressure by Sodium Nitroprusside
- 4.9 Input/output Modeling: Impulse Response and Deconvolution**
  - 4.9.1 Impulse Response Estimation
  - 4.9.2 The Convolution Integral
  - 4.9.3 Reconstructing the Input
- 4.10 Summary**
- 4.11 Exercises and Assignment Questions**

## 4.1 INTRODUCTION

So far, we have talked in general terms about the modeling process and the need for good modeling methodology. In this chapter and the one which follows, we



shall demonstrate how models can be developed as a means of representing physiological dynamics. This chapter focuses upon data modeling. Chapter 5 will concentrate on models as representations of the underlying systems which give rise to physiological data.

We need to consider first of all what we mean when we say ‘modeling data’, and when such approaches are applicable. Having discussed these issues, we shall go on to discuss some of the ways in which data modeling can be performed. This will be done by means of a range of examples, considering the different ways in which physiological data can arise.

## 4.2 THE BASIS OF DATA MODELING

Data modeling provides us with a means of representing the variables which characterize physiological dynamics as captured by the measurement process. A first point to make is that these models are in essence ‘black box’ models and as such are mathematical representations of our measurement data, having only implicit correspondence to the underlying physiology that gives rise to these measures. This contrasts with the approaches considered in Chapter 5 where the models formulated are in their various ways explicit representations of the physiology.

These data models do, however, provide us with concise descriptions of physiological data. As such they offer advantages over purely graphical representations. Whilst the graph does have an immediate visual appeal, a mathematical description is concise and can be used as a basis for generalization from the specific data in terms of characterizing patterns or features contained within the data.

## 4.3 THE WHY AND WHEN OF DATA MODELS

So when is it appropriate to adopt data models? First they are useful in situations where there is a lack of knowledge of the underlying physiology; for example, as is the case in a number of areas of electrophysiology and neurophysiology. These are situations where the very complexity of the system in question gives rise to this uncertainty in structure and behavior.

A second possibility that we should know is an overall input/output description of the system dynamics, without needing to understand specifically how the physiological mechanisms gave rise to such input/output behavior. Typical situations include the control of a physiological variable; for example, by means of drug therapy.

## 4.4 APPROACHES TO DATA MODELING

In essence, there are two major types of approaches to data modeling. These correspond to treating the system as being either deterministic or stochastic. In both cases the output measurement will generally be corrupted by noise, but in the first case the

system output is a deterministic function of the input. In the stochastic case the output is not a deterministic function of the input due to some unmeasurable disturbances (noise) within the system itself.

The stochastic modeling strategy is particularly important in electrophysiology and neurophysiology. However, this approach is not the subject of our book. The reader who is interested in the data modeling of such physiological signals should consult texts such as Marmarelis and Marmarelis (1978), Bruce (2000) or Westwick and Kearney (2003). What this book will be focusing on is the deterministic system approach.

The measurements that provide us with the physiological data can take a variety of forms. First the measurements can be discrete or continuous. Usually the variables themselves are continuous, but we can choose whether to collect the data as sample values at discrete time points or as continuous signals. For instance, the blood glucose concentration of a diabetic patient is a continuous signal, but typically such a patient might decide to measure his or her blood glucose concentration, say between four and eight times a day, corresponding to events such as meal times and bedtime. So although the variables are continuous, we have a set of data corresponding to values measured at discrete times. On the other hand, we may have continuous data in the form of signals monitoring the cardiac status of a patient with heart or circulatory problems over a period of 24 hours.

Equally, even if the data are continuous, we can elect to analyze them as such or as a set of discrete data obtained by sampling the continuous record (usually at equispaced time intervals for convenience of analysis). On the other hand, whilst discrete data points are usually analyzed using discrete time methods, it is possible to convert such discrete data to continuous form by the adoption of appropriate interpolation and extrapolation methods.

The emphasis in this chapter is placed upon time domain data. A number of examples of frequency domain approaches are included though, together with means by which time domain data can be converted into frequency domain forms. For more in-depth treatments of frequency domain approaches to data modeling, the reader should consult works such as Marmarelis and Marmarelis (1978) and Westwick and Kearney (2003).

Our discussion of approaches to data modeling will be grouped into four categories. These correspond to different types of physiological and clinical situations. The first, considered in section 4.5, focuses on situations in which we are interested in a single, measurable variable that arises as a spontaneously occurring signal. Examples would include body temperature, urine potassium and electrical rhythms in the gastro-intestinal tract.

Section 4.6 again focuses on a single variable, but this time on a signal that occurs as a direct response to some form of perturbation to the physiological system in question. The monitoring of the blood glucose concentration of a diabetic patient in response to a particular regimen of insulin injections would be one example of this case. Others could include evoked potential responses and the time course of arterial pressure in response to an anti-hypertensive agent administered in order to bring about its reduction.

The third case, treated in section 4.7, considers the causal relationship between two variables. Examples include the relationship between glucose and insulin in the normal subject and the impact of water loading on the level of sodium in urine.

Whilst this third category has focused on situations whereby the relationship between the two variables is something that arises naturally within the normally functioning human organism, the last case, discussed in section 4.8, deals with the situation in which there is explicit control. Examples include glucose/insulin relationships in the diabetic patient and the relationship between blood pressure and dosage of sodium nitroprusside administered to bring about its control.

The final example of data modeling that we shall discuss is the impulse response. This will be examined from a deconvolution perspective. We can either reconstruct the unknown input (for example, hormone secretion) when we know the system output and the impulse response, or determine the impulse response when both input and output of the system are known. An example of such an impulse response might be the circulatory transport function of an organ from knowledge of arterial and venous concentrations of an intravascular indicator.

## 4.5 MODELING A SINGLE VARIABLE OCCURRING SPONTANEOUSLY

As will be demonstrated in this and the sections that follow, a wide range of methods and techniques are available for providing quantitative descriptions of physiological and medical signals.

The first case to be considered is that of a single variable which can be regarded as having arisen spontaneously. In reality the signal which is observed will be the result of a range of interacting physical and chemical processes within the human body that give rise to the particular manifestation. Regarding the single variable as having arisen spontaneously is in effect a means of distinguishing this signal, essentially of endogenous origin, from one which arises as the explicit effect of having administered some test signal to the organism; for instance, a drug injection or the application of an electrical stimulus to the body.

The examples presented have been selected to demonstrate that the quantitative analysis (that is to say data modeling) is applicable across the broad range of physiological signals. Equally they show that such modeling can be applied to signals which are either non-periodic, or are periodic with frequencies which range from cycle times measured in seconds to those of one or more months.


### 4.5.1 Temperature

The cyclic change in body temperature during the menstrual cycle of a woman is a typical example of a biological rhythm. The basic pattern of the rhythm is broadly consistent from one month to the next, though some variation occurs from one monthly cycle to the next in any particular individual. As a first approximation it is reasonable to model such temperature data by a sine wave function.

An example of the temperature variation in a woman, not taking oral contraceptives, measured orally on waking each morning is shown in Figure 4.1. These are some of the data that were collected over a period of almost one year, with measurements being omitted on 94 days. They were modeled by the sine wave function given by (4.1) (McIntosh and McIntosh, 1980):

$$y = A_1 \sin \left[ \frac{6.2832(A_2 + t)}{A_3} \right] + A_4 \quad (4.1)$$

where  $y$  is the dependent variable (temperature), and  $t$  is the independent variable (time). Parameter  $A_1$  corresponds to the peak amplitude of the sinusoidal temperature variation, and  $A_2$  is a parameter for synchronizing the phases of the model and the data. Parameter  $A_3$  modifies the period or distance between peaks of the sinusoidal temperature variation, whilst  $A_4$  represents the displacement of the central mean value from zero. Figure 4.1 depicts the first ninety days of the experimental data, together with the fitted data model. In this case the fitted parameter values, together with their standard deviations, are:  $A_1 = 0.191 \pm 0.011^\circ\text{C}$ ,  $A_2 = 12.85 \pm 0.47$  days,  $A_3 = 27.07 \pm 0.07$  days, and  $A_4 = 36.56 \pm 0.008^\circ\text{C}$ .




**Figure 4.1** Temperature variation in a woman, not taking oral contraceptives, measured orally on waking each morning. Experimental data corresponding to the first 90 days are shown, together with the fitted data model (adapted from McIntosh and McIntosh, 1980).

Another approach which has been adopted in the analysis of this time series of temperature values has been to calculate the correlation between all pairs of values of the temperature variable, the *auto-correlation coefficient*, at each different lag or time interval apart (McIntosh and McIntosh, 1980). This correlation coefficient is calculated from the covariance of the same variable displaced in time. The *correlogram* provides a graphical representation of the variation of correlation as a function of the lag. As previously discussed, if there is more than a single rhythm present in the time series, then a corresponding number of peaks will be found in the correlogram. Correlograms of time series displaying obvious cyclicity may not provide new

information since they tend to mirror closely the rhythm of the data. Peaks may also occur at harmonics of the basic frequencies, and this fact can be confusing when interpreting the results obtained.


Performing this correlation analysis on the temperature data considered in this example results in the relationship between auto-correlation and lag as shown in Figure 4.2. In the analysis, all values of lag up to a maximum corresponding to 170 days were included.



**Figure 4.2** Correlation analysis on the temperature data showing the relationship between auto-correlation and lag (adapted from McIntosh and McIntosh, 1980).

The values of the correlation coefficients between pairs of measurements separated by a range of lags or time intervals varied in a sinusoidal manner which clearly reflected the dominant cyclicality of the temperature data. The peak in the autocorrelation function at a lag of approximately 27 days shows that there was a mean correlation of 0.33 between all measurements separated by this interval. Equally, a correlation also existed between observations that were 54 days apart, and so on.


An alternative means of analyzing these rhythms is to describe them as the sum of an arbitrary number of sine waves of different frequencies, phases and amplitudes. A model consisting of a sum of sine waves is known as a *spectral representation*. From the spectral representation one can construct a *spectral density function*, which is a graph showing the contributions of each frequency to the observed process. This spectrum is the Fourier transform of the auto-covariance function from which auto-correlations are calculated. Carrying out this transformation for our example of the temperature data yields the spectral density function shown in Figure 4.3 (McIntosh and McIntosh, 1980). The contributions of the different frequencies to the total variance about the mean of the data are represented as a function of the frequencies. In this figure the data are also expressed as periods. From this plot it can be observed that most of the variance is explained by a process with a period of between 26 and 28 days.



**Figure 4.3** Spectral density function of the daily temperature data (adapted from McIntosh and McIntosh, 1980).

### 4.5.2 Urine Potassium

A second example relates to a series of measurements of the concentration of potassium in a patient’s urine. In our example, the data were collected once a day from a road traffic accident patient who remained in an intensive care unit for a period of 27 days. A time series plot of the data is shown in Figure 4.4.



**Figure 4.4** Time series plot of urine potassium (adapted from Flood and Carson, 1993).

The reference range for urine potassium concentration is 40–120 mmol liter<sup>-1</sup>. The time series plot shows two outliers (highlighted by circles), which may have arisen due to errors in measurement. These could be removed by changing their actual values to their expected values. However, physiologically large changes can occur. Hence it may be difficult to determine whether these experimental values are due to poor measurement technique or physiological changes. For this reason, the values were left unchanged. Moreover, there were three missing values which were set to their expected values (Flood and Carson, 1993).




**Figure 4.5** Correlogram of the urine potassium data (adapted from Flood and Carson, 1993).

The correlogram of the raw data is presented in Figure 4.5. The autocorrelation function  $r_j$  clearly damps out slowly. This implies non-stationarity of the series which is not obvious from the basic time series data. Hence, the first differences of the series were taken. The autocorrelation function  $r_j$  of this is shown in Figure 4.6.

On the basis of subsequent statistical analysis (the scope of which is beyond the basic exposition being provided here) it can be shown that the data could be represented by an Autoregressive Integrated Moving Average (ARIMA) model. As indicated in section 4.7.2, an ARIMA process is conventionally written ARIMA( $p, d, q$ ), where  $p$  refers to the autoregressive part of the process,  $q$  is the moving average part, and  $d$  relates to the number of differences that are needed to achieve stationarity of a set of time series data. In our example here, the ARIMA model adopted was of the form ARIMA(2, 1, 0). Carrying out the processes of estimating the parameters of this model (the principles of which will be described in Chapters 7 and 8), led to the following model realization:

$$x_t = -0.6476x_{t-1} - 0.6817x_{t-2} + U_t \quad (4.2)$$

where the  $x$  values are the modeled values of the urine potassium concentration at the daily times of measurement.



**Figure 4.6** Autocorrelation function of the first differences of the urine potassium data (adapted from Flood and Carson, 1993).


This example illustrates how ARIMA modeling can be used in fitting time series data. In practice, however, this modeling approach can be difficult when the number of data points is comparatively low. In this case there were 27 clinical data points. General experience is that a time series of at least 50–100 values is needed if the errors in estimating the parameters of the ARIMA model are not to be unacceptably large. So this modeling approach would be more applicable in situations where there was on-line patient monitoring with frequent sampling, rather than with the more restricted regimen of daily data derived from laboratory results.

### 4.5.3 Gastro-intestinal Rhythms

The third example returns to a case of rhythmic data, namely the electrical rhythms of the gastro-intestinal system. This is a domain which has not received as much attention as, for instance, nerve-axon electrical potentials or the field of cardiac pacemakers. Reasons for this include the fact that smooth muscle (such as is found in the digestive system) does not have the dimensions and properties which lend them to easy measurement, unlike the physiological cellular measurements on nerve axons; nor are there the specialized areas of tissue corresponding to the cardiac pacemaker concepts. Nevertheless, there is increasing interest in the role of these gut electrical rhythms, both in the healthy subject and in the disease state, an interest which is advanced by the use of models as a vehicle for aiding description and understanding of these phenomena.

Spontaneous electrical rhythms occur in all parts of the digestive tract below the middle of the stomach. These rhythms are commonly called ‘slow waves’. A schematic representation of the gastro-intestinal tract, together with typical frequencies recorded in man, is given in Figure 4.7 (Linkens, 1979). The frequency and wave shape of the slow waves varies considerably between the organ and the






**Figure 4.7** A schematic representation of the gastro-intestinal tract, together with typical frequencies recorded in man (adapted from Linkens, 1979).

species being studied. For example, the canine stomach has narrow pulse-like waves of approximately 0.08 Hz, whereas the human stomach produces square-like waves of approximately 0.05 Hz. Figure 4.8 shows typical recordings from normal and diverticular-diseased colons. In the case of disease, it can be seen that there is a tendency for these waves to have a component higher in frequency than normal. Equally, colonic waveforms are seen to be nearly sinusoidal with the occurrence of considerable variation in amplitude.

In terms of modeling these data, one widely adopted approach has been to represent them in terms of Van der Pol type dynamics as given by (4.3) which is in effect a coupled oscillator model:

$$\frac{d^2x}{dt^2} - \epsilon(\alpha^2 - x^2)\frac{dx}{dt} + \omega^2x = 0 \quad (4.3)$$

in other words, a model of the form of a second order differential equation.



**Figure 4.8** Typical recordings from (a) normal and (b) diverticular-diseased colons (adapted from Linkens, 1979).


This equation as a model of the data has considerable advantages in that its three parameters  $\epsilon$ ,  $\alpha$  and  $\omega$  approximately determine the wave shape, amplitude and frequency of the nonlinear oscillation. These are the primary parameters under consideration in this slow wave modeling. Equally this equation has been treated extensively in nonlinear differential equation studies.

In order to produce a representation of the whole 240 cm of the small intestine it has been found necessary to adopt up to 100 oscillators linked in a chain with each being represented by an equation of the form of (4.3) (Linkens, 1979).

#### 4.5.4 Hormonal Time Series

Plasma concentrations of hormones exhibit cyclic behaviors which can range from seasonal to circadian to ultradian (hours) to rapid (minutes). It is worth noting that

while seasonal and circadian rhythms have been known for some time, it is only since the 1970s and 1980s (with the advent of very sensitive radioimmunoassay (RIA) methods) that both ultradian and rapid patterns have come to be understood. Three examples of hormonal time series are shown. Figure 4.9 shows plasma cortisol concentration over a 24 h window with uniform 15 min sampling: the circadian trend is shown by the dashed line and we can see on top of that the ultradian oscillations of smaller amplitude and period (3 to 5 h). Figure 4.10 shows C-peptide (a hormone secreted by the pancreas equimolarly with insulin, but not degraded by the liver) concentration in plasma measured every 10 min for 24 h in a normal (upper panel) and a type 2 diabetic (lower panel) subject. Ultradian oscillations with a period of 90–180 min are apparent in the normal subject while the diabetic subject time series appears much more irregular. Figure 4.11 shows an example of rapid oscillations: plasma C-peptide is sampled for 3 h every 2 min and 5–15 min oscillations can be seen. In both Figures 4.10 and 4.11 also shown in the lower panels are the associated glucose oscillations which will be commented on in section 4.7.1.




**Figure 4.9** Time series of cortisol concentration measured every 15 minutes for 24 hours in a normal subject (adapted from Van Cauter, 1990).


The hormonal time series usually consists of a finite number of samples  $\{y(t_k)\} = \{y(t_1), y(t_2), \dots, y(t_N)\}$  where the generic sample  $y(t_k)$  is related to the concentration  $c(t_k)$  by

$$y(t_k) = c(t_k) + v(t_k) \quad (4.4)$$

where  $v(t_k)$  is the measurement error at time  $t_k$ .



**Figure 4.10** Time series of C-peptide (upper panel) and glucose (lower panel) concentrations measured every 10 minutes for 24 hours in a normal subject (adapted from Sturis *et al.*,1991).



**Figure 4.11** Time series of C-peptide (upper panel) and glucose (lower panel) concentrations measured every 2 minutes for 3 hours in a normal subject.

A first means of characterizing a hormonal time series could be in terms of its mean and variance


$$\mu = \sum_{k=1}^N \frac{y(t_k)}{N} \quad (4.5)$$

$$\text{var} = \sum_{k=1}^N \frac{(y(t_k) - \mu)^2}{N - 1} \quad (4.6)$$

This has sometimes proved to be a useful representation. For example, it has enabled it to be shown that luteinizing hormone (LH) secretion in women is more variable in the luteinizing than in the follicular phase. However, this mean and variance model does not provide insight into the pulsatility features of the series, such as the number of secretory events and their amplitudes.


The recognition and analysis of peaks is not easy. For instance, one has to detect which are the true peaks and which are the spurious ones (due to measurement error). It is worth noting that classic pattern recognition techniques such as those used for QRS detection of ECG signals or for spike detection of EEG cannot be employed, given the nature of the data and the irregularity of secretory events. One possibility would be to recognize as true peaks only those whose levels are sufficiently greater, e.g. three standard deviations (SD), than their previous minimum (Figure 4.12).

This rough model, however, can be criticized in a number of aspects. For example, it is very sensitive to outliers and does not take advantage of the future history.



**Figure 4.12** Recognition as true peaks only those whose levels are sufficiently greater, e.g. three standard deviations (SD), than their previous minimum.

An interesting algorithm which was specifically developed for ultradian oscillations is ULTRA (Van Cauter, 1988). The idea is to polish the series by eliminating from it non-significant variations. A variation is assumed to be significant if it is sufficiently elevated, i.e. greater than  $\rho SD$  (where  $\rho$  is a parameter and SD is the standard deviation of measurement error), with respect to the previous data point. More specifically, if  $y(t_{k+1}) > y(t_k)$ , then the increment is significant if  $y(t_{k+1}) - y(t_k) > \rho SD$ . If  $y(t_{k+1}) < y(t_k)$ , then the decrement is significant if  $y(t_k) - y(t_{k+1}) > \rho SD$ . Thus, if the series has an increasing trend and one encounters a non-significant increment or a non-significant decrement, then either, respectively, one does nothing or maintains the value at the previous levels. The same applies if the series exhibits a decreasing trend and one encounters, respectively, a non-significant trend or a non-significant increment. An example of the performance of the algorithm is shown in Figure 4.13. Clearly the critical point of this algorithm is the choice of  $\rho$ , but one easily appreciates



**Figure 4.13** Performance of the algorithm (adapted from Van Cauter, 1990).

that the detection of peaks is much easier on the polished series. However, in many situations where pulses are brief, small in amplitude and irregular, peak detection is difficult.

Another widely used approach to study hormone pulsatility from plasma concentration time series is to look for cycles by time series spectral analysis, i.e. by computing the autocorrelation function or Fourier transform (Veldhuis *et al.*, 1987; Veldhuis and Johnson, 1988). Unfortunately, spectral analysis is hard to apply when small length and noisy data sets are considered; in addition, it does not handle cycles whose timing is inherently irregular, which is the most common situation (Merriam and Wachter, 1982). Finally, since both peak detection and spectral analysis ignore the morphology of the pulse, they cannot detect changes in the pattern of hormone episodic release which characterize some physiological and pathophysiological states (Pincus *et al.*, 1996b).

### *Approximate entropy*

A recently developed powerful tool for the analysis of hormonal time series is the approximate entropy algorithm (Pincus, 1991). Approximate entropy provides a model-independent measure of the 'regularity' of the underlying secretion process by calculating the logarithmic likelihood that patterns in the time series are similar on the next incremental comparison. Notably, such a notion of regularity is quite different from that usually considered in engineering, where, for a signal, regularity is meant as being synonymous with smoothness. The approximate entropy algorithm summarizes the time series into a single non-negative number, ApEn: the higher the value of ApEn, the more irregular is the process. Approximate entropy is not intended to replace peak detection or spectral analysis, but is complementary to them. In fact, approximate entropy discerns changes in the pulsatile behavior that are not reflected in changes in peak occurrences or amplitudes. Moreover, approximate entropy focuses on the similarity between pulses and nearly ignores the quiescent intervals of the secretory release, thus relaxing the spectral analysis requirement of a dominant set of frequencies at which some patterns within the time series are repeated.

The approximate entropy algorithm appears well suited to the clinical need of distinguishing the healthy from the abnormal. Therefore, since its inception in the early 1990s, the approximate entropy algorithm has been extensively applied in endocrinology to study the pulsatility of many hormones in various pathophysiological states (e.g. Hartman *et al.*, 1994; Pincus *et al.*, 1996a and b; Meneilly *et al.*, 1997; Schmitz *et al.*, 1997). Such a great interest in approximate entropy is motivated by the fact that many pathological or pre-pathological states are associated with an enhanced secretion disorder which ApEn was found able to measure with success. For instance, in Hartman *et al.* (1994) time series of growth hormone (GH) plasma concentration were considered in normal and acromegalic subjects. The average value of ApEn in the normal subjects was shown to be lower than that in the pathological ones, suggesting that the pathology is characterized by an increased disorder of the secretion process.

Briefly, ApEn index can be defined as follows. Let  $\{y(k)\} = \{y(1), y(2), \dots, y(N)\}$  denote the N-size time series from which we want to calculate the ApEn index. Let  $r$  (a real) and  $m$  (an integer) be two given positive parameters. In order to compute

ApEn, let us first form the sequence of vectors  $x(1)$  through  $x(N - m + 1)$ , where each  $x(i)$  is defined by:

$$x(i) = [y(i), y(i + 1), \dots, y(i + m - 1)], \quad i = 1, 2, \dots, N - m + 1 \quad (4.7)$$

Vector  $x(i)$  contains  $m$  consecutive samples of the time series  $\{y(k)\}$ , commencing with the  $i$ -th point.

Define the distance  $d[x(i), x(j)]$  between vectors  $x(i)$  and  $x(j)$  as the maximum difference in their respective scalar components:

$$d[x(i), x(j)] = \max_{k=1 \dots m} |y(i + k - 1) - y(j + k - 1)| \quad (4.8)$$

Now compute, given  $r$ , for each  $i \leq N - m + 1$  the number:

$$C_i^m(r) = \frac{\# \text{ of } j \text{ for which } d[x(i), x(j)] \leq r}{N - m + 1} \quad (4.9)$$

$C_i^m(r)$  values measure, within a tolerance  $r$ , the frequency, or regularity, of patterns similar to a given pattern of window of length  $m$ . Next, define  $\Phi^m(r)$  as the average value of  $\ln C_i^m(r)$ :

$$\Phi^m(r) = \frac{1}{N - m + 1} \sum_{i=1}^{N-m+1} \ln C_i^m(r) \quad (4.10)$$


Finally, define the ApEn index as:

$$\text{ApEn} = \Phi^m(r) - \Phi^{m+1}(r) \quad (4.11)$$

It is possible to demonstrate that ApEn measures the logarithmic likelihood that runs of patterns that are close (within a tolerance  $r$ ), for windows of  $m$  observations remain close for windows of  $m + 1$  observation. The greater the likelihood of remaining close (i.e. the regularity), the lower the value of ApEn.


ApEn depends on two positive parameters:  $m$ , an integer, and  $r$ , a real. While  $m$  gives the length of the compared runs,  $r$  represents the tolerance which determines if the runs are close enough. The choice of  $m$  and  $r$  is usually done by criteria based on statistical considerations and obviously influences the value of ApEn. To appreciate better the influence of  $m$  and  $r$  let us consider Figure 4.14 where a portion of the time series  $\{y(1), y(2), \dots, y(i), \dots, y(N)\}$  is shown. Assuming  $y(i)$  as a reference sample, we have to evaluate which are the samples similar to  $y(i)$  (within the tolerance band  $r$ ). If  $r$  is too small (short dashed) no sample (except  $y(i)$ ) will fall into the tolerance bands, ApEn will be small, and non-significant; if  $r$  is too large (long dashed lines) all samples will fall into the tolerance band and again ApEn will be useless as a means of distinguishing different signals (one will also consider as being similar samples which are not). In practice, since the number of data in endocrine-metabolic time series is not large, it is not possible to choose  $m$  too large and  $r$  too small. Available guidelines suggest for  $N > 1000$  samples,  $m = 2$  and  $r = 0.1 \div 0.25 \text{ SD}$ , where SD is the sample standard deviation of the series; for  $N < 1000$   $m = 1$ . The choice of  $r$  between 10 and 25% of signal SD is a compromise between the two case limits, i.e.  $r$  too small or too large.





**Figure 4.14** Role of the choice of the threshold  $r$  in ApEn calculation.

As an example, consider the case described in Sparacino and Cobelli (1998) where ApEn has been used to analyze the C-peptide series of Figure 4.10 together with those of obese and glucose intolerant subjects (Sturis *et al.*, 1991; O'Meara *et al.*, 1993). Results are shown in Figure 4.15. ApEn increases with the severity of the disease, i.e. obese, impaired glucose tolerant and diabetic subjects have less and less regularity in ultradian oscillations.



**Figure 4.15** ApEn values (mean  $\pm$  SD) in normal, obese, impaired glucose tolerant (IGT) and type 2 diabetic subjects (adapted from Sparacino and Cobelli, 1998).

## 4.6 MODELING A SINGLE VARIABLE IN RESPONSE TO A PERTURBATION

The second type of situation is that where we are again interested in modeling a single variable. However, this time we are viewing it as the response of a physiological system to a specific stimulus or perturbation that has been applied to that system. Examples of such situations are presented below.

### 4.6.1 Glucose Home Monitoring Data

With advances in telecare, it is becoming increasingly common for patients with chronic diseases to monitor their clinical and health status in their home setting. The data can then be transmitted to a clinical center where they can be analyzed and appropriate advice fed back to the patient. This is particularly relevant in the case of patients with type 1 diabetes who home-monitor their blood glucose concentration.


In many cases the diabetic patient will measure their blood glucose concentration up to four times a day. One approach to analyzing these data is to make use of structured time series modeling, an approach that has been widely adopted in the analysis of economic time series data (Harvey, 1989). This involves identifying patterns in these blood glucose time series as comprising four elements:

$$G_i = f(D_i, C_i, T_i, R_i) \quad (4.12)$$

where  $G_i$  refers to the observed blood glucose value at time  $t_i$ , whilst  $D_i$ ,  $C_i$ ,  $T_i$  and  $R_i$  are the daily pattern, cyclical component, trend component and random noise, respectively at time  $t_i$ . The explicit functional relationship,  $f$ , used to relate these four sub-patterns, can take a variety of forms. The most straightforward, adopted here in this example, is additive; simply adding the elements (Deutsch *et al.*, 1994).

Trend patterns representing long-term behavior exist when there is a general increase in the blood glucose values over time. Daily patterns (which in time series analysis are generally known as seasonality) exist when the blood glucose data observed on different days fluctuate according to some daily rhythm (in other words, periodic fluctuations of constant length which repeat themselves at fixed intervals). This may be due to an internal diurnal rhythm or inadequacy in the current insulin therapy.

A cyclic pattern is similar to a seasonal pattern, but the length of a single cycle is generally longer. In the context of the diabetic patient, this could arise as a consequence of the difference between workdays and weekends, or from the menstrual cycle in women. Although randomness, by definition, cannot be predicted, once it has been



**Figure 4.16** Home-monitored blood glucose measurements collected by a diabetic patient over a period of 21 days (adapted from Deutsch *et al.*, 1994).

isolated, its magnitude can be estimated and used to determine the extent of likely variation between actual and predicted blood glucose levels (Deutsch *et al.*, 1994).

Figure 4.16 depicts blood glucose data obtained from an adult patient over a 21-day period by home monitoring. During this time the patient recorded four blood glucose measurements per day, together with details of his diet and insulin regimen. In addition, he provided a brief commentary on his social activities and general well-being, information that could be helpful in interpreting the results of the time series analysis. The results of the time series analysis are shown in Figure 4.17 (Deutsch *et al.*, 1994).

### 4.6.2 Response to Drug Therapy – Prediction of Bronchodilator Response

The clinical focus of this example is chronic obstructive pulmonary disease in which a bronchodilator drug such as theophylline is administered in order to attempt to open obstructed airways. The aim is to be able to predict the response to theophylline using a simple data-driven model (Whiting *et al.*, 1984). This then enables drug dosage to be adjusted in order to achieve the target therapeutic concentration.

The model used to relate the drug effect on respiratory function to concentration in the steady state was of the form:

$$\text{FVC} = m \text{Cp}_{\text{ss}} + i \quad (4.13)$$

where FVC is the forced vital capacity,  $\text{Cp}_{\text{ss}}$  is the steady-state plasma concentration of theophylline,  $m$  ( $l \mu\text{g}^{-1} \text{ml}$ ) represents the sensitivity of an individual to theophylline and the intercept  $i$  is the untreated, baseline FVC. FVC values were used to assess ventilatory response since they closely reflected the extent to which the small airways were unobstructed. This linear (straight line) model of the data was assumed to provide an adequate representation over the range of concentrations encountered in the study.


Using Bayesian probability theory and maximum likelihood estimation, Whiting and colleagues were able to predict the response of an individual to any steady-state concentration of theophylline, provided that the mean values of the parameters  $m$  and  $i$  were known in a representative population of patients with chronic bronchitis.

Assuming that all the parameters are normally distributed and independent and that all measurements are also independent, the most likely set of values of  $m$  and  $i$  for an individual is obtained by minimizing the function  $M$  where:

$$M = \frac{(m - m_{\text{mean}})^2}{\sigma_m^2} + \frac{(i - i_{\text{mean}})^2}{\sigma_i^2} + \sum_{j=1}^n \left( \frac{(\text{FVC}_j - \text{FVC}_{j\text{est}})^2}{\sigma_{\text{FVC}}^2} \right) \quad (4.14)$$

and where  $\sigma_m^2$  and  $\sigma_i^2$  are the variances of the parameters  $m$  and  $i$ ,  $\sigma_{\text{FVC}}^2$  is the estimated variance of FVC and  $\text{FVC}_{j\text{est}}$  is the expected value of  $\text{FVC}_j$  given by the equation:

$$\text{FVC}_{j\text{est}} = m \text{Cp}_{\text{ss}} + i \quad (4.15)$$



**Figure 4.17** Analysis of the time series home-monitored blood glucose data in terms of (a) trend, (b) cyclical, (c) random, and (d) seasonal components (adapted from Deutsch *et al.*, 1994).

and  $n$  is the number of paired  $FVC - C_{p_{ss}}$  measurements. The estimates of the parameters  $m$ ,  $\sigma_m^2$ ,  $i$  and  $\sigma_i^2$  were subsequently obtained using the program NONMEM developed by Beal and Sheiner (1979).

## 4.7 TWO VARIABLES CAUSALLY RELATED


The third category is that of using input/output experimental data in order to establish quantitative relationships between two variables that are causally related. The underlying mechanisms can be different. For instance, two hormones may have their secretion controlled by the same factor, or the secretion of a hormone (e.g. testosterone) is under the control of another hormone (luteinizing hormone), or the same gland may simultaneously release two hormones. Also, substrate-hormone interaction can produce hormone and substrate concentration time series which are correlated, e.g. in Figures 4.10 and 4.11 glucose and C-peptide concentrations.

### 4.7.1 Hormone/hormone and Substrate/hormone Series

Cross-correlation and cross-spectrum (i.e. finding the maxima of the Fourier transform of the cross-correlation function) have been intensively applied to understand correlation in hormone/hormone, e.g. testosterone/LH (Veldhuis *et al.*, 1987), LH/FSH (Veldhuis *et al.*, 1988), and substrate/hormone, e.g. glucose/C-peptide (Sturis *et al.*, 1991, 1992; O'Meara *et al.*, 1993a,b) concentration time series. These techniques suffer from a number of limitations, including those already mentioned, in discussing autocorrelation and spectral analysis for analyzing a single time series. In particular, the small number of data and measurement noise make results difficult to interpret. In addition, it is also possible that slow or large trends that are present in one of the series (or in both, but in opposite directions) can mask possible concordances of oscillations of smaller amplitude and period. Finally, a different measurement error in the two series may produce misleading results, e.g. if measurement error variance in one series is sufficiently large so that spurious oscillations due to noise are comparable to true oscillations in the other series.

Another available approach is the extension of the single series peak detection, i.e. one analyzes concordance of peak positions in the two series. Each series is analyzed separately with a peak detection algorithm, so that peak position and amplitude are obtained. Since concordance analysis only examines peak positions, usually one considers the two on-off quantized series (see Figure 4.18). However, these two series cannot be looked at as such, i.e. for each instantaneous event present in one or the other series, in both series or in none, because a number of coincidences can occur by chance (and this increases with pulse frequencies). The two on-off series can be analyzed with various techniques including a Monte Carlo simulation strategy (Clifton *et al.*, 1988) and an analytical approach which calculates a 'specific concordance' index (Guardabasso *et al.*, 1991).

There are some intrinsic limitations in peak concordance analysis. First, peak amplitudes can only play a minor role in the analysis, e.g. a very large peak in



**Figure 4.18** Time series of luteinizing (LH) and prolactin (PRL) hormone and their two-level quantized version: high level (On) when active secretion occurs and low level (Off) at all other times (adapted from Guardabasso *et al.*, 1990).

one series can easily be associated with a very small peak in the other series. Secondly, when concordance analysis, like cross-correlation or cross-spectral analysis, indicates a statistical concordance, this does not necessarily mean a functional concordance, i.e. two hormones may be functionally independent, but can exhibit a high concordance due to the presence of a component of the same frequency, e.g. ultradian.

Recently a new technique, cross-approximate entropy has been introduced (Pincus *et al.*, 1996b). An index (Cross-ApEn) is provided, which measures the degree of synchrony between two series belonging to the same endocrine-metabolic axis, e.g. two interacting hormones. The theory on which cross-approximate entropy is based is the same of that behind approximate entropy. While single series regularity measured by ApEn refers to some relation existing in the signal between different time instants, Cross-ApEn assesses the synchrony of two signals with higher values of Cross-ApEn associated with increasingly asynchronous series.

Let  $y = \{y(1), y(2), \dots, y(N)\}$  and  $z = \{z(1), z(2), \dots, z(N)\}$  be two  $N$ -size time series. By using parameters  $r$  (a real) and  $m$  (an integer) we can build the sequence of  $N - m + 1$   $m$ -dimension vectors:

$$x(i) = [y(i), \dots, y(i + m - 1)] \quad (4.16)$$

$$s(i) = [z(i), \dots, z(i + m - 1)] \quad (4.17)$$

and can define for each  $i$  ( $1 \leq i \leq N - m + 1$ ):

$$C_i^m(r)(y||z) = \frac{\# \text{ of } j \text{ for which } d[x(i)s(j)] \leq r}{N - m + 1} \quad (4.18)$$

where:

$$d[x(i)s(j)] = \max_{k=1,2,\dots,m} |y(i+k-1) - z(j+k-1)| \quad j = 1, \dots, N - m + 1 \quad (4.19)$$

The terms  $C_i^m(r)(u||v)$  denote the fraction of  $N - m + 1$  vectors  $s(j)$  similar (within a tolerance  $r$ ) to vector  $x(i)$  of similar lengths  $m$ . One can calculate the quantity:

$$\Phi^m(r)(y||z) = \frac{1}{N - m + 1} \sum_{i=1}^{N-m+1} \ln C_i^m(r)(y||z) \quad (4.20)$$

The meaning of  $\Phi^m(r)(y||z)$  is similar to  $\Phi^m(r)$  as defined in section 4.5.4.

Finally, Cross-ApEn is defined as:


$$\text{Cross-ApEn} = \Phi^m(r)(y||z) - \Phi^{m+1}(r)(y||z) \quad (4.21)$$

Cross-ApEn is a meaningful index if the two series have the same mean and variance; in fact, if the two means are different, it is not possible to evaluate an index of synchronism because samples in the two series would never have been close (the same applies to the variance). This is the way in which Cross-ApEn is calculated on standardized time series, i.e. the mean is subtracted from each sample of the series which is then divided by its standard deviation. As far as the parameters  $m$  and  $r$  are concerned, the same considerations made when discussing ApEn apply.

Cross-ApEn has been used to assess the relationship between two variables of the same endocrine-metabolic network, thus allowing one to detect possible derangements in their mode of interaction. For instance, in Pincus *et al.* (1996b) a reduction in the synchrony between LH and testosterone in aging has been quantified through Cross-ApEn (in aging both LH and testosterone series are also more irregular as shown by ApEn). In Sparacino and Cobelli (1998) the relationship between the glucose and C-peptide time series already discussed in section 4.5.4 has been studied with Cross-ApEn. Cross-ApEn results (see Figure 4.19) show that, in moving from normal metabolism to diabetes, there is a significant deterioration in the synchronism between glucose and C-peptide oscillations with derangement already present in pre-diabetes states such as obesity and impaired glucose tolerance. In other words, the efficiency of the control system is progressively deteriorating.

## 4.7.2 Urine Sodium Response to Water Loading

Let us now consider a set of time series data which relate water intake as the input and urine sodium as the output. Physiologically the data are of interest as they provide insight as to the manner in which sodium is selectively excreted in the control of total



**Figure 4.19** Cross-ApEn values (mean  $\pm$ SD) in normal, obese, impaired glucose tolerant (IGT) and type 2 diabetic subjects (adapted from Sparacino and Cobelli, 1998).

body water. Figure 4.20 shows these time series data with  $x_t$  being the water input and  $y_t$  the urine sodium output. The number of samples,  $n$ , is 100.

The ARIMA model is adopted (Flood and Carson, 1993) and the modeling package MINITAB used to assess the type and order of the input time series as an ARIMA process. MINITAB is a statistical software package (developed at Pond Laboratory, University Park, Pennsylvania 16802, USA), which supports this ARIMA modeling. The overall objective of an ARIMA modeling exercise is to build a model of a univariate time series, expressed in terms of past observations, and errors between current and past observations, so as to make predictions about a particular variable of interest, in this case urine sodium output.


As already discussed in section 4.5.2, an ARIMA process is conventionally written  $ARIMA(p, d, q)$ , where  $p$  refers to the autoregressive part of the process,  $q$  is the moving average part, and  $d$  relates to the number of differences that are needed to achieve stationarity of a set of time series data.

The essence of an ARIMA process is that we are integrating both autoregressive and moving average components. This means that a given observation in a time series generated by an  $ARIMA(p, d, q)$  process may be expressed in terms of past observations of order  $p$ , and current and past disturbances of order  $q$ , where the series has been filtered by differencing  $d$  times in order to achieve stationarity. So we have:

$$\begin{aligned}
 x_t = & (1 + \phi_1)x_{t-1} + (\phi_2 - \phi_1)x_{t-2} + \cdots + (\phi_p - \phi_{p-1}) \\
 & - \phi_p x_{t-p-1} + \mu + u_t - \theta_1 u_{t-1} - \cdots - \theta_q u_{t-q}
 \end{aligned}
 \tag{4.22}$$

Initially the data should be checked for outliers, replacing actual outlier values with their expected values if errors in the data are suspected. The correlogram of the raw data is then inspected and assessed for stationarity. If the series displays non-stationarity, the first differences of the series are taken and these are inspected and assessed. If stationarity has still not been achieved, then the second has been identified as the number of times the differences have to be taken to achieve stationarity.





**Figure 4.20** Time series plot of water intake and urine sodium output (adapted from Flood and Carson, 1993).

When stationarity has been achieved, and after the partial autocorrelation function has been calculated, the standard errors of the autocorrelation and partial autocorrelation functions are taken, so that the standard error values of these function plots can be assessed for significance. This enables an appropriate ARIMA process to be selected by identifying the time lags  $p$  and  $q$ .

In relation to our example here, if a correlogram were to be drawn it would show that the raw data decay slowly. A partial-autocorrelation plot would spike at lag 1 and then tail off. This would seem to suggest that we were dealing with an ARIMA(1, 0, 0) process. However, adopting an ARIMA(2, 0, 0) process, the estimate of  $\phi_2$  was significantly different from zero. Exploring possible higher order models by adding a  $\phi_3$  or  $\theta_1$  term made no significant difference on the basis of the t-ratios.

The sums of squares for ARIMA(1, 0, 0) and ARIMA(2, 0, 0) were not significantly different. Hence the ARIMA(2, 0, 0) process was adopted as a representation of the water input process.

The MINITAB package was then used to derive the final parameter estimates for  $\phi_1$  and  $\phi_2$ . Maximum likelihood estimation is used for this process (see Chapter 8). Using these estimates, a series of transformations, cross-correlations ( $r_{\alpha\beta}$ ), and impulse responses of urine sodium response were simulated. The standard error was assumed to be 0.1 ( $n^{-1/2}$  evaluated for  $n = 100$ ). The results of these simulations are shown in Table 4.1, in which  $k$  is the lag between input and output. If these results are then compared with examples given in the classic work of Box and Jenkins (1976), the model which best fits the data is that of  $(r, s, b) = (2, 1, 4)$ , that is:

$$(1 - \delta_1 B - \delta_2 B^2)y_t = (\omega_0 - \omega_1 B)x_{t-4} \quad (4.23)$$

where  $x_t$  and  $y_t$  are respectively the water input and urine sodium output.

**Table 4.1** Cross-correlation ( $r_{\alpha\beta}$ ), standard error (SE) and impulse response ( $v_k$ ) of urine sodium response to water intake represented by an ARIMA(2, 0, 0) process

k	0	1	2	3	4	5	6	7	8	9	10
$r_{\alpha\beta}$	0.03	0.13	-0.14	0.13	0.36	0.14	0.28	0.30	0.26	0.14	-0.14
SE	0.10	0.10	0.10	0.10	0.10	0.10	0.10	0.10	0.10	0.10	0.10
$v_k$	0.10	0.05	-0.05	0.05	0.13	0.09	0.10	0.11	0.10	0.05	-0.02

In order to complete this statistical transfer function model, it is necessary to add an appropriate noise model. Making use of techniques described in Box and Jenkins (1976), implemented in the MINITAB package, a second order noise model was postulated and its parameters estimated.

This example has shown how a simple model may be adequate as a means of providing an adequate input/output representation. However, successful application of this ARIMA modeling is critically dependent upon an adequate set of time series samples; here there were 100 samples. Whilst this number may often be adequate, a figure of 200 or more is usually needed to ensure a successful modeling outcome.

## 4.8 INPUT/OUTPUT MODELING FOR CONTROL


The next type of model considered is one that corresponds to explicit physiological control systems. Here models are to be formulated based on input/output experiments in order to obtain greater understanding in quantitative terms of the dynamics of such control systems. Examples are presented which include both a naturally occurring physiological control, such as the pupil light reflex, as well as situations corresponding to therapeutic control. One classic instance presented is that of insulin control of blood glucose in diabetes.

### 4.8.1 Pupil Control

An example for adopting a frequency response approach to modeling an input/output situation for control purposes is provided by the classical pupil light reflex study of Stark and Sherman, as described by Toates (1975).

The quantity of light reaching the retina is determined by the size of the pupil aperture. When the intensity of light is higher than desired, the pupil light reflex causes a contraction of the pupil so as to reduce the quantity of admitted radiation. Conversely, in dim illumination the aperture enlarges so that more light falls on the retina. This pupil light reflex was first modeled as a feedback control system by Stark and Sherman (1957).


A simplified representation of the system is shown in Figure 4.21. The controlled variable is the quantity of light falling on the retina,  $L_c$ . There is also a reference light flux variable,  $L_{REF}$ , with which  $L_c$  is compared. The difference, or error  $L_c - L_{REF}$ , is the signal that operates the control system.



**Figure 4.21** Simplified representation of the pupil light reflex system (adapted from Stark and Sherman, 1957).

The experimental technique by which data were obtained for the purpose of building a mathematical model of the system involved measuring light stimulus and pupil area. Stark and Sherman (1957) devised a method for opening the feedback loop without interfering with the system. This involved focusing the light stimulus so that the light entering the eye had a diameter that was smaller than the smallest diameter of the pupil. In this way any changes the pupil made were unable to influence the quantity of light falling on the retina. A disturbance was introduced at the output of the system by modulating the intensity of the light falling on the retina in a sinusoidal manner. The response in the form of changes to the pupil, were measured. By ensuring that only small test signals were employed, it was reasonable to assume that linear analytical techniques would be valid.

By carrying out this input/output experiment over a range of frequencies, the open-loop frequency response was obtained, depicted as a Bode diagram in Figure 4.22. From this frequency response it can be seen that the low frequency gain is 0.16 and that at high frequencies the gain falls off with a slope of  $-18$  db/octave. Since a single exponential lag is responsible for  $-6$  db/octave, Stark and Sherman estimated that



**Figure 4.22** Open-loop frequency response of the pupil light reflex (adapted from Stark and Sherman, 1957).


three such lag elements must be present, each having a time constant of approximately 0.1 s. Hence the transfer function model proposed to describe the open-loop characteristic of the pupil is:

$$G(s) = \frac{0.16 \exp(-0.18 s)}{(1 + 0.1 s)^3} \quad (4.24)$$

The term  $\exp(-0.18 s)$  is the Laplace representation of the pure delay of 0.18 seconds, 0.16 is the gain constant, and  $1/(1 + 0.1 s)$  represents a lag, of which there are three present.

## 4.8.2 Control of Blood Glucose by Insulin

In Type 1 diabetes pancreatic beta cell function is lost and must be replaced externally (see Figure 4.23), i.e. insulin must be infused exogenously. Advances in glucose sensing and the availability of fast-absorbing insulin analogs can potentially lead to a closed-loop insulin delivery system or ‘artificial pancreas’ based on a subcutaneous site for glucose sensing and insulin delivery. One important ingredient of the artificial pancreas is the algorithm for calculating insulin delivery rate based on glucose measurements.



**Figure 4.23** The glucose-insulin control system in a healthy (upper) and type 1 diabetic (lower panel) subject. In type 1 diabetes pancreatic beta cells do not secrete insulin, thus the ‘physiological’ controller must be replaced by an ‘external’ one.

Various approaches have been proposed which have been recently reviewed by Bequette (2005). Here we briefly discuss one relatively simple approach, based on an input/output model, the so-called proportional-integral-derivative controller, PID, which is widely employed in industrial control systems. The PID controller responds to glucose with three components: a proportional component (P) that reacts to the difference between measured glucose and basal glucose; an integral component (I) that reacts to persistent hyper- or hypo-glycemia; and a derivative component (D) that reacts to the rate of change in glucose. More precisely:

$$\text{PID}(t) = P(t) + I(t) + D(t); \quad \text{PID} \geq 0 \forall t \quad (4.25)$$

where:

$$P(t) = K_p(G(t) - G_B) \quad (4.26)$$


$$I(t) = \frac{K_p}{T_I} \int_0^t (G(t) - G_B) dt; \quad I(0) = I_{D_B} \quad (4.27)$$

$$D(t) = K_p T_D \frac{dG(t)}{dt} \quad (4.28)$$

$K_p$  determines the rate of insulin delivery in response to glucose above the target  $G_B$ ,  $T_I$  the ratio of proportional to integral delivery, and  $T_D$  the ratio of derivative to proportional delivery.

This model has been recently used in diabetic dogs to show the feasibility of closed-loop insulin delivery using the subcutaneous route (Pantaleon *et al.*, 2006).

PID parameters were fixed from pilot-dog studies and from knowledge of the total daily dose of insulin that each dog required for open-loop glucose control. Glucose concentration was measured frequently in plasma and continuous glucose concentration was calculated by linear extrapolation of measured values. Figure 4.24 shows the performance of the PID controller in a six hour experiment with a meal given at the 4th hour for three different values of the gain  $K_p$ . A stable meal response for a wide range of gain can be observed.




**Figure 4.24** Blood glucose (upper), plasma insulin (middle) and PID algorithm insulin delivery (lower panel) during 10 hour closed-loop control in diabetic dogs ( $n = 8$ ) for three values of gain ( $K_p$ ). Meal occurs at the 4th hour (adapted from Pantaleon *et al.*, 2006).

One can note that, while pre-prandial glucose values are very similar for the different gains, the peak post-prandial glucose decreases significantly as the gain increases (Figure 4.24, upper panel) due to a higher early-phase insulin delivery (Figure 4.24, lower panel) which produces a higher insulin concentration (Figure 4.24, middle panel).

### 4.8.3 Control of Blood Pressure by Sodium Nitroprusside


This example considers the situation in which the drug sodium nitroprusside is administered to lower the blood pressure of patients in hospital (Slate and Sheppard, 1982). Closed-loop control methods are adopted, so that the drug infusion rate should be adjusted based on frequent measurements of arterial blood pressure. Feedback is needed to maintain pressure near a desired value because of disturbances that perturb pressure, the changing state of the patient and the wide range of response characteristics generally found amongst a population of patients.

In this study an automatic control system is adopted, with mean arterial pressure being controlled by a nonlinear proportional plus integral plus derivative (PID) controller as depicted in Figure 4.25. For the purpose of testing and evaluating the design of the controller, a model of the arterial pressure related features of the patient was developed. Such a model enables computer simulation studies to be performed as part of the controller evaluation process.



**Figure 4.25** Automated system for the infusion of sodium nitroprusside using a nonlinear PID digital controller (adapted from Slate and Sheppard, 1982).

The model in this case is partly derived on the basis of experimental data, but also in part derived using some physiological and pharmacological concepts. Experimental data, for example, provide evidence of the patient's sensitivity to the drug and the lagged response resulting from uptake, distribution and biotransformation of the drug. The resulting patient model, represented in transfer function form, is shown in Figure 4.26. A pseudo-random binary signal was used to program the drug infusion rate and cross-correlation analysis was used to estimate the impulse response.



**Figure 4.26** Model of a post-surgical cardiac patient developed to test drug dynamic and control effects (adapted from Slate and Sheppard, 1982).

This model was then incorporated in a simulation schema to examine a range of dynamic and control effects associated with this drug therapy.

## 4.9 INPUT/OUTPUT MODELING: IMPULSE RESPONSE AND DECONVOLUTION

Another important input/output model is the impulse response of the system. The impulse response is not only useful for characterizing the system under study, but it is the key ingredient of the convolution integral. As we shall see, this forms the basis for solving by deconvolution a number of important inverse biomedical problems; that is to say estimating inputs to the system, e.g. the secretion rate of a gland, which cannot be directly measured *in vivo*.

### 4.9.1 Impulse Response Estimation


Consider the linear time-invariant dynamic system depicted in Figure 4.27. One can write the integral equation:

$$c(t) = \int_{-\infty}^t g(t - \tau)u(\tau)d\tau \quad (4.29)$$


where  $u(t)$ ,  $c(t)$  and  $g(t)$  denote the input, the output and the impulse response of the system, respectively. The function  $g(t)$  describes the input/output behavior of the system and is called the impulse response of the system. In fact,  $g(t)$  is the time course



of the output when the system is forced by a unitary pulse  $\delta(t)$ , the Dirac impulse, occurring at time zero.



**Figure 4.27** A linear time-invariant physiological system.  $g(t)$  is the impulse response,  $u(t)$  the input and  $c(t)$  the output.



**Figure 4.28** Plasma disappearance curve of a drug or a tracer after a unitary bolus at time 0 sampled at discrete times (open circles). The data are fitted with a two exponential model (continuous line).

The impulse response is a model of data which can be used to characterize the system. For instance, consider the disappearance curve of Figure 4.28 which may, for example, represent the disappearance of a drug or of a radioactive or stable isotope tracer of glucose injected as a unit bolus at time 0. One can fit the data say by a two exponential model:

$$g(t) = A_1 e^{-\alpha_1 t} + A_2 e^{-\alpha_2 t} \quad (4.30)$$

From knowledge of  $g(t)$  one can calculate some parameters of the system, e.g. the area under the curve, AUC:

$$\text{AUC} = \int_0^{\infty} g(t) dt \quad (4.31)$$

or the initial distribution volume,  $V$ :

$$V = \frac{D}{g(0^+)}$$

where  $D$  is the dose amount, or the clearance rate, CR:

$$\text{CR} = \frac{1}{\int_0^{\infty} g(t) dt} = \frac{1}{\text{AUC}} \quad (4.32)$$

Since the system is linear, one can also work, instead of in time, in the Laplace domain. From (4.29), one has:

$$C(s) = G(s) \cdot U(s) \quad (4.33)$$


where  $G(s)$  is the transfer function of the system.

The impulse response is not only a model of data that is useful *per se*, but also because it is the key ingredient for solving the convolution and deconvolution problems.

## 4.9.2 The Convolution Integral

The integral (4.29) is called the convolution integral, i.e.  $c(t)$  is the convolution of  $u(t)$  with  $g(t)$ . Thus, knowing  $g(t)$ , we can use convolution for predicting the output response  $c(t)$  for a variety of known inputs  $u(t)$ . For instance we could investigate administering the drug as a bolus at different times during the day with the goal of reaching and maintaining therapeutic levels of its concentration. This is a direct problem: knowing the input and the impulse response, to predict the output.

The most powerful use of the convolution integral is in tackling what in the mathematics/physics/engineering literature, is referred to as an inverse problem; that is, instead of following the cause-effect chain (direct problem), one follows the reversal of this chain. If the unknown signal is the input of the system, the inverse problem is an input estimation problem (Figure 4.29) which is solved by deconvolution. This is very important because many signals of interest for the quantitative understanding of physiological systems are not directly measurable *in vivo*. Some examples include the secretion rate of a gland, the production rate of a substrate, or the appearance rate of a drug in plasma after oral administration. Very often, it is only possible to measure the causally related effects of these signals in the circulation (e.g. the time course of plasma concentrations). Thus, there is the need of reconstructing the unknown causes (e.g. hormone secretion rate) from the measured effects (e.g. hormone plasma concentration).



**Figure 4.29** The input estimation problem: from knowledge of response of the system and of the output, e.g. plasma concentration, reconstruct the input, e.g. substrate production, hormone secretion rate or drug absorption rate.


### 4.9.3 Reconstructing the Input

Deconvolution is known to be *ill-posed* (i.e. the problem of reconstructing  $u(t)$  from the finite number of samples of  $c(t)$  does not permit a unique solution, and *ill-conditioned* (i.e. a small percentage error in the measured effect (e.g. hormone concentration in plasma) can produce a much greater percentage error in the estimated cause (e.g. secretion rate)). Moreover, dealing with physiological signals adds to the complexity of the problem, since they are often non-negative and sampled at a non-uniform and/or infrequent rate. We shall discuss these problems and how to solve them in Chapter 9. Here the focus is on the basic concepts, illustrating by way of examples the potential of deconvolution for solving important biomedical problems.


Let us consider some examples taken from Sparacino *et al.* (2001). Suppose we want to reconstruct insulin secretion rate from C-peptide concentration data (C-peptide is used instead of insulin because they are secreted equimolarly by the pancreas, but C-peptide does not, unlike insulin, undergo any extraction by the liver). In normal conditions, the pancreas releases C-peptide (and insulin) in an oscillatory fashion with at least two detectable modes: rapid pulses, with period between 8 and 15 min, which are superimposed on to slower and larger oscillations, named ultradian oscillations, whose period ranges between 90 and 150 min. If glucose concentration increases rapidly, for instance during an intravenous glucose tolerance test, the spontaneous oscillations are obscured by the response of the pancreas. A sudden and large secretory peak (first phase) is followed by a smooth release (second phase). The pancreatic secretion is not directly measurable and the only available information is the plasma concentration of C-peptide. Figure 4.30 (upper panel) shows the C-peptide plasma concentration measured every 20 minutes for 12 hours in a normal subject (Sturis *et al.*, 1991).

The ultradian oscillatory pattern of the secretion (i.e. the cause) is evident from the measured concentration (i.e. the effect). The sampling rate is, however, insufficient to reveal the rapid pulses. Figure 4.30 (lower panel) depicts the C-peptide plasma concentrations non-uniformly sampled for four hours in a normal subject during an intravenous glucose tolerance test (IVGTT) (Shapiro *et al.*, 1988). The time series clearly reflects the biphasic response of the pancreas to the glucose stimulus. For both cases, since C-peptide kinetics are linear, the problem of reconstructing C-peptide (insulin) secretion rate (i.e. the input of Figure 4.29) from the C-peptide plasma concentrations (i.e. the output of Figure 4.29) is a deconvolution problem. To solve it, the impulse response of the system is required. In the C-peptide case, an *ad hoc* experiment can be performed in the same individual on a separate occasion. After suppressing the spontaneous pancreatic secretion by means of a somatostatin infusion, an intravenous bolus of C-peptide is administered and plasma concentration samples are collected frequently.

The impulse response  $g(t)$  is obtained by fitting a sum of two exponentials to the data by nonlinear least squares. A representative data set (Shapiro *et al.*, 1988) with the model fit is reported in Figure 4.31. Now, looking at (4.29), we know  $c(t)$  and  $g(t)$  and need to estimate  $u(t)$ . By using the techniques discussed in Chapter 9, we can reconstruct insulin secretion for the two experimental situations of Figure 4.30.




**Figure 4.30** C-Peptide plasma concentration time series. Upper panel: Spontaneous ultradian oscillations. Lower panel: Intravenous glucose tolerance test (IVGTT) (adapted from Sparacino *et al.*, 2001).



**Figure 4.31** The C-peptide impulse response. A bolus of C-peptide is administered at time 0 (endogenous secretion has been suppressed) and plasma concentration is frequently sampled (open circles). A sum of two exponentials is fitted against the data (continuous line) (adapted from Sparacino *et al.*, 2001).

Results are shown in Figure 4.32: the left panels show the reconstructed insulin secretion (upper panel: ultradian oscillations; lower panel: intravenous glucose tolerance test) while the right panels show the corresponding reconvolution, i.e. with the estimated  $u(t)$ , knowing  $g(t)$ , we can solve (4.29) for  $c(t)$ .




**Figure 4.32** Estimation of insulin secretion rate by deconvolution. Left panels: Ultradian oscillations (upper) and IVGTT (lower). Right panels: Ultradian oscillations (upper) and IVGTT (lower) reconvolution against data (adapted from Sparacino *et al.*, 2001).

Another problem, which could be tackled similarly to the one discussed above, would be to use deconvolution on the C-peptide time series of Figure 4.10 to quantitatively assess the derangement of the physiological control system in diabetes.


A further application is to study hormone secretion after a hormonal stimulus. For instance, an injection of growth hormone releasing hormone (GHRH) is given to adolescents to assess the ability of the pituitary gland to properly secrete growth hormone (GH). Plasma concentrations of GH are measured for 2 h following the stimulus (Figure 4.33). By using the GH impulse response we can thus reconstruct the GH secretion rate, thus being better informed with regard to designing a hormonal therapy that favors a normal growth.

A final example concerns the use of deconvolution to reconstruct the rate of appearance in plasma of a drug taken orally or injected subcutaneously. This could enable therapy to be optimized, or drug design enhanced, by improving the mechanisms by which the drug is absorbed and released. The only measurements available are those of the drug in plasma (e.g. after an oral administration) (Figure 4.34, upper panel). By using deconvolution we can reconstruct the drug rate of appearance (Figure 4.34, lower panel), thus estimating a non-measurable key ingredient for therapy or drug design.

We conclude by noting that there are a number of biomedical applications of deconvolution, including hormone secretion/substrate production (Pilo *et al.*, 1977; Polonsky *et al.*, 1986; Veldhuis *et al.*, 1987; Caumo and Cobelli, 1993; De Nicolao and Liberati, 1993; De Nicolao *et al.*, 1995; Sparacino and Cobelli, 1996, 1997;



**Figure 4.33** Plasma concentration of growth hormone (GH) after a bolus of growth hormone releasing hormone (GHRH) at time 0 (adapted from De Nicolao *et al.*, 1995).



**Figure 4.34** Estimation of the rate of appearance of a drug in plasma. Upper panel: Plasma concentration of the drug after an oral administration at time 0. Lower panel: The pharmacokinetic system. From knowledge of drug plasma concentration  $c(t)$ , and its distribution and metabolism (the impulse response,  $g(t)$ ), it is possible to reconstruct by deconvolution the drug rate of appearance in the circulation.

Sartorio *et al.*, 1997); pharmacokinetics (Cutler, 1978; Dix *et al.*, 1986; Gillespie and Veng-Pedersen, 1985; Iga *et al.*, 1986; Cobelli *et al.*, 1987; Charter and Gull, 1991; Tett *et al.*, 1992; Verotta, 1996; Hovorka *et al.*, 1998; Vicini *et al.*, 1999; Pillonetto *et al.*, 2001); radiography (Hunt, 1971); tracer data processing (Commenges and Brendel, 1982; Bates, 1991; Sparacino *et al.*, 1997); and transport through organ studies (Bassingthwaight *et al.*, 1966; Knopp *et al.*, 1976; Nakai, 1981; Bronikowsky *et al.*, 1983; Clough *et al.*, 1993; Sparacino *et al.*, 1998).

## 4.10 SUMMARY

This chapter has examined in some detail the process of modeling experimental data. Four cases have been examined, namely: modeling a single variable occurring spontaneously; modeling a single variable in response to a perturbation; modeling two variables that are causally related; and input/output modeling for control. A range of examples has illustrated these four cases. Both time and frequency domain approaches to modeling have been demonstrated. The basis of convolution and deconvolution has also been outlined. The next chapter will go on to illustrate approaches to model formulation, where the aim is to produce mathematical formalisms corresponding to the underlying physical and chemical mechanisms that are the basis of physiological systems.

## 4.11 EXERCISES AND ASSIGNMENT QUESTIONS

1. Discuss the nature of the relationship between physiological measurement and data modeling.
2. Data modeling can be applied to either a single variable or to two inter-related (input/output) variables, with or without control. Give some examples for each of these different situations.
3. Plasma concentrations of hormones exhibit a spontaneous cyclic behavior. Which are the most powerful modeling methods to analyze hormonal time series?
4. Input/output models are often needed either to understand quantitatively naturally occurring control in physiological systems, or to control a severely diseased physiological system. Give an example for each case.
5. The impulse response of the system is the key ingredient of the convolution integral. Define the deconvolution problem and discuss why it is important in physiology and medicine by also giving some examples.

# 5 MODELING THE SYSTEM

## Chapter Contents

### **5.1 Introduction**

### **5.2 Static Models**

### **5.3 Linear Modeling**

- 5.3.1 The Windkessel Circulatory Model
- 5.3.2 Elimination from a Single Compartment
- 5.3.3 Gas Exchange
- 5.3.4 The Dynamics of a Swinging Limb
- 5.3.5 A Model of Glucose Regulation

### **5.4 Distributed Modeling**

- 5.4.1 Blood-tissue Exchange
- 5.4.2 Hepatic Removal of Materials
- 5.4.3 Renal Medulla

### **5.5 Nonlinear Modeling**

- 5.5.1 The Action Potential Model
- 5.5.2 Enzyme Dynamics
- 5.5.3 Baroreceptors
- 5.5.4 Central Nervous Control of Heart Rate
- 5.5.5 Compartmental Modeling
- 5.5.6 Insulin Receptor Regulation
- 5.5.7 Insulin Action Modeling
- 5.5.8 Thyroid Hormone Regulation
- 5.5.9 Modeling the Chemical Control of Breathing

### **5.6 Time-varying Modeling**

- 5.6.1 An Example in Cardiac Modeling

### **5.7 Stochastic Modeling**

- 5.7.1 Cellular Modeling
- 5.7.2 Insulin Secretion
- 5.7.3 Markov Model

### **5.8 Summary**

### **5.9 Exercises and Assignment Questions**



## 5.1 INTRODUCTION

In the previous chapter, it was shown how models could be developed in such a way as to provide a correspondence with available physiological data. In essence the objective was to produce a mathematical expression which was capable of describing the available data. In such situations successful modeling would be characterized primarily by a good fit of the model to the data (or of the data to the model, depending on one's perspective). However, such models do not necessarily correspond explicitly to the relevant underlying physiology.

Where there is a need for the model to correspond to the relevant physiology, then some other means of modeling is required. This is the theme of this chapter. The aim is to describe approaches to modeling the physiology (which can be regarded as the system of interest). It will be shown that this can be done at a number of levels. The particular approach to be adopted depends upon the available *a priori* knowledge that is available, and the extent to which it is reasonable to make simplifying assumptions regarding the physiology.

A number of approaches will be compared and contrasted. Comparisons will be made of static and dynamic, deterministic and stochastic, time-invariant and time-varying, lumped and distributed, linear and nonlinear, and continuous and discrete forms. Between them these represent different levels of complexity of models. However, we shall begin with the simple static case and then systematically progress to more complex forms of dynamic representation.

## 5.2 STATIC MODELS

Let us begin by considering a static model; that is to say a model of a system in which there is no change occurring over a period of time.

In the circulatory system, a relationship can be developed between the rate at which blood flows through a blood vessel and the pressure drop along that length of blood vessel. For simplicity, assume that there is a steady volume flow  $Q$  of blood along a blood vessel which is treated as being rigid, where the pressure drop along its length ( $L$ ) is  $P$ , and let the internal diameter of the vessel be  $D$ . Then, given the assumptions stated above, the relationship between flow and pressure can be expressed as:

$$Q = \frac{KPD^4}{L} \quad (5.1)$$

where  $K$  is the parameter which creates the equality. In fact,  $K$  varies with the viscosity of the fluid (in this case blood), which means that (5.1) can be re-written as:

$$Q = \frac{(P_1 - P_2)\pi r^4}{8\rho L} \quad (5.2)$$

$P_1$  and  $P_2$  are the pressures at the two ends of the blood vessel,  $r$  is the internal radius and  $\rho$  is the viscosity of the blood. In other words, the ratio of the mean pressure


gradient to mean flow is a measure of the extent to which the system *resists* flow. We can term this ratio as the *vascular resistance*  $R$  where:

$$R = \frac{8\rho L}{\pi r^4} \quad (5.3)$$

Therefore, we can write the relation between pressure and flow as:

$$(P_1 - P_2) = RQ \quad (5.4)$$

Hence from measurement of mean values of pressure and flow, the resistance can be calculated. In the context of the circulatory system, if  $P_1$  is the mean ascending aortic pressure,  $P_2$  is venous pressure, and  $Q$  is the mean aortic flow (cardiac output), then  $R$  represents the total systemic peripheral resistance. If, in this model, the assumption can be made to neglect the effect of venous pressure (since it is only a few mm Hg), then an estimate of the total peripheral resistance can be obtained from the ratio of mean ascending aortic pressure and cardiac output. This linear relationship is depicted in graphical form in Figure 5.1.



**Figure 5.1** Graphical representation of a linear relationship between blood pressure,  $P$ , and blood flow,  $Q$ .

The linear model above is a particular case of the more general model which states that pressure  $P$  is a function of flow  $Q$ . This can be expressed mathematically as:

$$P = f(Q) \quad (5.5)$$

where  $f( )$  represents a general form of functional relationship.

In the case of the flow of air in the respiratory system, a linear model relationship between pressure and flow only applies in the case of laminar flow of air. Where there is turbulent flow, the resistance to flow is no longer a constant, but is now a function of gas flow:

$$R = R_0 + R_1(Q) \quad (5.6)$$

$R_0$  corresponds to the value of resistance at zero flow and  $R_1(\ )$  is the general nonlinear functional relationship defining the manner in which the resistance in the steady state increases with increase in air flow.

The turbulent flow which occurs in the upper respiratory tract at high flow rates, such as occur in the case of mechanical ventilation, can be reasonably approximated by a model of the form:

$$P = R_0Q + R_1Q^2 \quad (5.7)$$

This model is nonlinear, since in addition to the first term  $R_0Q$  – which is linear – there is a second term in which there is a component of pressure proportional to the square of the flow  $R_1Q^2$ .

Another example of a static, nonlinear model is provided by the Michaelis-Menten equation. This describes the steady-state (static) condition of an enzyme-controlled chemical reaction, the model being of the form:


$$v = \frac{V_{\max}s}{(K_m + s)} \quad (5.8)$$

The variable  $v$  is the rate or velocity, or flux, of the chemical reaction in the steady state and  $s$  is the concentration of the chemical substrate involved in the reaction. Two parameters characterize the effects of the enzyme involved in the reaction.  $V_{\max}$  is the maximal rate of the chemical reaction as the concentration of the substrate becomes very large and tends towards infinity. The second parameter ( $K_m$ ), corresponds to the concentration of chemical substrate  $s$  for which the reaction velocity would be half of the maximum value of  $V_{\max}$ . It can be seen that this model is nonlinear, since a doubling of the value of the substrate concentration  $s$  does not result in a doubling of the reaction of the chemical velocity  $v$ . The nonlinear nature of this model relationship is shown graphically in Figure 5.2 where, in effect, the steady-state reaction velocity or flux saturates towards its maximal value as the substrate concentration tends towards infinity.


However, if one examines the form of this model as it would apply in the case of low values of substrate concentration, the relationship approximates to one in which the reaction velocity is directly proportional to the substrate concentration. In other words, for small values of  $s$ , the denominator of (5.8) approximates to  $K_m$ , since  $s$  is small compared to  $K_m$ , and so the model equation for reaction velocity can be written as:

$$v = \frac{V_{\max}s}{K_m} \quad (5.9)$$

Under appropriate conditions, this is an example of being able to approximate a full nonlinear model by a linear one. It should be noted, however, that this model is only valid for small values of substrate concentration. Graphically, this linearized model would give rise to the relationship shown in Figure 5.3.



**Figure 5.2** Nonlinear relationship between chemical flux and the concentration of the chemical substrates.



**Figure 5.3** Linearized relationship between chemical flux and substrate concentration.

### 5.3 LINEAR MODELING

Whilst analysis of the steady-state condition can provide some useful information regarding the characteristics of a physiological system, the extent of this information is necessarily limited. More often than not, one would wish to have some knowledge of the manner in which a particular system responds to a stimulus, not just being limited to knowledge of the final state that one or more of the variables ultimately achieve. This means that we must move from a static view of the world to one in which we examine the richness of dynamic behavior that a system may exhibit.

As we have already seen, a model is by definition an approximation of a system in terms of its representation. In other words, in modeling the dynamics of a system a number of assumptions are going to be made, and it is important that such assumptions should be made in an explicit manner. To begin with let us consider the simplest case. We shall assume that our system can be treated as being deterministic, linear and time-invariant (that is to say, that the parameters are constant, rather than changing in some way over time). Furthermore, effects which in reality may be spatially distributed are treated as if they could be lumped together in a way

which removes the need for this spatial dimension. As a first example we shall derive a simple dynamic model to represent a portion of the circulatory system.

### 5.3.1 The Windkessel Circulatory Model


In the windkessel model, the arteries are treated as if they comprise an elastic reservoir with fluid storage capacity. The compliance of this reservoir is assumed to represent the total arterial compliance. The term compliance is the parameter that specifies the elastic nature of the blood vessels. It is defined as the incremental change in volume that would result from an incremental change in pressure. In other words:

$$C = \frac{\Delta V}{\Delta P} \quad (5.10)$$

where  $C$  is compliance,  $\Delta P$  is the change in pressure and  $\Delta V$  is the change in the volume.

In terms of Figure 5.4, blood enters the arterial reservoir as a result of ventricular ejection from the heart, and flows out at the other end of the reservoir through the peripheral resistance. A mathematical model of these dynamics can be formulated as follows. The input flow into the arterial system  $\dot{Q}_{in}(t)$ , is equal to the sum of the outflow  $\dot{Q}_{out}(t)$ , of blood from the arterial system into the venous system and the rate  $dV/dt$  of storage (the continuity equation):

$$\dot{Q}_{in}(t) = \frac{dV(t)}{dt} + \dot{Q}_{out}(t) \quad (5.11)$$



**Figure 5.4** Representation of a portion of the circulatory system depicting the flow of blood from the left ventricle of the heart into the systemic circulation.

If one makes the assumption that there is a linear relationship between pressure and volume, then the total arterial compliance  $C$  will be constant throughout a heart beat.

$$C = \frac{dV(t)}{dP(t)} \quad (5.12)$$

Assuming that the outflow  $\dot{Q}_{\text{out}}(t)$  can be assumed to be proportional to the arterio-venous pressure difference  $P(t)$  then:

$$\dot{Q}_{\text{out}}(t) = \frac{P(t)}{R} \quad (5.13)$$

where  $R$  is the total peripheral resistance. Substituting (5.12) and (5.13) into (5.11) yields:

$$\dot{Q}_{\text{in}}(t) = C \frac{dP(t)}{dt} + \frac{P(t)}{R} \quad (5.14)$$

Since there is flow into the arterial system only during ventricular systole,  $\dot{Q}_{\text{in}}(t)$  is zero in diastole. If we define  $t^*$  as the time at which ventricular ejection ends, and let  $T$  be the total duration of a cardiac cycle, the dynamic behavior of the system during any time interval during diastole can be described by:

$$C \frac{dP(t)}{dt} + \frac{P(t)}{R} = 0, \quad t^* < t < T \quad (5.15)$$

The solution of this equation is:

$$P(t) = P^* \exp \left[ -\frac{(t - t^*)}{\tau} \right], \quad t^* < t < T \quad (5.16)$$

where  $\tau = RC$ .

In other words, given the assumption that ascending aortic flow is zero during diastole, the windkessel model describes the diastolic aortic pressure decay as a mono-exponential function with a time constant  $\tau$ , equal to the product of arterial compliance and peripheral resistance. An estimate of  $\tau$  can be made from fitting an exponential function to the plot of diastolic pressure decay. If cardiac output is measured, peripheral resistance can be computed from the ratio of mean pressure to cardiac output. Eventually, the ratio  $\tau/R$  yields an estimate of the compliance  $C$ . Equation (5.16) is an example of the exponential response as a function of time that is the solution to any first order, linear differential equation model.

### 5.3.2 Elimination from a Single Compartment

As a further example of a simple dynamic model, consider the elimination of a drug from the bloodstream. As an approximation it will be assumed that the bloodstream can be considered to be a single compartment, in which the drug is uniformly distributed. In other words, the concentration of the drug will be the same at all points within this bloodstream compartment. If the drug has been injected into the bloodstream, this assumption that there is a uniform concentration corresponds to neglecting the rapid mixing effects of the drug which would occur immediately

following injection. Mathematically we can describe this model as follows:

$$\frac{dQ(t)}{dt} = -p_1 Q(t) + U(t), \quad Q(0) = 0 \quad (5.17)$$

$$C(t) = \frac{Q(t)}{V} \quad (5.18)$$

In equation (5.17), the variable  $Q$  represents the mass of drug in plasma as a function of time. The input variable  $U(t)$  is the mass of drug input into the bloodstream again as a function of time. The parameter  $p_1$  is the estimated fractional rate constant for the drug, and  $V$  is the plasma distribution volume. In other words this equation states that the rate of change of mass of the drug is given by the difference between the flux of drug out of the compartment (the first term on the right-hand side of the equation) and the flux of drug into the compartment (the second term). The initial condition of this equation  $Q(0)$  is the mass of drug in the compartment at time zero.

For any value of input function  $U(t)$ , the general solution of this pair of (5.17) and (5.18) can be shown to be the convolution integral:

$$C(t) = \frac{1}{V} \int_0^t \exp(-p_1(t - \tau)) U(\tau) d\tau \quad (5.19)$$

However, a simpler solution is obtained for the case where the drug is introduced rapidly as a brief pulse of unit magnitude, that is it approximates to a unit impulse,  $U(t) = \delta(t)$ . Now the solution becomes:

$$C(t) = \frac{1}{V_1} \exp(-p_1 t) \quad (5.20)$$

which is a single exponential decay characteristic of the response to an impulse for a lumped, linear, time-invariant, deterministic first order system.

### 5.3.3 Gas Exchange

As a further example of simple linear dynamic modeling, let us consider the process of gas exchange between the alveolus of the lung and the blood capillary (Flenley and Warren, 1988). This takes place by passive diffusion across the alveolar-capillary membrane down a concentration gradient. For an inert solute in a single solvent, diffusion can be described by Fick's Law as follows:

$$\frac{\Delta Q}{\Delta t} = -dA \frac{\Delta C}{l} \quad (5.21)$$

where the quantity of solute  $\Delta Q$  diffusing per unit time  $\Delta t$  is a function of the cross-sectional area  $A$  and distance  $l$  over which diffusion is occurring. The concentration gradient is  $\Delta C$ , and the diffusion coefficient is  $d$ , a physical rate constant which is dependent on properties of the system such as the molecular weight of the solute and

the temperature and viscosity of the solvent. The quantity of the substance which is dissolved in the surface layers of the alveolar-capillary membrane, and hence the concentration gradient across the membrane, are determined by the product of the partial pressure of the substance in the adjoining compartment (alveolar or capillary) and the solubility coefficient  $\alpha$ , for the substance in the membrane. Hence, we can re-write Fick's Law as follows:

$$\frac{\Delta Q}{\Delta t} = - \left[ dA \frac{\alpha}{l} \right] [P_A - P_C] \quad (5.22)$$

where  $P_A$  and  $P_C$  are the partial pressures that are exerted by the gas in the alveoli and capillaries respectively.

It might seem intuitively obvious that a thickening of the alveolar-capillary membrane; that is to say an increase in  $l$ , as can occur as a result of a disease process, should reduce the rate of diffusion. This would suggest that measurement of the rate of diffusion would be a useful diagnostic tool. However, there are a number of complications when it comes to applying this simple Fick's Law Model to the lungs. First, the alveolar-capillary membrane consists of a layer of alveolar epithelial cells and capillary endothelial cells, both of which have a basement layer which in some areas are fused together, whilst in others are separated by a narrow interstitium. Hence the use of a single solubility coefficient cannot be justified. Moreover, the gases in question are not inert, but do in fact combine with haemoglobin in the capillary red blood cells. As such, the assumption that this chemical interaction is infinitely rapid and does not provide a rate limiting step in the gas exchange process is probably not valid. Finally, the total area involved in gas exchange and the thickness of the alveolar-capillary membrane vary with the degree of inflation of the lungs and cannot readily be measured. Hence, in clinical practice the term  $-d\alpha A/l$  is replaced by the single term  $D$ , which is defined as the diffusing capacity of the lungs. Fick's equation can therefore be re-written as:

$$\frac{\Delta Q}{\Delta t} = D(P_A - P_C) \quad (5.23)$$


This is the standard first order linear model which is widely adopted in respiratory measurement.

### 5.3.4 The Dynamics of a Swinging Limb

The next example is that of a freely swinging human limb. Specifically, let us consider the situation in which the leg swings freely under the action of gravity, after its release from contact with the ground in its rearward position by raising the toe. This situation, depicted in Figure 5.5, is the basis of the mathematical model that has been developed by Milsum (1966).

The model described here makes a number of simplifying assumptions. For instance, the complexities of leg shortening and hip raising necessary for the heel to be able to clear the ground are excluded. Equally the focus is on the controlled





**Figure 5.5** Model of swinging limb (adapted from Milsum, 1966).

system, which means that the controlling effects arising from the neuromuscular feedback loops of the antagonistic pairs of effector muscles are not considered.

The angular motion of the leg is based on Newton's second law of motion:

$$T = J \frac{d^2\theta}{dt^2} = J \frac{d\omega}{dt} \quad (5.24)$$

where  $T$  = net torque, or turning moment about the axis of rotation;  $J$  = moment of inertia of the accelerating body about this axis;  $\theta$  = angle of rotation; and  $\omega$  = angular velocity of rotation.


As a further simplifying assumption in the modeling process, the leg will be assumed to be a stiff uniform cylinder as shown in Figure 5.6 with the dimensions of:

$$\text{Length, } L = 90 \text{ cm; diameter, } d = 12 \text{ cm; and density, } \rho = 1.1 \text{ g cm}^{-2} \quad (5.25)$$

from which: Volume,  $V = (\pi/4)d^2L = 10,300 \text{ cm}^3$ , and mass,  $m = \rho V = 11.5 \text{ kg}$ , which approximates to a typical value for a 70 kg male subject despite the simplifying assumptions which have been made.

If it is further assumed that there are neither viscous nor nonlinear retarding torques due to joint stiffness, air friction, tissue deformation, etc. then the net torque is only that resulting from the forces of gravity. This net torque is thus equal to the product of the leg-weight component perpendicular to the leg ( $mg \sin \theta$ ) and the moment arm  $L/2$ , as shown in Figure 5.6:

$$T = -mg \frac{L}{2} \cdot \sin \theta \quad (5.26)$$



**Figure 5.6** The leg modeled as a stiff uniform cylinder (adapted from Milsum, 1966).

The right-hand term of equation (5.24) is termed the *inertia torque* which may be evaluated using the moment of inertia of the thin-cylindrical leg swinging about its hip joint:

$$J = \frac{mL^2}{3} \quad (5.27)$$

Substituting (5.26) and (5.27) into equation (5.24) leads to the following second order differential equation of motion:

$$\frac{d^2\theta(t)}{dt^2} + \left(\frac{3g}{2L}\right) \sin\theta(t) = 0 \quad (5.28)$$

Due to the presence of the term  $\sin\theta$ , equation (5.28) is in fact nonlinear. However, the equation may be linearized if the deflections of the limb may be considered as being small, in which case  $\sin\theta$  is approximately equal to  $\theta$  (where  $\theta$  is measured in radians).


Milsum (1966) had assessed the error associated with making such a small deflection, linearizing assumption. For a leg of length 90 cm, and with a half pace of 38 cm,  $\theta$  is equal to 0.4 radians, whereas  $\sin\theta$  would be 0.39 radians. This implies a maximum error arising from this assumption of 2.5%, with the average error being much

less than this figure. Hence equation (5.28) becomes:

$$\frac{d^2\theta}{dt^2} + \left(\frac{3g}{2L}\right)\theta = 0 \quad (5.29)$$

Solving this equation yields a sinusoidally varying pattern of angular position of the swinging limb, without there being any damping of the oscillations. In other words, the solution of this equation would correspond to unending sinusoidal oscillation as shown in Figure 5.7. In reality, however, there are of course energy dissipation effects during working, which in the model can be included in the form:

$$T_b = -b\frac{d\theta}{dt} \quad (5.30)$$



**Figure 5.7** Dynamics of swinging limb model (adapted from Milsum, 1966).

This simple linear representation is, of course, an approximation to what in practice is probably a more complex effect. The negative sign indicates that this torque opposes the motion. This viscous friction causes the oscillatory response as depicted in Figure 5.7 to decay, as shown by the dashed line, towards the terminal state of zero energy stored in the system. In steady walking the relevant muscles in the leg must pump in enough energy to make up for this viscous dissipation as well as providing the various forces required in relation to posture which this simple model formulation has neglected (Milsum, 1966). It is therefore necessary to add an appropriate torque,  $T_m(t)$ , as a function of time, so that equation (5.24) becomes:

$$T_m - b\frac{d\theta}{dt} - mg\left(\frac{L}{2}\right)\theta = J\frac{d^2\theta}{dt^2} \quad (5.31)$$

or


$$J\frac{d^2\theta(t)}{dt^2} + b\frac{d\theta(t)}{dt} + k\theta(t) = T_m(t) \quad (5.32)$$

where the gravity coefficient has been defined as a generalized spring constant  $k = mg(L/2)$ . This equation represents a basic second order linear system with an input

forcing function and viscous damping in addition to the inertia and spring effects of the system modeled as equation (5.29). From an energy perspective, the spring stores potential energy, the inertia stores kinetic energy, and the viscous damping dissipates both.

### 5.3.5 A Model of Glucose Regulation

The glucose regulatory system is a classic negative feedback system (Figure 5.8) maintaining glucose homeostasis. When blood glucose concentration increases after a perturbation, e.g. a meal, an oral glucose tolerance test or an intravenous infusion of glucose, the beta cells of the pancreas secrete more insulin. The resulting increased plasma level of insulin, in turn, enables blood glucose to return to its basal concentration by enhancing glucose utilization by the tissues and inhibiting endogenous glucose production.



**Figure 5.8** The glucose regulatory system depicted as a classic negative feedback system.

Let us assume that the glucose and insulin systems are each describable by a single compartment representation with, respectively, substrate and hormonal fluxes entering and outgoing from the compartment (Figure 5.9). The next step then is to detail the control signals from the glucose to the insulin system and from the insulin to the glucose system. A general scheme depicting the glucose and insulin fluxes of material and the control signals following a glucose perturbation is shown in Figure 5.10. The model equations are:


$$\dot{Q}_1(t) = P(Q_1, Q_2) - U(Q_1, Q_2) + J(t) \quad Q_1(0) = Q_{10} \quad (5.33)$$

$$\dot{Q}_2(t) = S(Q_1, Q_2) - D(Q_2) \quad Q_2(0) = Q_{20} \quad (5.34)$$


$$C_1(t) = \frac{Q_1(t)}{V_1} \quad (5.35)$$

$$C_2(t) = \frac{Q_2(t)}{V_2} \quad (5.36)$$

where  $Q_1$  and  $Q_2$  denote glucose and insulin masses respectively, with the suffix 'o' denoting the basal state;  $P$  and  $U$  are respectively glucose production and utilization



**Figure 5.9** The glucose regulatory system depicting the compartmental structure of controller and controlled system.



**Figure 5.10** Glucose and insulin fluxes and their control following a glucose perturbation  $J$ . The measured concentrations of glucose  $C_1$  and insulin  $C_2$  are also shown.

assumed to be functions of  $Q_1$  and  $Q_2$ ;  $J$  is the glucose input which can be either an intravenous injection or infusion or the absorption rate of glucose during a meal or an oral glucose tolerance test;  $S$  and  $D$  are insulin secretion and degradation assumed to be functions of  $Q_1$ ,  $Q_2$  and  $Q_2$  only, respectively;  $V_1$  and  $V_2$  are the glucose and insulin distribution volumes.

The pioneering model of the glucose regulatory system developed by Bolie (1961), which we describe below, is a linearized version of the model described by (5.33)–(5.36). To arrive at this model one can write:

$$P(Q_1, Q_2) = P_0 - \alpha Q_1 - \beta Q_2 \quad (5.37)$$

$$U(Q_1, Q_2) = U_0 + \gamma Q_1 + \delta Q_2 \quad (5.38)$$

$$S(Q_1, Q_2) = S_0 + \varepsilon Q_1 - \eta Q_2 \quad (5.39)$$

$$D(Q_2) = D_0 - \mu Q_2 \quad (5.40)$$

where  $\alpha, \beta, \gamma, \delta, \varepsilon$  and  $\mu$  are rate parameters  $\geq 0$  (the ‘minus’ and ‘plus’ signs in (5.37)–(5.40) denote the modalities of glucose-insulin control, e.g. insulin secretion is stimulated by glucose and inhibited by insulin) and  $P_0, S_0, U_0$  and  $D_0$  denote values in the basal state.

By defining the variables which represent the deviation of glucose and insulin from their basal values:

$$q_1 = Q_1 - Q_{10} \quad (5.41)$$

$$q_2 = Q_2 - Q_{20} \quad (5.42)$$

one has:

$$\dot{q}_1(t) = -p_1 q_1(t) - p_2 q_2(t) + J(t) \quad q_1(0) = 0 \quad (5.43)$$

$$\dot{q}_2(t) = -p_3 q_2(t) + p_4 q_1(t) \quad q_2(0) = 0 \quad (5.44)$$

$$c_1(t) = \frac{q_1(t)}{V_1} \quad (5.45)$$

$$c_2(t) = \frac{q_2(t)}{V_2} \quad (5.46)$$

where  $p_1 = \alpha + \gamma$ ;  $p_2 = \beta + \delta$ ;  $p_3 = \eta + \mu$ ;  $p_4 = \varepsilon$ .

This linear model has been used in conjunction with intravenous injections or infusions (Bolie, 1961; Segre *et al.*, 1973; Ceresa *et al.*, 1973) and also during an oral glucose tolerance test (Ackerman *et al.*, 1964; Gatewood *et al.*, 1968a,b) to obtain a four-parameter portrait the glucose regulation system in various states of glucose intolerance including diabetes. For the intravenous inputs one has  $J(t) = D \cdot \delta(t)$  for the injection and  $J(t) = J[1(t) - 1(t - t_a)]$  for the infusion, where the term  $\delta(t)$  is the Dirac function and  $1(t - T)$  the Heaviside function ( $=0$  for  $t < T$  and  $1$  for  $t \geq T$ ). For the oral input one has  $J(t) = J[1(t) - 1(t - t_a)] [1 - e^{-\beta(t-t_a)}]$ .

An alternative simpler parameterization has also been used to characterize the glucose regulatory system. To do so, (5.43)–(5.46) have been recast as second order differential equations in  $C_1$  and  $C_2$  by first writing (5.43) and (5.44) in term of  $C_1$  and  $C_2$ :

$$\dot{C}_1(t) = -m_1 c_1(t) - m_2 c_2(t) + J'(t) \quad C_1(0) = 0 \quad (5.47)$$

$$\dot{C}_2(t) = -m_3 c_2(t) + m_4 c_1(t) \quad C_2(0) = 0 \quad (5.48)$$

with  $m_1 = p_1$ ,  $m_2 = p_2 V_2 / V_1$ ,  $m_3 = p_3$ ,  $m_4 = p_4 V_1 / V_2$  and  $J'(t) = J(t) / V_1$ , and then differentiating (5.47) and (5.48) with respect to time. This leads, after some algebraic manipulation, to a pair of second order equations:

$$\ddot{C}_1(t) + 2\alpha \dot{C}_1(t) + \varpi_0^2 C_1(t) = S_1(t) \quad (5.49)$$

$$\ddot{C}_2(t) + 2\alpha \dot{C}_2(t) + \varpi_0^2 C_2(t) = S_2(t) \quad (5.50)$$

where  $\alpha = (m_1 + m_3)/2$ ,  $\varpi_0^2 = m_1 m_3 + m_2 m_4$ ,  $S_1(t) = m_3 J'(t) + \dot{J}(t)$  and  $S_2(t) = m_4 J'(t)$ .

The linearity of the system allows us to obtain an analytical solution, if the input  $J(t)$  is a simple function of time. For instance if  $J(t)$  is such that:

$$S_1(t) = B \cdot \delta(t) \quad (5.51)$$

one has:

$$C_1(t) = \frac{B}{\varpi} e^{-\alpha t} \sin \varpi t \quad (5.52)$$

where  $\varpi^2 = \varpi_0^2 - \alpha^2$ .

For situations in which equation (5.51) can be considered to be a good approximation for an intravenous infusion (certainly it is for an injection) and for an oral administration, interpreting glucose concentration measurement using equation (5.52) provides a two-parameter classification of the blood glucose control system. In particular  $\varpi_0$  was suggested in Ackerman *et al.* (1964) as being the most significant parameter in distinguishing diabetics from normal subjects. Moreover, the natural period  $T_0 = 2\pi/\varpi_0$  was used as a classification parameter: normal subjects showed  $T_0$  values less than 3 h whilst diabetics were greater than 5 h. However, a significant gray area was observed.

This linear model made a conceptually important contribution to work in this field in the 1970s. However, this linear description has been subsequently shown to be not valid, e.g. if insulin is also measured and the model of (5.42)–(5.46) is fitted simultaneously to both glucose and insulin concentration data. This will be discussed later. This, in some sense, is not surprising since glucose and insulin concentrations hardly show a small change during an intravenous or an oral perturbation, thus violating the assumption that would justify linearization of the model of (5.33)–(5.36), i.e. that deviations from steady-state equilibrium are sufficiently small.

## 5.4 DISTRIBUTED MODELING

In many cases metabolic processes can be adequately represented in terms of a lumped model. This assumes that it is reasonable to consider that a chemical substance is uniformly distributed in a physical space treated as a single compartment. This was the assumption made in the example of drug elimination considered in section 5.3.2. In that case the drug was assumed to be uniformly distributed throughout the bloodstream, resulting in the concentration of drug at any particular time being of equal value throughout that space. Such a simple model clearly neglects the effects of blood flow and mixing during the early period following injection of the drug.

In distributed modeling, no such assumption of homogeneity is made. This leads to a more complicated form of mathematical representation. The examples of lumped models presented in section 5.3 gave rise to ordinary differential equations. These were equations in which the left-hand side of the equality took the form  $dx/dt$ , the rate at which the dependent variable  $x$  is changing with respect to time  $t$ , the independent

variable. In other words, because a lumped model had been adopted, one only had to consider variation of drug concentration with respect to time. In a distributed model there would also be the need to represent the variation of drug concentration with respect to spatial position.

Mathematically this gives rise to equations involving two partial derivatives: for example  $\partial x/\partial z$ , the partial derivative (rate of change) of  $x$  (say drug concentration) with respect to  $z$ , a spatial variable (say the distance along a particular blood vessel), as well as  $\partial x/\partial t$ , the partial rate of change of drug concentration with respect to time.

The solution for models realized as sets of partial differential equations is much more complicated than that of the ordinary differential equations of lumped models. Normally one has to resort to numerical computational techniques, the scope of which lies beyond this introductory text.


### 5.4.1 Blood-tissue Exchange

An important area of distributed parameter modeling is that concerning transport and metabolism of a substance at the organ level. This is a topic that has been considered in detail by Vicini (2001) in Carson and Cobelli (2001) (extracts from these treatments are included here). Every organ *in vivo* is perfused by its own vascular tree and capillaries are the most important elements since they allow exchange of substrates between blood and tissue through passive or active transport. The capillary-tissue unit is therefore the elementary functional unit discussed here, in order to describe transport and metabolism of a substance at the organ level. The substance that reaches the capillary is proportional to the flow that perfuses it. The flow to the system is partitioned in all the branches of the capillary network and these partitions come together in the outlet vein. The flow sub-division is not uniform and is referred to as the heterogeneity of flow. As a result there is heterogeneity of metabolism in every capillary-tissue unit. This is shown schematically in Figure 5.11. Every capillary-tissue unit is positioned between an arteriole and a venule. Blood reaches the capillaries through an arteriole and leaves them through a venule, but from an arteriole, blood can be distributed to numerous meta-arterioles before reaching the capillary.


A typical capillary can be thought of as a thin wall tube (capillary membrane), formed by endothelial cells 'embedded' in one another. The transport modality through the capillary membrane is twofold. Some substances are subject exclusively to passage through the small spaces between endothelial cells and endothelial gaps; this is especially true for smaller molecules (e.g., proteins). Other substances can also flow through the endothelial cells by means of facilitated diffusion or active transport. Fundamentally, blood-tissue exchange consists of the passage of molecules from the plasma, through the capillary membrane, to the interstitial fluid and, from there, through the cellular membrane or sarcolemma, to the parenchymal cell where metabolism takes place. An example of the elementary processes of blood-tissue exchange is shown in Figure 5.12.

The experimental techniques for the study of blood-tissue exchange are based on the use of tracers and include multiple tracer dilution, positron emission tomography (PET) and nuclear magnetic resonance (NMR) spectroscopy. Here we concentrate





**Figure 5.11** Schematic representation of the vascular network of an organ showing the heterogeneity of blood-tissue exchange. Transport and metabolism occur in the capillary-tissue unit (adapted from Vicini, 2001).




**Figure 5.12** Basic steps of blood-tissue exchange. Glucose is transported via convection by plasma flow, diffuses in the interstitial volume, and from there is transported through the cell membrane, and is irreversibly metabolized there (adapted from Vicini, 2001).

on multiple tracer dilution and will discuss PET and interpretative system models in Chapter 11 in Case Studies.

This method consists of the simultaneous injection, upstream of the organ, of more than one tracer, each with different molecular characteristics. The simultaneous use of several differing tracers allows separate monitoring of the elementary processes of blood-tissue exchange. For example, consider the case when the objective of the experiment is the measurement of all the elementary processes (convection, diffusion, transport, and metabolism). In such a situation one can usually inject four tracers simultaneously upstream of the organ (in an artery that transports blood flow entering the organ), and then measure them downstream (from a vein that collects the flow leaving the organ).

The first tracer is distributed only in the capillary bed (intravascular tracer), the second is subject to the bidirectional exchange through the capillary membrane (extracellular tracer), the third, once subjected to the two previous steps, also permeates the cell through the sarcolemma (permeating not metabolizable tracer), and, finally, the fourth is also metabolized (permeating metabolizable tracer). These tracers must obviously be distinguishable one from the other once they reach the organ outflow. The venous outflow curves (Figure 5.13) must then be analyzed by means of plausible and physiologically reasonable mathematical models of the organ.



**Figure 5.13** Multiple indicator dilution washout curves to measure glucose transport and phosphorylation in human skeletal muscle in the basal (left) and insulin stimulated (right) state. Three tracers are injected in the brachial artery, an extracellular (D-[ $^{12}\text{C}$ ]-mannitol), a transportable but not metabolizable (3-O-[ $^{14}\text{C}$ ]-methyl-D-Glucose) and a metabolizable (D-[ $^3\text{H}$ ]glucose), and their concentration measured in a vein (adapted from Saccomani *et al.*, 1996).

### The single-capillary model


Let us consider a generic single tracer confined within the capillary. In the hypothesis of negligible radial diffusion (radius of capillary is small), the concentration of tracer (expressed, for example, in  $\text{mmol ml}^{-1}$ ) will be defined by the surface  $c(x, t)$  (where  $x$  is the space coordinate and  $t$  the temporal coordinate). The fundamental equation of

the distributed parameter model for the single capillary (Figure 5.14) is given by the classic equation describing convection and axial diffusion:

$$\frac{\partial c(x, t)}{\partial t} = -v(x) \frac{\partial c(x, t)}{\partial x} + D \frac{\partial^2 c(x, t)}{\partial x^2} \quad (5.53)$$

where  $v$  is the velocity of convection ( $\text{cm s}^{-1}$ ) and  $D$  the diffusion coefficient ( $\text{cm}^2 \text{s}^{-1}$ ). At this point, we can introduce some simplifications. First, let us suppose that the system is in a steady state. Moreover, it is known that the presence of red blood cells creates, in the capillaries, inner spaces of purely convective transport (this is the so-called plug flow): a limited error is then introduced if we neglect the effect of axial diffusion. Transport in the single capillary therefore remains defined by convection alone:

$$\frac{\partial c(x, t)}{\partial t} = -v(x) \frac{\partial c(x, t)}{\partial x} \quad (5.54)$$



**Figure 5.14** Single-region, single-capillary blood-tissue exchange model (adapted from Vicini, 2001).

If, at this point, we establish that the capillary diameter is uniform everywhere, we can write  $v(x) = v$ . From now on, we shall refer to the plasma tracer concentration in the capillary as  $c_p(x, t)$ . Let us denote with  $V_p$  ( $\text{ml g}^{-1}$ ) the volume of the capillary (independent from the axial coordinate, since the diameter of the capillary is constant as a reasonable approximation), the flow of plasma with  $F_p$  ( $\text{ml min}^{-1} \text{g}^{-1}$ ), and the length of the capillary with  $L$  (cm). We can write:

$$v = \frac{F_p L}{V_p} \quad (5.55)$$

and therefore:

$$\frac{\partial c_p(x, t)}{\partial t} = -\frac{F_p L}{V_p} \frac{\partial c_p(x, t)}{\partial x} \quad (5.56)$$

This is a first order partial differential equation with boundary condition:  $c_p(0, t) = u(t)$ , where  $u(t)$  is the concentration profile ( $\text{mmol ml}^{-1}$ ) at the capillary inlet. Its solution is:

$$c_p(L, t) = \delta \left( t - \frac{V_p}{F_p} \right) \otimes u(t) = u \left( t - \frac{V_p}{F_p} \right) \quad (5.57)$$

where  $\otimes$  is the convolution operator. Briefly, the response of a single capillary to the generic input  $u(t)$  is the input itself, shifted forward in time by an amount equal to the transit time of the capillary. It is useful to observe that the length of the capillary  $L$ , since axial diffusion is negligible, does not influence the profile of outflow concentration. In agreement with the fact that the capillaries do not have contractile ability, the profile at the inlet is not deformed by passage through the capillary.

### The capillary-interstitial fluid model

Let us suppose now that the capillary is dipped in a homogeneous and stagnant medium (convection happens only in the capillary), the so-called interstitial fluid, which in the microcirculatory system separates the capillary membrane from the cellular membrane. As we have already indicated, the capillary membrane is characterized by the presence of endothelial gaps, that is, of 'fissures' between the endothelial cells. The possibility that a generic substance will pass from one side of the membrane to the other will depend on many factors, including the width of the gaps and their distribution on the membrane. We now define the permeability of a membrane (Crone and Lassen, 1970) as:

$$P = \frac{\text{flow through the membrane}}{\text{membrane surface} \times \text{concentration gradient through the membrane}} \quad (5.58)$$

Let us now consider the concentration gradient through the capillary membrane. The concentration in the capillary is  $c_p(\mathbf{x}, t)$ ; that in the interstitial fluid (referred to as the interstitial volume,  $V_{isf}$ ) is  $c_{isf}(\mathbf{x}, t)$ . The dynamics of the concentration through the capillary membrane can therefore be described, as a function of the discontinuity of the concentration across the membrane, with the equation (first order process):

$$\frac{\partial c_p(\mathbf{x}, t)}{\partial t} = -\frac{S_g(\mathbf{x})}{V_p} [P_-(\mathbf{x})c_p(\mathbf{x}, t) - P_+(\mathbf{x})c_{isf}(\mathbf{x}, t)] \quad (5.59)$$


where  $S_g(\mathbf{x})$  is the capillary membrane surface interested to the exchange ( $g$  indicates the endothelial pores, or endothelial gaps),  $P_-(\mathbf{x})$  is the permeability in the direction leaving from the membrane (centrifuge permeability),  $P_+(\mathbf{x})$  is the permeability in the direction entering the capillary (centripetal permeability) (Bassingthwaight and Goresky, 1984).

At this point, we make the following hypotheses:

- the dimensions of capillary and tissue are uniform with respect to the axial direction; therefore, the surface relating to the exchange is independent of the axial dimension:  $S_g(\mathbf{x}) = S_g$ ;
- the permeability is uniform in both the axial,  $P(\mathbf{x}) = P$ , and the radial direction,  $P_+ = P_- = P$ ; the product permeability-surface  $PS_g$  ( $\text{ml min}^{-1} \text{g}^{-1}$ ) is therefore a constant;

- the radial diffusion in the interstitial fluid is fast; if the capillary is situated in a well-perfused organ (e.g., the cardiac tissue), the distance between the capillaries is usually small, so that the equilibrium time in the lateral direction of the concentration of the substance subject to diffusion is a negligible fraction of the transit time of the capillary.

We can now derive a simple two-region model that describes transcapillary transfer (Figure 5.15). The explicit solution of this model was derived by Rose and Goresky (1976), Sangren and Sheppard (1953) and Sheppard (1962), while Bassingthwaight *et al.* (1992) proposed efficient numerical algorithms.



**Figure 5.15** The two-region single-capillary blood-tissue exchange model (adapted from Vicini, 2001).

The plasma region equation is the following:

$$\frac{\partial c_p(x, t)}{\partial t} = -\frac{F_p L}{V_p} \frac{\partial c_p(x, t)}{\partial x} - \frac{PS_g}{V_p} [c_p(x, t) - c_{isf}(x, t)] \quad (5.60)$$

and analogously for the interstitial fluid equation:

$$\frac{\partial c_{isf}(x, t)}{\partial t} = \frac{PS_g}{V_{isf}} [c_p(x, t) - c_{isf}(x, t)] \quad (5.61)$$

where  $V_{isf}$  is the volume of the interstitial fluid.

The system of two equations defined above describes transport through the endothelial gaps of the capillary membrane for a single capillary. One can show that the solution to this system is given, again for the boundary condition  $c_p(0, t) = u(t)$ , by this function:

$$c_p(L, t) = e^{-PS_g/F_p} \delta \left( t - \frac{V_p}{F_p} \right) + \sum_{n=1}^{+\infty} \frac{\left( \frac{V_p}{F_p} \frac{PS_g}{V_p} \frac{PS_g}{V_{isf}} \right)^n \left( t - \frac{V_p}{F_p} \right)^{n-1} e^{-PS_g/V_{isf}(t-V_p/F_p) - PS_g/F_p} \mathbf{1}(t - \tau)}{n!(n-1)!} \quad (5.62)$$

where  $l(t - \tau)$  is the step function (zero before  $\tau$  and one at and after  $\tau$ ). Equation (5.62) can be written more conveniently if we define the auxiliary constants  $\tau = V_p/F_p$ ,  $k_a = PS_g/V_p$ ,  $k_b = PS_g/V_{isf}$ :

$$c_p(L, t) = e^{-\tau k_a} \delta(t - \tau) + \sum_{n=1}^{+\infty} \frac{(\tau k_a k_b)^n (t - \tau)^{n-1} e^{-k_b(t-\tau) - \tau k_a} \mathbf{1}(t - \tau)}{n!(n-1)!} \quad (5.63)$$

The first addendum (throughput fraction) represents the molecules of substance that flow directly through the capillary without ever leaving it and is, therefore, equal to the intravascular response of the single capillary, scaled by the factor  $e^{-\tau k}$ . The second addendum (tail function) describes the return (backdiffusion) of the substance from the interstitial fluid to the capillary (Bassingthwaighte and Goresky, 1984).

### The capillary-interstitial fluid-cell model


At this point, we can model the kinetics of a substance leaving interstitial fluid and entering the cell membrane through the parenchymal cell. The model (Figure 5.16), a rather straightforward extension of the two-region model, is described by:

$$\begin{aligned} \frac{\partial c_p(x, t)}{\partial t} &= -\frac{F_p L}{V_p} \frac{\partial c_p(x, t)}{\partial x} - \frac{PS_g}{V_p} [c_p(x, t) - c_{isf}(x, t)] \\ \frac{\partial c_{isf}(x, t)}{\partial t} &= -\frac{PS_g}{V_{isf}} [c_{isf}(x, t) - c_p(x, t)] \\ &\quad - \frac{PS_{pc}}{V_{isf}} [c_{isf}(x, t) - c_{pc}(x, t)] \\ \frac{\partial c_{pc}(x, t)}{\partial t} &= -\frac{PS_{pc}}{V_{pc}} [c_{pc}(x, t) - c_{isf}(x, t)] - \frac{G_{pc}}{V_{pc}} c_{pc}(x, t) \end{aligned} \quad (5.64)$$

where  $PS_{pc}$  ( $\text{ml min}^{-1} \text{g}^{-1}$ ) is the permeability-surface product of the cell membrane,  $V_{pc}$  ( $\text{ml g}^{-1}$ ) is the volume of the parenchymal cell, and  $G_{pc}$  ( $\text{ml min}^{-1} \text{g}^{-1}$ ) is irreversible metabolism. The explicit solution is again due to Rose and Goresky (1976); an efficient numerical solution, also including the contribution from diffusion, is reported in Bassingthwaighte *et al.* (1992).

### The whole-organ model

Until now, we have limited our analysis to the single capillary. In a more generalized setting, and as noted at the beginning of this chapter, an organ is characterized by a network of interconnected capillaries (King *et al.*, 1996). The total flow into the organ becomes divided between the capillaries in an unequal and non-uniform way. This is the so-called spatial heterogeneity of flow (Bassingthwaighte and Goresky, 1984). Flow heterogeneity causes heterogeneity of the local capillary permeability,




**Figure 5.16** The three-region single-capillary blood-tissue exchange model. ISF is interstitial fluid; PC is parenchymal cell (adapted from Vicini, 2001).

thus limiting the quantity of substances that can be exchanged between blood and tissue.


Knowledge of such a prominent phenomenon is very important for modeling blood-tissue exchange of substrates. In fact, neglecting flow heterogeneity can result in biased estimation of extravascular parameters (King *et al.*, 1996; Kuikka *et al.*, 1986). Thus, the availability of a description of flow heterogeneity (even an approximate one) in the organ of interest is a prerequisite for physiologically sound kinetic modeling (Vicini *et al.*, 1998).

The most common approaches to assess flow heterogeneity in an animal, or in isolated and perfused tissue, are microsphere deposition (Bassingthwaighte and Goresky, 1984) and autoradiography (Stapleton *et al.*, 1995); both very invasive techniques that require sectioning of the organ under study. In contrast to animal studies, there is little knowledge about flow heterogeneity in humans. PET provides a potentially valuable tool for the assessment of regional flow heterogeneity (Vicini *et al.*, 1997; Utrainen *et al.*, 1997). In fact, the PET image of a given organ, when obtained with an appropriate marker such as [ $^{15}\text{O}$ ] water, provides information not only of average flow in a region of interest but also of its spatial distribution (Figure 5.17).

There are two landmark models to describe the heterogeneity of flow. The first is that by Goresky and colleagues (see for example Rose and Goresky, 1976). The second is that by Bassingthwaighte and colleagues (see for instance King *et al.*, 1996). Below we describe the salient features of this second model, also referred to as the parallel capillary model or parallel network model (King *et al.*, 1996). Such an approach stems directly from the fact that, especially in muscle, capillaries are arranged in a more or less parallel fashion. However, the method assumes that the capillaries all end at the same point ( $x = L$ ), and this can be a more difficult condition to satisfy (Jacquez, 1985). It is important to note that any parallel capillary heterogeneity model does not allow the description of phenomena, such as the shunting between capillaries that may have a crucial importance on a correct description of the problem.



**Figure 5.17** Example of a frequency histogram in a normal subject showing relative flow in human muscle in the basal state. Flow measurement was made with  $[^{15}\text{O}]$ -labeled water and positron tomography. In the abscissa the relative flow is normalized to the mean flow. The ordinate shows the frequency with which a given range of relative flows is observed. Mean flow ( $F_p$ ,  $\text{ml min}^{-1} \text{g}^{-1}$ ) and relative dispersion (expressed in %) of the distribution are also presented (adapted from Vicini, 2001).



**Figure 5.18** Structure of the distributed parameter organ model.

Let us suppose that the organ is describable with a number  $N$  of parallel pathways (Figure 5.18), along which the blood-tissue exchange occurs. Every pathway represents a region of the organ characterized by a fraction  $F_i$  of the total input flow  $F$  and a fractional mass  $W_i$ . Based on this definition, a ‘pathway’ is a compact description



of sub-regions within the organ, each one characterized by the same flow for unit of tissue mass. It is useful to point out that these regions also need not be adjacent. Every pathway therefore is characterized from a regional relative flow,  $f_i = F_i/F_p$ ,  $i = 1, \dots, N$ , where  $F_p$  is the total input flow, and a fractional mass  $W_i$ ,  $i = 1, \dots, N$  (which we define as the percentage of the mass of the organ interested from the regional relative flow  $f_i$ ). The output of the model is therefore given by the total outflow, which is the weighted (with  $J$ ; and  $W_i$ ) sum of the single capillaries responses.

Let us formally define the width of the  $i$ -th flow class  $\Delta f_i$ ,  $i = 1, \dots, N$  for a generic flow distribution as:

$$\begin{aligned}\Delta f_1 &= f_2 - f_1 \\ \Delta f_i &= \frac{f_{i-1} + f_{i+1}}{2}, \quad i = 2, \dots, N-1 \\ \Delta f_N &= f_N - f_{N-1}\end{aligned}\tag{5.65}$$

The distribution of relative flows has unitary area:

$$\sum_{i=1}^N w_i \Delta f_i = 1\tag{5.66}$$

and unitary mean:

$$\sum_{i=1}^N f_i w_i \Delta f_i = 1\tag{5.67}$$

The response of such a model to a pulse input  $u(t) = \delta(t)$  is then:

$$h(t) = h_A(t) \otimes \left[ \sum_{i=1}^N w_i f_i \Delta f_i h_{a,i}(t) \otimes h_{c,i}(t) \otimes h_{v,i}(t) \right] \otimes h_V(t)\tag{5.68}$$

where  $\otimes$  is the convolution operator,  $h_A(t)$  is the artery impulse response (situated at the inlet, does not take part in blood-tissue exchange),  $h_V(t)$  is the vein impulse response (situated at the outlet, does not take part in blood-tissue exchange),  $h_{a,i}(t)$  is the impulse response of the arterioles in the  $i$ -th path,  $h_{v,i}(t)$  is the impulse response of the venules in the  $i$ -th path, and  $h_{c,i}(t)$  is the impulse response of the capillaries in the  $i$ -th path.

$$h_{c,i}(t) = \delta(t - \tau_i) = \delta\left(t - \frac{V_p}{F_i}\right)\tag{5.69}$$

where  $V_p$  (volume per unit tissue) is capillary volume. Thanks to the associative and commutative property of convolution, we can simplify such a model:

$$h(t) = h_{AV}(t) \otimes \left[ \sum_{i=1}^N w_i f_i \Delta f_i h_{av,i}(t) \otimes h_{c,i}(t) \right]\tag{5.70}$$


where  $h_{AV}(t) = h_A(t) \times h_V(t)$  and  $h_{av,i}(t) = h_{a,i}(t) \otimes h_{v,i}(t)$ ,  $i = 1, \dots, N$ . This formulation is rather general. However, such parameter richness means that, for achieving identifiability of the physiologically relevant parameters, it is necessary to assume some characteristics of the model, such as flow heterogeneity and large vessel volumes, according to prior information (e.g., using labelled microspheres allows to measure flow heterogeneity). When this kind of information is indeed available (e.g., the case of the isolated and perfused animal heart, where the model has been initially developed), the model is identifiable.

A classic application of this model has been to describe transport and metabolism of glucose in the isolated and perfused heart (Kuikka *et al.*, 1986). In this study four tracers were injected into the aorta; an intravascular, an extracellular, a permeating not metabolizable and a permeating metabolizable tracer. The four outflow dilution curves measured in the coronary sinus were interpreted with the model of Figure 5.18 by using the capillary-Interstitial-cell model of equation (5.63).

## 5.4.2 Hepatic Removal of Materials

Estimating the rate constants associated with the hepatic removal of materials from the circulation is a problem for clinicians as well as physiologists and pharmacologists. A large group of compounds of special interest in this regard are extensively bound to plasma proteins with the result that they are removed almost exclusively by the liver. In the short interval during which this occurs, their extrahepatic distribution is largely confined to the vascular volume. Endogenous products such as bilirubin and bile acids, diagnostic agents such as indocyanine green, rose bengal, sulfobromophthalein (BSP) as well as many drugs are familiar examples.


A classic representation which allows the estimation of the rate constants for hepatic transport from the plasma disappearance curve of the material is the lumped model of Figure 5.19. The model specifically predicts that after an instantaneous injection of material into compartment P, plasma concentration will decline as the sum of two exponentials whose slopes and intercepts are simple functions of the rate constant for hepatic uptake ( $k_1$ ), the rate constant for the return of material from liver cells to plasma ( $k_2$ ), and the rate constant for irreversible removal from liver cells ( $k_3$ ). Experimentally determined disappearance curves are often closely approximated by two exponentials. Moreover, the initial volume of distribution determined by extrapolation of the plasma concentration to  $t = 0$  is usually consistent with the model assumption of a single well-stirred plasma compartment. These observations together with the mathematical and experimental simplicity of the methods and its feasibility for human studies have led to its wide and continuing use ever since it was originally suggested for BSP removal by Richards *et al.* (1959).



**Figure 5.19** Lumped model for the estimation of hepatic transport.

This model, however, drastically simplifies the physiological variables in a living system. Specifically, the plasma volume is not a single well-stirred compartment, and liver cells are exposed to a profile of concentrations along the sinusoids – not as the model assumes to the mean concentration in the plasma volume as a whole. The model by Forker and Luxon (1978), which we describe below, has been principally developed to analyze the validity of the assumptions involved in treating the circulating plasma volume and liver cells as homogeneous compartments and deriving quantitative estimates of the errors that can occur as a result of this simplification.

The model is shown in Figure 5.20 and is partly lumped and partly distributed. It is assumed that lumped compartmental representation is adequate for the heart and lungs, peripheral mixing and splanchnic mixing. However, the assumption of



**Figure 5.20** A hybrid (part lumped, part distributed) model.  $F$  denotes the total hepatic plasma flow,  $m$  is the total number of sinusoids,  $f_1, f_2, \dots, f_m$  are respectively the plasma flows into the first, second and  $m$ -th sinusoids, and  $k_4$  and  $k_5$  are the fractional transfer rate constants between compartments P and R (adapted from Forker and Luxon, 1978).

homogeneity which a lumped representation would imply is removed when describing the dynamics of the material in the liver. The model contains a small central compartment, P, which receives the pulse of injected material at  $t = 0$ . The volume of this compartment,  $V_p$ , represents a fraction of the total plasma volume considered to undergo instantaneous mixing and is visualized here as equivalent to the combined plasma volume of the heart and lungs. A splanchnic circuit receives plasma from and delivers it to P at the rate of hepatic plasma flow, F. Compartment R contains the remainder of the plasma volume,  $V_r$ , not contained in  $V_p$  or the splanchnic circuit and provides for delayed mixing in the peripheral circulation. Compartments R and P exchange with each other at a flow rate, H, equivalent to the cardiac output less the hepatic plasma flow. The splanchnic segment of the model contains a parallel array of liver sinusoids in series with a mixing compartment, C, and a simple delay represented by compartment D. The latter two compartments are included to simulate delay and dispersion in the extrahepatic portion of the splanchnic loop.

The sinusoidal array comprises many identical units whose liver cells all operate with the same rate constants, but the fraction of liver plasma flow assigned to individual sinusoids has been given a normal distribution to simulate the shape of hepatic indicator dilution curves. The model for the generic  $l$ -th sinusoid is shown in Figure 5.21 and is based on the assumptions discussed in Goresky *et al.* (1973). Specifically the fractional transfer constants,  $k_1$ ,  $k_2$ , and  $k_3$ , are first order rate constants, flow-limited distribution of material to the cell surface is assumed, and axial diffusion is neglected so that dispersion at the outflow of the sinusoidal system is wholly attributable to delayed return of material from liver cells and to the non-uniform distribution of plasma flows. In Figure 5.21,  $x$  (the location variable) is the cumulative vascular volume (instead of sinusoidal length – this simplifies the notation);  $u_l, v_l, z_l$ , denote the material concentration in the sinusoid, Disse space and liver cells:  $V_u$  is the total volume of  $m$  identical sinusoids,  $f_l$  is the plasma flow to the  $l$ -th sinusoid,  $\gamma$  is the ratio of extravascular, extracellular volume to sinusoid volume, and  $\theta$  is the ratio of intracellular volume to sinusoidal volume.

Consider  $m$  identical sinusoids grouped in  $n$  classes according to  $n$  values of  $f_l$ , the plasma flow per sinusoid. The flow distribution scheme assigns a fraction,  $\alpha_l$ , of the  $m$  sinusoids to each flow class. Thus the  $i$ -th class has  $m\alpha_i$  elements, each element is characterized by flow  $f_i$  with:


$$\sum_{i=1}^n \alpha_i = 1 \quad \sum_{i=1}^n m\alpha_i f_i = F \quad (5.71)$$

The model consists of three ordinary and  $2n$  partial differential mass balance equations:

$$V_p \dot{P} = FC(t - \tau_d) + k_5 V_r R - (F + k_4 V_p) P \quad (5.72)$$

$$V_c \dot{C} = \sum_{i=1}^n (\alpha_i m f_i) u_i \left( \frac{V_u}{m}, t \right) - FC \quad (5.73)$$

$$V_r \dot{R} = k_4 V_p P - k_5 V_r R \quad (5.74)$$



**Figure 5.21** Representation of a liver sinusoid unit of the distributed model.  $x$  denotes the cumulative sinusoidal volume,  $V_u$  is the total volume of  $m$  identical sinusoids,  $f_1$  is the plasma flow to the  $l$ -th sinusoid,  $\gamma$  is the ratio of extravascular, extracellular volume to sinusoidal volume,  $\theta$  is the ratio of intracellular volume to sinusoidal volume, and  $k_1$ ,  $k_2$  and  $k_3$  are fractional transfer rate constants as indicated in the figure;  $u$ ,  $v$  and  $z$  denote concentrations in the indicated sites as functions of distance and time (adapted from Forker and Luxon, 1978).

$$\dot{u}_i(x, t) + \gamma \dot{v}_i(x, t) + \vartheta \dot{z}_i(x, t) + f_i \cdot \frac{\partial u_i(x, t)}{\partial x} = -\vartheta k_3 z_i(x, t) \quad (5.75)$$

$$\vartheta \dot{z}_i(x, t) = k_1 \gamma v_i(x, t) - \vartheta (k_2 + k_3) z_i(x, t) \quad (5.76)$$

where  $\tau_d = V_p/F$  is the delay provided by compartment D and the volume term  $\Delta x$  which multiplies each term in equations 5.75 and 5.76 is not shown because it drops out.

The initial conditions are:

$$P(0) = 1 \quad (5.77)$$

$$u_i(x, 0) = v_i(x, 0) = z_i(x, 0) = C(0) = R(0) = 0 \quad (5.78)$$

since an impulsive input of material at time  $t=0$  in P is assumed, with P being the concentration normalized to its initial value.

The auxiliary conditions are:

$$u_i(0, t) = P(t) \quad (5.79)$$

$$v_i(x, t) = u_i(x, t) \quad (5.80)$$

the first denoting that the input concentration to the sinusoids is  $P$  while the second denotes that the material in Disse space is in rapid equilibrium with that in plasma sinusoids.

The model variable of interest is the time course of the concentration in the peripheral compartment,  $R$ . However, an analytical solution in closed form is not possible. The authors have obtained its Laplace transform,  $R(s)$ , which was subsequently inverted numerically. Volumes and flows in the model were mostly assigned from published data on dogs (Table 1 in Foraker and Luxon, 1978). Given these values, the lumped-distributed model generates plasma disappearance curves uniquely determined by the choice of the three hepatic rate constants  $k_1$ ,  $k_2$  and  $k_3$ . A wide range of rate constant values, all functionally significant, was examined.

The major findings of this simulation study can be summarized as follows. First, the lumped-distributed model generates disappearance curves that are fitted almost exactly by the sum of two exponentials. As a result, the clearance of material recovered by the lumped model has a small error. Similarly, the initial volume of distribution is only slightly (20%) lower than that of the lumped-distributed model. However, the picture changes when estimates of the rate constant of the lumped model are considered. Estimates of  $k_1$  and  $k_2$  were consistently lower with errors in the range of 4% to 57%, and 6% to 73%, respectively, while a relatively minor underestimation error was encountered in  $k_3$  estimate, ranging from 1% to 7%. Also of note is that errors in estimating  $k_1$  and  $k_2$  increase rapidly with increasing values of the initial extraction fraction. In fact, in the lumped-distributed model the plasma concentration of the material in the liver is less than in the periphery. The lumped model ignores this effect and compensates for this error by lowering the values of the rate constants. This underestimation effect is obviously more pronounced when the plasma disappearance curves vary more rapidly, and is thus amplified in the first portion of the disappearance curve. In effect  $k_1$  and  $k_2$  which are estimated from the first portion of the curve have a greater error.


Although this lumped-distributed model cannot be used *in vivo* to estimate hepatic removal of substances, it provides a cautionary lesson when disappearance curves are analyzed with conventional lumped representation. It also stresses the importance of relying on the entire disappearance curves and not just on initial slope estimates for hepatic removal, in order to ensure that estimates for clearance are robust.

### 5.4.3 Renal Medulla

As a final example of distributed modeling, let us consider the development of a model of the medulla of the kidney which could be used to simulate human renal function. The model presented here focuses on the conservation of water and electrolytes and the production of urine within the medulla. The renal medulla is unusual in the degree

to which its anatomical structure is essential to its function due to the transverse interactions between longitudinal flows in the parallel tubules. By formulating an appropriate mathematical model it is possible to provide a controlled and quantitative method of studying the contributions of the individual components of the kidney to the dynamic behavior of the overall system (Cage *et al.*, 1977).

A schematic diagram of the structure of the model is shown in Figure 5.22, where this corresponds to the anatomy of the kidney. The mass of the cortex and the medulla is composed of many tubular structures. These are divided into four classes: the cortical nephrons, the juxtamedullary (JM) nephrons (since they are anatomically and functionally distinct), the collecting ducts, and the vasa recta. All members of a class are assumed to behave similarly and each class is simulated by tubes made up by a series of segments in which fluid flows from one segment to the next. A set of adjacent segments makes up a functionally distinct section of a tube, such as the thick ascending limb of the loop of Henle (THAL). The medulla is not treated as a continuous structure, but rather is modeled as a set of discrete terraces, recognizing the distributed nature of flows in the kidney. A terrace contains segments of different sections and the depth of the terrace is the length of a single segment.



**Figure 5.22** Schematic model of the renal medulla. Abbreviations: DESC – descending limb of the loop of Henle; THIL – thin ascending limb of the loop of Henle; THAL – thick ascending limb of the loop of Henle; DIST – distal convoluted tubule; COLL – collecting duct;  $C_{iso}$ , CO and CI are total interstitial solute concentrations (adapted from Cage *et al.*, 1977).

### Model assumptions

A number of assumptions have been made in developing the model and these can be stated explicitly as follows. First, all the segments within a section of tube are given the same values for area, volume and permeability coefficients. The values for area

and volume for each segment are the sum of the surface areas and volumes of all the members of a class within the depth of one terrace.

In the cortical nephrons, which make up 85% of the total, the loops of Henle pass only as far as the inner zone of the medulla (see Figure 5.22). Concerning the juxtamedullary nephrons (JM), the effect of the reducing numbers of the loops of Henle towards the tip of the medulla is represented by reducing the numbers of tubes in this class, and by allowing a proportion of the fluid descending through each terrace to be passed directly to the ascending limb. The JM nephrons are reduced by a geometric process to 30% of their number by the medullary tips, equivalent to 4.5% of all nephrons.

The vasa recta are treated as if they act only as a passive drain for the medulla. Therefore, they are modeled as a class of tubes which loop once through the entire length of the medulla. The flux of solutes for the vasa recta is treated as for other segments, except that the flow rate down the descending limbs is held constant and the ascending flow is determined directly from the other tubes. The ascending vasa recta are assumed to take up excess fluid from the interstitium.

The glomeruli and proximal tubules are part of a complex control system which supplies the nephrons with fluid. The effect of this early part of the nephron is represented by a fixed flow rate at the beginning of the descending limbs of the loops of Henle. By changing the value of this input to the model, it is possible to investigate how the medulla responds to changes in glomerular filtration rate (GFR) and proximal resorption.

#### *Principles of the mathematical formulation for the tubular structures*

Consider an elemental segment of an individual tube, as shown in Figure 5.23, which is assumed to be well mixed radially and to be unaffected by axial diffusion. The mass balance for water passing through this segment is given by:

$$(\pi R_j^2 \Delta x) \cdot \frac{\partial \rho(x, t)}{\partial t} = \rho(x - \Delta x, t) \cdot Q(x - \Delta x, t) - \rho(x, t) \cdot Q(x, t) - (2\pi R_j \Delta x) \cdot J(x, t) \quad (5.81)$$

where  $J$  is the water efflux rate per unit area,  $Q$  is the flow rate of water,  $R$  is the inner radius of tubule cross-section,  $t$  is time in seconds,  $x$  is distance along the tubule, and  $\rho$  is fluid density. The term  $\Delta x$  represents a small increment of distance and the subscript  $j$  specifies the tubule section number.

Assuming that the density of water remains constant at  $1.0 \text{ g cm}^{-3}$ , equation (5.81) can be simplified to:


$$Q(x, t) = Q(x - \Delta x, t) - (2\pi R_j \Delta x) \cdot J(x, t) \quad (5.82)$$

Since the concentration of solute does not remain constant, no equivalent simplification is possible. Hence the equation describing mass balance for solutes is:

$$(\pi R_j^2 \Delta x) \cdot \frac{\partial C_i(x, t)}{\partial t} = C_i(x - \Delta x, t) \cdot Q(x - \Delta x, t) - C_i(x, t) \cdot Q(x, t) - (2\pi R_j \Delta x) \cdot N_j(x, t) \quad (5.83)$$

where  $C$  is the concentration of solute and the subscript  $I$  defines the solute species.





**Figure 5.23** Diagram showing a segment within a terrace in the renal medulla (adapted from Cage *et al.*, 1977).

To represent the various tubular structures which are simulated as a number of functionally distinct classes of tubes, the values for the areas and volumes of the segments are increased by the number of tubes in the class. The equations are re-written, labeling the segment at distance  $x$  along the tube as  $n$ . Equation (5.82) then becomes:

$$Q(n, t) = Q(n - 1, t) - (2\pi R_j \Delta x B_j) \cdot J(n, t) \quad (5.84)$$

where  $B$  is the total number of nephrons in both kidneys. In a similar way, equation (5.83) becomes:

$$\begin{aligned} (\pi R_j^2 \Delta x B_j) \cdot \frac{dC_i(n, t)}{dt} = & C_i(n - 1, t) \cdot Q(n - 1, t) - C_i(n, t) \cdot Q(n, t) \\ & - (2\pi R_j \Delta x B_j) \cdot N_i(n, t) \end{aligned} \quad (5.85)$$

These equations can be modified to take account of the reduction in JM nephron numbers towards the tip of the medulla. The value of  $B_j$  is reduced, and the mass flows of water and solutes from DESC to THIL are incorporated in the model. Hence, the loop of Henle in the inner medulla,  $B_j$  is a function of  $x$ .

Fluid flow in (5.84) and (5.85) is constrained in the model to be greater than or equal to zero so as to avoid the possibility of reverse flow through the tubule.

#### *Interstitial compartment*

The equation for the interstitial compartments includes assumptions for the tubular structures similar to those adopted above. It is assumed that transverse mixing results in homogeneity in each terrace, and that there is insignificant diffusion or mass flow between terraces. The equation for a solute at level  $p$  is thus:

$$V_p \cdot \frac{dC_i(p, t)}{dt} = \Sigma_n (2\pi R_m \Delta x B_m) \cdot N_i(m, t) \quad (5.86)$$

where  $V_p$  is the interstitial volume of terrace  $p$  and  $m$  is the number of different segments within the terrace.

#### *Transmural flux*

It is assumed that the layer of cells which constitutes a segment of a tube acts as a simple semi-permeable membrane with specific permeabilities. The transmural flux rates for the solutes and solvent can then be calculated using Fick's Law and the laws of osmosis. For the solvent, the volume efflux rate per unit area is given by:

$$J(n, t) = k_{wj} \cdot \Sigma_i (C_i(p, t) - C_i(n, t)) \quad (5.87)$$

where  $k$  is the re-absorption coefficient of the solute species. It is assumed that all the segments and terraces in the model have constant volume.

As stated above, the vasa recta flow is held constant in the descending vasa recta, and so  $J$  is set equal to zero in equation (5.87). The ascending vasa recta are assumed to remove all the excess fluid from the interstitium as the result of hydrostatic and oncotic forces acting on its very permeable membrane. Thus for the ascending limb:

$$J(p, t) = \Sigma_m J(m, t) \cdot (2\pi R_m \Delta x B_m) \quad (5.88)$$

where  $R_m$  and  $B_m$  are the radius and number of nephrons represented by segment  $m$ .

The equations for the solutes within the vasa recta are of the same form as for the other classes, but their permeability coefficients are very high, allowing the solutes to move easily into the vasa recta, which act as a drain for the medulla. When only passive diffusion is involved, the flux of solute is given by Fick's Law:

$$N_i(n, t) = k_{ij} (C_i(n, t) - C_i(p, t)) \quad (5.89)$$

where  $N$  is the molar flux per unit area. In the sections where re-absorption of electrolyte in the nephron is caused by active transport, it is assumed that passive diffusion occurs in parallel with active transport and that the effects are additive:

$$N_e(n, t) = k_{ej} (C_e(n, t) - C_e(p, t)) + N_{\text{active}} \quad (5.90)$$

where the subscript  $e$  refers to electrolyte and  $N_{\text{active}}$ , the active transport component, is given by:

$$N_{\text{active}} = \begin{cases} a_{ej} \cdot C_e(n, t) & \text{for } C_e(n, t) < C_{e \text{ iso}} \\ a_{ej} \cdot C_{e \text{ iso}} & \text{for } C_e(n, t) \geq C_{e \text{ iso}} \end{cases} \quad (5.90a)$$

$$(5.90b)$$

with the subscript  $\text{iso}$  indicating that the electrolyte is isotonic to blood plasma.

Having formulated the mathematical model in this fashion, parameter values and boundary conditions can be inserted into the equations and simulation studies performed.

## 5.5 NONLINEAR MODELING

In section 5.3 the examples presented were of systems that were being modeled as if they exhibited linear dynamics. Mathematically the models were composed of linear, ordinary differential equations. This concept of linearity can be illustrated by considering the following equation:

$$\frac{dx(t)}{dt} = -a x(t) + b u(t) \quad (5.91)$$

The dynamics of the dependent variable  $x$  are being represented in this equation as a function of the independent variable time;  $u$  is the input variable and  $a$  and  $b$  are (constant) parameters. Examining the first term on the right-hand side of this equation, a doubling of the value of the dependent variable would result in a doubling of the value of that right-hand term since the parameter  $a$  is a constant.

In contrast, consider equation (5.92) below:

$$\frac{dx(t)}{dt} = -c x^2(t) + b u(t) \quad (5.92)$$


where  $c$  is a constant parameter. Now if we double the value of  $x$ , this first right-hand term is no longer doubled due to the presence of this  $x^2$  term. In other words this  $x^2$  term makes the equation, and hence the model, one that is nonlinear. Let us now consider some examples of nonlinear models.

### 5.5.1 The Action Potential Model

Several cellular functions depend on the generation and propagation of the action potential. For instance, receptors convert chemical, thermal and electrical signals into an action potential: signals which control muscle contraction and hormone secretion are action potentials. The action potential is an electrical signal which consists of the local depolarization of the cell membrane as a result of a stimulus (Figure 5.24). Since the action potential is generated only if the stimulus is above a certain threshold, this perturbation of the electrical equilibrium of the membrane produces the depolarization of the adjacent region, thus allowing (in the case of a neuron) the propagation of the signal along the axon. The main advantage of this complex signal transmission system is that the signal is regenerated at each section of the membrane and is thus less sensitive to noise.

#### **An electrical model of the cell membrane**

The cell membrane lipid bilayer structure is an insulating component and also at rest there is a difference of potential between the intracellular and extracellular space. The simplest model to describe the electrical behavior of the membrane is thus a




**Figure 5.24** Dynamics of the action potential.

capacitance (Figure 5.25). The model equation is:

$$C_m \frac{dV}{dt} + I_{\text{ion}}(V, t) = 0 \quad (5.93)$$

where  $V = V_i - V_e$  (the intracellular and extracellular potentials respectively),  $C_m$  is the membrane capacitance, and  $I_{\text{ion}}$  are the ionic currents through the membrane, the most important being those of sodium ( $\text{Na}^+$ ), potassium ( $\text{K}^+$ ) and chloride ( $\text{Cl}^-$ ).



**Figure 5.25** Capacitance model of the cell membrane. Note that  $V = V_i - V_e < 0$ .


One can now build on the schema of Figure 5.25 by taking into account the following facts: (a) the ion fluxes occur along ion-specific channels each characterized by a certain resistance; (b) ions move along the channels due to a membrane potential (described by the Goldman equation which combines the Nernst potential of the individual ions); and (c) at equilibrium the different ion concentrations are maintained by an active pump which balances the passive fluxes of sodium and chloride into the cell and of potassium outside the cell.

The contribution of sodium and potassium ions to the action potential is explicitly considered, since it is assumed that it is predominant with respect to that of all the other ions, including chloride, which are lumped into a leakage current.


With the above logic, equation (5.93) becomes:

$$C_m \frac{dV}{dt} + g_{Na}(V - V_{Na}) + g_K(V - V_K) + g_L(V - V_L) = I_{pump} + I_{app} \quad (5.94)$$

where  $g_{Na}$ ,  $g_K$  and  $g_L$  are the channel conductances of sodium, potassium and leakage, and  $V_{Na}$ ,  $V_K$  and  $V_L$  are the respective Nernst potentials of sodium, potassium and all other ions.  $I_{pump}$  is the active pump current and  $I_{app}$  is the applied current stimulus. By incorporating these concepts, the electrical analog of the cell membrane becomes that shown in Figure 5.26. This linear model is valid only if a small current is applied (Figure 5.27), but we have seen that, with an elevated current, the system response is completely different (Figure 5.24).



**Figure 5.26** Expanded electrical analog model of the cell membrane. Note that  $V_{Na} < 0$  and  $V_K > 0$ .




**Figure 5.27** Membrane voltage in response to a small current.

### The Hodgkin-Huxley model

This model focuses on sodium and potassium ions only and does not consider the role of the active sodium pump (see Figure 5.28). Thus, the model equation becomes:

$$C_m \frac{dV}{dt} = -g_{Na}(V - V_{Na}) - g_K(V - V_K) + I_{app} \quad (5.95)$$



**Figure 5.28** The model of Figure 5.26 focusing on sodium and potassium ions only.

It is useful to define membrane potential at equilibrium, i.e. when  $I_{app} = 0$  (this is known as the Goldman equation and combines the Nernst potential of the individual ions):

$$V_{eq} = \frac{(g_K V_K + g_{Na} V_{Na})}{(g_K + g_{Na})} \quad (5.96)$$

The key piece of intuition which led to the formulation of this model was that the individual ion conductances of the cell membrane are not constant, but rather are a function of the membrane potential, i.e.  $g_{Na} = g_{Na}(V)$ ,  $g_K = g_K(V)$  and  $g_L = g_L(V)$ . In addition, it was perceived that for an increase of the membrane potential, the permeability increases differently for various ions with the dominant ion being the one with the highest permeability.

Since the system is a closed-loop feedback system, i.e. the membrane potential is a function of the ion conductances which in turn depend on the membrane potential, the only possibility to investigate the system experimentally was to open the feedback loop by maintaining a potential that was constant over time. For this purpose Hodgkin and Huxley (1952) developed the voltage clamp technique. This involved imposing step changes of the membrane potential (of different amplitudes) and measuring (at constant voltage) the ionic current in response to the stimulus, thus eliminating the dependence of the conductances from the membrane voltage.


In order to derive the time course of the conductances  $g_{Na}$  and  $g_K$  as a function of  $V$ , it has been necessary to separate the individual components of  $I_{Ion}$ , i.e.  $I_{Na}$  and  $I_K$ . It was assumed that, following an increase in the membrane potential, the current going into the cell is mostly due to  $Na^+$  ions, whilst that going out of the cell (responsible for the return to equilibrium of the potential) is mostly due to the  $K^+$  ion. Hence the two components of  $I_{Ion}$  were separated by substituting 90% of extra-cellular  $Na^+$  with coline (a substance which makes the axon non-excitable) and by assuming that, immediately after the increase of  $V$ , the current is due to  $Na^+$  only.

Under these circumstances, let us denote by  $I_{\text{Na}}^1$  and  $I_{\text{Na}}^2$  the sodium current under normal conditions and when  $[\text{Na}^+]_{\text{ext}} = 0$  respectively. Assuming also that the ratio  $I_{\text{Na}}^1/I_{\text{Na}}^2 = K$ , a constant over time, and that  $I_{\text{K}}^1 = I_{\text{K}}^2$ , one has from  $I_{\text{Ion}} = I_{\text{Na}} + I_{\text{K}}$  that:


$$I_{\text{Na}}^1 = \frac{K}{K-1} (I_{\text{Ion}}^1 - I_{\text{K}}^1) \quad (5.97)$$

Figure 5.29 shows the time course of  $I_{\text{Ion}}$  and of its components  $I_{\text{Na}}$  and  $I_{\text{K}}$ . It is now possible to determine the time course of  $g_{\text{Na}} = I_{\text{Na}}/(V - V_{\text{Na}})$  and  $g_{\text{K}} = I_{\text{K}}/(V - V_{\text{K}})$  as functions of  $V$ .

Figure 5.30a shows  $g_{\text{K}}$  for a step increase and decrease of  $V$ , whilst Figure 5.30b and c show  $g_{\text{K}}$  and  $g_{\text{Na}}$  for various values of step increase of  $V$ . It should be noted that  $g_{\text{Na}}$ , for a step increase of  $V$ , first increases and then decreases.



**Figure 5.29** Time course of  $I_{\text{Ion}}$  and its components  $I_{\text{K}}$  and  $I_{\text{Na}}$ .



**Figure 5.30** (a) Dynamic response of potassium conductance,  $g_K$ , for step increase and decrease of  $V$ ; (b) and (c) Dynamic response of potassium,  $g_K$ , and sodium,  $g_{Na}$ , conductances for various step increases in  $V$ .



### Potassium conductance

By observing Figure 5.30a and b, one notes that  $g_K$  increases after a step increase in  $V$  in a sigmoidal fashion. However, it decreases exponentially when the stimulus ends. Accordingly, the following description has been proposed for  $g_K$

$$g_K = g_{Kn}^4 \quad (5.98)$$

where  $g_K$  is a constant and  $n$  obeys the differential equation:

$$\tau(v) \frac{dn}{dt} - n_{\infty}(v) - n = 0 \quad (5.99)$$

with  $v = V - V_{eq}$ . This can also be re-written as:

$$\frac{dn}{dt} = \alpha_n(v)(1 - n) - \beta_n(v)n \quad (5.100)$$

where:

$$\tau(v) = \frac{1}{\alpha_n(v) + \beta_n(v)}; \quad n_{\infty}(v) = \frac{\alpha_n(v)}{\alpha_n(v) + \beta_n(v)} \quad (5.101)$$

For values of  $V$  higher than the threshold,  $n(t)$  increases exponentially towards its regimen value and thus activates the potassium current:  $n(t)$  is called the potassium activation. For  $V$  increasing from 0 to  $V_0$ ,  $n(t)$  is described by:

$$n(t) = n_{\infty}(v_0) \left[ 1 - \exp\left(-\frac{t}{\tau_n(v_0)}\right) \right] \quad (5.102)$$

and  $n^4(t)$  is a sigmoidal function (Figure 5.31), whilst for  $V$  decreasing from  $V_0$  to 0  $n(t)$  is given by:

$$n(t) = n_{\infty}(v_0) \exp\left(-\frac{t}{\tau_n(v_0)}\right) \quad (5.103)$$

and  $n^4(t)$  decreases exponentially.

One can estimate the values of  $\alpha_n$  and  $\beta_n$  for each value of  $V$  of the step function by fitting the function to the data. Since the number of  $V$  values was finite, to obtain the values of  $\alpha_n$  and  $\beta_n$  for every value of  $V$  a function was fitted to the  $\alpha_n, \beta_n$  data (Figure 5.32).


### Sodium conductance

By observing Figure 5.30c it can be seen that, after a step increase in  $V$ , the sodium channels are first activated and then de-activated. The following description has been proposed for  $g_{Na}$ :


$$g_{Na}(v) = g_{Na} m^3 h \quad (5.104)$$

where  $m$  and  $h$  obey the differential equation:

$$\frac{dw}{dt} = \alpha_w(1 - w) - \beta_w w \quad (5.105)$$





**Figure 5.31** Dynamics of  $n(t)$  and  $n^4(t)$  following a step increase in membrane voltage.




**Figure 5.32** Fitted values of  $\alpha_n$  and  $\beta_n$ .

where  $w = m$  or  $w = h$ .


The value of  $m$  is small in the steady state, but it is the first to increase after the stimulus and is called sodium activation. The term  $h$  is called sodium de-activation ( $h=0$  means that sodium channels are not active). As with  $g_K$ ,  $\alpha_w$  and  $\beta_w$  are estimated first for the various values of step function after which a curve is fitted to the  $\alpha_w$ ,  $\beta_w$  data (Figure 5.33). The components of  $g_{Na}$  following a step increase in membrane voltage are shown in Figure 5.34, whilst Figure 5.35 shows the function describing  $g_{Na}$  and  $g_K$  during an action potential with Figure 5.36 showing



**Figure 5.33** Curve fitting to the  $\alpha_w$  and  $\beta_w$  data.  $\alpha_w$  and  $\beta_w$  data were obtained by using two different methods A and B.




**Figure 5.34** Components of  $g_{\text{Na}}$  following step increase in membrane voltage.



**Figure 5.35** Conductances  $g_{\text{Na}}$  and  $g_{\text{K}}$  during an action potential.

their gating variables. It is worth noting that since  $\tau_m(V)$  is very much greater than  $\tau_n(V)$  and  $\tau_h(V)$ ,  $m(t)$  responds to voltage variations much faster than  $n$  and  $h$  (Figure 5.36). Thus, the first effect of a step change in membrane voltage is the activation of sodium currents. This process in turn causes a further increase in membrane potential. For elevated values of  $V$ ,  $h$  tends to 0 and thus sodium currents are de-activated, whilst potassium currents are activated, hence returning the system to equilibrium.



**Figure 5.36** Responses of  $m$ ,  $n$  and  $h$  during an action potential.

### 5.5.2 Enzyme Dynamics

The dynamics of chemical processes taking place within the human organism are complex, and only rarely can one truly consider such dynamics to be linear. The nonlinear form of mathematical models in this domain can be illustrated by examining a simple enzyme reaction.

In the simplest of enzyme reactions, an enzyme  $E$  and a chemical substrate  $S$  form an enzyme-substrate complex  $X$ . In turn, this complex decomposes into the original enzyme  $E$  and the reaction product  $P$ . In other words the enzyme acts as a catalyst in this chemical reaction, but remains unchanged at the end of the reaction. The standard chemical representation of this set of reactions is as depicted in equation (5.106):



In other words, the substrate to complex reaction is reversible, whereas the conversion of complex into reaction product can only proceed in the forward direction. The parameters  $k_1$ ,  $k_2$  and  $k_3$  are the constants associated with the respective reactions defining the rates at which they proceed.

If first order reaction dynamics are assumed, these enzyme dynamics can be represented by the following set of differential equations.

$$\frac{ds}{dt} = -k_1se + k_2x \quad (5.107)$$

$$\frac{dx}{dt} = k_1se - (k_2 + k_3)x \quad (5.108)$$

$$\frac{de}{dt} = (k_2 + k_3)x - k_1se \quad (5.109)$$

$$\frac{dp}{dt} = k_3x \quad (5.110)$$

where  $s$ ,  $x$ ,  $e$  and  $p$  are the concentrations of the chemical ingredients S, X, E and P, respectively. The conservation equation:

$$e_0 = e + x \quad (5.111)$$

also applies, where the subscript refers to the initial concentration. In other words, the enzyme exists either in free form, or else chemically combined as complex.

In this model the nonlinearity arises through the term  $k_1 se$ , meaning that there is a component of rate of change of complex that is proportional to the product of the concentrations of substrate and enzyme. The other terms in the model are linear.

Thus, on examining the components of equation (5.107), we see that there is a negative rate of change of concentration of substrate due to the conversion into complex defined by the first nonlinear term on the right-hand side of the equation; and a positive rate of change due to the linear second term corresponding to the conversion of complex back into substrate.

Equation (5.106) represents the simplest possible enzyme reaction. In practice, enzyme dynamics are usually very much more complex, involving additional layers of nonlinearity through the action of multiple substrates, co-enzymes, etc. So the nonlinear model considered above is in fact a highly simplified representation of reality, involving a large number of assumptions.

Returning to the model, since the enzyme present at any time is either still pure substance or has been combined, molecule for molecule, with the substrate as the complex X, a 'steady state' is normally said to exist over the period when the rate of change of substrate concentration,  $dx/dt$  is approximately zero. Providing that the initial concentration of substrate,  $s_0$ , is very much greater than the initial concentration of enzyme,  $e_0$ , then we can write:

$$v = \frac{dp}{dt} = \frac{k_3e_0s}{s + \frac{k_1+k_2}{k_1}} \quad (5.112)$$

which can be re-written as:

$$v = \frac{V_{\max}s}{K_m + s} \quad (5.113)$$

where:

$$V_{\max} = k_3e_0 \quad (5.114)$$

and


$$K_m = \frac{k_2 + k_3}{k_1} \quad (5.115)$$

Equation (5.113) is the Michaelis-Menten equation which was referred to in section 5.2. Thus, if the assumption that  $s_0 \gg e_0$  is valid, the rate law is completely determined by the two parameters  $V_{\max}$  and  $K_m$ . The former is the limiting velocity as  $s \rightarrow \infty$  whilst the latter is the concentration of substrate for which  $v = V_{\max}/2$ . These parameters provide the conventional method for determining the rate law for enzymic reactions.

### 5.5.3 Baroreceptors

Baroreceptors are specialist cells which monitor blood pressure in certain of the main arteries of the body and transmit this information to the central nervous system (CNS). As such, these receptors form part of the short-term feedback mechanisms responsible for the control of blood pressure.

A nonlinear approach to modeling is necessary in order to capture the dynamic behavior of these receptors. The basis of this approach is presented below. The overall relationship between blood pressure,  $P$ , and the baroreceptor output function,  $B$ , will be developed in the form of the block diagram shown in Figure 5.37, where  $s_A - s_D$  are dummy variables. This block diagram indicates that  $B$  is given by a linear combination of a dynamic estimate ( $s_C$ ) of the positive derivative ( $s_A$ ) and the dynamic mean pressure estimate ( $s_B$ ), together with a threshold pressure below which the baroreceptor does not fire. A further constraint is incorporated into the model in order to ensure that the firing rate is always positive (Leaning *et al.*, 1983).



**Figure 5.37** Block diagram representation of the relationship between blood pressure,  $P$ , and the baroreceptor output,  $B$  (adapted from Leaning *et al.*, 1983).

The equations for each baroreceptor area can be developed as follows:

$$s_A = \frac{dP^+}{dt} \quad (5.116)$$

that is to say that  $s_A = dP/dt$  for  $(dP/dt) > 0$ , and  $s_A = 0$  otherwise.

$$\frac{ds_B}{dt} = \frac{P - s_B}{\tau_1} \quad (5.117)$$

$$\frac{ds_C}{dt} = \frac{s_A - s_C}{\tau_2} \quad (5.118)$$

$$s_D = s_B + K_C s_C - K_D \quad (5.119)$$

and:

$$B_2 = s_D^+ \quad (5.120)$$

that is to say that there is a firing of the baroreceptor whenever  $s_D$  is positive ( $s_D^+$ ). As depicted in Figure 5.37,  $K_D$  is the threshold below which firing of the baroreceptor does not occur, and  $K_C$  is the average contribution of the positive pressure derivative term over one cardiac cycle. In the model,  $K_C$  is estimated by assuming that the average value of  $K_C s_C$  over one cycle is 60 (Leaning *et al.*, 1983), that is:

$$\frac{1}{T_H} \int_0^{T_H} K_C s_C dt = 60$$


or

$$K_C = \frac{60T_H}{\int_0^{T_H} s_C dt} \quad (5.121)$$

where  $T_H$  is the heart period, i.e. one cardiac cycle. Thus, for normal values of heart rate and blood pressure the value of  $K_C$  calculated in this fashion is approximately 1.0.

The effective input to the CNS can then be assumed to be a static linear function of the output of the aortic arch baroreceptor  $B_{AA}$  and the carotid sinus baroreceptor  $B_{CS}$ , where these are the two baroreceptor locations designated respectively by the subscripts AA and CS. The combination of these two baroreceptor outputs is depicted in Figure 5.38. Hence:

$$B = \alpha B_{CS} + (1 - \alpha) B_{AA} \quad (5.122)$$



**Figure 5.38** Combination of two baroreceptor outputs (adapted from Leaning *et al.*, 1983).



where  $\alpha$  is typically assumed to be 0.7. In formulating this model it should be noted that the nonlinearity has arisen as a result of the unidirectionality of the baroreceptor response; that is, it fires only when the rate of change of pressure in the blood vessel in question is positive.


### 5.5.4 Central Nervous Control of Heart Rate

This nonlinear approach to modeling can be adopted in a similar manner in relation to the CNS control of heart rate. In this case a two region dynamic formulation is adopted, one for blood pressures above normal and the other for pressures below normal. For raised blood pressure, the CNS input function  $B$  is greater than a threshold value  $K_E$  and the dynamics of this region (region A) are approximated by a first order system. This is described by the following equations in which  $U$  is a CNS variable. These equations form components of the block diagram shown in Figure 5.39 (Leaning *et al.*, 1983):

$$U_A = \begin{cases} (B - K_E), & B > K_E \\ 0, & B \leq K_E \end{cases} \quad (5.123)$$

$$U_B = \begin{cases} 1.5, & \frac{dU_A}{dt} > 0 \\ 4.5, & \frac{dU_A}{dt} \leq 0 \end{cases} \quad (5.124)$$

$$\frac{dU_C}{dt} = \frac{(U_A - U_C)}{U_B} \quad (5.125)$$



**Figure 5.39** Block diagram model for CNS control of heart rate, relating baroreceptor function as input to the output of the heart period (adapted from Leaning *et al.*, 1983).

For the other region (region B), the dynamics are approximated by a second order system described by the following equations:

$$U_D = \begin{cases} K_E, & B > K_E \\ 0, & B \leq K_E \end{cases} \quad (5.126)$$

$$\frac{dU_E}{dt} = \frac{U_D - U_E}{\tau_3} \quad (5.127)$$

$$\frac{dU_F}{dt} = \frac{U_E - U_F}{\tau_4} \quad (5.128)$$

The overall response of the heart rate controller, which is a linear combination of the outputs of regions A and B, is given by:

$$U_G = K_F(U_C + U_F) \quad (5.129)$$

where  $U_G$  represents a continuously varying estimate of the heart rate which is utilized in the next cardiac cycle, subject to the following constraint, which limits the heart rate,  $f_H$ , to lie in the range 30–200 beats per minute:

$$U_H = \begin{cases} 2.0, & U_G \geq 2.0 \\ U_G, & 0.3 < U_G < 2.0 \\ 0.3, & U_G \leq 0.3 \end{cases} \quad (5.130)$$

Taken together, this set of model equations can be represented by the block diagram depicted in Figure 5.39 above which relates baroreceptor function as input to the output of the heart period.

### 5.5.5 Compartmental Modeling

Compartmental models are a class of dynamic (i.e. differential equation) models derived from mass balance considerations which are widely used for studying quantitatively the kinetics of materials in physiological systems. Materials can be either exogenous, such as a drug or tracer, or endogenous, such as a substrate or hormone, and kinetics include processes such as the production, distribution, transport, utilization, and substrate-hormone control interactions.

Compartmental models have been widely employed for solving a broad spectrum of physiological problems related to the distribution of materials in living systems in research, diagnosis and therapy at whole-body, organ and cellular levels. Examples and references can be found in a number of books including Gibaldi and Perrier (1982), Carson *et al.* (1983), Godfrey (1983), Jacquez (1996), Cobelli *et al.* (2000) and Carson and Cobelli (2001). We have already seen some examples of linear compartmental models in section 5.3. Here we shall define and discuss the general nonlinear compartmental model.

Let us begin with some definitions. A compartment is a quantity of material that acts as though it is well-mixed and kinetically homogeneous. A compartmental model consists of a finite number of compartments with specified interconnections among them. The interconnections represent fluxes of material which physiologically constitute transport from one location to another or a chemical transformation or both. These fluxes of material can be controlled not only by the two interconnected compartments, but also by other compartments of the system.

Given these introductory definitions, it is useful before explaining well-mixed and kinetic homogeneity to consider possible candidates for compartments. Consider the notion of a compartment as a physical space. Plasma is a candidate for a compartment; a substance such as plasma glucose could be a compartment. Zinc in bone could be a compartment, as could thyroxine in the thyroid gland. In some experiments, different substances could be followed in plasma; plasma glucose, lactate and alanine provide examples. Thus, in the same experiment there can be more than one plasma compartment, one for each of the substances being studied. This notion also extends beyond plasma: glucose and glucose-6-phosphate could be two different compartments inside a liver cell. Thus, a physical space may actually represent more than one compartment.

In addition, one must distinguish between compartments that are accessible and those that are non-accessible for measurement. Researchers often try to assign physical spaces to the non-accessible compartments. This is a very difficult problem which is best addressed once it is understood that the definition of a compartment is actually a theoretical construct which may, in fact, lump material from several different physical spaces in a system. To equate a compartment with a physical space depends upon the system under study and assumptions about the model.

With these notions of what might constitute a compartment, it is easier to define the concepts of well-mixed and kinetic homogeneity. 'Well-mixed' means that any two samples taken from the compartment at the same time would have the same concentration of the substance being studied, and therefore be equally representative. Thus the concept of well-mixed relates to uniformity of information contained in a single compartment.

Kinetic homogeneity means that every particle in a compartment has the same probability of taking the pathways leaving the compartment. Since, when a particle leaves a compartment, it does so because of metabolic events relating to transport and utilization, it means that all particles in the compartment have the same probability of leaving due to one of these events.


The notion of a compartment, i.e. lumping material with similar characteristics into collections that are homogeneous and behave identically, is what allows one to reduce a complex physiological system into a finite number of compartments and pathways. The required number of compartments depends both on the system being studied and on the richness of the experimental configuration. A compartmental model is clearly unique for each system studied, since it incorporates known and hypothesized physiology and biochemistry. It provides the investigator with insights into the system structure and is as good as the assumptions that are incorporated in the model.

### The model

Let Figure 5.40 represent the  $i$ -th compartment of an  $n$ -compartment model, in which  $Q_i \geq 0$  denotes the mass of the compartment. The arrows represent fluxes into and out of the compartment. The fluxes into the compartment from outside the system, i.e. endogenous (*de novo* synthesis of material) and exogenous inputs are represented by  $P_i$  and  $U_i$  respectively. The flux to the environment and therefore out of the system is given by  $F_{0i}$ , the flux from compartment  $i$  to  $j$  by  $F_{ji}$  and the flux from compartment  $j$  to  $i$  by  $F_{ij}$ . All fluxes are  $\geq 0$ . The general equations for the compartmental model are obtained by writing the mass balance equation for each compartment:

$$\dot{Q}_i(t) = \sum_{\substack{j=1 \\ j \neq i}}^n F_{ij}(t) - \sum_{\substack{j=1 \\ j \neq i}}^n F_{ji}(t) + P_i(t) - F_{0i}(t) + U_i(t) \quad Q_i(0) = Q_{i0} \quad i = 1, 2, \dots, n \quad (5.131)$$

where  $Q_{i0}$  denotes the mass in the compartment at time 0. In equation (5.131) some terms may be zero, e.g.  $U_i$  and  $P_i$  would be zero if there was no exogenous or endogenous input, respectively.



**Figure 5.40** The  $i$ -th compartment with its input and output fluxes and the output measurement of concentration.

Fluxes  $F_{ij}$  are in general functions of all compartmental masses  $Q_1, Q_2, \dots, Q_n$  and sometimes also of time (for the sake of simplicity we shall ignore this dependency here):

$$F_{ij}(t) = F_{ij}[Q_1(t), Q_2(t), \dots, Q_n(t)] \quad i = 0, 1, 2, \dots, n; \quad j = 1, 2, \dots, n; \quad j \neq i \quad (5.132)$$

A similar dependence on  $Q_1, Q_2, \dots, Q_n$  can also apply for each of the  $P_i$ .

Not all compartments are usually accessible to measurement, as already indicated. Let us assume that we can measure the concentration of the material in  $M$  compartments. Then one can couple equation (5.131) with the measurement equation:

$$C_i(t) = \frac{Q_i(t)}{V_i} \quad i \in M \quad (5.133)$$

where  $V_i$  denotes the volume of the compartment.

It is always possible to write equation (5.132) as:

$$F_{ij}[Q_1(t), Q_2(t), \dots, Q_n(t)] = k_{ij}[Q_1(t), Q_2(t), \dots, Q_n(t)]Q_j(t) \\ i = 0, 1, 2, \dots, n; j = 1, 2, \dots, n; j \neq i \quad (5.134)$$

where  $k_{ij}$  is defined as the fractional transfer coefficient from compartment  $j$  to  $i$ . With this definition one has:

$$k_{ij}[Q_1(t), Q_2(t), \dots, Q_n(t)] \geq 0 \quad i = 0, 1, 2, \dots, n; j = 1, 2, \dots, n; j \neq i \quad (5.135)$$

Thus, by substituting equation (5.134) into equation (5.131), the system of equations:

$$\dot{Q}_i(t) = \sum_{\substack{j=1 \\ j \neq i}}^n k_{ij}[Q_1(t), Q_2(t), \dots, Q_n(t)]Q_j(t) \\ - \sum_{\substack{j=1 \\ j \neq i}}^n k_{ji}[Q_1(t), Q_2(t), \dots, Q_n(t)]Q_i(t) + P_i[Q_1(t), Q_2(t), \dots, Q_n(t)] \\ - k_{0i}[Q_1(t), Q_2(t), \dots, Q_n(t), t]Q_i(t) + U_i(t) \quad i = 1, 2, \dots, n \quad (5.136)$$

describes the generic  $n$ -compartment nonlinear model.

There are several candidate mathematical descriptions of the  $k_{ij}$  functional dependencies. The simplest one is that where there is no control on  $k_{ij}$ , i.e.  $k_{ij}$  is a constant:

$$k_{ij}[Q_1(t), Q_2(t), \dots, Q_n(t)] = k_{ij} \quad (5.137)$$

and thus:

$$F_{ij}(t) = k_{ij}Q_j(t) \quad (5.138)$$

i.e. the flux is a linear function of  $Q_j$  (see Figure 5.41).


A more realistic description, allowing a saturation control from the source compartment, is that of Michaelis-Menten:

$$k_{ij}[Q_j(t)] = \frac{V_M}{K_m + Q_j(t)} \quad (5.139)$$

and thus:

$$F_{ij}[Q_j(t)] = \frac{V_M Q_j(t)}{K_m + Q_j(t)} \quad (5.140)$$

where  $V_M$  is the saturation value and  $K_M$  is the value of  $Q_j$  giving  $V_M/2$  (Figure 5.41). It is of interest to note that for  $Q_j \ll K_M$ , equation (5.139) becomes equation (5.137)



**Figure 5.41** Four examples of functional dependence of flux between compartments: (a) no control; (b) control from the source compartment; (c) control from the remote compartment; and (d) control from source and remote compartments.

with  $k_{ij} = V_M/K_M$ . This means that the Michaelis-Menten relation starts linearly for small values of  $Q_j$ . This is a potential limitation in certain situations, e.g. in addition to saturation, the threshold phenomenon is also often present in physiological systems.

This additional complexity is taken care of by the Hill relationship:

$$k_{ij}[Q_j(t)] = \frac{V_M Q_j^{q-1}(t)}{K_m + Q_j^q(t)} \quad (5.141)$$

with  $q$  being a positive integer. Note that for  $q = 1$  the Hill relation collapses to the Michaelis-Menten form.

Control usually also occurs from compartments other than  $Q_j$ , say  $Q_h$ . For instance, one can have linear control of  $k_{ij}$  from  $Q_h$ :

$$k_{ij}[Q_h(t)] = \alpha + \beta Q_h(t) \quad (5.142)$$

or linear plus derivative control from  $Q_h$ :

$$k_{ij}[Q_h(t)] = \alpha + \beta Q_h(t) + \gamma \dot{Q}_h(t) \quad (5.143)$$

It should be noted that linear parametric control on  $k_{ij}$  implies nonlinear dependence of the flux  $F_{ij}$ , e.g. for equation (5.142) one has:

$$F_{ij}[Q_j(t)] = k_{ij}[Q_h(t), Q_j(t)]Q_j(t) = \alpha Q_j(t) + \beta Q_j(t)Q_h(t) \quad (5.144)$$

The control compartment  $Q_h$  can also coincide with the destination compartment  $Q_i$ . In this case an example is provided by the Langmuir relation (see Figure 5.41):

$$\begin{aligned} k_{ij}[Q_i(t)] &= \alpha \left[ 1 - \frac{Q_i(t)}{\beta} \right] & Q_i < \beta \\ k_{ij}[Q_i(t)] &= 0 & Q_i \geq \beta \end{aligned} \quad (5.145)$$

It is also possible that control occurs from more than one compartment. An example of this is shown in Figure 5.41 where the parameters of the Michaelis-Menten relationship describing  $k_{02}$  are functions of  $Q_3$ , thus giving:

$$k_{02}[Q_2(t), Q_3(t)] = \frac{V_M[Q_3(t)]}{K_m[Q_3(t)] + Q_2(t)} \quad (5.146)$$

It is useful to put the compartmental model (5.136) and (5.133) in compact vector-matrix notation. To do so, let us define:

$$\begin{aligned} k_{ii}[Q_1(t), Q_2(t), \dots, Q_n(t)] &= -k_{0i}[Q_1(t), Q_2(t), \dots, Q_n(t)] \\ &\quad - \sum_{\substack{j=1 \\ j \neq i}}^n k_{ji}[Q_1(t), Q_2(t), \dots, Q_n(t)] \end{aligned} \quad (5.147)$$

Equations (5.136) and (5.131) thus become:

$$\begin{aligned}\dot{Q}_i(t) &= \sum_{j=1}^n k_{ij}[Q_1(t), Q_2(t), \dots, Q_n(t)]Q_j(t) + P_i[Q_1(t), Q_2(t), \dots, Q_n(t)] + U_i(t) \\ Q_i(0) &= Q_{i0}\end{aligned}\quad (5.148)$$

and:

$$C_i(t) = \frac{Q_i(t)}{V_i} \quad i \in M \quad (5.149)$$

Now, defining the vectors:

$$\mathbf{Q}(t) = [Q_1(t), Q_2(t), \dots, Q_n(t)]^T \quad (5.150)$$

$$\mathbf{P}(t) = [P_1(t), P_2(t), \dots, P_n(t)]^T \quad (5.151)$$

$$\mathbf{U}(t) = [U_1(t), U_2(t), \dots, U_n(t)]^T \quad (5.152)$$

$$\mathbf{C}(t) = [C_1(t), C_2(t), \dots, C_m(t)]^T \quad (5.153)$$

one has:

$$\dot{\mathbf{Q}}(t) = \mathbf{K}[\mathbf{Q}(t)]\mathbf{Q}(t) + \mathbf{P}[\mathbf{Q}(t)] + \mathbf{U}(t) \quad \mathbf{Q}(0) = \mathbf{Q}_0 \quad (5.154)$$

$$\mathbf{C}(t) = \mathbf{H}\mathbf{Q}(t) \quad (5.155)$$

where:  $\mathbf{K}[\mathbf{Q}(t)]$  is the compartmental  $n \times n$  matrix and  $\mathbf{H}$  is the measurement  $m \times n$  matrix.

The compartmental matrix has some properties which arise from the mass balance principle upon which compartmental models rely, namely:

$$k_{ii}[\mathbf{Q}(t)] \leq 0 \quad \text{for all } i \quad (5.156)$$

$$k_{ij}[\mathbf{Q}(t)] \geq 0 \quad \text{for all } i \neq j \quad (5.157)$$

In addition,  $\mathbf{K}[\mathbf{Q}(t)]$  is diagonally dominant with respect to columns, i.e.:

$$|k_{ii}[\mathbf{Q}(t)]| \geq \sum_{\substack{j=1 \\ j \neq i}}^n |k_{ji}[\mathbf{Q}(t)]| = \sum_{\substack{j=1 \\ j \neq i}}^n k_{ji}[\mathbf{Q}(t)] \quad \text{for all } i \quad (5.158)$$

$$\text{since } \sum_{j=1}^n k_{ji}[\mathbf{Q}(t)] = \sum_{\substack{j=1 \\ j \neq i}}^n k_{ji}[\mathbf{Q}(t)] + k_{ii}[\mathbf{Q}(t)] = -k_{oi} \leq 0 \quad (5.159)$$


By using properties of (5.156) to (5.158), one can state some stability properties of nonlinear compartmental models (Jacquez and Simon, 1993).



An interesting class of compartmental models is that where  $K$  is a constant matrix, i.e.  $k_{ij}[Q(t)] = k_{ij}$ . In this case one has:


$$\dot{Q}(t) = K \cdot Q(t) + P(t) + U(t) \quad (5.160)$$

and compared to the nonlinear case it is relatively easy to state the stability properties (Jacquez and Simon, 1993). It can be shown that no eigenvalues can have positive real parts and that there are no purely imaginary eigenvalues. This means that all the solutions are bounded and if there are oscillations they must be damped. Also, for particular classes of linear compartmental models, such as mamillary and catenary models (see Figure 5.42), the eigenvalues are always real.



**Figure 5.42** Examples of mamillary and capillary compartmental models.

It is worth commenting that whilst physiological systems almost invariably exhibit nonlinear dynamics, the linear dynamic model of equation (5.160) is very useful due to an important result. The kinetics of a tracer in a constant steady-state system, linear or nonlinear, is linear with constant coefficients. An example is shown in Figure 5.43. This can be used to study tracer glucose kinetics in the steady-state at the whole-body level. Linear compartmental models, in conjunction with tracer experiments, have been used extensively in studying the distribution of materials in living systems at whole-body, organ and cellular levels. Examples and references can be found in Carson *et al.* (1983), Jacquez (1996), Cobelli *et al.* (2000) and Carson and Cobelli (2001).




**Figure 5.43** The linear compartmental model of glucose kinetics.

An interesting application of linear compartmental models at the organ level is in describing the exchange of materials between blood, interstitial fluid, and cellular tissue from multiple tracer indicator dilution data. Compartmental models provide a finite difference approximation in the space dimension of a system described by partial differential equations which may be more easily resolved from the data. These models are discussed in Jacquez (1985). An example of a model describing glucose transport and metabolism in human skeletal muscle is shown in Figure 5.44 (Saccomani *et al.*, 1996). This model is, in some sense, the compartmental alternative to the distributed modeling discussed in section 5.4.1 for describing blood-tissue exchange. The two models clearly rely on different assumptions and exhibit different degrees of parsimony.

### 5.5.6 Insulin Receptor Regulation

Representing the dynamics of insulin receptor regulation offers another example of nonlinear modeling. A conceptual representation of the model is given in Figure 5.45, showing the cell and the processes being modeled (Quon and Campfield, 1991). Surface and intracellular pools of insulin receptors are connected by the rate constants for receptor translocation between the two pools (rates of bound and unbound receptor internalization and receptor recycling); receptor synthesis and the degradation of intracellular receptors. No distinction is made in the model between insertion into the cell membrane of newly synthesized receptors and insertion of receptors which have been internalized, bound or unbound, and then retro-endocytosed. In the model it is assumed that all processes are characterized by first order rate constants, with the exception of receptor synthesis which is modeled as a zero order state dependent process. More complex representations were considered, including higher order rate constants and saturable processes. However, insufficient data were available to justify such more complex forms of model representation.



**Figure 5.44** Compartmental model of transport and metabolism of glucose in skeletal muscle. P denotes plasma; P&ISF denotes plasma and interstitial fluid; C denotes cell; and RBC represents red blood cells. Parameters  $k_{in}$ ,  $k_{out}$  and  $k_{met}$  denote glucose transport into and out of the cell and its metabolism.

The mathematical realization of this model is as follows:


$$\dot{x}_1(t) = k_{-1}x_2(t) - [k_1(1 - x_3(t) + k'_1x_3(t))x_1(t)] \quad (5.161)$$

$$\dot{x}_2(t) = [k_1(1 - x_3(t) + k'_1x_3(t))x_1(t) - k_{-1}x_2(t) + k_2 - k_{-2}x_2(t)] \quad (5.162)$$

$$\dot{x}_3(t) = 0 \quad (5.163)$$

where  $x_1$  = number of surface receptors (% total basal receptors);  $x_2$  = number of intracellular receptors;  $x_3$  = fraction of bound receptors;  $k_1$  = unbound receptor internalization rate;  $k'_1$  = bound receptor internalization rate;  $k_{-1}$  = receptor recycling rate;  $k_2$  = state dependent synthesis rate;  $k_{-2}$  = intracellular receptor degradation rate.

The nonlinearity in this model stems from the presence of the multiplicative terms involving the product  $x_3x_1$ . There is a component of positive rate of change in the number of intracellular receptors which is proportional both to the number of surface




**Figure 5.45** A schematic diagram of insulin receptor regulation model. The parameter  $k_1$  is the unbound receptor internalization rate constant,  $k_1'$  is the bound internalization rate constant,  $k_{-1}$  is the receptor recycling rate constant,  $k_2$  is the state dependent receptor synthesis rate constant, and  $k_{-2}$  is the intracellular receptor degradation rate constant. The symbol  $\tau$  denotes a free insulin molecule,  $\vee$  denotes an insulin receptor, and  $\blacktriangledown$  denotes a bound insulin receptor complex.

receptors and to the fraction of bound receptors. All of the other terms in the model are linear, but the presence of this one nonlinear effect means that, overall, the model is nonlinear.

### 5.5.7 Insulin Action Modeling

The ability to measure *in vivo* insulin action is of great value since it is well-established that abnormalities in insulin action are an important determinant of diabetes and other states of glucose intolerance. A model-based noninvasive method to measure insulin action or insulin sensitivity is to resort to an intravenous glucose tolerance test (IVGTT) and to interpret the plasma glucose and insulin concentrations with the so-called minimal model (Bergman *et al.*, 1979). The salient features of this method are discussed later in this chapter, and for a more detailed presentation of the model we refer to Case Study 6 (section 11.6). The glucose-insulin system is a negative feedback system and can be profitably thought of as being composed of the glucose and insulin systems connected by the measured plasma glucose and insulin concentrations (Figure 5.46).

The rationale behind the glucose minimal model is to treat the measured insulin as a known input and to predict the measured glucose concentration. To do so, a description of the glucose kinetics and insulin action must be incorporated into the model. However, with this system decomposition there is no need to simultaneously describe the upper portion of the system, i.e. all processes related to glucose-stimulated insulin




**Figure 5.46** The glucose-insulin system represented as two inter-connected subsystems linked by their measured signals.

secretion, insulin kinetics and degradation. The physiological scheme of the glucose minimal model is shown in Figure 5.47 and its mass balance equations are:

$$\dot{Q}(t) = NHGB(t) - R_d(t) \quad Q(0) = Q_b + D \quad (5.164)$$

$$\dot{I}'(t) = -k_3 I'(t) + k_2 [I(t) - I_b] \quad I'(0) = 0 \quad (5.165)$$

$$G(t) = \frac{Q(t)}{V} \quad (5.166)$$



**Figure 5.47** The glucose minimal model. The rate constants,  $k$ , characterize either material fluxes (solid lines) or control actions (dashed lines).

where  $Q$  is glucose mass, with  $Q_b$  denoting its basal value;  $D$  is the glucose dose;  $NHGB$  is net hepatic glucose balance;  $R_d$  is plasma glucose disappearance rate;  $I'$  is insulin concentration (deviation from basal) in a compartment remote from plasma (interstitial fluid – from where insulin action signaling occurs) and  $I$  is plasma

insulin concentration with  $I_b$  denoting its basal value;  $G$  is plasma glucose concentration, with  $G_b$  denoting its basal value; and  $V$  is the distribution value. Clearly  $G_b V$  equals  $Q_b$ .

NHGB is controlled by glucose and remote insulin:

$$\text{NHGB}(t) = \text{NHGB}_0 - [k_5 + k_6 I'(t)]Q(t) \quad (5.167)$$

where  $\text{NHGB}_0$  is net endogenous glucose balance at zero glucose.

$R_d$  is controlled by glucose and remote insulin:

$$R_d(t) = [k_1 + k_4 I'(t)]Q(t) + R_{d_0} \quad (5.168)$$

where  $R_{d_0}$  is glucose disappearance rate at zero glucose. Thus, by incorporating (5.167) and (5.168) into (5.164), the following expressions are obtained:

$$\dot{Q}(t) = -[(k_5 + k_1) - (k_6 + k_4)I'(t)]Q(t) + (\text{NHGB}_0 - R_{d_0}) \quad Q(0) = Q_b + D \quad (5.169)$$

$$\dot{I}'(t) = -k_3 I'(t) + k_2 [I(t) - I_b] \quad I'(0) = 0 \quad (5.170)$$

$$G(t) = \frac{Q(t)}{V} \quad (5.171)$$

where the term  $(\text{NHGB} - R_{d_0})$  can be written as  $(k_3 + k_1)Q_b$  by using the basal constraint  $dQ/dt = 0$ . The model is nonlinear due to the presence of the product of  $Q$  and  $I'$  in (5.169).

Unfortunately, the model has too many parameters to be resolved, assuming plasma insulin concentration  $I$  as a known input, from plasma glucose concentration data  $G$ , i.e. the model is *a priori* unidentifiable (see Chapter 7). To be resolved numerically, the model must be made more parsimonious by the following reparameterization that is the classic minimal model representation:

$$\dot{Q}(t) = -[p_1 + X(t)]Q(t) + p_1 Q_b \quad Q(0) = Q_b + D \quad (5.172)$$

$$\dot{X}(t) = -p_2 X(t) + p_3 [I(t) - I_b] \quad X(0) = 0 \quad (5.173)$$

$$G(t) = \frac{Q(t)}{V} \quad (5.174)$$

This parameterization has new parameters, the  $p$ 's, and a new variable,  $X$ , which are related to the parameters and variable of the original scheme of Figure 5.47 as follows:

$$X(t) = (k_4 + k_6)I'(t) \quad (5.175)$$

$$p_1 = k_1 + k_5 \quad (5.176)$$

$$p_2 = k_3 \quad (5.177)$$

$$p_3 = k_2(k_4 + k_6) \quad (5.178)$$

The model can thus predict the time course of  $X$ , a variable related to insulin action by an unknown scale factor ( $k_4 + k_6$ ). However, it can also provide an index of insulin action called insulin sensitivity. To do this one needs to formally define insulin sensitivity. Let us first define glucose effectiveness, i.e. the ability of glucose *per se* to enhance its own disappearance:

$$S_G = - \left. \frac{\partial \dot{Q}}{\partial Q} \right|_{ss} \quad (5.179)$$

where  $ss$  denotes steady state. Then, insulin sensitivity is simply the ability of insulin to enhance glucose effectiveness:

$$S_I = - \left. \frac{\partial S_G}{\partial I} \right|_{ss} \quad (5.180)$$


By applying these definitions,  $S_I$  can be calculated as:

$$S_I = \frac{p_3}{p_2} = \frac{k_2(k_4 + k_6)}{k_3} \frac{\text{min}^{-1}}{(\mu\text{U} \cdot \text{ml}^{-1})} \quad (5.181)$$

The intuitive meaning of  $S_I$  is clear from the right-hand side of the expression in terms of the  $k_i$  parameters: it is directly proportional to the stimulatory action on the periphery ( $k_4$ ) and inhibitory action on the liver ( $k_6$ ), but it is also proportional to the insulin input magnitude ( $k_2$ ) and to the time constant of action ( $1/k_3$ ).

### 5.5.8 Thyroid Hormone Regulation

Another model containing a nonlinear element is that developed to increase understanding of physiological mechanisms regulating the thyroid hormones focusing on the relationships between the anterior pituitary and thyroid glands. The basic features of the thyroid hormone regulating system are shown in Figure 5.48. The regulated variables are assumed to be the free concentrations of the two thyroid hormones, thyroxine  $T_4$  and triiodothyronine  $T_3$  in the plasma. Regulation is assumed to take place through feedback of information relating to these two hormones to the anterior pituitary. In this manner the secretion of thyrotrophin (TSH), the thyroid-stimulating hormone, by the anterior pituitary can be modified. TSH is secreted in response to



**Figure 5.48** Conceptual model of the principal features of the thyroid-pituitary axis of the hormone regulatory system.

TRH, the thyrotrophic-releasing hormone that is produced by the hypothalamus. Stimulation of the thyroid gland by TSH brings about the secretion of  $T_3$  and  $T_4$ . These hormones undergo reversible binding to three plasma proteins (TBG, TBPA and albumin). Free (i.e. unbound) hormone is distributed into extravascular sites where breakdown of  $T_3$  and  $T_4$  is assumed to occur. A proportion of  $T_4$  is converted to  $T_3$ .

To gain increased quantitative understanding of the nature of the feedback regulatory system, a number of models have been developed, based on the early work of Saratchandran *et al.* (1976). The fundamental postulates underpinning these models are as follows:

1. Feedback signals act by altering the secretion rate of the hormones produced by the regulated organ.
2. TSH secretion is inhibited by  $T_3$  or  $T_4$  or both. Secretion is proportional to the logarithm of the current level of TRH in the pituitary portal circulation (introducing a nonlinear component here).
3. The secretion rates of  $T_3$  and  $T_4$  are dependent on TSH, there being no autonomous secretion of either thyroid hormone.
4. Destruction of all hormones occurs by means of first order processes.
5. Less than 20% of  $T_3$  production is by direct secretion in the basal state. The remainder is produced by peripheral de-iodination of  $T_4$ .
6. Circulatory mixing dynamics are sufficiently rapid to be ignored.

Let us consider first the mathematical description of the portion of the model describing the dynamics of binding, distribution and disposal of  $T_3$  and  $T_4$  (DiStefano *et al.*, 1975). Each of the hormones is described in terms of a three compartment model representing plasma and two extravascular sites, those with fast and slow dynamics, respectively (Figure 5.49). A linearized model can be adopted in terms of which the following equations can be written defining the rate of change of concentration of the hormone:

$$\frac{dx_1}{dt} = a_1x_1 + a_2x_2 + a_3x_3 + \frac{u_1}{V} \quad (5.182)$$

$$\frac{dx_2}{dt} = a_4x_1 + a_5x_2 + a_6x_5 \quad (5.183)$$


$$\frac{dx_3}{dt} = a_7x_1 + a_8x_3 + a_9x_6 \quad (5.184)$$

$$\frac{dx_4}{dt} = a_{10}x_4 + a_{11}x_5 + a_{12}x_6 + \frac{u_2}{V} \quad (5.185)$$

$$\frac{dx_5}{dt} = a_{13}x_4 + a_{14}x_5 \quad (5.186)$$

$$\frac{dx_6}{dt} = a_{15}x_4 + a_{16}x_6 \quad (5.187)$$





**Figure 5.49** A six compartment model depicting the coupled dynamics of the binding, distribution and disposal of  $T_3$  and  $T_4$ . The thyroid hormone binds to the three proteins thyroid hormone-binding globulin, TBG, thyroid hormone-binding pre-albumin, TBPA, and albumin, AL. (adapted from DiStefano *et al.*, 1975).

where:  $x_1$  = plasma total  $T_3$  concentration;  $x_2$  = fast compartment total  $T_3$  concentration;  $x_3$  = slow compartment total  $T_3$  concentration;  $x_4$  = plasma total  $T_4$  concentration;  $x_5$  = fast compartment total  $T_4$  concentration;  $x_6$  = slow compartment total  $T_4$  concentration;  $u_1$  = rate of secretion of  $T_3$ ;  $u_2$  = rate of secretion of  $T_4$ ;  $V$  = plasma volume,  $a_1, a_2, \dots, a_{16}$  are constant parameters reflecting the various rates of material transfer. Some of these are composite parameters so that, for instance,  $a_1$  reflects transport of  $T_3$  from plasma to both fast and slow compartments.

Since it is assumed that the free fractions of  $T_3$  and  $T_4$  are involved in feedback regulation, equations are required relating free concentration to the total (i.e. free and protein-bound fractions) concentration. The following two algebraic equations provide an approximate description of these dynamics:

$$x_7 = a_{17}x_1 \quad (5.188)$$

$$x_8 = a_{18}x_4 \quad (5.189)$$

In its first form, the following descriptions were assumed for the rates of secretion of  $T_3$  and  $T_4$  and for the dynamics of TSH:

$$u_1 = k_1x_9 \quad (5.190)$$

$$u_2 = k_2 x_9 \quad (5.191)$$

$$\frac{dx_9}{dt} = k_3 \log u_3 - k_4 x_7 - k_5 x_9 \quad (5.192)$$

where  $x_9$  = concentration of TSH in plasma;  $u_2$  = perceived secretion rate of TRH in portal plasma;  $k_1, k_2$  = parameters representing the stimulatory effect of TSH on the thyroid gland;  $k_3$  = parameter representing the stimulatory effect of TRH on the rate of TSH secretion;  $k_4$  = parameter representing the inhibitory effect of free  $T_3$ ;  $k_5$  = rate constant for loss of TSH in plasma.

With values inserted for the various parameters, simulation studies can then be undertaken with the model in order to gain quantitative insights regarding the regulatory processes. However, on the basis of such simulation studies it was found that the model assumptions of proportional control for the rate of release of  $T_3$ , acceptable model responses could not be achieved with the adoption of parameter values which were physiologically plausible. The model was therefore extended by assuming that the rate of release of  $T_3$  is not only proportional to the current concentration of TSH, but also to the cumulated past excess of TSH concentration (compared with the steady-state level). This assumption of proportional and what is known as integral control did lead to results which were plausible with the adoption of physiologically acceptable parameters. In other words, in terms of the model, (5.190) is replaced by (5.193) below:

$$u_1 = k_1 x_9 + k_6 \int_0^t (x_9 - x_{9s}) dt \quad (5.193)$$

where  $x_{9s}$  is the steady-state concentration of TSH and  $k_6$  is a positive parameter.


### 5.5.9 Modeling the Chemical Control of Breathing

Large scale mathematical models of the human respiratory system can play an important role in testing hypotheses concerning the control of breathing. The example presented here incorporates the inspiratory and expiratory processes of breathing and has been used to explore the relationships between the elements of the breathing pattern (inspiratory, TI, and expiratory, TE, times, and tidal volume, VT). By assuming a triangular waveform pattern of breathing, separate controllers are provided for inspiratory and expiratory times. This enables a variety of hypotheses relating to the chemical control of breathing to be investigated.

In developing the model, the respiratory system is presented in conventional control system terms with its two major components of the controlled system and the controller (Sarhan *et al.*, 1988).

#### *The controlled system*

The model adopted for the controlled system is depicted in Figure 5.50. This consists of four major compartments: lung, brain tissue, muscle and other tissue connected by




**Figure 5.50** The model structure of the controlled respiratory system. The rates of change of  $M$  and  $U$  represent  $\text{CO}_2$  production and  $\text{O}_2$  utilization, with the subscripts  $B$ ,  $M$  and  $OT$  corresponding to brain tissue, muscle tissue and other tissue respectively (adapted from Sarhan *et al.*, 1988).

the circulatory bloodstream. The lung is represented as a single chamber of variable volume, thus permitting the generation of oscillating blood gas concentrations and pH in the arterial blood. The model incorporates a dead space corresponding to the portion of the lung in which gas exchange does not occur. This is partly of fixed volume (the anatomical dead space  $V_{D\text{anat}}$ ) and partly expansible, the alveolar dead space  $V_{D\text{alv}}$  which encroaches on the lung volume  $V_L$ . Thus alveolar gas exchanging volume  $V_A$  is equal to  $V_L$  minus  $V_{D\text{alv}}$ .

The model also includes a shunt, whereby a portion of mixed venous blood can bypass the lung. It is assumed that the alveolar gas equilibrates perfectly with end-capillary blood, and that similarly the partial pressures of gases in the tissue compartments are equal to the pressures in the venous blood from that compartment. Mixing within compartments is assumed to be instantaneous and complete.

The full equations for the controlled system describe the rate of change of the blood gases in each of the compartments. They are not given here since the emphasis in this example is in showing how the model can be developed for the controller. They

can be found in Sarhan *et al.* (1988). The equations correspond to: the alveolar gas exchanging and dead space compartments; the tissue compartments; CO<sub>2</sub> and O<sub>2</sub> dissociation curves in blood and tissues; hydrion concentration equations; control of cardiac output and brain blood flow equations; calculation of lag times due to circulatory delays; mixed venous blood; and dead space and shunt. The equations defining gas exchange and metabolism are restricted to carbon dioxide and oxygen.



**Figure 5.51** Pattern of breathing (adapted from Sarhan *et al.*, 1988).

By representing the pattern of breathing with a triangular waveform (as shown in Figure 5.51) separate controllers can be provided for inspiration and expiration, thus enabling relations between the components of the respiratory cycle and chemical drive to be investigated. The instantaneous lung volume is therefore defined by the two equations:

### Inspiration

$$V_A = V_{FRC} + \frac{VT(t - t_0)}{TI} \quad (5.194)$$

where  $V_{FRC}$  is the functional residual capacity,  $VT$  is the tidal volume,  $TI$  is the inspiratory time,  $t$  is time and  $t_0$  is the starting time of the current breath. The rate of change of lung volume,  $dV_A/dt$  is given by:

$$\frac{dV_A}{dt} = \frac{VT}{TI} \quad (5.195)$$

## Expiration


$$V_A = \frac{V_{FRC} + VT - VT(t - t_0)}{TE} \quad (5.196)$$

where TE is the expiratory time and  $dV_A/dt$  during expiration is given by

$$\frac{dV_A}{dt} = -\frac{VT}{TE} \quad (5.197)$$

### The controller

The form of the controller for the pattern of breathing is shown in Figure 5.52. The equations are derived partly on an empirical basis using data derived from Cunningham and Gardner (1977).



**Figure 5.52** Controller of the breathing pattern (adapted from Sarhan *et al.*, 1988).

## Inspiratory flow controller

$$\frac{VT}{TI} = p_1(P_{aCO_2} - p_2) \quad (5.198)$$

where  $P_{aCO_2}$  is the arterial partial pressure of  $CO_2$ .

## Inspiratory time controller

$$TI = p_3 - p_4 VT \quad (\text{for } VT < 2.08 \text{ liters}) \quad (5.199)$$

$$TI = p_5(VT - p_6) + p_7 \quad (\text{for } VT \geq 2.08 \text{ liters}) \quad (5.200)$$

### Expiratory time controller

$$TE = p_8 TI + \frac{p_9}{(P_{aCO_2} - p_2) - p_{10}} \quad (5.201)$$

where  $p_1 - p_{10}$  are parameters evaluated from the data of Cunningham and Gardner (1977) with values:  $p_1 = 0.11$ ;  $p_2 = 35.2$ ;  $p_3 = 1.29$ ;  $p_4 = 0.07$ ;  $p_5 = 0.65$ ;  $p_6 = 0.88$ ;  $p_7 = 0.59$ ;  $p_8 = 0.64$ ;  $p_9 = 11.1$  and  $p_{10} = -2.73$ .

Tidal volume is evaluated from:

$$VT = \left( \frac{VT}{TI} \right) \cdot TI \quad (5.202)$$

where  $(VT/TI)$  is taken from (5.198) and  $TI$  from (5.199) or (5.200), and the total time for one respiratory cycle,  $TT$ , is:

$$TT = TI + TE \quad (5.203)$$

so that the respiratory frequency ( $f$ ) and lung ventilation ( $dV/dt$ ) are given by:

$$f = \frac{60}{TT \text{ min}^{-1}} \quad (5.204)$$

$$\frac{dV}{dt} = f \cdot VT \quad (5.205)$$

thus providing a definition of ventilation as the product of the separately calculated variables, respiratory frequency and tidal volume.


Having developed the basic form of this complex model, it can then be used in simulation studies to test hypotheses and gain quantitative insight regarding the control of breathing in situations such as that of exercise.

## 5.6 TIME-VARYING MODELING

There is a correspondence between nonlinear modeling and model elements that are time-varying. In the examples of nonlinear models presented above, the nonlinear terms were an attempt to incorporate the inherently nonlinear structural effects occurring within the underlying physiology. An alternative means of producing the same effects in terms of dynamic response is to incorporate into a model components which are treated as if they were time-varying.

### 5.6.1 An Example in Cardiac Modeling

An illustration of this time-varying approach to modeling can be seen in a representation of the short-term dynamics of the cardiovascular system (Leaning *et al.*, 1983). The basic structure of the model is depicted in Figure 5.53. The mathematical



**Figure 5.53** Structure of the uncontrolled hemodynamics (adapted from Leaning *et al.*, 1983).

model incorporates differential equations which describe the blood flow dynamics. In arriving at these equations, time-varying representations are adopted for the elastic properties of the heart chambers. In other words, rather than treating such parameters as being constant, as was the case earlier in this chapter, here that simplifying assumption is dispensed with, given that the time scale of this model is seconds and minutes; a time frame in which the time-varying nature of these parameters must be incorporated. The assumption of time-invariance would result in an invalid model, in contrast to a time frame of tens of minutes or hours in which case the simplifying assumption would be valid.

The heart is considered as a set of four separate unidirectional pumps. Cardiac timing events are described by linear approximations based on earlier research of Beneken and De Wit (1967):

$$T_{AS} = 0.1 + 0.09T_H \quad (5.206)$$

$$T_{AV} = T_{AS} - 0 \quad (5.207)$$

$$T_{VS} = 0.16 + 0.2T_H \quad (5.208)$$

where  $T_{AS}$  is the duration of the arterial systole,  $T_{AV}$  is the time between the onset of arterial systole and the onset of ventricular systole,  $T_{VS}$  is the duration of ventricular systole, and  $T_H$  is the heart period.

For a heart period,  $T_H$ , of 0.8 s, corresponding to a heart rate of 75 beats per minute,  $T_{AS} = 0.172$  s,  $T_{AV} = 0.132$  s and  $T_{VS} = 0.32$  s.

The pumping action of the heart is described by the equation relating pressure and volume:

$$P = a(t)[V - V_u] \quad (5.209)$$

where  $a(t)$  is the time-varying elastance function (elastance being the reciprocal of compliance).

The elastance functions for the four heart chambers are given by the equations derived using the time courses of the four elastances shown in Figure 5.54.

$$a_{RA} = x(a_{RAS} - a_{RAD}) + a_{RAD} \quad (5.210)$$

$$a_{RV} = y(a_{RVS} - a_{RVD}) + a_{RVD} \quad (5.211)$$

$$a_{LA} = x(a_{LAS} - a_{LAD}) + a_{LAD} \quad (5.212)$$

$$a_{LV} = y(a_{LVS} - a_{LVD}) + a_{LVD} \quad (5.213)$$

where the subscripts RA, RV, LA and LV refer to the right and left atria and ventricles, and the S and D subscripts correspond to systolic and diastolic values respectively. In (5.210) to (5.213):

$$x = \sin\left(\frac{\pi t_c}{T_{AS}}\right), \quad 0 < t_c < T_{AS} \quad (5.214)$$


$$x = 0, \quad t_c \geq T_{AS}$$

$$y = 0, \quad t_c \leq T_{AV}$$

$$y = \sin\left[\frac{\pi(t_c - T_{AV})}{T_{VS}}\right], \quad T_{AV} < t_c < (T_{AV} + T_{VS}) \quad (5.215)$$

$$y = 0, \quad t_c \geq (T_{AV} + T_{VS})$$





**Figure 5.54** Elastances of the four heart chambers (adapted from Leaning *et al.*, 1983).

The minimum (diastolic) and maximum (systolic) values of elastance are given by:

$$a_D = \frac{P_D}{V_D - V_u}; \quad a_S = \frac{P_S}{V_S - V_u} \quad (5.216)$$

where  $t_c$  is the elapsed time during each cardiac cycle ( $0 \leq t_c \leq T_H$ ),  $V$  is volume and the subscript  $u$  denotes its unstressed value.

These time-varying components can then be incorporated into the differential equations to describe the pressure/flow dynamics during the cardiac cycle. As an

illustration, consider the right atrium. This can be modeled by the following set of equations:

$$P_{RA} = a_{RA}(t)[V_{RA} - V_{uRA}] \quad (5.217)$$

$$\frac{dV_{RA}}{dt} = F_1 - F_{RARV}, \quad V_{RA} \geq 0 \quad (5.218)$$

$$F_{RARV} = \frac{P_{RA} - P_{RV}}{R_{RARV}}, \quad P_{RA} > P_{RV}$$

$$F_{RARV} = 0, \quad P_{RA} \leq P_{RV} \quad (5.219)$$

$$F_1 = F_{SVCRA} + F_{IVCRA} + F_{BRONC} + F_{COR} \quad (5.220)$$

Double subscripts relate to flow,  $F$ , and resistance,  $R$ , between heart chambers, e.g.  $F_{RARV}$  corresponds to flow from right atrium to right ventricle. The four terms on the right of (5.220) are the flows from superior vena cava to right atrium, inferior vena cava to right atrium, bronchial flow and coronary flow respectively.

Equation (5.219) approximates the action of the tricuspid valve with  $R_{RARV}$  being the resistance of the fully opened valve.  $F_1$  represents the total inflow of the right atrium.

The basic flows through the coronary and bronchial vascular beds are given by:

$$F_{COR} = \frac{P_{AO1} - P_{RA}}{R_{COR}} \quad (5.221)$$

$$F_{BRONC} = \frac{P_{AO3} - P_{RA}}{R_{BRONC}} \quad (5.222)$$

where the subscripts AO1 and AO3 correspond to ascending aorta and thoracic aorta respectively.

The right atrial inlet contraction which assists the pumping action introduces resistance to the inflow. Whilst this is negligible in the case of bronchial and coronary flow, it is a significant effect in the case of blood flow from the inferior and superior venae cavae, represented in the model by equations (5.223) and (5.224).

$$F_{IVCRA} = F_9, \quad F_9 \geq 0$$

$$F_{IVCRA} = 0.1F_9, \quad F_9 < 0 \quad (5.223)$$

$$F_{SVCRA} = F_{10}, \quad F_{10} \geq 0$$

$$F_{SVCRA} = 0.1F_{10}, \quad F_{10} < 0 \quad (5.224)$$

where  $F_9$  and  $F_{10}$  are the respective flows, assuming no contraction.

In a similar manner, we can write equations describing the dynamics occurring in the left atrium, taking into consideration the action of the mitral valve.

Thus we have demonstrated an example of how time-varying behavior can be incorporated into model parameters. This illustration in the context of the short-term

dynamics of the cardiovascular system has also demonstrated some of the physiological complexity that may need to be included in the model if it is to provide a valid representation of what is undoubtedly complex physiology.

## 5.7 STOCHASTIC MODELING

Deterministic models are widely, and successfully, used to provide quantitative descriptions of the dynamics of a wide variety of types of physiological systems. All of the models considered so far in this chapter have been of a deterministic form, whether the mathematical realization was lumped or distributed, linear or nonlinear. In some cases, however, particularly when modeling physiological phenomena at the cellular level, a purely deterministic approach is not adequate. Such an approach fails to take account of probabilistic effects. Probabilistic (random) effects that are particularly important in the modeling of metabolic processes are those that evolve over time. Such effects are known as *stochastic processes*.

Stochastic processes can be incorporated into models of physiological systems in a number of ways. One particular class of deterministic model that has been extended to embrace certain forms of stochasticity is the one where the formulation involves a description in terms of a number of interconnected compartments. In this case the stochasticity is incorporated into the basic elements of the compartmental model in one of two ways. The first is to treat the compartmental variables as being stochastic variables, with the time-invariant or time-varying transport rate parameters defining flux between compartments as being deterministic. The alternative approach is to incorporate the intrinsic stochasticity into the transfer rate parameters. In this second case, the stochasticity in the transfer rate parameters can arise from a number of factors, including interindividual variability; variation of system parameters as functions of time, drug concentrations, cell membrane volume/area ratios; measurement and sampling conditions; environmental effects; and so on. It is also possible to combine the two types of representation of stochasticity, in both variables and parameters, into a single model.


### 5.7.1 Cellular Modeling

For a classic example of the formulation of a stochastic model, let us consider the processes occurring at the cellular level by which granulocyte-macrophage progenitor cells proliferate and differentiate. Francis and Leaning (1985) produced a model which included all the major processes associated with such proliferation and differentiation such that it could be validated quantitatively using data from *in vitro* experiments.

#### *The conceptual model*

The conceptual basis of the proposed mathematical model is shown in Figure 5.55. In this, the population of cells in the granulocyte-macrophage differentiation pathway

is partitioned into a set of distinct generations. The model also incorporates the observed association between the proliferation and differentiation processes, in that movement between successive generations occurs through cell division (shown as double-headed arrows).



**Figure 5.55** Conceptual form of the cellular stochastic model. The boxes represent successive generations in the granulocyte differentiation pathway, from the first generation (1) of committed progenitor cells, to the final generation (N), incapable of further division, corresponding to mature granulocytes. Proliferation and differentiation (double-headed arrows) are induced by the specific growth stimulus gm-CSA (open arrows). Vertical arrows indicate loss of cells from each generation by death rather than transition to the next generation (adapted from Francis and Leaning, 1985).

The input to this system of cell production is the first generation of granulocyte-macrophage progenitor cells, which is treated as a time-dependent supply rate. The final generation of cells in the model is mature neutrophil granulocytes which can divide no further. Between these extremes lie intermediate stages corresponding to later progenitors and recognizable granulocyte precursors (including myeloblasts, promyeloblasts and myelocytes).

The processes of proliferation and differentiation are under the control of at least one agent. Operationally this is termed granulocyte-macrophage colony-stimulating activity (gm-CSA), and this is required at each stage for progression down the pathway of the conceptual model shown in Figure 5.55.

An important implication of the model is that when a sample of marrow cells are seeded *in vitro*, cells of different generations have a different capacity with respect to the size of clone that they are able to produce. Clone size is a function of the number of cell divisions before the mature cell generation is reached. For a cell seeded in generation I, the theoretical maximum size of a clone is  $2^{(N-i)}$ , where N is the number of generations between the first and final generations of cells.


The occurrence of a proliferation/differentiation event depends monotonically on the level of gm-CSA, but is subject to random variations. The system is therefore modeled as a stochastic process, adopting probability distributions which are functions of the concentration of gm-CSA. In the model, the level of gm-CSA determines the probability that a cell will divide per unit time into the next generation. Since the process of DNA replication and cell division occupies a certain minimum time, the model adopts an eight hour time unit, so that two successive divisions could not take place

within this time span (Francis and Leaning, 1985). It is also assumed in the model that at each stage there is a small but finite probability of cell death.

The division of granulocyte-macrophage progenitor cells is not totally synchronous. The fate of any individual cell in a particular generation within the model is either to divide to the next generation, to die, or to remain in the same cell generation for later action. The model is thus asynchronous despite the fact that discrete time points are adopted. In addition to cell differentiation giving to each successive generation of cells a change limiting the number of cell divisions before mature end cell production, the model also incorporates a graduated change in the sensitivity of the cell to gm-CSA; so, in the model, for each generation of cells, the greater the level of gm-CSA the larger the probability of proliferation/differentiation. Also, as each new stage in the pathways is reached, the cells become increasingly sensitive to CSA and thus are more likely to reach completion.

#### *The mathematical model*

An annotated version of Figure 5.55 is shown as Figure 5.56, where the parameters used in the mathematical formulation are included. The variable  $k$  represents each discrete time unit of eight hours. Hence values of  $k$  of 0, 1, 2, etc. correspond to real times of 0, 8 and 16 hours, etc. The stochastic nature of the model is governed by two sets of probabilities:  $p_i$  is the probability that a cell in generation  $I$  divides to become two cells in generation  $i + 1$  during the time interval from  $k$  to  $k + 1$ , and  $\alpha_i$  is the probability that a cell in generation  $I$  dies in the same time interval  $k$  to  $k + 1$ .




**Figure 5.56** The mathematical model (adapted from Francis and Leaning, 1985).

Since a cell must either divide, die or do nothing, it follows that  $p_i + \alpha_i \leq 1$ . The probability that a cell remains in the same generation for the next time period is thus  $1 - p_i - \alpha_i$ . The dependency upon age in the processes of proliferation and differentiation and death within a generation is neglected except in that there is a delay of eight hours before any event occurs. When cells reach generation  $N$ , they are mature neutrophil granulocytes which are incapable of proliferation and thus  $p_N = 0$ .

$A(k)$  is the supply rate of generation 1 cells over the time interval  $k$  to  $k + 1$ . This is used only in calculating the proportions of cells in each generation *in vivo*. It is not used in *in vitro* simulations.

Figure 5.57 shows the relationship between the probability of proliferation/differentiation and gm-CSA dose for each cell generation. This set of probability functions incorporates the two main features of the conceptual model, namely increasing

probability of proliferation/differentiation with increasing gm-CSA for each individual generation, and increasing sensitivity to gm-CSA with transition to each successive generation.



**Figure 5.57** Relationship between the probability of a proliferation/differentiation event and gm-CSA level for different cell generations (gm-CSA in arbitrary units);  $p_1 - p_9$  are the probability functions for generations 1 to 9, respectively ( $p_{10} = 0$ );  $p_{\max}$  is the maximum probability of a proliferation/differentiation event within any one time interval,  $p_{\min}$  the minimum. For simplicity, the slopes of the probability functions over their operating ranges are assumed to be equal. The threshold sensitivities of the generations to CSA are given by  $d_1 - d_9$  (adapted from Francis and Leaning, 1985).

It should be noted that in Figure 5.57 the maximum probability of proliferation/differentiation over a single time interval is less than unity. This allows for a distribution of cell survival times before proliferation/differentiation even when there is maximal CSA stimulation. For example, if  $p_{\max} = 0.3$ , approximately 59% of cells will have undergone a proliferation/differentiation event in 24 hours, and 72% in 48 hours under conditions of maximal gm-CSA stimulation. This allows for 10% cell death per unit time.

In order to provide a complete stochastic description of the system of interest, it would be necessary to incorporate difference equations for the probability distributions of the number of cells in each generation at any time. Such a representation would be extremely complicated to formulate. In this example, therefore, a simpler approach has been adopted. This involves the setting up of a set of recursive difference

equations in terms of the mean or expected number of cells  $n_i(k)$  in generation  $i$  at time  $k$ :

$$\begin{aligned} n_i(k+1) &= A(k) + N_1(k)(1 - p_i - \alpha_i) \\ n_i(k+1) &= 2n_{i-1}(k)p_{i-1} + n_i(k)(1 - p_i - \alpha_i), \quad i = 2, 3, \dots, N \end{aligned} \quad (5.225)$$

Having formulated the mathematical model in this fashion, simulation studies can then be carried out in order to obtain a quantitative understanding of the results of *in vitro* cellular experiments.

### 5.7.2 Insulin Secretion

A classic example of stochastic modeling can be found in the realization developed by Grodsky (1972) to represent short-term glucose-stimulated insulin secretion. This model focused on phenomena occurring at organ level, in this case relating to the pancreas.

Consider a process  $v$  that is controlled by the concentration  $S$  of a substance. The process is said to be a threshold process if there exists a value  $\theta$  of the concentration such that:

$$v = 0, \quad \text{if } S < \theta \quad (5.226)$$

$$v = f(S, \theta), \quad \text{if } S \geq \theta \quad (5.227)$$

Now consider a secretory process controlled by a stimulus  $S$  for the case where the substance does not behave in a homogeneous manner with respect to  $S$ , but can be regarded as being formed of a number of *packets*. For each packet the release mechanism is a threshold process. With each packet a value of concentration  $\theta$  may be associated so that:

If  $S < \theta$ , the packet cannot release the substance (it is closed)

If  $S \geq \theta$ , the packet can release the substance (it is open)

Under these conditions, there exists a probability density function of the threshold,  $\xi(\theta, t)$ , so that  $\xi(\theta, t) d\theta$  represents the quantity of substance contained in the packets the threshold of which lies between  $\theta$  and  $\theta + d\theta$ , which can be released when the stimulus passes from  $\theta$  to  $\theta + d\theta$ . The quantity of substance,  $X$ , that can be released for a certain value of the stimulus at time  $t$ ,  $S(t)$  is given by:


$$X(S, t) = \int_0^{S(t)} \xi(\theta, t) d\theta \quad (5.228)$$

This model has been used by Grodsky (1972) as the basis of a more comprehensive model to represent first-phase and second-phase secretion of insulin by the pancreas.

### 5.7.3 Markov Model

As a final example of stochastic modeling we shall consider Markov processes. These are models in which the system of interest, say the state of health of a patient, is characterized by a finite number of distinct states of health, and with the likelihood of the patient making a transition from one state of health to another being defined by a set of transition probabilities.

A simple example of such a model is depicted in Figure 5.58. In this case the patient is classified as being in one of three categories: WELL, ILL and DEAD. At any time  $i$ , he or she resides in just one of these states. The possible changes of state, or transitions, that occur over the fixed time interval from  $i$  to  $i + 1$  are represented in Figure 5.58 by arrows leading to the states at time  $i + 1$ . In this Markov model the passage of time is represented by cycles on an implicit clock, where  $i$  denotes the cycle count. Transitions between states occur instantaneously at each of these finite time intervals. In this simple example, the state DEAD can be defined as an absorbing state, since once reached it is not possible to make a transition to any other state. In contrast, WELL and ILL are non-absorbing states since transitions are possible from those states to other states.



**Figure 5.58** A simple Markov model depicting patient transitions between the three states WELL, ILL and DEAD (adapted from Beck and Pauker, 1983).

In Figure 5.58 each change of state is represented by a single transition from one health status to another. This implies that the process has no memory of prior states. In other words, a transition is dependent only upon the transition probability and does not in any way depend on how the patient arrived in his or her current state.

Two types of the Markov model are used in clinical decision making. The first is those in which the state transition probabilities are constant and these are known as ‘Markov chains’. The second allows for the transition probabilities to vary over time according to preset regular rules, these being the more general Markov processes in which transition probabilities are time-dependent.

The simpler Markov chain models can be applied to clinical problems only if the chances of moving amongst clinical states can be assumed to be constant. The assumption of such constant transition probabilities is reasonable only for diseases with a short time horizon. In situations of chronic disease, the annual mortality of a healthy population increases with age. Given that clinical Markov models use death as the absorbing state, the population mortality needs to be built into the model.



For conditions with short time horizons an approximate average annual mortality rate can be adopted. If the disease-specific probabilities of mortality and morbidity are approximately constant, then the whole problem may be modeled as a Markov chain.

In constructing a model such as that depicted in Figure 5.58, the distinct states of health must first be defined. As with many models there is a trade-off here in terms of the number of states which are to be incorporated; the larger the number of states, the closer the model corresponds to reality. For instance, a range of states corresponding to different gradations of illness is more realistic than one which simply lumps all illnesses into a single state. On the other hand, a larger number of states means that there will be a larger number of transition probabilities which need to be estimated.

Having specified the states of the model, all of the allowable transitions need to be defined. In the example shown, from WELL it is possible to move to each of the other states in addition to remaining in the WELL state. Transitions from ILL to WELL are not permitted in this particular case, but may in general be allowed in a Markov model where recovery from illness is a possibility.

There is then the need to specify the probabilities associated with allowable state transitions. In the clinical literature, state transitions are often expressed as rates (Beck and Pauker, 1983). Rates can range from zero to infinity and are expressed as per unit time (e.g. the mortality rate associated with disease X is 5% per year). Probabilities, on the other hand, vary from zero to one, having time built in to them implicitly. So, for a rate  $r$ , the probability that an event will occur over a time interval of  $t$  time units is:

$$P(t) = 1 - e^{-rt} \quad (5.229)$$

By way of example, suppose that in a published study of the clinical problem being modeled in Figure 5.58, 100 well patients were followed over a three year period, and that 70 became ill during that period. The data represent 70 transitions from WELL to ILL per 100 patients over a three-year period or  $(70/100/3)$  which equals to 0.233 transitions per patient year. This is the annual rate associated with the transition from WELL to ILL. Hence, if the cycle length chosen for the Markov model is one year, the transition probability from WELL to ILL,  $P_{wi}$ , would be  $1 - e^{-0.233}$  or 0.208. On the other hand, if the cycle length had been chosen to be one month, then  $P_{wi}$  would be  $1 - e^{-0.233/12}$  or 0.019. Thus, the rate, whilst unchanged on an annual basis, leads to very different transition probabilities with differing cycle lengths for the Markov model.

Using a model such as this, the dynamics of a patient population can be calculated over time as they make their allowable transitions between the set of patient states (Beck and Pauker, 1983).

## 5.8 SUMMARY

This chapter has focused on the situation in which the model should correspond to the relevant physiology, in contrast to the data-driven approach described in Chapter 4. The extent to which the model reflects this underlying physiology is dependent

on the *a priori* knowledge that is available, and the extent to which it is reasonable to make simplifying assumptions regarding the physiology. Examples have been presented which compare and contrast a range of approaches to formulating models that correspond to the underlying physiology. These have included static and dynamic, deterministic and stochastic, time-invariant and time-varying, lumped and distributed, linear and nonlinear, and continuous and discrete forms. Between them they have illustrated different levels of model complexity. This chapter concludes the part of the book that has focused on the formulation of mathematical models. Chapter 6 provides a framework for the model identification process, by means of which estimates can be made for unknown model parameters.

## 5.9 EXERCISES AND ASSIGNMENT QUESTIONS

1. Discuss the benefits of developing mathematical models that are based on the underlying physiology of the relevant system.
2. Give examples of the way in which assumptions can be made in relation to a particular physiological system's impact on the approach to be adopted in formulating the mathematical model of that system.
3. Which are the key different assumptions behind lumped and distributed linear dynamic system models? What are the mathematical consequences? Illustrate these concepts by using an appropriate example.
4. Compartmental models are a widely used class to describe nonlinear dynamic physiological systems based on the mass balance principle. First, define a compartment and a compartmental model, and then describe the equations of the general nonlinear compartment model and of the measurements made upon it.
5. Deterministic, either lumped or distributed, linear or nonlinear, models are powerful quantitative tools to describe physiological system dynamics. Why and when does stochastic modeling become important? Illustrate your answer using an appropriate example.

*This page intentionally left blank*

# 6 MODEL IDENTIFICATION

## Chapter Contents

### 6.1 Introduction

### 6.2 Data for Identification

6.2.1 Selection of Test Signals

6.2.2 Transient Test Signals

6.2.3 Harmonic Test Signals

6.2.4 Random Signal Testing

### 6.3 Errors

### 6.4 The Way Forward

6.4.1 Parameter Estimation

6.4.2 Signal Estimation


### 6.5 Summary

### 6.6 Exercises and Assignment Questions

## 6.1 INTRODUCTION

To complete the transformation from system to model (the essence of the modeling process), we must have both a model structure and a fully determined set of parameters corresponding to that structure. In other words, we require a complete model.

By this stage of the modeling process we have at least one candidate model. It is equally possible, however, that we could have more than one, with the need to choose between them as to which is the most appropriate. Focusing on a single model, if it is incomplete this will be due to some of the parameter values being unknown. This is true whether the modeling approach has been driven by data or by the physiology of the system. We may be dealing with the whole model or just part of it. This chapter aims to provide a framework for dealing with this situation. The basic concepts are depicted in Figure 6.1 and these will be explained further as the chapter proceeds.



**Figure 6.1** The overall basis of model identification.

## 6.2 DATA FOR IDENTIFICATION

To solve this identification problem, as it is known, we need data. Data sometimes occur from the intrinsic dynamics of the system; for instance, in the form of spontaneous oscillations or noise. The signals recorded as the electrocardiogram would be an example of this. More usually, however, we need to design experiments. So the question arises: what experiments should be designed in order to yield appropriate data?

In essence, the experiment will involve applying some type of test signal to our system and measuring the response of one or more variables. In doing this it is vital to ensure that the resulting input/output data contain that part of the model which has the unknown parameter values that we are trying to estimate.

### 6.2.1 Selection of Test Signals

The selection of appropriate test signals is of essential importance to the identification process. There are a number of general criteria that we can list in this regard:

1. The test signals should be convenient to generate. Examples would be the administration of a drug or metabolic compound in the form of an injection, or applying a step change in the concentration of oxygen being inhaled by a subject in an investigation of the dynamics of the respiratory system.
2. The signals should be as large as possible so as to produce a high output signal-to-noise ratio. However, the magnitude of the test signal is limited by


practical constraints. First, the extent of perturbation of the system under test must not be excessive. Thus, for example, the dose of a drug administered in a pharmacokinetic test, or the quantity of radioactivity in tracer kinetic trials, is restricted by health and safety considerations. Furthermore, the extent of the disturbance to the system posed by the test signal must not move it outside the region for which the assumed model is valid. For example, in the case of a linearized model the disturbance must conform to the assumption that disturbances are small.

3. The test signal should, as far as possible, minimize the time required for the identification process.
4. The test signal should, when taken together with the model to be identified, result in a convenient and accurate identification procedure. This issue will be discussed further later in the chapter.

In general, test signals can be classified into those that result in a transient response, those that result in harmonic signal analysis (frequency response), and those that involve random signal analysis.

### 6.2.2 Transient Test Signals

The most commonly applied test signals in metabolic and endocrine studies and in studies on physiological organ systems are those that result in a transient response of one or more system variable. Impulse (e.g. injection) or step (e.g. infusion or step change in concentration of a gas inhaled) inputs are the usual form of input in this context. When applied and the time course of the appropriate output variable is observed, the impulse response or the step response is obtained for the corresponding portion of the system as shown in Figure 6.2.



**Figure 6.2** Diagrammatic representation of the use of transient test signals in model identification for impulse (e.g. injection) and step (e.g. infusion) inputs.

The information yielded by the impulse and step tests is theoretically the same for linear systems. Since the step (infusion) is the integral of the impulse (injection), the

step response is correspondingly the integral of the impulse response. The choice of input should be such that any effects on the experimental data due to constraints on the perturbation are minimized. For example, in tracer studies, if the radioactivity content of specimens used to define the terminal portion of the impulse response is low (e.g. not more than twice background radioactivity), substantial errors may arise because of the inefficiency of radioactivity counting. Errors due to this cause would be much less significant if a step (infusion) test was carried out, in which case the specific activity would in most instances tend to a finite, readily measurable value rather than to zero, as in the case of the impulse test.

Transient testing offers the advantages of simplicity and short duration of test, since it is the transient and not the steady state that contains the information relating to the system behavior.

Although impulse testing is straightforward in application, in practice a disadvantage can arise because of the restrictions imposed on the magnitude of the impulse. This can result in inadequate excitation of some modes of the system. Although the impulse should be of such a magnitude as to provide adequate stimulation, it must not be so large as to drive the system into a nonlinear mode of operation.

Equally, no filtering of noise is provided in transient testing and hence there is the possibility of high errors, including interference from other system inputs.

The number of sites at which test signals can be applied is generally restricted. For instance, often it is only possible (in the case of metabolic systems) to inject material into the bloodstream. Constraints are particularly rigorous in the case of clinical studies. Here the number of accessible sites is severely restricted. Moreover, where output measurement is made by removal of blood samples on a discrete basis in order to measure the concentration of a metabolite in the blood, the number of samples and the frequency of their withdrawal is limited by considerations of patient well-being. In physiological studies, however, greater freedom may be available to the experimenter in terms of both the number of accessible sites and the form of permitted test signals. It is worth noting that in some instances it may be possible to overcome some of the limitations of blood sampling by making use of new healthcare technology. For example, by using appropriate imaging modalities, it may be possible to achieve continuous measurement of the time source of concentration of radioactivity in one of the organs of the body. This assumes that the imaging technology is sufficiently well able to define precisely the particular organ in question, for example the liver.

### 6.2.3 Harmonic Test Signals

As an alternative to transient testing, in some situations harmonic test signals can be applied. Frequency response testing involves applying harmonic (sinusoidally varying) signals of various frequencies and observing the amplification or attenuation and phase shift of the corresponding frequency components in the output variables of the system under test.

For a linear system that is stable, it can be shown that if an input signal of the form  $A \sin \omega t$  is applied; once any transient components have died away, the 'steady state' output will be of the form  $A |G(j\omega)| \sin(\omega t + \angle G(j\omega))$ . In other words, the output

exhibits oscillations of the same frequency as the applied input, but the magnitude is amplified or attenuated by the factor  $|G(j\omega)|$  and the oscillations are phase shifted by  $\angle G(j\omega)$ .  $|G(j\omega)|$  and  $\angle G(j\omega)$  vary with change in the frequency of the applied sine wave in a manner that is dependent upon the intrinsic dynamics of the system under test.

Harmonic test signals are, in general, less convenient to apply in our physiological context than transient test signals. They may require special instrumentation for output measurement. However, such test signals do offer some advantages in terms of accuracy and convenience of identification.

Firstly, in comparison with transient testing, all the test power in harmonic testing is concentrated at a single frequency. This means that all significant modes can be adequately excited in a series of tests without applying signals of excessive amplitude.

However, a consequent disadvantage is the duration of the test since, in general, the experiment needs to be repeated with sine wave inputs for some 10 to 15 different frequencies, with the lowest applied frequency being well below that corresponding to the longest time constant in the system. Also, in each test it is necessary to wait for the transient effects to decay and then carry out the harmonic test for 5 to 10 cycles of the test frequency. On the other hand, frequency response testing has the merit of effectively filtering noise which may be present in the data, since one is only seeking that frequency component in the output that corresponds to the frequency of the sine wave applied as the input.

The frequency response forms for a linear system a complete non-parametric model of the system. Parametric models of the frequency response may be fitted to the experimental data obtained in order to estimate parameters.

One area of physiology where frequency response testing has been applied over the past 30 years is in relation to the respiratory system. For example, pioneering experiments were those of Swanson and Belville (1974) who sought to identify the dynamics of a linear mathematical model of the respiratory system. This they did by applying sinusoidally varying inputs of alveolar  $\text{CO}_2$  and  $\text{O}_2$  over a range of frequencies, and plotting the variation of output amplitude as a function of frequency.

### 6.2.4 Random Signal Testing

Random signals, or signals so constructed to approximate to random signals (e.g. pseudo-random binary sequences), may be used as test inputs. We now consider a linear, time-invariant system to which an input  $m(t)$  is applied, resulting in an output  $y(t)$ . If that system is characterized by a unit impulse response  $g(t)$ , then it can be shown that:

$$R_{my}(\tau) = \int_{-\infty}^{\infty} g(t)R_{mm}(t - \tau) dt \quad (6.1)$$

That is, the cross-correlation function between the input and the output,  $R_{my}(\tau)$ , is equal to the convolution of the autocorrelation function of the input,  $R_{mm}(t - \tau)$ , and the unit impulse response of the system,  $g(t)$ .



Now, if the input to the system is white noise, a totally random signal in which all frequency components are present at equal power levels, the cross-correlation function,  $R_{my}(\tau)$ , is equal to the unit impulse response of the system.

$$R_{my}(\tau) = g(\tau) \quad (6.2)$$

Random signal testing consists then of applying to the system a test signal approximating to white noise and then cross-correlating input and output. The cross-correlation function then gives the unit impulse response.

Random fluctuations approximating to white noise may occur spontaneously on one of the variables of the physiological system and they may be used as a test signal without introducing an external stimulus. Such a situation is convenient, but in practice does not often occur. Hence, in general, it is necessary to generate the random test signals specially. They often take the form of so-called pseudo-random binary sequences, a sequence of pulses of equal duration and taking the values of zero (no disturbance for the pulse duration) or one (a pulse of fixed amplitude). The sequence of zero and unity pulses, which is cyclically repeatable, is such that over one cycle it has the properties of white noise. Such white noise analysis has found application particularly in the domain of electrophysiology; for example, in the work of Marmarelis and Marmarelis (1978).


Random signals represent the simultaneous injection of all frequencies into a system and thus lead to shorter test times than harmonic signals. Test duration must, however, be sufficiently long for the time averaging in the autocorrelation function to be accurate. The output of the random test procedure is a cross-correlation function corresponding to the unit impulse response of the system. This correlation process effectively filters out noise present in the data.

### 6.3 ERRORS

In the identification process, data are mapped into parameter values by means of the model. However, problems can arise in estimating the values of unknown parameters due to a number of sources of errors. These are shown schematically in Figure 6.3. The four types of error are:

- imperfections in the test signal that do not correspond to the form assumed in the interpretation of the result;
- errors due to imperfections in measurement of output variables;
- influence on observed output of variables other than the test signal; and
- model error, which is the effect of using in the identification process a model that does not satisfactorily represent the system being identified

Clearly, if the values of some of the model parameters are obtained from independent sources (either direct measurement or from *a priori* knowledge), rather than from estimation schemes, then the errors associated with these parameter values must be taken into account.



**Figure 6.3** Practical experimental design, indicating a number of sources of error.

From a theoretical point of view, considerable difficulties arise when trying to account simultaneously for more than one type of error. Measurement errors are always present. Hence, this is the problem that has received most attention.

With regard to errors in the test signal, normally these are either known explicitly, in which case this information can be directly taken into account, or can often be neglected. Consider, for example, an injection of material (an impulse) applied to a metabolic system that is of finite duration. One possibility is to treat it as a pulse input (that is a step increase followed by a step decrease). The alternative is that it might be neglected if its duration is short compared to the most rapid dynamics that one is seeking to identify from the experimental data.

Disturbances may be neglected if, for example, they have only minimal effect on the experimental data that are being obtained in a short-term study on the particular physiological system. Alternatively, it may be assumed that the disturbance simply results in a component of error in the measured variable.

Having proposed a false or inappropriate model constitutes an important source of error. In general, there are few theoretical approaches available for dealing with this type of uncertainty. It is usually only at the stage of model validation that consideration can be given to assessing whether or not a given model structure is appropriate. In some instances the problem may be approached by considering a number of candidate identifiable model structures and carrying out the parameter estimation procedure for each of them. The results of estimating the parameters of these alternative configurations can then be compared in terms of a set of validity criteria as will be outlined in Chapter 10. Normally, this will lead to a ranking of the candidate model structures in relation to the given experimental data.

The only error that can be dealt with in a rigorous manner is that which arises due to imperfections in the measurement process. In most practical situations it is reasonable and normal to assume that any errors are additive.

$$z_l(t_i, \mathbf{p}) = y_l(t_i, \mathbf{p}) + v_l(t_i), \quad i = 1, 2, \dots, N_l; \quad l = 1, 2, \dots, m \quad (6.3)$$

Equation (6.3) thus describes, for each of the  $m$  measured variables, the relation between the actual noisy, discrete-time measurement  $z_1$  and the noise-free measurable output  $y_1$ , with  $v_1$  being the error associated with the measurement performed at time  $t_j$ .

To carry out the parameter estimation process, it is highly desirable to be able to provide a statistical description of the errors. In some instances it may be possible to assume that the errors are characterized by either a Gaussian or a Poisson distribution. In other cases it may only be possible to assume, for instance, that the errors are white; that is to say uncorrelated. The extent of such statistical information, which is available *a priori* regarding these errors, is closely related to the goodness of the results of the parameter estimation procedure. The more complete the statistical description, the more desirable will the properties of the estimation algorithm be, and the greater the confidence that can be placed in the results obtained. Equally, good *a priori* statistical information can provide evidence leading to the rejection of unsuitable models.

## 6.4 THE WAY FORWARD

Since errors in model structure cannot be dealt with explicitly, they can only be solved by considering each competing model in turn. Thus it is customary to focus on a single model, and concentrate on the impact of measurement errors that are assumed to be additive as indicated above. The available approaches can be divided into two groups; situations with parametric models and those with non-parametric models. These are considered briefly below under the headings of parameter estimation and signal estimation. A full treatment for these two cases is given in Chapters 8 and 9.

### 6.4.1 Parameter Estimation

In relation to parametric models, as discussed in Chapter 7, the first consideration is that of identifiability. This involves asking the question as to whether it is theoretically possible to make unique estimates of all the unknown parameters on the assumption that the data we have available for the identification process are complete and noise-free. In other words, we are examining the balance between the availability of experimental data and the number of unknown parameters to be estimated. Are the data rich enough for the parameter estimation problem? Difficulties arise where there is a mismatch between the complexity of the model (as evidenced by the number of unknown parameters) and the richness of the data. The problem can be viewed as there being either too many parameters to be estimated or the data are not sufficient in relation to the model in question.

If this problem arises, there are two possible approaches. The first is to consider whether it might be possible to reduce the complexity of the model, including reducing the number of unknown parameters needing to be estimated. There would, however, be the need to ensure that the reduced model was still valid in relation to the purpose of the modeling activity. The second would be to examine whether it was possible to

enrich the available experimental data; for instance, by making measurements of an additional variable.

If the model is uniquely identifiable, on the assumption that the data are perfect, it is possible to proceed with the process of estimating the parameters as discussed in Chapter 8. In some situations multiple solutions may be theoretically possible for some of the parameters. This means two or more, but a finite number of solutions. In cases such as this, it might be possible to choose between alternative solutions at the stage of validating the complete model by considering which parameter values are most plausible in a physiological sense. Where an infinite number of values are theoretically possible for one or more parameters, there is the need to tackle the mismatch between model and data as indicated above.

Once the model has passed the identifiability test, there are a number of techniques available for estimating the parameters. Most commonly adopted are linear or non-linear least squares estimation. These are least demanding in terms of the quantity of *a priori* information needed. Other techniques available include maximum likelihood and Bayesian estimation. However, both of these require *a priori* knowledge regarding the statistics of the situation being modeled.

## 6.4.2 Signal Estimation

The other type of estimation problem relates to models which do not explicitly contain parameters and hence are referred to as non-parametric models. What we are seeking to estimate here is not parameters, but rather a signal. As described in section 4.9, we are dealing with an overall input/output model that is specified as an integral equation. Such a description has three main ingredients: the input, the output, and the impulse response that provides the connection between them. In our signal identification problem we know two out of the three, and we need to determine the third.

The most usual situation is that in which the output signal is known, and we need to identify one of the other two ingredients. The techniques available for solving this problem can be classified as *raw deconvolution* and *deterministic regularization*. Further details are given in Chapter 9. The domain of electrophysiology is an example where this is often the identification problem which must be solved. For instance, the evoked electrical response may be measured in response to a known sensory stimulation. In this case the identification problem is that of determining the impulse response that maps the known applied stimulus into the measured evoked response.

## 6.5 SUMMARY

This chapter has described an overall framework for model identification. This process enables us to achieve a complete model; that is to say that we have both a model structure and a fully determined set of parameters corresponding to that structure. The following two chapters deal with the identification of parametric models in full detail. Chapter 7 begins this process by addressing the problem of identifiability.

## 6.6 EXERCISES AND ASSIGNMENT QUESTIONS

1. What are the desirable characteristics of physiological measurements in order to provide appropriate test signals for system identification?
2. What are the relative merits of transient, harmonic and random signals in the context of system identification?
3. Discuss the relationship between experimental design and system identifiability if the process of estimating the unknown parameters of a physiological model is to be successfully completed.
4. Give an account of the different types of error that can arise in the identification process and the means by which such errors might be treated in order to achieve successful parameter estimation.

# 7 PARAMETRIC MODELING – THE IDENTIFIABILITY PROBLEM

## Chapter Contents

**7.1 Introduction**

**7.2 Some Examples**

**7.3 Definitions**

**7.4 Linear Models: The Transfer Function Method**

**7.5 Nonlinear Models: The Taylor Series Expansion Method**

**7.6 Qualitative Experimental Design**

7.6.1 Fundamentals

7.6.2 An Amino Acid Model

**7.7 Summary**

**7.8 Exercises and Assignment Questions**

## 7.1 INTRODUCTION

Once a parametric model has been formulated, the next fundamental step in its development is the assignment of numerical values to its unknown parameters  $p_1, p_2, \dots, p_p$ . This parametric model might be an input/output one; say the sum of three decaying exponentials describing the disappearance of a substance in the body after an impulse dose. Examples of such data models are discussed in Chapter 4. Alternatively, it might be a structural model of a system such as that described in Chapter 5; for instance, a resistance-compliance model describing the dynamic

pressure-flow relationships of respiratory mechanics. In the case of the data model the unknown parameters  $p_1, p_2, \dots, p_P$  would be the coefficients of the exponential function. In the latter case they would be the resistance and compliance parameters of the differential equation model.

In practice, this assignment of numerical values is done by exploiting the information contained in the measurements performed on the physiological system which are functions of time  $t$  and of the parameter vector  $\mathbf{p} = [p_1, p_2, \dots, p_P]^T$ . Let us consider for the sake of argument the case where a single measurement signal is available. This has the general form:


$$y(t) = g(t, \mathbf{p}) \quad (7.1)$$

where  $g(t, \mathbf{p})$  is a function that links the model to the measurement. In the examples discussed above  $y(t)$  could be a plasma concentration or a flow signal, respectively.

In practice the signal  $y(t)$  is not available. What is measured is a noise-corrupted signal, usually at a number of discrete time points  $t_1, t_2, \dots, t_N$ , which can be described as:

$$z(t_i) = z_i = y_i + v_i = g(t_i, \mathbf{p}) + v_i \quad (7.2)$$

where  $v_i$  denotes the error on the  $i$ -th measurement (Figure 7.1) which can be viewed as a random variable having its expected value equal to zero. Usually some statistical information on  $v_1 \dots v_N$  is available, e.g. they are usually uncorrelated, with either a constant variance  $\sigma^2$  or with different variances  $\sigma_i^2$  for the various  $v_i$ .




**Figure 7.1** The physiological system, the input  $u$  and the output  $y$ . Measurements  $z(t_i)$  are taken at discrete times and are corrupted by noise  $v(t_i)$ .

The function  $g(t, \mathbf{p})$  is related to the model of the system. As anticipated in the examples above, this can be an input/output (data driven) or a structural model. Let us clarify this with a simple example and consider the data shown in Figure 7.2. These data refer to the concentration of a drug disappearing from blood after an intravenous unit dose bolus injection given at time 0. The data  $z_1 \dots z_N$  of Figure 7.2 can be described by (7.2) with  $g(t, \mathbf{p})$  of (7.1) expressed either as an input/output model or a structural model. An input/output model would typically be of the form:

$$y(t, \mathbf{p}) = A_1 e^{-\lambda_1 t} + A_2 e^{-\lambda_2 t} \quad (7.3)$$

and the model identification problem becomes that of estimating from the measurements  $z_1 \dots z_N$  the parameters  $A_1, \lambda_1, A_2, \lambda_2$ , i.e.  $\mathbf{p} = [A_1, \lambda_1, A_2, \lambda_2]^T$ .




**Figure 7.2** The plasma concentration disappearance curve of a drug after a bolus injection.

The same data can also be described by a structural model of the kinetics of the drug in the body. A candidate model is the one shown in Figure 7.3. Linear kinetics are assumed and the existence in the body of two compartments with irreversible elimination of the drug taking place from compartment 1 is postulated. Compartment 1 is the accessible compartment, i.e. the one where the drug is injected and where the concentration is measured at discrete times. The model equations are:

$$\dot{Q}_1(t) = (k_{01} + k_{21})Q_1(t) + k_{12}Q_2(t) + U(t) \quad Q_1(0) = 0 \quad (7.4)$$

$$\dot{Q}_2(t) = k_{21}Q_1(t) - k_{12}Q_2(t) \quad Q_2(0) = 0 \quad (7.5)$$

$$y(t) = \frac{Q_1(t)}{V_1} \quad (7.6)$$



**Figure 7.3** A two compartment model of the kinetics of a drug.

where  $Q_1, Q_2$  denote the masses of drug in compartments 1 and 2, respectively;  $u$  is the drug input, e.g.  $U(t) = D \cdot \delta(t)$  where  $d$  is the dose and  $\delta(t)$  is the Dirac function;  $V_1$  is the distribution volume of compartment 1;  $k_{21}, k_{12}$  and  $k_{01}$  are rate parameters describing the transfer of drug between compartments and to the outside of the system respectively. In this case the model identification problem becomes that of estimating from the measurements  $z_1, z_2, \dots, z_N$  the parameters  $k_{21}, k_{01}, k_{02}, V_1$ , i.e.  $\mathbf{p} = [k_{21}, k_{01}, k_{12}, V_1]^T$ .




It is important to note that, when choosing a structural model in order to understand the system, there is, in general, the possibility of describing the data with more than one model, even without changing the model order. For instance, the data of Figure 7.2 can also be described by the model shown in Figure 7.4:

$$\dot{Q}_1(t) = -(k_{01} + k_{21})Q_1(t) + k_{12}Q_2(t) + U(t) \quad Q_1(0) = 0 \quad (7.7)$$

$$\dot{Q}_2(t) = k_{21}Q_1(t) - (k_{02} + k_{12})Q_2(t) \quad Q_2(0) = 0 \quad (7.8)$$

$$y(t) = \frac{Q_1(t)}{V_1} \quad (7.9)$$



**Figure 7.4** Another two compartment model of the kinetics of the drug.

This model is similar to the previous one described by (7.4) and Figure 7.3, but postulates that the drug is irreversibly removed not only from compartment 1, but also from compartment 2. This means that the model has an additional parameter, i.e.  $k_{02}$ , and the identification problem becomes more difficult to solve since the parameters to be estimated from the data are now five, i.e.  $\mathbf{p} = [k_{21}, k_{01}, k_{12}, k_{02}, V_1]^T$ .

This example also serves to highlight an important issue that will be discussed in the next section. While (with an input/output model such as that of (7.3)) it is always possible to obtain an estimate of all its unknown parameters from the data, this is generally not true for a structural model. For instance, it will be shown that while the experiment that has been designed (i.e. injection into compartment 1 and measurement of its concentration) is sufficiently informative to estimate all the four parameters of the model of Figure 7.3, this is not true for the model of Figure 7.4. Not all of its five parameters can be estimated from the data. In other words, in the case of structural models, but not of input/output models, it is necessary to assess if the designed experiment has enough information to estimate all the unknown parameters of the postulated model structure. This assessment can be made by resorting to a data-independent test that is called *a priori* identifiability.

*A priori* identifiability is a key step in the formulation of a structural model whose parameters are going to be estimated from a set of data. The question that *a priori* identifiability addresses is the following: do the data contain enough information to estimate all of the unknown parameters of the postulated model structure? This question is usually referred to as the *a priori* identifiability problem. It is set in the ideal context of an error-free model structure and noise-free, continuous time measurements,

and is an obvious prerequisite for well-posed parameter estimation from real data. In particular, if it turns out that the postulated model structure is too complex for the particular set of ideal data (i.e. some model parameters are not identifiable from the data) there is no possibility that a real situation – where there is error in the model structure and noise in the data – the parameters can be identified. The *a priori* identifiability problem is also referred to as the *structural identifiability* problem because it is set independently of a particular set of values for the parameters. For the sake of simplicity, in what follows, only the term *a priori* will be used to qualify the problem.

Only if the model is *a priori* identifiable is it meaningful to use the techniques to estimate the numerical values of the parameters from the data discussed in section 7.4. If the model is *a priori* non-identifiable, a number of strategies can be considered. One would be to enhance the information content of the experiment by adding, when feasible, inputs and/or measurements. Another possibility would be to reduce the complexity of the model by simplifying its model structure, e.g. by lowering the model order, or by aggregating some parameters. These simple statements allow one to foresee the importance of *a priori* identifiability also in relation to qualitative experiment design, e.g. definition of an experiment which allows one to obtain an *a priori* identifiable model with the minimum number of inputs and measurements.

Before discussing the problem in depth and the methods available for its solution, it is useful to illustrate the fundamentals through some simple examples. Then some formal definitions will be given, using these simple examples where the identifiability issue can be easily addressed.


## 7.2 SOME EXAMPLES

### Example 1

Consider a single compartment model shown in Figure 7.5, where the input is a bolus injection of a drug given at time zero and the measured variable is the drug concentration. The model and measurement equations are:

$$\dot{Q}(t) = -kQ(t) + U(t) \quad Q(0) = 0 \quad (7.10)$$

$$y(t) = \frac{Q(t)}{V} \quad (7.11)$$



**Figure 7.5** A single compartment model.

where  $U(t) = D \cdot \delta(t)$ , that is  $d$  is the magnitude of the bolus dose. The unknown parameters for the model are the rate constant  $k$  and the volume  $V$ .

Equation (7.11) defines the observation on the system, i.e. drug concentration, in an ideal context of noise-free and continuous-time measurements. In other words, (7.11) is the *model output* describing what is measured continuously and without errors; it does not represent the noisy discrete times measurements. The word ‘output’ is used here in the information sense. Specifically, in the context of Figure 7.5,  $U(t)$  and  $y(t)$  define an input/output experiment, and should not be confused with the material output or outflow from the compartment.

To see how the experiment can be used to obtain estimates of these parameters, note that the solution of (7.10) is the mono-exponential:

$$Q(t) = De^{-kt} \quad (7.12)$$

The model output  $y(t)$  can thus be given by:

$$y(t) = \frac{D}{V}e^{-kt} \equiv Ae^{-\lambda t} \quad (7.13)$$

The model output or ideal data are thus described by a function of the form  $Ae^{-\lambda t}$ , and the parameters that can be determined by the experiment are  $A$  and  $\lambda$ . These parameters are called the *observational parameters*.

What is the relationship between the unknown model parameters  $k$  and  $V$ , and the observational parameters  $A$  and  $\lambda$ ? From Equation (7.13) one sees immediately:

$$A = y(0) = \frac{D}{V} \quad (7.14)$$

$$\lambda = k \quad (7.15)$$

In the example above, the unknown parameters  $k$  and  $V$  of the model are *a priori uniquely* or *globally identifiable* from the designed experiment since they can be evaluated uniquely from the observational parameter  $A$  and  $\lambda$ . Since all model parameters are uniquely identifiable, the model is said to be *a priori uniquely* or *globally identifiable* from the designed experiment.

This first example was limited to a bolus injection input. The same identifiability results hold for different inputs as well. This is a general result of dealing with linear, time-invariant models such as the one described above: the identifiability properties of a model are the same irrespective of the shape of the inputs. This is true for a single input situation, but is no longer true in a general multiple input experiment or in nonlinear models.

So far we have analyzed the identifiability properties of the model by inspecting the expression of the model output in order to derive the relationships between the observational parameters and the unknown model parameters. The method is easy to understand, since it only requires some fundamentals of differential calculus. However, the approach is not practicable in general, since it works easily only for some simple linear models of order one and two. For linear models of higher order the

method becomes quite cumbersome and its application is practically impossible. It is worth noting that in these introductory examples emphasis has been placed on linear dynamic models: for nonlinear models it is usually simply impossible to obtain the expression of the model output.

Returning to linear models, a simpler method is available to derive the desired relationships between observational parameters and unknown model parameters. It consists of writing the Laplace transform for the model output and is known as the *transfer function method*. Briefly, the advantage of the Laplace transform method is that there is no need to use the analytical solution of the system of linear differential equations. By writing the Laplace transform of the state variables (e.g. masses), and then of the model outputs (e.g. concentrations), one obtains an expression which defines the observational parameters as a function of the unknown model parameters. This gives a set of nonlinear algebraic equations in the original parameters.

For the model of Figure 7.5, the Laplace transforms of (7.10) and (7.11) are, respectively:

$$\begin{cases} sQ(s) = -kQ(s) + D & (7.16) \\ Y(s) = \frac{Q(s)}{V} & (7.17) \end{cases}$$

where  $s$  is the Laplace variable and the capital letter denotes the Laplace transform of the corresponding lower case letter variable.

The transfer function is:

$$H(s) \equiv \frac{Y(s)}{U(s)} = \frac{\frac{Q(s)}{V}}{D} = \frac{\frac{[D/s+k]}{V}}{D} = \frac{\frac{1}{V}}{s+k} \equiv \frac{\beta}{s+\alpha} \quad (7.18)$$

The coefficients  $\alpha$  and  $\beta$  are determinable from the experiment, i.e. they are the observational parameters and thus one has:


$$\begin{cases} \beta = \frac{1}{V} & (7.19) \\ \alpha = k & (7.20) \end{cases}$$

that is, the model is *a priori* uniquely identifiable.

For this simple model the advantage of the Laplace transform method is not evident, but its power will be appreciated when we consider the next example.

### Example 2

Consider next the two compartment model of the kinetics of a substance in the body shown in Figure 7.6, where a bolus injection of material is given into compartment 1. The accessible compartment is compartment 2. Assume the measured variable is the concentration  $y(t) = Q_2(t)/V_2$ .



**Figure 7.6** A two compartment model.

The equations describing this model, assuming a bolus input, are:

$$\dot{Q}_1(t) = -k_{21}Q_1(t) + U(t) \quad Q_1(0) = 0 \quad (7.21)$$

$$\dot{Q}_2(t) = k_{21}Q_1(t) - k_{02}Q_2(t) \quad Q_2(0) = 0 \quad (7.22)$$

$$y(t) = \frac{Q_2(t)}{V_2} \quad (7.23)$$

where  $U(t) = D \cdot \delta(t)$ .

The unknown model parameters are  $k_{21}$ ,  $k_{02}$  and  $V_2$ . To see how the experiment can be used to obtain estimates of these parameters, one can use either the time domain solution of (7.22) (a sum of two exponentials) or the transfer function method which is much more straightforward. The transfer function is:

$$H(s) = \frac{Y(s)}{U(s)} = \frac{\frac{k_{21}}{V_2}}{(s + k_{21})(s + k_{02})} \equiv \frac{\beta_1}{s^2 + \alpha_2 s + \alpha_1} \quad (7.24)$$

where the coefficients  $\alpha_1$ ,  $\alpha_2$ ,  $\beta_1$  are the observational parameters (known from the experiment) linked to the unknown model parameters by:

$$\left\{ \begin{array}{l} \beta_1 = \frac{k_{21}}{V_2} \end{array} \right. \quad (7.25)$$

$$\left\{ \begin{array}{l} \alpha_2 = k_{21} + k_{02} \end{array} \right. \quad (7.26)$$


$$\left\{ \begin{array}{l} \alpha_1 = k_{21}k_{02} \end{array} \right. \quad (7.27)$$

The equations (7.25)–(7.27) are nonlinear and it is easy to verify that it is not possible to obtain a unique solution for the unknown parameters. In fact, from (7.26) and (7.27) parameters  $k_{21}$  and  $k_{02}$  are interchangeable and thus each has two solutions, say  $k_{21}^I$ ,  $k_{21}^{II}$  and  $k_{02}^I$ ,  $k_{02}^{II}$ . As a result, from (7.25)  $V_2$  has two solutions also,  $V_2^I$  and  $V_2^{II}$ . The two solutions provide the same expression for the model output  $y(t)$ . When there is a finite number of solutions (more than one; two in this case), the unknown parameters are said to be *a priori nonuniquely* or *locally identifiable* from the designed experiment. When all the model parameters are identifiable (uniquely or nonuniquely) and there is at least one of the model parameters which is nonuniquely

identifiable (in this case, all three are), the model is said to be *a priori nonuniquely or locally identifiable*.

In Figure 7.7 we show the two curves defined by equations  $k_{21} + k_{02} = \alpha_2$  and  $k_{21}k_{02} = \alpha_1$ : the existence of two solutions is confirmed by the presence of two points of intersection.

It is worth noting that also in this case one has parameters which are *a priori* uniquely identifiable, but these are not the original parameters of interest. They are combinations of the original parameters, in particular  $k_{21}k_{02}$ ,  $k_{21} + k_{02}$  and  $k_{21}/V_2$ .



**Figure 7.7** A plot of  $k_{21}k_{02} = \alpha_1$  and  $k_{21} + k_{02} = \alpha_2$ .

To achieve unique identifiability of this nonuniquely identifiable model, one could design a more complex experiment or, if available, exploit additional independent information available on the system. In this particular case, knowledge of  $V_2$ , or a qualitative relationship between  $k_{21}$  and  $k_{02}$ , i.e.  $k_{21}$  greater or less than  $k_{02}$  (see Figure 7.7), allows one to achieve unique identifiability of all model parameters.

### Example 3


Consider next the two compartment model shown in Figure 7.8 where a bolus injection of a drug is given at time zero and where the measured variable is the concentration of drug in plasma. The equations describing this model are:

$$\dot{Q}_1(t) = -(k_{01} + k_{21})Q_1(t) + U(t) \quad Q_1(0) = 0 \quad (7.28)$$

$$\dot{Q}_2(t) = k_{21}Q_1(t) \quad Q_2(0) = 0 \quad (7.29)$$

$$y(t) = \frac{Q_1(t)}{V_1} \quad (7.30)$$

The unknown model parameters are  $k_{21}$ ,  $k_{01}$  and  $V_1$ .



**Figure 7.8** A two compartment model.

To see how the experiment can be used to obtain estimates of these parameters, one notes that the transfer function is:


$$H(s) = \frac{Y(s)}{U(s)} = \frac{\frac{1}{V_1}}{s + k_{21} + k_{01}} \equiv \frac{\beta}{s + \alpha} \quad (7.31)$$

and thus

$$\beta = \frac{1}{V_1} \quad (7.32)$$

$$\alpha = k_{21} + k_{01} \quad (7.33)$$

It is easy to see that, while  $V_1$  is uniquely identifiable,  $k_{01}$  and  $k_{21}$  are not. In fact, as illustrated in Figure 7.9, there are an infinite number of solutions lying on the straight line  $k_{01} + k_{21} = \alpha$ .



**Figure 7.9** A plot of  $k_{21} + k_{01} = \alpha$ .

When there is an infinite number of solutions for a parameter, one says that the parameter is *a priori nonidentifiable* from the designed experiment. When there is at least one of the model parameters which is nonidentifiable (in this case, there are two), the model is said to be *a priori nonidentifiable*.

As with the previous example, one can find a uniquely identifiable parameterization, i.e. a set of parameters that can be evaluated uniquely. In this case, the parameter is the sum  $k_{01} + k_{12}$  ( $V_1$  has been seen to be uniquely identifiable). Again to achieve unique identifiability of  $k_{01}$  and  $k_{21}$ , either a more informative experiment is needed, e.g. measuring also in compartment 2, or additional information on the system such as a relationship between  $k_{01}$  and  $k_{21}$  is required.

When a model is nonidentifiable, however, it is usually possible to obtain for the nonidentifiable parameters upper and lower bounds for their values, i.e. to identify an interval of values in which the parameters may lie. The reasoning is the following. Since by definition  $k_{01}$  and  $k_{21}$  are greater than zero, one sees immediately from (7.33) that the upper bound for each is  $\alpha$ . For instance, for  $k_{21}$ , one has:

$$k_{21} = \alpha - k_{01} \quad (7.34)$$

and thus the upper bound for  $k_{21}$ ,  $\alpha$ , will be achieved when  $k_{01}$  is zero. Similar results hold for  $k_{01}$ . The parameter bounds for  $k_{01}$  and  $k_{21}$  are:

$$k_{01}^{\min} = 0 \leq k_{01} \leq \alpha = k_{01}^{\max} \quad (7.35)$$

$$k_{21}^{\min} = 0 \leq k_{21} \leq \alpha = k_{21}^{\max} \quad (7.36)$$

In this example, the intervals are the same; normally, this is not the case.

When there is an upper and lower bound for the values that a nonidentifiable parameter can assume, one says the parameter is *a priori interval identifiable*. When all of the nonidentifiable model parameters are interval identifiable (in this case, all are), the model is said to be *a priori interval identifiable*.

## 7.3 DEFINITIONS

The simple examples on linear dynamic models in the previous section emphasized the importance of understanding the *a priori* identifiability problem, and provided a means of introducing, in an appropriate context, some basic definitions. In this section, generic definitions will be given which also hold for more general model structures, i.e. nonlinear dynamic models. A general nonlinear model is a system of  $n$ -first order nonlinear ordinary differential equations, depending on a set of  $P$  unknown constant parameters  $\mathbf{p} = [p_1, p_2, \dots, p_P]^T$  which can be written conveniently in vector notation as:

$$\dot{\mathbf{x}}(t, \mathbf{p}) = \mathbf{f}[\mathbf{x}(t, \mathbf{p}), \mathbf{u}(t), t; \mathbf{p}] \quad \mathbf{x}_0 = \mathbf{x}(t, \mathbf{p}) \quad (7.37)$$

$$\mathbf{y}(t, \mathbf{p}) = \mathbf{g}[\mathbf{x}(t, \mathbf{p}); \mathbf{p}] \quad (7.38)$$

where the  $n$  state variables of the model are denoted by the vector  $\mathbf{x} = [x_1, x_2, \dots, x_n]^T$ ;  $\mathbf{u} = [u_1, u_2, \dots, u_r]^T$  is the vector of  $r$  known inputs;  $\mathbf{y} = [y_1, y_2, \dots, y_m]^T$  is the vector of  $m$  outputs (measurements); the observation interval is  $t_0 \leq t \leq T$  and the initial state  $\mathbf{x}_0 = \mathbf{x}(t_0) = \mathbf{x}(t_0, \mathbf{p})$  is allowed to depend on  $\mathbf{p}$ ;



$\mathbf{f}$  is the vector of  $n$  nonlinear functions that defines the structure of the model, i.e. the input-state coupling parameterized by  $\mathbf{p}$ ;  $\mathbf{g}$  is a vector of  $m$  nonlinear functions which defines the state-output coupling, also parameterized by  $\mathbf{p}$ . It is worth noting that often the  $\mathbf{g}$  functions are linear functions of the state variables, so that the output equation becomes:

$$\mathbf{y}(t, \mathbf{p}) = \mathbf{C}(\mathbf{p})\mathbf{x}(t, \mathbf{p}) \quad (7.39)$$

where  $\mathbf{C}$  is a  $m \times n$  matrix.

Define the observational parameter vector  $\Phi = [\phi_1, \dots, \phi_R]^T$  having the observational parameters  $\phi_j, j = 1, \dots, R$  as entries. Each particular input/output experiment will provide a particular value  $\hat{\Phi}$  of the parameter vector  $\Phi$ , i.e. the components of  $\hat{\Phi}$  can be estimated uniquely from the data by definition. Moreover, the observational parameters are functions of the basic model parameters  $p_i$  which may or may not be identifiable:

$$\Phi = \Phi(\mathbf{p}) \quad (7.40)$$

Thus, to investigate the *a priori* identifiability of model parameters  $p_i$ , it is necessary to solve the system of nonlinear algebraic equations in the unknown  $p_i$  obtained by setting the polynomials  $\Phi(\mathbf{p})$  equal to the observational parameter vector  $\hat{\Phi}$ :

$$\Phi(\mathbf{p}) = \hat{\Phi} \quad (7.41)$$

These equations are called the *exhaustive summary*.

Examples of this have already been provided in working out Examples 1, 2 and 3 in (7.14)–(7.15) and (7.19)–(7.20); (7.25)–(7.27) and (7.32)–(7.33), respectively.

One can now generalize definitions. Let us give them first for a single parameter of the model, and then for the model as a whole.

The single parameter  $p_i$  is a *a priori – uniquely or globally identifiable* if and only if the system of (7.41) has one and only one solution:

- *nonuniquely or locally identifiable* if and only if the system of (7.41) has for  $p_i$  more than one but a finite number of solutions;
- *nonidentifiable* if and only if the system of (7.41) has for  $p_i$  infinite solutions;
- *interval identifiable* if it is nonidentifiable and has finite upper and lower bounds that can be calculated from the system of (7.41).

The model is *a priori*:

- *uniquely or globally identifiable* if all of its parameters are uniquely identifiable;
- *nonuniquely or locally identifiable* if all of its parameters are identifiable, either uniquely or nonuniquely, and at least one is nonuniquely identifiable;
- *nonidentifiable* if at least one of its parameters is nonidentifiable; and
- *interval identifiable* if all its nonidentifiable parameters are interval identifiable.

## 7.4 LINEAR MODELS: THE TRANSFER FUNCTION METHOD

The problem now is to assess, only on the basis of knowledge of the assumed model structure and of the chosen experimental configuration, whether the model is *a priori* nonidentifiable, nonuniquely identifiable, or uniquely identifiable.

A linear dynamic model as specified by the linear case of (7.37), is described by:

$$\dot{\mathbf{x}}(t) = \mathbf{A}(\mathbf{p})\mathbf{x}(t) + \mathbf{B}(\mathbf{p})\mathbf{u}(t), \quad \mathbf{x}_0 = \mathbf{x}(t_0, \mathbf{p}) \quad (7.42)$$

$$\mathbf{y}(t, \mathbf{p}) = \mathbf{g}[\mathbf{x}(t, \mathbf{p}); \mathbf{p}] \quad (7.43)$$

where  $\mathbf{A}$  and  $\mathbf{B}$  are constant coefficient matrices of suitable dimensions. Again one often has an output equation linear in the states (see (7.39)), i.e.

$$\mathbf{y}(t, \mathbf{p}) = \mathbf{C}(\mathbf{p})\mathbf{x}(t, \mathbf{p}) \quad (7.44)$$

For sake of simplicity it will be assumed in the following that  $\mathbf{x}_0(t_0, \mathbf{p}) = 0$ , but all comments and results which will be presented hold for the general case.

The most common method to test *a priori* identifiability of linear models described by (7.42) and (7.43) or (7.44) is the transfer function method. The approach is based on the analysis of the  $r \times m$  transfer function matrix:

$$\mathbf{H}(s, \mathbf{p}) = [\mathbf{H}_{ij}(s, \mathbf{p})] = \frac{\mathbf{Y}_i(s, \mathbf{p})}{\mathbf{U}_j(s)} = \mathbf{C}(\mathbf{p})[s\mathbf{I} - \mathbf{A}(\mathbf{p})]^{-1}\mathbf{B}(\mathbf{p}) \quad (7.45)$$

where each element  $\mathbf{H}_{ij}$  of  $\mathbf{H}$  is the Laplace transform of the response in the measurement variable at port  $i$ ,  $y_i(t, \mathbf{p})$  to a unit impulse at port  $j$ ,  $u_j(t) = \delta(t)$ , and  $\mathbf{I}$  is the identity matrix. Thus each element  $\mathbf{H}_{ij}(s, \mathbf{p})$  reflects an experiment performed on the system between input port  $j$  and output port  $i$ .

The transfer function approach makes reference to the coefficients of the numerator and denominator polynomials of each of the  $m \times r$  elements  $\mathbf{H}_{ij}(s, \mathbf{p})$  of the transfer function matrix, respectively,  $\beta_1^{ij}(\mathbf{p}), \dots, \beta_n^{ij}(\mathbf{p})$  and  $\alpha_1^{ij}(\mathbf{p}), \dots, \alpha_n^{ij}(\mathbf{p})$ . These coefficients are the  $2n \times (r \times m)$  observational parameters  $\phi_\ell^{ij}$ . Therefore, the exhaustive summary can be written as:

$$\begin{aligned} \beta_1^{11}(\mathbf{p}) &= \phi_1^{11} \\ &\vdots \\ \alpha_n^{11}(\mathbf{p}) &= \phi_{2n}^{11} \\ &\vdots \\ \beta_1^{rm}(\mathbf{p}) &= \phi_1^{rm} \\ &\vdots \\ \alpha_n^{rm}(\mathbf{p}) &= \phi_{2n}^{rm} \end{aligned} \quad (7.46)$$

This system of nonlinear algebraic equations needs to be solved for the unknown parameter vector  $\mathbf{p}$  to define the identifiability properties of the model.

Let us consider two examples of physiological systems, one dealing with the glucose-insulin control system and one with respiratory mechanics.

**Example 4: A Model of Glucose-Insulin Control**

Consider the linear model discussed in section 5.3.5 (equations (5.43)–(5.46), Figure 5.10) and assume for the moment that only glucose concentration is measured after an impulse input, i.e. the model is:

$$\dot{q}_1(t) = -p_1q_1(t) - p_2q_2(t) + \delta(t) \quad q_1(0) = 0 \quad (7.47)$$

$$\dot{q}_2(t) = -p_3q_2(t) + p_4q_1(t) \quad q_2(0) = 0 \quad (7.48)$$

$$c_1(t) = \frac{q_1}{V_1} \quad (7.49)$$

The unknown parameter vector is  $\mathbf{p} = [p_1, p_2, p_3, p_4, V]^\top$ .

Let us study the identifiability properties of this model. The transfer function is:

$$\begin{aligned} H_{11}(s) &= \frac{c_1(s)}{u(s)} = \frac{\frac{(s+p_3)}{V_1}}{s^2 + (p_1 + p_2)s + p_1p_3 + p_2p_4} \\ & \Big| \\ & \equiv \frac{\beta_2s + \beta_1}{s^2 + \alpha_2s + \alpha_1} \end{aligned} \quad (7.50)$$

and the exhaustive summary is given by:

$$\left\{ \begin{array}{l} \frac{p_3}{V_1} = \phi_1 \end{array} \right. \quad (7.51)$$

$$\left\{ \begin{array}{l} \frac{1}{V_1} = \phi_2 \end{array} \right. \quad (7.52)$$

$$\left\{ \begin{array}{l} p_2p_4 + p_1p_3 = \phi_3 \end{array} \right. \quad (7.53)$$

$$\left\{ \begin{array}{l} p_1 + p_3 = \phi_4 \end{array} \right. \quad (7.54)$$

Therefore, the model is *a priori* nonidentifiable and the set of *a priori* uniquely identifiable parameters is  $p_1, p_3, V_1$  and  $p_2p_4$ .

If, however, the plasma concentration of insulin is also measured, i.e. one has:

$$c_2(t) = \frac{q_2(t)}{V_2} \quad (7.55)$$

then a second transfer function can be defined:

$$H_{21}(s) = \frac{c_2(s)}{u(s)} = \frac{\frac{p_4}{V_2}}{s^2 + (p_1 + p_3)s + p_1p_3 + p_2p_4} \quad (7.56)$$

and the identifiability properties improve. In fact, a new equation can now be added to the exhaustive summary of (7.51)–(7.54):

$$\frac{p_4}{V_2} = \phi_5 \quad (7.57)$$


This means that the set of *a priori* uniquely identifiable parameters becomes  $p_1, p_3, V_1, p_2V_2$  and  $p_4/V_2$ . Note that if the assumption can be made that  $V_2$  is known or that  $V_1 = V_2$ , the model becomes *a priori* uniquely identifiable.

### Example 5: A Model of Respiratory Mechanics

Many techniques for estimating respiratory system mechanics are based on the assumption that the lungs can be described by the general equation of motion, a linear first order system:

$$P(t) = R\dot{V}(t) + \frac{1}{C}V(t) + I\ddot{V}(t) \quad (7.58)$$

where  $P$  denotes airway pressure,  $\dot{V}$  air flow,  $V$  lung volume,  $\ddot{V}$  volume acceleration,  $R$  total breathing resistance,  $C$  respiratory compliance and  $I$  inertial effects. The electric analog of the model is shown in Figure 7.10.



**Figure 7.10** The resistance-elasticity first order model of respiratory mechanics.

For most practical applications the inertial components are negligible and can be ignored. Thus (7.58) reduces to:

$$P(t) = R\dot{V}(t) + \frac{1}{C}V(t) \quad (7.59)$$

Taking ventilatory airflow,  $\dot{V}(t)$ , as input and pressure at the airway opening,  $P(t)$ , as output we can rewrite (7.59) in terms of the pair of differential equations:

$$\begin{cases} \dot{x}(t) = \frac{\dot{V}(t)}{C} & (7.60) \\ P(t) = R\dot{V}(t) + x(t) & (7.61) \end{cases}$$

where  $x(t)$  is the elastic component of pressure. The unknown parameter vector is  $\mathbf{p} = [R, C]^T$ . The transfer function is:

$$H(s) = \frac{Y(s)}{U(s)} = \frac{P(s)}{\dot{V}(s)} = R + \frac{1}{sC} = \frac{sRC + 1}{sC} \equiv \frac{\beta s + 1}{\alpha s} \quad (7.62)$$

Thus the exhaustive summary is given by:

$$RC = \phi_1 \quad (7.63)$$

$$C = \phi_2 \quad (7.64)$$

Therefore the model is *a priori* uniquely identifiable.

We have discussed the Laplace transform method to generate the exhaustive summary of the models. The method is simple to use even for system models of order greater than two. What becomes more and more difficult is the solution, i.e. to determine which of the original parameters of the model are uniquely determined by the system of nonlinear algebraic equations. In fact, one has to solve a system of nonlinear algebraic equations which is increasing both in number of terms and in degree of nonlinearity with the model order. In other words, the method works well for models of low dimension, e.g. order two or three, but fails when applied to relatively large, general structure models because the system of nonlinear algebraic equations becomes too difficult to be solved.

To deal with the problem in general there is the need to resort to computer algebra methods. In particular, there is the need for a tool to test *a priori* identifiability of linear compartmental models of general structure which combines the transfer function method with a computer algebra method. Such a tool, named the Gröbner basis, is available (Audoly *et al.*, 1998).

## 7.5 NONLINEAR MODELS: THE TAYLOR SERIES EXPANSION METHOD

For a nonlinear model described by (7.37) and (7.38) or (7.39), the problem becomes even more difficult. Below, we illustrate a method based on the analysis of the coefficients of the Taylor series expansion in  $t_0$  of the output variable  $y$  (Pohjanpalo, 1978).

For sake of simplicity, let us consider the scalar case and more precisely the  $i$ -th measurement variable  $y_i$ . The Taylor series expansion in  $t_0$  of  $y_i$  is:

$$y_i(t) = y_i(t_0) + t\dot{y}_i(t_0) + \frac{t^2}{2!}\ddot{y}_i(t_0) + \frac{t^3}{3!}\dddot{y}_i(t_0) + \dots \quad (7.65)$$

where  $y_i(t_0), \dot{y}_i(t_0), \dots$  are known and are the observational parameters  $\phi_i$ . By expressing  $y_i(t_0), \dot{y}_i(t_0), \dots$ , as functions of the unknown parameters  $\mathbf{p}$  of the model one has

the exhaustive summary of the model as:

$$y_i^k(t_0, \mathbf{p}) = \phi_k \quad k = 0, 1, 2, \dots \quad (7.66)$$

where  $k$  denotes the derivative order.


The system of nonlinear algebraic (7.66) needs to be solved for  $\mathbf{p}$ . If it has a unique solution, then one can conclude that the model is uniquely identifiable. Unfortunately, nothing can be said about the identifiability properties of the model if this is not the case, e.g. if one is not able to prove, due to the complexity of (7.66), that the system of (7.66) has a unique solution. However, this does not necessarily mean that the model is nonidentifiable. In other words, the method only provides necessary and sufficient conditions for *a priori* unique identifiability.

In addition to this limitation, it should also be noted that one does not know how many coefficients of the power series expansion are needed to study *a priori* identifiability of a given model and experiment. In other words, theory does not provide the value of  $k$ , i.e. the order of the derivatives, at which one can stop. This makes the analysis even more difficult.

The power series expansion method also holds for linear models. In this case one knows (from the Cayley Hamilton theorem) that one can stop at  $k=2n-1$ , i.e. there is no independent information in the derivatives of order higher than  $2n-1$ . To illustrate this point, let us consider an example of a receptor model.

### Example 7: A Langmuir Receptor Model

Let us consider the model in Figure 7.11. Assume that the material is injected at time 0 as a bolus of dose  $d$ , i.e.  $U(t) = D \cdot \delta(t)$ , in plasma (compartment 1) and its concentration is measured. While irreversible elimination occurs linearly, i.e. it is characterized by parameter  $k_{01}$ , transfer of material into the nonaccessible compartment 2 takes place with Langmuir saturation kinetics (see Figure 5.41c), i.e. the parameter  $k_{21}$  decreases linearly as the material is accumulated into 2.



**Figure 7.11** A two compartment with the flux from compartment 1 to 2 described by a Langmuir relationship.

The model equations are:

$$\begin{cases} \dot{Q}_1(t) = -k_{01}Q_1(t) - k_{21} \left(1 - \frac{Q_2(t)}{s_2}\right) Q_1(t) + U(t) & Q_1(0) = 0 & (7.67) \\ \dot{Q}_2(t) = k_{21} \left(1 - \frac{Q_2(t)}{s_2}\right) Q_1(t) & Q_2(0) = 0 & (7.68) \\ y(t) = \frac{Q_1(t)}{V_1} & & (7.69) \end{cases}$$

The unknown parameter vector is  $\mathbf{p} = [V_1, k_{01}, k_{21}, s_2]^T$ .

To study *a priori* identifiability one now has to obtain the various  $y(0), \dot{y}(0), \ddot{y}(0), \ddot{y}(0), \dots$  (Note that 0 is a  $0^+$ , i.e. an instant immediately after the impulse). Let us thus calculate  $y(0), \dot{y}(0), \ddot{y}(0)$  and  $\ddot{y}(0)$ .  $Q_1(0)$  is easy to calculate:

$$Q_1(0) = D \quad (7.70)$$

For  $\dot{Q}_1(0)$  one has from (7.67):

$$\dot{Q}_1(0) = -(k_{01} + k_{21})Q_1(0) \quad (7.71)$$

since  $Q_2(0) = 0$ .

For  $\ddot{Q}_1(0)$  one has:

$$\ddot{Q}_1(t) = -\left[k_{01} + k_{21} \left(1 - \frac{Q_2(t)}{s_2}\right)\right] \dot{Q}_1(t) + k_{21} \frac{\dot{Q}_2(t)}{s_2} Q_1(t) \quad (7.72)$$

and thus:

$$\ddot{Q}_1(0) = -(k_{01} + k_{21})\dot{Q}_1(0^+) + \frac{k_{21}}{s_2} k_{21} Q_1^2(0^+) \quad (7.73)$$

For  $\ddot{Q}_1(0)$  one has:

$$\begin{aligned} \ddot{Q}_1(t) = & -\left[k_{01} + k_{21} \left(1 - \frac{Q_2(t)}{s_2}\right)\right] \ddot{Q}_1(t) + k_{21} \frac{\dot{Q}_2(t)}{s_2} \dot{Q}_1(t) \\ & + \frac{k_{21}}{s_2} \dot{Q}_2(t) \dot{Q}_1(t) + \frac{k_{21}}{s_2} \dot{Q}_2(t) Q_1(t) \end{aligned} \quad (7.74)$$

and thus:

$$\ddot{Q}_1(0) = -\frac{k_{21}^2}{s_2} \left( \frac{k_{21}}{s_2} Q_1^2(0^+) - 3\dot{Q}_1(0^+) \right) Q_1(0^+) - (k_{01} + k_{21})\ddot{Q}_1(0^+) \quad (7.75)$$

Now it is easy from (7.71) to obtain  $y(0), \dot{y}(0), \ddot{y}(0), \ddot{y}(0)$  from (7.70), (7.71), (7.73) and (7.75), respectively. The exhaustive summary of (7.65) is:

$$\frac{D}{V_1} = \phi_1 \quad (7.76)$$

$$\frac{1}{V_1} [-(k_{01} + k_{21}) Q_1(0^+)] = \phi_2 \quad (7.77)$$

$$\frac{1}{V_1} \left[ -(k_{01} + k_{21}) Q_1(0^+) + \frac{k_{21}^2}{s_2} Q_1^2(0^+) \right] = \phi_3 \quad (7.78)$$

$$-\frac{k_{21}^2}{s_2} \left( \frac{k_{21}}{s_2} Q_1^2(0) - 3\dot{Q}_1(0) \right) Q_1(0) - (k_{01} + k_{21}) \ddot{Q}_1(0) = \phi_4 \quad (7.79)$$

It is easy to see that (7.76) provides  $V_1$  uniquely, (7.77) provides  $k_{01} + k_{21}$  uniquely, (7.78) gives  $k_{21}^2/s_2$  uniquely and (7.79) gives  $k_{21}/s_2$ . In other words one has:

$$V_1 = c_1 \quad (7.80)$$

$$k_{01} + k_{21} = c_2 \quad (7.81)$$

$$\frac{k_{21}^2}{s_2} = c_3 \quad (7.82)$$

$$\frac{k_{21}}{s_2} = c_4 \quad (7.83)$$

where  $c_1, c_2, c_3, c_4$  are known constants. Since one has  $s_2 = k_{21}/c_4$ , then  $k_{21} = c_3/c_4$  and thus  $k_{01} = c_1 - \frac{c_3}{c_4}$ . Therefore the model is *a priori* uniquely identifiable.

It is interesting to note that if we consider a linearized version of the model, i.e. with  $Q_2 \ll s_2$  one has  $k_{21}(1 - Q_2/s_2) \simeq k_{21}$ , the model becomes nonidentifiable. In fact, the equations for  $Q_1(0), \dot{Q}_1(0)$  become:

$$Q_1^k(0) = -(k_{01} + k_{21}) Q_1^{k-1}(0) \quad k = 1, 2, \dots \quad (7.84)$$

i.e. only the aggregated parameter  $k_{01} + k_{21}$  is uniquely identifiable (in addition to  $V_1$ ). Note that in this case the model of Figure 7.11 reduces to that of Figure 7.8 and we have already proven the above in section 7.2.

## 7.6 QUALITATIVE EXPERIMENTAL DESIGN

### 7.6.1 Fundamentals

Having defined a model structure and an input/output experiment for its identification, *a priori* identifiability analysis permits one to avoid doing an experiment if the parameters of interest are not identifiable, or conversely to define which would be



the uniquely identifiable parameter combinations of the model. This is particularly important in physiological and clinical studies where ethical as well as practical issues come into play. For instance, if the general two compartment model of Figure 7.4 is the model of choice for the system under study, but only compartment 1 is accessible for input and measurement, *a priori* identifiability analysis can show that  $k_{21}$ ,  $k_{12}$ ,  $k_{01}$  and  $k_{02}$  are nonidentifiable. However, some combinations of them are uniquely identifiable, i.e.  $k_{11} = k_{21} + k_{01}$ ,  $k_{22} = k_{12} + k_{02}$  and  $k_{21}k_{12}$ .

*A priori* identifiability is also an essential ingredient of *qualitative experiment design*. Qualitative experiment design consists of selecting the site of inputs and outputs, among those that are experimentally feasible, which will guarantee *a priori* unique identifiability of the model parameters. Since severe constraints exist on experiment design when dealing with *in vivo* studies, i.e. the number of inputs and outputs is severely limited for both ethical and practical reasons, it is of great interest to define a minimal input/output configuration, i.e. necessary and sufficient to guarantee *a priori* unique identifiability. Minimal means here minimum number of inputs and outputs: obviously more than one minimal input/output configuration can exist, i.e. having the same minimum number of inputs and outputs which take place in different compartments.

The definition of a minimal input/output configuration thus relies on *a priori* identifiability. For instance, the minimal input/output configuration of the general two compartment model of Figure 7.4 is not the most general two input/four output configuration, but a two input/three output one. There are thus four minimal configurations available in this case.


## 7.6.2 An Amino Acid Model

An example of qualitative experiment design and minimal input/output configuration can be provided using a model of leucine metabolism which is an essential amino acid (Saccomani and Cobelli, 1992). Leucine metabolism can be described in the context of the unit processes shown in Figure 7.12. The first metabolite in the degradation via transamination is  $\alpha$ -ketoisocaproate (Kic). Leucine and Kic are interconvertible via the transamination process. Irreversible oxidation occurs with the next step in metabolism which releases  $\text{CO}_2$ . Leucine can enter the system from protein breakdown, and be incorporated into protein.


To quantitate the steps in leucine metabolism outlined in Figure 7.12, knowledge of leucine, Kic and bicarbonate kinetics is required. To develop a model of this complex system, a pilot two-stage (A and B) tracer experiment described in Figure 7.13 was performed.

### Stage A

This is a two input/five output experiment where carbon labeled leucine and tritium – or deuterium labeled Kic are simultaneously administered into plasma (e.g. as a bolus). The corresponding four plasma leucine and Kic tracer concentration curves are measured; in addition, the carbon labeled  $\text{CO}_2$  is measured in expired air.



**Figure 7.12** Schematic representation of the major unit processes of leucine metabolism (adapted from Saccomani and Cobelli, 1992).




**Figure 7.13** Two-stage pilot tracer experiment designed for model formulation and identification. Tracer inputs and measurements are denoted by large arrows and dashed lines with a bullet, respectively. The open and closed bullets correspond to the labeled leucine (open) and Kic (closed) inputs respectively. The closed square bullet corresponds to the bicarbonate input (adapted from Saccomani and Cobelli, 1992).

**Stage B**

This is a single input/single output experiment performed on a separate occasion where labeled bicarbonate is administered into plasma, e.g. as a bolus, and labeled CO<sub>2</sub> is measured in expired air.

The modeling strategy employed to describe the pilot experimental data was as follows. First, the single input/single output data of bicarbonate kinetics (Stage B)


were interpreted using the known three compartment model of bicarbonate kinetics shown in Figure 7.14. Then, assuming the bicarbonate model is known in each individual (from Stage B), the Stage A two input/five output data were interpreted using the model shown in Figure 7.15 where, besides assuming a known bicarbonate system, the model is subject to the constraint  $k_{03} = k_{05}$ .



**Figure 7.14** The three-compartment model of bicarbonate kinetics used to interpret the single input/single output data of the Stage B experiment. The number of compartments has been chosen to be consistent with the leucine metabolism model shown in Figure 7.12. Irreversible loss from compartment 8 is comprised of a respiratory  $k_{08}^R$  and non-respiratory  $k_{08}^{NR}$  component. The large arrow denotes tracer input while the dashed line with the bullet denotes the measurement of labeled bicarbonate in the expired air, i.e.  $k_{08}^R Q_8$ .

Having postulated a plausible model structure, both in terms of physiology and consistency with the pilot experimental data, the first question is: do the Stage A and Stage B experiments ensure *a priori* unique identifiability of the leucine-Kic-bicarbonate model? The answer is yes. In fact, one can show first that the Stage B single input/single output experiment allows *a priori* unique identifiability of all the unknown parameters of the model in Figure 7.15, i.e.  $k_{89}$ ,  $k_{98}$ ,  $k_{8,10}$ ,  $k_{10,8}$ ,  $k_{08}^R$  and  $k_{08}^{NR}$ , once the structural symmetry problem is resolved by labeling compartments 9 and 10 as fast and slow, respectively. Then it can be shown that the Stage A two input/five output experiment allows *a priori* unique identifiability of all the remaining sixteen unknown parameters. These are the remaining  $k_{ij}$  together with  $V_1$  and  $V_2$ , of the model shown in Figure 7.14 (subject to the constraint  $k_{03} = k_{05}$  and assuming the bicarbonate system parameters are known from the Stage B experiment).

Knowing that the model is *a priori* uniquely identifiable, the minimal input/output configuration problem can be addressed. In particular, the following qualitative



**Figure 7.15** Ten-compartment model of leucine-Kic-bicarbonate kinetics used to interpret the Stage A tracer experiment. The bicarbonate model shown in Figure 7.14 has been appended to the intracellular Kic compartment. Two tracer inputs (large arrows) and five measured variables are indicated: three measured variables (open bullets) refer to the labeled leucine input, and the two closed bullets refer to labeled Kic. The model is subject to the constraint that  $k_{03} = k_{05}$ .

experiment design questions must be addressed: is the two-stage pilot experiment a minimal one which guarantees *a priori*, unique identifiability? In particular, is Stage B necessary? If not, are all the four plasma outputs of Stage A necessary? Which are the sufficient ones? In particular, is the expired  $\text{CO}_2$  measurement of Stage A needed?

To answer these questions, it is necessary to analyze the *a priori* identifiability of the model from the Stage A experiment only.

#### *Stage B is not necessary*

*A priori* identifiability analysis of the leucine-Kic-bicarbonate model of Figure 7.15 from data of only Stage A experiment, i.e. without assuming the parameters of the bicarbonate portion of the model to be known, shows the unique *a priori* identifiability of all the parameters including those related to the bicarbonate model. This theoretical result indicates that the independent assessment of bicarbonate kinetics (Stage B) is not necessary since the information content of the five curves of Stage A is sufficient to solve for all the unknown parameters of the leucine-Kic-bicarbonate model. In terms of experiment design, this theoretical result is of particular interest

since it shows that the model is *a priori* identifiable with a reduced experimental effort. The two-stage pilot tracer experiment originally designed for model identification is *a priori* not necessary; in particular, the single input/single output experiment (Stage B) performed on a separate occasion from the dual input/five output one (Stage A) is not required.

#### *Dual input/four output experiment*

So far the sufficiency of the dual input/five output experiment for *a priori* unique identifiability of the leucine-Kic-bicarbonate model shown in Figure 7.15 has been demonstrated. Is this experiment design also necessary? In other words, is it a minimal experiment design for model identifiability? An examination of the Stage A exhaustive summary reveals that measurements of labeled leucine concentration after a labeled leucine injection and of labeled Kic concentration after a labeled Kic injection are necessary. However, either the measurement of leucine concentration after a labeled Kic injection or the measurement of labeled Kic after labeled leucine injection is redundant. Thus, not all the four plasma curves are necessary for the *a priori* unique identifiability of the model. Only three of them are needed, i.e. the two disappearance curves of leucine and Kic plus one of the two appearance curves are required. So far, we have proved that the two input/four output experiment, i.e. the measurement of the three plasma curves described above and of the labeled CO<sub>2</sub> in the expired air, is sufficient.

#### *Two input/three output experiment*

Now remaining to be proved is the necessity of the two input/four output experiment. Having demonstrated the necessity of three plasma curves, one must examine the necessity of the measurement of expired CO<sub>2</sub>. This is of particular interest since it would allow the model to be identified with less experimental effort, i.e. from plasma measurements only.


With such a two input/three output experiment, the model is that of Figure 7.15 without the bicarbonate portion of the model, and with  $k_{84}$  replaced by  $k_{04}$ . Examination of the exhaustive summary shows that all of the parameters of the leucine-Kic portion of the model are *a priori* uniquely identifiable from the two input/three output tracer experiment, an experiment based on plasma measurement only.

## 7.7 SUMMARY

This chapter has explored the nature of the identifiability problem in relation to parametric models and discussed methods that are available for addressing it. In essence this involved asking the question as to whether or not it is theoretically possible to make unique estimates of all the unknown model parameters on the basis of data obtained from particular input/output experiments. This is an exercise that needs to be undertaken prior to performing any actual experiment, thereby avoiding unnecessary resource expenditure that would be ineffective in terms of securing useful parameter estimates. The various approaches to addressing the problem have been illustrated by a number of examples. Having considered this issue of identifiability, Chapter 8 will now go on to consider the next step in dealing with parametric models, namely ways of estimating the model parameters.


## 7.8 EXERCISES AND ASSIGNMENT QUESTIONS

1. Discuss the role of the assessment of *a priori* identifiability in the overall problem of parameter estimation.
2. Why does the *a priori* identifiability problem become more and more difficult to solve when the model order increases?
3. A model of a given physiological system has been shown to be *a priori* nonidentifiable. Discuss possible strategies to cope with nonidentifiability.
4. The kinetics of a drug in the body are described by the model shown below:



$$\begin{cases} \dot{Q}_1(t) = -(k_{21} + k_{01}) \cdot Q_1(t) + U_1(t) & Q_1(0) = 0 \\ C_1(t) = \frac{Q_1(t)}{V_1} \end{cases}$$


- Show that the model is *a priori* nonidentifiable and derive the uniquely identifiable parametrization
- Examine the *a priori* identifiability of this model if it now includes an additional output from compartment 2:



$$\begin{cases} \dot{Q}_1(t) = -(k_{21} + k_{01}) \cdot Q_1(t) + U_1(t) & Q_1(0) = 0 \\ \dot{Q}_2(t) = -k_{02} \cdot Q_2(t) + k_{21} \cdot Q_1(t) & Q_2(0) = 0 \\ C_1(t) = \frac{Q_1(t)}{V_1} \\ C_2(t) = \frac{Q_2(t)}{V_2} \end{cases}$$


Consider the two cases,  $V_2$  unknown and  $V_2$  known.

- Examine *a priori* identifiability of the model with an additional input in compartment 2 simultaneous with that into compartment 1:



$$\begin{cases} \dot{Q}_1(t) = -(k_{21} + k_{01}) \cdot Q_1(t) + U_1(t) & Q_1(0) = 0 \\ \dot{Q}_2(t) = -k_{02} \cdot Q_2(t) + k_{21} \cdot Q_1(t) + U_2(t) & Q_2(0) = 0 \\ C_1(t) = \frac{Q_1(t)}{V_1} \end{cases}$$

5. Assume that the kinetics of a drug are described by the nonlinear model shown below:



$$\begin{cases} \dot{Q}(t) = -\frac{V_M}{K_M + Q(t)} \cdot Q(t) + U(t) & Q_1(0) = 0 \\ C(t) = \frac{Q(t)}{V} \end{cases}$$

where  $V_M$  and  $K_M$  are the parameters of the Michaelis-Menten description of irreversible drug elimination.

Examine the *a priori* identifiability problem.

# 8 PARAMETRIC MODELS – THE ESTIMATION PROBLEM

## Chapter Contents

### **8.1 Introduction**

### **8.2 Linear and Nonlinear Parameters**

### **8.3 Regression: Basic Concepts**

8.3.1 The Residual

8.3.2 The Residual Sum of Squares

8.3.3 The Weighted Residual Sum of Squares

8.3.4 Weights and Error in the Data

### **8.4 Linear Regression**

8.4.1 The Problem

8.4.2 Test on Residuals

8.4.3 An Example

8.4.4 Extension to the Vector Case

### **8.5 Nonlinear Regression**

8.5.1 The Scalar Case

8.5.2 Extension to the Vector Case

8.5.3 Algorithms

8.5.4 An Example

### **8.6 Tests for Model Order**

### **8.7 Maximum Likelihood Estimation**

### **8.8 Bayesian Estimation**

### **8.9 Optimal Experimental Design**

### **8.10 Summary**

### **8.11 Exercises and Assignment Questions**



## 8.1 INTRODUCTION

The focus of this chapter is the estimation problem in the context of mathematical models that explicitly include unknown parameters. Having formulated the basic estimation problem, descriptions are given of the major approaches which include linear and nonlinear least squares, maximum likelihood and Bayes. Also discussed is the basis of the related problem of optimal experimental design. For a more detailed account of estimation methods, including least squares, maximum likelihood and Bayesian methods, Walter and Pronzato (1997) provides a good description.

A model of the system – whether an input/output or a structural one – has now been formulated. The model contains a set of unknown parameters to which we would like to assign numerical values from the data of an experiment. For a structural model we assume that we have checked its *a priori* identifiability. However, this is not necessary for an input/output model because, by definition, its unknown parameters are the observational ones. The experimental data are available, e.g. they have been obtained after a qualitative experiment design phase. In mathematical terms the ingredients we have are the model output (as shown earlier in (7.1)):

$$y(t) = g(t, \mathbf{p}) \quad (8.1)$$

where  $g(t, \mathbf{p})$  is related to the model of the system, e.g. a structural or an input/output one, and the discrete-time noisy output measurements,  $z_i$  (as shown earlier in (7.2)):

$$z(t_i) = z_i = y_i + \mathbf{v}_i = g(t_i, \mathbf{p}) + \mathbf{v}_i \quad (8.2)$$

where  $\mathbf{v}_i$  is the measurement error of the  $i$ -th measurement.

The problem is to assign a numerical value to  $\mathbf{p}$  from the data  $z_i$ . As an example, suppose the model of data:


$$y(t) = \mathbf{p}_1 + \mathbf{p}_2 t + \mathbf{p}_3 t^2 \quad (8.3)$$

is used to describe the data  $z_i$ : in this case one needs to assign a numerical value to  $\mathbf{p} = [\mathbf{p}_1, \mathbf{p}_2, \mathbf{p}_3]^T$ . On the other hand, suppose that the model of data:

$$y(t) = A_1 e^{-\alpha_1 t} + A_2 e^{-\alpha_2 t} \quad (8.4)$$

is the candidate one for describing  $z_i$ : in this case one needs to assign a numerical value to  $\mathbf{p} = [A_1, \lambda_1, A_2, \lambda_2]^T$ . The same also holds for models of systems, e.g. consider the model of Figure 7.3 in Chapter 7. In this case one needs to assign a numerical value to  $\mathbf{p} = [k_{21}, k_{12}, k_{01}, V_1]^T$  or  $\mathbf{p} = [k_{21}, k_{12}, k_{01}, V_1]^T$ , respectively.

If either of these models were being used to describe a set of data, the parameters characterizing them need to be ‘adjusted’ until a set of values for them is obtained which provides the ‘best fit’ to the data (Figure 8.1). Regression analysis, which is defined and described in detail below, is the most widely used method to ‘adjust’ the parameters characterizing a particular function to obtain the ‘best fit’ scenario to a set of data.



**Figure 8.1** The parameter estimation scheme showing its iterative nature.

It will be seen that there are fundamentally two kinds of regression: linear and nonlinear. The theory of linear regression is mathematically precise with the formulae for the parameters characterizing the function specifically defined. Nonlinear regression is more complex and results only in approximations for the estimates of the parameters. In addition to the parameter estimates, for both linear and nonlinear regression, one usually wants information on the errors of the parameter estimates. To obtain estimates of these errors, one moves to weighted regression. In weighted regression, knowledge of the error structure of the data is needed. These errors are used to calculate the weight assigned to a datum during the regression process. The importance of understanding the nature of the error in the data and how this relates to weighted and unweighted regression is an essential ingredient of the regression problem as will be made clear later. Thus there are several ingredients to the regression problem. These will be isolated and explained in detail with examples provided.

## 8.2 LINEAR AND NONLINEAR PARAMETERS

What constitutes a linear or nonlinear parameter? It is important to understand this since, as will be seen in section 8.4, there is an exact solution when the model contains only linear parameters. In contrast, as will be seen in section 8.5, the solution is only approximate if the model contains a nonlinear parameter.

There are many kinds of functions that are linear in their parameters. Polynomials such as the following one are an example:

$$y(t) = p_1 + p_2 \cdot t + p_3 \cdot t^2 + \dots + p_n \cdot t^{n-1} \quad (8.5)$$

This polynomial  $y(t)$  is characterized by the coefficients  $p_1, p_2, \dots, p_n$  which are the parameters to be estimated in data fitting, and the independent variable is  $t$ . Why are polynomials linear? The reason why can be illustrated by using the simple polynomial

$$y(t) = pt = y(p, t) \quad (8.6)$$

When  $y(t) = y(p, t)$  is written in this manner, it indicates that  $y$  is a function of the independent variable  $t$  and of the value assigned to the parameter  $p$ . That is,  $y(t)$  will assume different values depending upon a specific value for  $p$ . The function  $y(t)$  is linear in the parameter  $p$ , or equivalently the parameter  $p$  in (8.6) is linear because if the value  $p + p'$  is considered, then:

$$y(p + p', t) = (p + p')t = pt + p't = y(p, t) + y(p', t) \quad (8.7)$$

For example, doubling the value for the parameter  $p$  will double the value for the function  $y(t)$ .

If  $y(t)$  is nonlinear in at least one of its parameters, or equivalently if not all parameters describing  $y(t)$  are linear, then  $y(t)$  is nonlinear. Nonlinearity is seen when the counterpart of (8.7) cannot be written for a particular function. For example, the exponential function  $y(t)$  given in (8.4) is nonlinear since  $y(A_1 + A'_1, \lambda_1 + \lambda'_1, A_2 + A'_2, \lambda_2 + \lambda'_2, t)$  is not equal to the sum of  $y(A_1, \lambda_1, A_2, \lambda_2, t)$  and  $y(A'_1, \lambda'_1, A'_2, \lambda'_2, t)$ . This function is linear in  $A_1$  and  $A_2$  and nonlinear in  $\lambda_1$  and  $\lambda_2$ .

For a model linear in the parameters exact solutions are available based on linear regression theory. However, for a model nonlinear in the parameters only approximate solutions are available based on the linear theory. That is why an understanding of the linear theory is essential to discuss the nonlinear problem.

One final remark that is worth emphasizing relates to the difference between linearity in the parameters and linearity of the dynamics. To exemplify this, consider the simplest linear dynamic model, e.g. a one compartment model:

$$\dot{q}(t) = -kq(t) + d\delta(t) \quad q(0) = 0 \quad (8.8)$$

In terms of parameter estimation, this is a model nonlinear in the parameters since the solution of (8.8) is:

$$q(t) = de^{-kt} \quad (8.9)$$

and, thus, the parameter estimation problem is nonlinear in  $k$  ( $d$  is known).

### 8.3 REGRESSION: BASIC CONCEPTS

Here we examine one by one the essential ingredients of regression.


### 8.3.1 The Residual

The basic notions of regression, i.e. finding a set of parameter values which define a function that will provide the best fit for a set of data, can be described using Figure 8.2. Suppose an investigator wishes to obtain the best fit of the data to the straight line

$$y(t) = pt \quad (8.10)$$

How can this fit be obtained?

To solve the problem, one sees that, for different values of  $p$ , different straight lines will be generated. How does one find the particular value for  $p$  which provides



**Figure 8.2** (a): A set of data with a straight line through them obtained by linear regression. (b): A plot of the residuals illustrating the pattern of 'above' or 'below' zero. (c): Plot of  $WRSS(\mathbf{p})$  versus  $p$  which shows that there is a unique value of  $p$  for which  $WRSS(\mathbf{p})$  is minimal (adapted from Cobelli *et al.*, 2001).

the best fit? Note that for each point at time  $t_i$  where there is a *datum*, denoted  $z_i$ , there is a corresponding *prediction* from  $y(t)$ ,  $y_i$ . Once a value for  $p$  is chosen, the difference between the experimentally observed datum and the calculated value, i.e.  $z_i - y_i$ , can be calculated; this is called the *residual*. In general, if  $y(t)$  is a function to be fitted to a set of data, and if  $z_i$  is the  $i^{\text{th}}$  observation, the residual is written:

$$\text{res}_i = z_i - y_i \quad (8.11)$$

### 8.3.2 The Residual Sum of Squares

The expression:

$$\text{RSS} = \sum_{i=1}^N (z_i - y_i)^2 = \sum_{i=1}^N \text{res}_i^2 \quad (8.12)$$

where  $N$  is the number of observations is called the *residual sum of squares*, RSS, or *sum of squares of errors* since  $z_i - y_i$  can be considered as the error between the observed and predicted value for each sample time  $t_i$ .

The residual sum of squares, RSS, can be considered a measure of how good the fit is to the given set of data. For different numerical values of the parameter characterizing (8.10), i.e. for different numerical values for  $p$ , one will obtain a different RSS. Therefore, RSS itself can be considered as a function of the parameter characterizing the linear function chosen to describe a set of data. One can write  $\text{RSS} = \text{RSS}(p)$  for (8.12) to emphasize this fact.

The idea behind regression is to minimize RSS with respect to the parameter values characterizing the function to be fitted to the data, i.e. to find a set of parameter values for  $y(t)$  which minimizes RSS. The process is called *least squares*. In the case of the function defined in (8.10), the problem would be to find a value for  $p$  which minimizes RSS for the set of data given in Figure 8.2.

The theory behind this minimization utilizes differential calculus. It also depends upon a number commonly encountered in statistics: degrees of freedom. Suppose a function  $y(t)$  described by  $P$  parameters is to be fitted to a set of  $N$  data points; *the degrees of freedom* is defined as the number  $N - P$ . For the example above,  $y(t)$  given in (8.10) is characterized by the single parameter  $p$ , hence  $P = 1$ . The number of data given in Figure 8.2 is 10, hence  $N = 10$ . In this example, the degrees of freedom are 9. The degrees of freedom are important since in order to solve the regression problem, i.e. to find one set of parameter values for which RSS is minimum, it is necessary that the degrees of freedom should be one or greater. If the degrees of freedom are less than one, there is an infinite number of parameter values which will minimize RSS.

### 8.3.3 The Weighted Residual Sum of Squares

Data have errors associated with them. This basically means more confidence may be placed in one type of data than in another, i.e. some data may be more ‘important’ than others in the fitting process. For instance, some data are less noisy than others, so the preferred description/explanation would be for the less noisy outcome rather

than for the noisier, i.e. small residuals are desired for the less noisy while larger ones are tolerated for the noisier. Therefore, some means by which to give greater importance to these data is sought. This is accomplished through assigning weights to each datum.

The assignment of weights is reflected in the sum of squares. If  $y(t)$  is a function to be fitted to a set of data and  $z_i$  is the  $i^{\text{th}}$  observation, the expression:

$$\text{WRSS} = \sum_{i=1}^N w_i (z_i - y_i)^2 = \sum_{i=1}^N \text{wres}_i^2 \quad (8.13)$$

where  $N$  is the number of observations is called the *weighted residual sum of squares*, WRSS, or *weighted error sum of squares* since  $\sqrt{w_i}(z_i - y_i)$  can be considered as the weighted error between the observed and predicted value for each sample time  $t_i$ . Extending the above, the theory behind minimizing WRSS is called *weighted least squares* (WLS). In this expression  $w_i$  is the *weight* assigned to the  $i^{\text{th}}$  datum, and the *weighted residual* is written:

$$\text{wres}_i = \sqrt{w_i}(z_i - y_i) \quad (8.14)$$

RSS and WRSS are functions of the parameters characterizing a function  $y(t)$ . They are examples of what in the theory of optimization are called an *objective or cost function*. While there are other objective functions that can be used, RSS and WRSS are most commonly used in the modeling of physiological systems. Other objective functions will be briefly described in section 8.7 where the Maximum Likelihood and Bayes estimators are discussed.

### 8.3.4 Weights and Error in the Data

It is natural to link the choice of weights to what is known about the precision of each individual datum. In other words, it is necessary to give more credibility, or weight, to those data whose precision is high and less credibility, or weight, to those data whose precision is small.

Suppose that fitting a function  $y(t)$  to a set of data is required. In what follows, it will be assumed that the function  $y(t)$  is the correct model for the data being considered. As part of the theory to be developed, information is recovered from the fitting process to test if this assumption is in fact correct.

To start, for each datum  $z_i$  at sample time  $t_i$ , there is an error term  $v_i$ . It is usually assumed that this term is additive, i.e. can be expressed as:

$$z_i = y_i + v_i \quad (8.15)$$

$v_i$  is a random variable and assumptions about its characteristics must be made. The most common assumption is that the sequence of  $v_i$  is a random process with zero mean (i.e. no systematic error) independent samples and variance known. This can be

formalized in the statistical setting using the notation  $E$ ,  $\text{Var}$ , and  $\text{Cov}$  to represent, respectively, mean, variance and covariance. Then:

$$E(\mathbf{v}_i) = 0 \quad (8.16)$$

$$\text{Cov}(\mathbf{v}_i, \mathbf{v}_j) = 0 \quad \text{for } t_i \neq t_j \quad (8.17)$$

$$\text{Var}(\mathbf{v}_i) = \sigma_i^2 \quad (8.18)$$

Equation (8.16) indicates that the errors  $\mathbf{v}_i$  have zero mean; (8.17) signifies that they are independent, and (8.18) shows that the variance is known. A standardized measure of the error is provided by the *fractional standard deviation* (FSD) or *coefficient of variation* (CV):

$$\text{FSD}(\mathbf{v}_i) = \text{CV}(\mathbf{v}_i) = \frac{\text{SD}(\mathbf{v}_i)}{z_i} \quad (8.19)$$

where SD is the standard deviation of the error:

$$\text{SD}(\mathbf{v}_i) = \sqrt{\text{Var}(\mathbf{v}_i)} \quad (8.20)$$

The FSD or CV is often expressed as a percentage, i.e. the percentage fractional standard deviation or percentage coefficient of variation, by multiplying  $\text{SD}(\mathbf{v}_i)/z_i$  in (8.19) by 100.

Three remarks are in order here. First, if the errors  $\mathbf{v}_i$  are Gaussian, then (8.16)–(8.18) specify completely the probability distribution; otherwise they can be seen to provide a description based on the first two moments (mean and variance). Second, using the fact that if  $Y$  is a random variable, and  $\alpha$  and  $\beta$  are constants,  $\text{Var}(\alpha + \beta Y) = \beta^2 \text{Var}(Y)$  one has from (8.15) that, since  $y_i$  is constant,  $\text{Var}(z_i) = \text{Var}(\mathbf{v}_i)$ , that is, the variance of an individual datum and of its error are equal.

Finally, we have considered the case where the variance is known (see equation (8.18)). However, one can also easily handle the case where the variance is known up to a proportionality constant, i.e.  $\text{Var}(\mathbf{v}_i) = b_i \sigma^2$  with  $b_i$  known and  $\sigma^2$  unknown. It is beyond the scope of this book to consider this case further. For more details the reader is referred to Cobelli *et al.* (2001; Chapter 10).

Knowing the error structure of the data, how are the weights  $w_i$  chosen? The natural choice is to weight each datum according to the inverse of the variance, i.e.:

$$w_i = \frac{1}{\sigma_i^2} \quad (8.21)$$

It can be shown that this natural choice of weights is optimal in the linear regression case, i.e. it produces the minimum variance of the parameter estimates. Therefore, it is very important to have correct knowledge of the error of the data, and to weight each datum according to this error.

The problem now is how to estimate the error variance. Ideally one would like to have a direct estimate of the variance of all sources of error. This is a difficult problem. For instance, the measurement error is just one component of the error; it

can be used as an estimate of the error only if the investigator believes that the major source of error arises after the sample is taken. To have a more precise estimate of the error, the investigator should have several independent replicates of the measurement  $z_i$  at each sampling time  $t_i$  from which the sample variance  $\sigma_i^2$  at  $t_i$  can be estimated. If there is a major error component before the measurement process (for instance, an error related to drawing a plasma sample or preparing a plasma sample for measurement), then it is not sufficient to repeat the measurement *per se* on the same sample several times. In theory, in this situation it would be necessary to repeat the experiment several times. Such repetition is not often easy to handle in practice. Finally, there is the possibility that the system itself can vary during the different experiments.

In any case, since the above-mentioned approach estimates the variance at each sampling time  $t_i$ , it requires several independent replicates of each measurement. An alternative more practical approach consists of postulating a model for the error variance and estimating its unknown parameters from the experimental data.

A flexible model that can be used for the error variance is:

$$\sigma_i^2 = \alpha + \beta(y_i)^\gamma \quad (8.22)$$

which can be approximated in practice by:

$$\sigma_i^2 = \alpha + \beta(z_i)^\gamma \quad (8.23)$$

where  $\alpha$ ,  $\beta$  and  $\gamma$  are non-negative model parameters relating the variance associated with an observation to the value of the observation itself. Values can usually be assigned to these parameters, or they can also be estimated from the data themselves.

## 8.4 LINEAR REGRESSION

The fundamental ideas of linear regression are discussed by fitting a straight line through the data of Figure 8.2. The concepts introduced here, based on least squares theory, carry over to any linear function. The equation for the straight line used here is:

$$y = y(\mathbf{p}, t) = \mathbf{p}t \quad (8.24)$$

where  $t$  is the independent variable. The parameter describing this line,  $\mathbf{p}$ , is linear as described above. Different values for  $\mathbf{p}$  will produce different lines. Hence, for each value of  $\mathbf{p}$  there is a different calculated value of RSS, or  $\text{RSS}(\mathbf{p})$  to denote the functional relationship with  $\mathbf{p}$ ; this is shown in Figure 8.2. What one seeks is the value of  $\hat{\mathbf{p}}$ , which minimizes  $\text{RSS}(\mathbf{p})$ . This point is indicated in Figure 8.2. As part of the theory of linear regression, it is known that when the degrees of freedom are greater than one, there is a unique value for  $\mathbf{p}$  which will minimize  $\text{RSS}(\mathbf{p})$ .



### 8.4.1 The Problem

It is important to take into account measurement errors. This is done by weighted least squares, WLS, which takes errors in the data explicitly into account through weights. The expression to be minimized is WRSS:

$$\text{WRSS}(\mathbf{p}) = \sum_{i=1}^N \text{wres}_i^2 = \sum_{i=1}^N w_i (z_i - y_i)^2 = \sum_{i=1}^N \frac{1}{\sigma_i^2} (z_i - \mathbf{p}t_i)^2 \quad (8.25)$$

To find the unique value for  $\mathbf{p}$  which minimizes  $\text{WRSS}(\mathbf{p})$ , one takes the derivative of  $\text{WRSS}(\mathbf{p})$  with respect to  $\mathbf{p}$ , sets the resulting expression equal to zero, and solves this equation for  $\mathbf{p}$ :

$$\frac{d(\text{WRSS}(\mathbf{p}))}{d\mathbf{p}} = -2 \sum_{i=1}^N \frac{t_i}{\sigma_i^2} (z_i - \mathbf{p}t_i) = 0 \quad (8.26)$$

From differential calculus, it is known that the value of  $\mathbf{p}$  which is a solution of (9.26),  $\hat{\mathbf{p}}$ , will minimize  $\text{WRSS}(\mathbf{p})$ . This is given by:

$$\hat{\mathbf{p}} = \frac{\left( \sum_{i=1}^N \frac{z_i \cdot t_i}{\sigma_i^2} \right)}{\left( \sum_{i=1}^N \frac{t_i^2}{\sigma_i^2} \right)} \quad (8.27)$$

It is also possible to obtain an expression for the precision of  $\hat{\mathbf{p}}$ ,  $\text{Var}(\hat{\mathbf{p}})$ . Since data  $z_i$  are affected by a measurement error  $v_i$  as specified in (8.15), one has that  $\hat{\mathbf{p}}$  is also affected by an error which we call estimation error. The estimation error can be defined as:

$$\tilde{\mathbf{p}} = \mathbf{p} - \hat{\mathbf{p}} \quad (8.28)$$

$\tilde{\mathbf{p}}$  is a random variable because  $\hat{\mathbf{p}}$  is random. One can measure the ability of the estimation error to vary through its variance:

$$\text{Var}(\tilde{\mathbf{p}}) = E(\tilde{\mathbf{p}}^2) = \frac{1}{\sum_{i=1}^N \left( \frac{t_i^2}{\sigma_i^2} \right)} = \frac{1}{\sum_{i=1}^N \sigma_i^2 t_i^2} = \text{Var}(\hat{\mathbf{p}}) \quad (8.29)$$

The precision of the estimate  $\hat{\mathbf{p}}$  of  $\mathbf{p}$  is often expressed in terms of standard deviation, i.e. the square root of the variance  $\text{Var}(\hat{\mathbf{p}})$ :

$$\text{SD}(\hat{\mathbf{p}}) = \sqrt{\text{Var}(\hat{\mathbf{p}})} \quad (8.30)$$

It can also be given in terms of the fractional standard deviation FSD or the coefficient of variation CV, which measures the relative precision of the estimate:

$$\text{FSD}(\hat{\mathbf{p}}) = \text{CV}(\hat{\mathbf{p}}) = \frac{\text{SD}(\hat{\mathbf{p}})}{\hat{\mathbf{p}}} \quad (8.31)$$

As noted previously, FSD and CV can be expressed as a percent by multiplying it by 100.

From (8.27) and (8.29), one sees that both  $\hat{\mathbf{p}}$  and  $\text{VAR}(\hat{\mathbf{p}})$  depend upon the  $\sigma_1^2$ . This is why it is essential that the investigator appreciates the nature of the error in the data.

### 8.4.2 Test on Residuals

Up to this point, an assumption has been made that the model is correct, i.e. that  $y(t) = \mathbf{p}t$  provides the correct functional description of the data. In this case, from the comparison between the equation describing the data:

$$z_i = y_i + v_i = \mathbf{p}t_i + v_i \quad (8.32)$$

and from the definition of the residual (8.11):

$$\text{res}_i = z_i - y_i = z_i - \hat{\mathbf{p}}t_i \quad (8.33)$$


it can immediately be concluded that residuals  $\text{res}_i$  must reflect the measurement errors  $v_i$ . For this in fact to be true, two conditions must hold: (i) the correct model or functional description of the data has been selected, and (ii) the parameter estimation procedure has converged to values close to the 'true' values. The sequence of residuals can thus be viewed as an approximation of the measurement error sequence.

We can check if the above two conditions hold by testing on the sequence of residuals the assumptions made regarding the measurement error. As discussed in previous sections, the measurement error is usually assumed to be a zero mean, the independent random process having a known variance. These assumptions can be checked on the residuals by means of statistical tests. This analysis can reveal the presence of errors in the model structure, i.e. in the above example if  $y(t) = \mathbf{p}t$  is not an appropriate model for a given set of data, or the failure of the parameter estimation procedure to converge, i.e. if  $\hat{\mathbf{p}}$  are not close to the true values for  $\mathbf{p}$ .

Independence of the residuals can be tested visually by using a plot of residuals versus time. It is expected that the residuals will oscillate around their mean, which should be close to zero, in an unpredictable way. Systematic residuals, i.e. a long run sequence of residuals above or below zero, suggests that the model is an inappropriate description of the system since it is not able to describe a non-random component of the data. In Figure 8.3 a typical plot is shown for a sequence of independent and correlated residuals.

A formal test of non-randomness of residuals is called the *run test*. A run is defined as a subsequence of residuals having the same sign (assuming the residuals have zero mean); intuitively a very small or very large number of runs in the residual sequence is an indicator of non-randomness, i.e. of systematic errors in the former and of periodicity in the latter case. For details and examples we refer the reader to Cobelli *et al.* (2001; Chapter 8).

In WLS estimation a specific assumption on the variance of the measurement errors has been made. If the model is correct, the residuals must reflect this assumption.



**Figure 8.3** Plot of residuals versus time. (a) shows a pattern of independent residuals; (b) of correlated residuals (adapted from Cobelli *et al.*, 2001).

Since:


$$\text{Var}\left(\frac{v_i}{\sigma_i}\right) = \frac{1}{\sigma_i^2} \text{Var}(v_i) = 1 \quad (8.34)$$

if we define the weighted residuals as:

$$\text{wres}_i = \frac{\text{res}_i}{\sigma_i} \quad (8.35)$$

there should be a realization of a random process having unit variance. By plotting the weighted residual versus time it is thus possible to visually test the assumption on the variance of the measurement error: weighted residuals should lie in a  $-1, +1$  wide band. A typical plot of weighted residuals is shown in Figure 8.4.

A pattern of residuals different from that which was expected indicates either the presence of errors in the functional description of the data or that the model is correct but that the measurement error model is not appropriate. In this case, it is necessary



**Figure 8.4** Plot of weighted residuals versus time. See text for additional explanation (adapted from Cobelli *et al.*, 2001).

to modify the assumptions on the measurement error structure. Some suggestions can be derived by examining the plot. As an example, consider the case where the variance of the measurement error is assumed to be constant. The residuals are expected to be confined in a  $-1, +1$  wide region. If their amplitude tends to increase in absolute value with respect to the observed value, a possible explanation is that the variance of the measurement error is not constant, thus suggesting a modification of the assumption on the measurement error variance.

A formal test on the variance of weighted residuals based on  $\chi^2$  statistics can also be applied; this test is exact for linear regression with Gaussian measurement errors, while it is approximate in the general case. For details and examples we refer the reader to Cobelli *et al.* (2001; Chapter 8).


### 8.4.3 An Example

Consider the data shown in Figure 8.5 (these data have already been shown in Figure 8.2). Assume that the linear function to be fitted to the data is  $y(t) = pt$  and let us consider two different weighting schemes. The fitted data and the linear function prediction are shown in Figure 8.6a.

In the first weighting scheme,  $\sigma^2$  was constant and equal to 900, hence the weights  $w_i$  were constant and equal to 0.01. Evaluating (8.27), one finds the numerator and denominator are, respectively, 170.11 and 48.72, hence  $\hat{A} = 900 \hat{p}$ . In the second weighting scheme,  $\sigma^2 = (0.15z_i)^2$ . In this case, the numerator and denominator of (8.27) are 0.343 and 0.089, respectively, hence  $900 \hat{p} = 3.845$ .

The assignment of weights has a substantial effect upon the estimate  $\hat{A}$  and its estimated standard deviation. The effect of the two weighting schemes can be evaluated by using (8.27) and (8.29). The results are summarized below in Table 8.1.

The plot of residuals for testing independence is shown in Figure 8.6b: residuals are randomly scattered around the origin. The plot of weighted residuals to test the



**Figure 8.5** A set of data (those of Figure 8.2) to be fitted with a linear function (adapted from Cobelli *et al.*, 2001).

assumption on the variance of the measurement error is shown in Figure 8.6c: most weighted residuals lie between  $-1$  and  $1$  indicating that they are consistent with the above assumption.

#### 8.4.4 Extension to the Vector Case

We have seen in detail the simple case with one parameter:

$$y(t) = \mathbf{p} \cdot \mathbf{t} \quad (8.36)$$

An easy extension, and one which will allow us a straightforward handling of the general case, is to two model parameters:

$$y(t) = \mathbf{p}\mathbf{t} + q \quad (8.37)$$

The measurement equation is:

$$z_i = y_i + \mathbf{v}_i = \mathbf{p}\mathbf{t}_i + q + \mathbf{v}_i \quad (8.38)$$


In this case, the weighted residual sum of squares, WRSS, is given by:

$$\text{WRSS} = \sum_{i=1}^N \frac{1}{\sigma_i^2} (z_i - \mathbf{p}\mathbf{t}_i - q)^2 \quad (8.39)$$

To get  $\hat{\mathbf{p}}$  and  $\hat{q}$  we follow the same line of reasoning discussed for the model (8.36), and so calculate:

$$\frac{\partial \text{WRSS}(\mathbf{p}, q)}{\partial \mathbf{p}} = 0 \quad (8.40)$$

$$\frac{\partial \text{WRSS}(\mathbf{p}, q)}{\partial q} = 0 \quad (8.41)$$



**Figure 8.6** Effect of two different weighting schemes on parameter estimation. (a): Plot of data versus model fits. The solid line is a plot of  $y(t) = 3.977t$  and the dotted line is  $y(t) = 3.845t$ . (b): Plot of residuals. (c): Plot of weighted residuals (adapted from Cobelli *et al.*, 2001).

**Table 8.1** Estimation results for two weighting schemes

	Constant Variance Var( $v_i$ ) = 900 $w_i = 1/900$	Constant FSD Var( $v_i$ ) = $z_i^2 \cdot 0.015$ $w_i = 1/(z_i^2 \cdot 0.015)$
$\hat{p}$	3.977	3.845
Var( $\hat{p}$ )	0.023	0.034
SD( $\hat{p}$ )	0.153	0.185
FSD( $\hat{p}$ )	4%	5%
WRSS	0.095	2.074

and obtain explicit expressions for  $\hat{p}$  and  $\hat{q}$ . We can also calculate Var( $\hat{p}$ ) and Var( $\hat{q}$ ), but this time there will be the covariance between  $\hat{p}$  and  $\hat{q}$  available,  $\text{cov}(\hat{p}, \hat{q}) = \text{cov}(\hat{p}, \hat{q})$ .

Let us put this example in compact matrix-vector notation. By writing the measurement equation (8.38) for all measurements  $i = 1, 2, \dots, N$  we get:

$$\begin{bmatrix} z_1 \\ z_2 \\ \dots \\ \dots \\ z_{N-1} \\ z_N \end{bmatrix} = \begin{bmatrix} y_1 \\ y_2 \\ \dots \\ \dots \\ y_{N-1} \\ y_N \end{bmatrix} + \begin{bmatrix} v_1 \\ v_2 \\ \dots \\ \dots \\ v_{N-1} \\ v_N \end{bmatrix} = \begin{bmatrix} t_1 & 1 \\ t_2 & 1 \\ \dots & \dots \\ \dots & \dots \\ t_{N-1} & 1 \\ t_N & 1 \end{bmatrix} \begin{bmatrix} m \\ q \end{bmatrix} + \begin{bmatrix} v_1 \\ v_2 \\ \dots \\ \dots \\ v_{N-1} \\ v_N \end{bmatrix} \quad (8.42)$$

and thus:

$$\mathbf{z} = \mathbf{y} + \mathbf{v} = \mathbf{G}\mathbf{p} + \mathbf{v} \quad (8.43)$$

with:

$$\mathbf{z} = [z_1, z_2, \dots, z_N]^T \quad (8.44)$$

$$\mathbf{y} = [y_1, y_2, \dots, y_N]^T \quad (8.45)$$

$$\mathbf{v} = [v_1, v_2, \dots, v_N]^T \quad (8.46)$$

$$\mathbf{v} = [v_1, v_2, \dots, v_N]^T \quad \mathbf{p} = [mq]^T \quad (8.47)$$

$$\mathbf{G} = \begin{bmatrix} t_1 & \dots & 1 \\ t_2 & \dots & 1 \\ \vdots & & \vdots \\ t_N & \dots & 1 \end{bmatrix} \quad (8.48)$$

The measurement error  $\mathbf{v}$ , assuming a second order description, i.e. mean and covariance matrix ( $N \times N$ ), is:

$$E[\mathbf{v}] = 0 \quad (8.49)$$

$$E[\mathbf{v}\mathbf{v}^T] = \boldsymbol{\Sigma}_v \quad (8.50)$$

Since independence is assumed,  $\Sigma_v$  is diagonal:

$$\Sigma_v = \text{diag}(\sigma_1^2, \sigma_2^2, \dots, \sigma_N^2) \quad (8.51)$$

Now it is straightforward to generalize. We can write:

$$\mathbf{z} = \mathbf{y} + \mathbf{v} = \mathbf{G} \mathbf{p} + \mathbf{v} \quad (8.52)$$

$$\begin{bmatrix} z_1 \\ z_2 \\ \dots \\ \dots \\ z_N \end{bmatrix} = \begin{bmatrix} y_1 \\ y_2 \\ \dots \\ \dots \\ y_N \end{bmatrix} + \begin{bmatrix} v_1 \\ v_2 \\ \dots \\ \dots \\ v_N \end{bmatrix} = \begin{bmatrix} g_{11}, g_{12}, \dots, g_{1M} \\ g_{21}, g_{22}, \dots, g_{2M} \\ \dots \\ \dots \\ g_{N1} \quad \dots \quad g_{NM} \end{bmatrix} \begin{bmatrix} p_1 \\ p_2 \\ \dots \\ p_M \end{bmatrix} + \begin{bmatrix} v_1 \\ v_2 \\ \dots \\ \dots \\ v_N \end{bmatrix} \quad (8.53)$$

with:

$$\mathbf{p} = [p_1, p_2 \dots p_M]^T \quad (8.54)$$

$$\mathbf{G} = \begin{bmatrix} g_{11} & \dots & g_{1M} \\ \vdots & & \vdots \\ g_{N1} & \dots & g_{NM} \end{bmatrix} \quad (8.55)$$

Now, if we define the residual vector  $\mathbf{r}$ :

$$\mathbf{r} = \mathbf{z} - \mathbf{Gp} \quad (8.56)$$

the weighted residual sum of squares is:

$$\text{WRSS}(\mathbf{p}) = \sum_{i=1}^N \frac{1}{\sigma_i^2} r_i^2 = \mathbf{r}^T \Sigma_v^{-1} \mathbf{r} = (\mathbf{z} - \mathbf{Gp})^T \Sigma_v^{-1} (\mathbf{z} - \mathbf{Gp}) \quad (8.57)$$

The WLS estimate of  $\mathbf{p}$  is that which minimizes  $\text{WRSS}(\mathbf{p})$ :

$$\hat{\mathbf{p}}_{\text{WLS}} = \arg \min_{\mathbf{p}} \text{WRSS}(\mathbf{p}) = \arg \min_{\mathbf{p}} (\mathbf{z} - \mathbf{Gp})^T \Sigma_v^{-1} (\mathbf{z} - \mathbf{Gp}) \quad (8.58)$$

and we get the expression:

$$\hat{\mathbf{p}}_{\text{WLS}} = (\mathbf{G}^T \Sigma_v^{-1} \mathbf{G})^{-1} \mathbf{G}^T \Sigma_v^{-1} \mathbf{z} \quad (8.59)$$

We can also extend the test of residuals to the vector case and the estimation of the precision of parameter estimates.



As far as the residuals are concerned, since we now have  $\hat{\mathbf{p}}$ , we can obtain the residuals and the weighted residuals, respectively, as:

$$\mathbf{r} = \mathbf{z} - \mathbf{G}\hat{\mathbf{p}} \quad (8.60)$$

$$\mathbf{w}\mathbf{r} = \boldsymbol{\Sigma}_v^{-1}\mathbf{r} \quad (8.61)$$

As far as the precision is concerned, the covariance matrix is:

$$\boldsymbol{\Sigma}_{\tilde{\mathbf{p}}} = \text{cov}(\tilde{\mathbf{p}}) = \mathbb{E}[\tilde{\mathbf{p}}\tilde{\mathbf{p}}^T] = \boldsymbol{\Sigma}_{\hat{\mathbf{p}}} \quad (8.62)$$

with  $\tilde{\mathbf{p}} = \mathbf{p} - \hat{\mathbf{p}}$ .

Since  $\hat{\mathbf{p}}_{\text{WLS}} = (\mathbf{G}^T \boldsymbol{\Sigma}_v^{-1} \mathbf{G})^{-1} \mathbf{G}^T \boldsymbol{\Sigma}_v^{-1} \mathbf{z}$ , we get:

$$\tilde{\mathbf{p}} = \mathbf{p} - \hat{\mathbf{p}} = \underbrace{\left[ \mathbf{I}_M - (\mathbf{G}^T \boldsymbol{\Sigma}_v^{-1} \mathbf{G})^{-1} \mathbf{G}^T \boldsymbol{\Sigma}_v^{-1} \mathbf{G} \right]}_{\text{deterministic}} \mathbf{p} - \underbrace{(\mathbf{G}^T \boldsymbol{\Sigma}_v^{-1} \mathbf{G})^{-1} \mathbf{G}^T \boldsymbol{\Sigma}_v^{-1} \mathbf{v}}_{\text{random}} \quad (8.63)$$

By using the definition (8.62),  $\boldsymbol{\Sigma}_{\tilde{\mathbf{p}}}$  can be immediately obtained as the covariance of the random addendum:

$$\boldsymbol{\Sigma}_{\tilde{\mathbf{p}}} = (\mathbf{G}^T \boldsymbol{\Sigma}_v^{-1} \mathbf{G})^{-1} = \boldsymbol{\Sigma}_{\hat{\mathbf{p}}} \quad (8.64)$$

## 8.5 NONLINEAR REGRESSION

What happens in the case where  $y(t)$ , instead of being described by a set of linear parameters, has nonlinear parameters as well? The problem of how to estimate the parameters becomes more complex.

In the previous section, the major points were illustrated using the function  $y(\mathbf{p}, t) = \mathbf{p}t$ . In this section, the major points will be illustrated using the mono-exponential function  $y(t) = g(t, \alpha) = e^{-\alpha t}$  where  $\alpha$  is the nonlinear parameter to be estimated. Later in this section, the function  $y(t) = g(\mathbf{A}, \alpha, t) = \mathbf{A}e^{-\alpha t}$  will be used to then generalize to the vector case. How is the nonlinear case handled? The problem is solved through a number of iterations that draws on the linear regression theory discussed previously.

### 8.5.1 The Scalar Case

In this section, the same notation from the previous section will be used where  $w_i = 1/\sigma_i^2$  is the weight assigned to each datum  $z_i$ , and the expression to be minimized is:

$$\text{WRSS}(\alpha) \sum_{i=1}^N w_i (z_i - y_i)^2 = \sum_{i=1}^N w_i (z_i - e^{-\alpha t_i})^2 \quad (8.65)$$

In order to keep the formulae as simple as possible we shall retain  $w_i$  in the derivation instead of  $1/\sigma_i^2$ . As noted previously,  $y(t)$  is a nonlinear function of the parameter  $\alpha$ , so an explicit analytical solution for  $\alpha$  analogous to (8.27) is not possible. In fact if one takes the derivative of WRSS with respect to  $\alpha$  and sets it equal to zero:

$$\frac{d\text{WRSS}(\alpha)}{d\alpha} = \frac{d\left(\sum_{i=1}^N w_i(z_i - e^{-\alpha t_i})^2\right)}{d\alpha} = 0 \quad (8.66)$$

one obtains:

$$-2 \sum_{i=1}^N w_i t_i e^{-\alpha t_i} (z_i - e^{-\alpha t_i}) = 0 \quad (8.67)$$

which does not yield an explicit expression for  $\alpha$  as a function of the known quantities  $z_i$ ,  $t_i$ , and  $w_i$ .

To arrive at an estimate of  $\alpha$  one possible strategy is based on iterative linearizations of the model, i.e. the Gauss-Newton method. Let us consider the expression of  $y(t)$  obtainable through its Taylor series expansion around a specific value of  $\alpha$ , say  $\alpha^0$ :

$$y(t) = g(\alpha, t) = g(\alpha^0, t) + \left. \frac{dg(\alpha, t)}{d\alpha} \right|_{\alpha=\alpha^0} (\alpha - \alpha^0) + \frac{1}{2} \left. \frac{d^2g(\alpha, t)}{d\alpha^2} \right|_{\alpha=\alpha^0} (\alpha - \alpha^0)^2 + \dots \quad (8.68)$$

where the derivatives are evaluated at  $\alpha = \alpha^0$ . The Taylor series is an infinite series, i.e. the expression on the right hand side of (8.68) contains an infinite number of terms. Normally, however, a truncated version of this expression can be used, e.g. a finite number of terms of the series given on the right-hand side of (8.68). When this is done, the right-hand side of (8.68) no longer equals  $y(t)$  exactly, but approximates it with an approximation that generally improves as more terms of the series are retained.

Now assume that an initial estimate  $\alpha^0$  of  $\alpha$  is available. The idea behind linearizing the problem is to assume that the terms in (8.68) which contain derivatives of second order and higher are small and can be neglected. This means that (8.68) can be re-written as:

$$y_i(t) \approx g(\alpha, t) \Big|_{\alpha=\alpha^0} + \left. \frac{dg(\alpha, t)}{d\alpha} \right|_{\alpha=\alpha^0} (\alpha - \alpha^0) = e^{-\alpha^0 t} - t e^{-\alpha^0 t} (\alpha - \alpha^0) \quad (8.69)$$

Notice that this equation is now linear in  $\alpha$ , since  $\alpha^0$  is known as the assumed initial estimate of  $\alpha$ . Define:

$$\Delta\alpha = \alpha - \alpha^0 \quad (8.70)$$

Equation (8.69) can be re-written for the generic time  $t_i$  as:

$$y_i(t) \approx g(\alpha, t) \Big|_{\alpha=\alpha^0, t=t_i} + \left. \frac{dg(\alpha, t)}{d\alpha} \right|_{\alpha=\alpha^0, t=t_i} \Delta\alpha = e^{-\alpha^0 t_i} - t_i e^{-\alpha^0 t_i} \Delta\alpha \quad (8.71)$$

which is an equation linear in  $\Delta\alpha$ . Assuming that the weights  $w_i$  for the data  $z_i$  are known, one can write the following expression for  $WRSS(\alpha)$ :

$$\begin{aligned} WRSS(\alpha) &= \sum_{i=1}^N w_i (z_i - y_i)^2 \\ &\approx \sum_{i=1}^N w_i \left( z_i - g(\alpha, t) \Big|_{\substack{\alpha=\alpha^0 \\ t=t_i}} - \frac{dg(\alpha, t)}{d\alpha} \Big|_{\substack{\alpha=\alpha^0 \\ t=t_i}} \cdot \Delta\alpha \right)^2 \\ &= \sum_{i=1}^N w_i (z_i - e^{-\alpha^0 t_i} + t_i \cdot e^{-\alpha^0 t_i} \cdot \Delta\alpha)^2 \end{aligned} \quad (8.72)$$

For convenience, define a new term:

$$\Delta z_i = z_i - y(\alpha^0, t_i) = z_i - e^{-\alpha^0 t_i} \quad (8.73)$$

Equation (8.72) can be re-written:

$$\begin{aligned} WRSS(\alpha) &= \sum_{i=1}^N w_i \left( \Delta z_i - \frac{dg(\alpha, t)}{d\alpha} \Big|_{\substack{\alpha=\alpha^0 \\ t=t_i}} \Delta\alpha \right)^2 \\ &= \sum_{i=1}^N w_i (\Delta z_i t_i e^{-\alpha^0 t_i} \Delta\alpha)^2 \end{aligned} \quad (8.74)$$

$WRSS$  can now be considered as a linear function of  $\Delta\alpha$ , and hence  $\Delta\alpha$  can be estimated using the linear regression machinery. Briefly, in (8.27),  $\Delta z_i$  is substituted for  $z_i$ , and  $\frac{dg(\alpha, t)}{d\alpha} \Big|_{\substack{\alpha=\alpha^0 \\ t=t_i}}$  for  $t_i$ . Then one obtains:

$$\begin{aligned} \Delta\hat{\alpha} &= \frac{\sum_{i=1}^N w_i \Delta z_i \frac{dg(\alpha, t)}{d\alpha} \Big|_{\substack{\alpha=\alpha^0 \\ t=t_i}}}{\sum_{i=1}^N w_i \left( \frac{dg(\alpha, t)}{d\alpha} \Big|_{\substack{\alpha=\alpha^0 \\ t=t_i}} \right)^2} \\ &= \frac{-\sum_{i=1}^N w_i \Delta z_i t_i e^{-\alpha^0 t_i}}{\sum_{i=1}^N w_i t_i^2 e^{-2\alpha^0 t_i}} \\ &= \frac{-\sum \frac{1}{\sigma_i^2} \Delta z_i t_i e^{-\alpha^0 t_i}}{\sum \frac{1}{\sigma_i^2} t_i^2 e^{-2\alpha^0 t_i}} \end{aligned} \quad (8.75)$$

At this stage, a new estimate for  $\alpha$  can be obtained:

$$\alpha^1 = \alpha^0 + \Delta\hat{\alpha} \quad (8.76)$$

and the process repeated using  $\alpha^1$  instead of  $\alpha^0$  in the above formulae.  $\text{WRSS}(\alpha^1)$  is obviously smaller than  $\text{WRSS}(\alpha^0)$  since  $\Delta\alpha$  was chosen to minimize  $\text{WRSS}$  in the neighborhood of  $\alpha^0$ . At each iteration, both the model function  $y(t) = g(\alpha, t)$  and its derivative with respect to the parameter  $\alpha$  need to be evaluated at the sample times.

The iterative process, which technically could go on forever, usually stops when some preset criterion, for example comparing two consecutive values of  $\text{WRSS}$ , is satisfied.

The linear regression machinery used to obtain an estimate for  $\alpha$  can also be used to obtain an estimate of the precision of this estimate. The extension of the linear WLS equation, (8.29), for  $\text{Var}(\hat{\mathbf{p}})$  to the nonlinear case provides (using the rationale behind (8.75)) an estimate of  $\text{Var}(\hat{\alpha})$ :

$$\text{Var}(\hat{\alpha}) \approx \frac{1}{\sum_{i=1}^N \frac{1}{\sigma_i^2} \left( \left. \frac{dg(\alpha, t)}{d\alpha} \right|_{\substack{\alpha=\hat{\alpha} \\ t=t_i}} \right)^2} \quad (8.77)$$

The derivative term is known:


$$\left. \frac{dg(\alpha, t)}{d\alpha} \right|_{\substack{\alpha=\hat{\alpha} \\ t=t_i}} = -t_i e^{-\hat{\alpha}t_i} \quad (8.78)$$

Therefore, one has:

$$\text{Var}(\hat{\alpha}) \approx \frac{1}{\sum_{i=1}^N \frac{t_i^2}{\sigma_i^2} e^{-2\hat{\alpha}t_i}} \quad (8.79)$$

In the case of linear regression, the expressions for  $\text{Var}(\hat{\alpha})$  are exact whereas in the case of nonlinear regression, the expression given in (8.77) only provides an approximation for  $\text{Var}(\hat{\alpha})$ . As far as the residuals and weighted residuals are concerned, the treatment of the linear case in section 8.4.2 also holds here, with model prediction being produced by  $g(\hat{\alpha}, t)$ .

The linear machinery has been used to solve the nonlinear case. However, it is worth remarking that the nonlinear case is more complex to handle than the linear case. This is true not only from a computational point of view (see section 8.5.3), but also conceptually due to presence of local minima of  $\text{WRSS}(\alpha)$  and the necessity of specifying an initial estimate of  $\alpha$ ,  $\alpha^0$ . To graphically illustrate this additional complexity, let us consider  $\text{WRSS}(\alpha)$  as a function of  $\alpha$  as shown in Figure 8.7. There is more than one minimum for  $\text{WRSS}$ , and this is distinctly different from the linear case where there is only one (unique) minimum. The minima shown in Figure 8.7 are



**Figure 8.7** Plot of  $WRSS(\alpha)$  as a function of  $\alpha$  illustrating several local minima but only one global minimum over the domain of the function. Notice also that some of the minima are quite well-defined, or sharp, while others are much more gradual (adapted from Cobelli *et al.*, 2001).

called *local minima*. The difference, then, between the linear and nonlinear case is that in linear regression there is a ‘unique’ minimum for  $WRSS$  while in the nonlinear case there may be several local minima for  $WRSS$ . Among the local minima, the smallest is called the *global minimum*. This has obvious implications for the choice of  $\alpha^0$ . Generally, to be sure one is not ending up at a local minimum, several tentative values of  $\alpha^0$  are used as starting points.

### 8.5.2 Extension to the Vector Case

Let us now extend the machinery to the case where there is more than one unknown parameter. This will accommodate functions  $y(t)$  such as:

$$y(t) = Ae^{-\alpha t} \quad (8.80)$$

or

$$y(t) = A_1e^{-\alpha_1 t} + A_2e^{-\alpha_2 t} \quad (8.81)$$

where, in (8.80) there are two parameters,  $A$  and  $\alpha$ , and in (8.81) there are four,  $A_1$ ,  $A_2$ ,  $\alpha_1$  and  $\alpha_2$ ; the ideas carry over to arbitrary functions  $y(t)$  described by a set of parameters  $\mathbf{p} = [p_1, p_2, \dots, p_p]^T$ .

To set the scene, let us consider the model of (8.80), i.e.:

$$y(t) = g(t, \mathbf{p}) = g(t, A, \alpha) = Ae^{-\alpha t} \quad (8.82)$$

Let us assume we have an initial estimate  $\mathbf{p}^0 = [A^0, \alpha^0]$ . For  $A$  and  $\alpha$  in the neighborhood of  $A^0, \alpha^0$  one has:

$$g(t, A, \alpha) \cong g(t, A^0, \alpha^0) + \frac{\partial g(t, A, \alpha)}{\partial \alpha} \Big|_{\substack{A=A^0 \\ \alpha=\alpha^0}} (\alpha - \alpha^0) + \frac{\partial g(t, A, \alpha)}{\partial A} \Big|_{\substack{A=A^0 \\ \alpha=\alpha^0}} (A - A^0) \quad (8.83)$$

where now partial derivatives are used in the Taylor series since we have more than a single parameter and so we have:

$$g(t, A^0, \alpha^0) = A^0 e^{-\alpha^0 t} \quad (8.84)$$

$$\frac{\partial g(t, A, \alpha)}{\partial \alpha} \Big|_{\substack{A=A^0 \\ \alpha=\alpha^0}} = -A^0 t e^{-\alpha^0 t} \quad (8.85)$$

$$\frac{\partial g(t, A, \alpha)}{\partial A} \Big|_{\substack{A=A^0 \\ \alpha=\alpha^0}} = e^{-\alpha^0 t} \quad (8.86)$$

Thus, we can write (8.83) as:

$$g(t, A, \alpha) \cong A^0 e^{-\alpha^0 t} - A^0 t e^{-\alpha^0 t} (\alpha - \alpha^0) + e^{-\alpha^0 t} (A - A^0) \quad (8.87)$$

Let us now consider the data:

$$z_i = g(t_i, A, \alpha) + v_i = A e^{-\alpha t_i} + v_i \quad (8.88)$$

and by using (8.87) one has:

$$z_i = A^0 e^{-\alpha^0 t_{ik}} - A^0 t_i e^{-\alpha^0 t_{ik}} (\alpha - \alpha^0) + e^{-\alpha^0 t_{ik}} (A - A^0) + v_i \quad (8.89)$$

Now, by defining:

$$\Delta z_i = z_i - A^0 e^{-\alpha^0 t_i} \quad (8.90)$$

one has:

$$\Delta z_i = A^0 t_i e^{-\alpha^0 t_i} (\alpha - \alpha^0) e^{-\alpha^0 t_i} (A - A^0) + v_i \quad (8.91)$$

If we now further define:

$$\Delta \alpha = \alpha - \alpha^0 \quad \Delta A = A - A^0 \quad (8.92)$$

one has:

$$\Delta z_i = -A^0 t_i e^{-\alpha^0 t_i} \Delta \alpha + e^{-\alpha^0 t_i} \Delta A + v_i \quad (8.93)$$

and thus, by considering all measurements, we have the matrix vector formulation:

$$\begin{bmatrix} \Delta z_1 \\ \Delta z_2 \\ \dots \\ \dots \\ \Delta z_{N-1} \\ \Delta z_N \end{bmatrix} = \begin{bmatrix} e^{-\alpha^0 t_1} & -A^0 t_1 e^{-\alpha^0 t_1} \\ e^{-\alpha^0 t_2} & -A^0 t_2 e^{-\alpha^0 t_2} \\ \dots & \dots \\ \dots & \dots \\ e^{-\alpha^0 t_{N-1}} & -A^0 t_{N-1} e^{-\alpha^0 t_{N-1}} \\ e^{-\alpha^0 t_N} & -A^0 t_N e^{-\alpha^0 t_N} \end{bmatrix} \begin{bmatrix} \Delta A \\ \Delta \alpha \end{bmatrix} + \begin{bmatrix} v_1 \\ v_2 \\ \dots \\ \dots \\ v_{N-1} \\ v_N \end{bmatrix} \quad (8.94)$$

We have now the linear model formulation:

$$\Delta z = \mathbf{G} \Delta \mathbf{p} + \mathbf{v} \quad (8.95)$$

where  $\Delta z$  is known and  $\Delta \mathbf{p}$  unknown. The WLS solution (see 8.59):

$$\Delta \hat{\mathbf{p}} = (\mathbf{G}^T \boldsymbol{\Sigma}_v^{-1} \mathbf{G})^{-1} \mathbf{G}^T \boldsymbol{\Sigma}_v^{-1} \Delta z \quad (8.96)$$

Now, having estimated  $\Delta \hat{\mathbf{p}}$ , the initial estimate can be improved (we have moved in the parameter space by decreasing WRSS):

$$\mathbf{p}^1 = \mathbf{p}^0 + \Delta \hat{\mathbf{p}} \quad (8.97)$$

and the procedure can be iterated till WRSS ( $A, \alpha$ ) stops decreasing according to some preset criterion.

Now we are in a position to extend the machinery to the generic nonlinear model  $y(t) = g(t, \mathbf{p})$ . Paralleling the general linear model development (as described in section 8.4.4) we have:

$$\mathbf{z} = \mathbf{y} + \mathbf{v} = \mathbf{G}(\mathbf{p}) + \mathbf{v} \quad (8.98)$$

where:

$$\mathbf{z} = [z_1, z_2, \dots, z_N]^T \quad (8.99)$$

$$\mathbf{y} = [y_1, y_2, \dots, y_N]^T \quad (8.100)$$

$$\mathbf{p} = [p_1, p_2, \dots, p_N]^T \quad (8.101)$$

$$\mathbf{G}(\mathbf{p}) = [g(t_1, \mathbf{p}), g(t_2, \mathbf{p}), \dots, g(t_N, \mathbf{p})]^T \quad (8.102)$$

$$\mathbf{v} = [v_1, v_2, \dots, v_N]^T \text{ with } \boldsymbol{\Sigma}_v = \text{cov}(\mathbf{v}) \quad (8.103)$$

The WLS estimate of  $\mathbf{p}$  is the one which minimizes WRSS( $\mathbf{p}$ ):

$$\hat{\mathbf{p}}_{\text{WLS}} = \underset{\mathbf{p}}{\text{argmin}} [\mathbf{z} - \mathbf{G}(\mathbf{p})]^T \boldsymbol{\Sigma}_v^{-1} [\mathbf{z} - \mathbf{G}(\mathbf{p})] \quad (8.104)$$

Let us denote with  $\mathbf{p}_0$  the initial estimate of  $\mathbf{p}$ :

$$\mathbf{p}^0 = [p_1^0, p_2^0, \dots, p_M^0]^T \quad (8.105)$$

The model prediction at time  $t_i$  is:

$$g(t_i, \mathbf{p}) \cong g(t_i, \mathbf{p}^0) + \begin{bmatrix} \frac{\partial g(t_i, \mathbf{p}^0)}{\partial p_1} & \frac{\partial g(t_i, \mathbf{p}^0)}{\partial p_2} & \dots & \frac{\partial g(t_i, \mathbf{p}^0)}{\partial p_M} \end{bmatrix} \begin{bmatrix} p_1 - p_1^0 \\ p_2 - p_2^0 \\ \dots \\ p_M - p_M^0 \end{bmatrix} \quad (8.106)$$

where notation has been compacted with respect to (8.83) by bringing the  $\left. \begin{array}{l} \mathbf{p}=\mathbf{p}^0 \\ t=t_i \end{array} \right\}$  inside the argument of  $g(t, \mathbf{p})$ . The data relate with  $g(t_k, \mathbf{p})$  as:

$$z_i = g(t_i, \mathbf{p}) + v_i \quad i = 1, 2, \dots, N \quad (8.107)$$

Thus, using (8.106) and moving to vector notation one has:

$$\begin{bmatrix} z_1 - g(t_1, \mathbf{p}^0) \\ z_2 - g(t_2, \mathbf{p}^0) \\ z_3 - g(t_3, \mathbf{p}^0) \\ \dots \\ z_N - g(t_N, \mathbf{p}^0) \end{bmatrix} = \begin{bmatrix} \frac{\partial g(t_1, \mathbf{p}^0)}{\partial p_1} & \frac{\partial g(t_1, \mathbf{p}^0)}{\partial p_2} & \dots & \frac{\partial g(t_1, \mathbf{p}^0)}{\partial p_M} \\ \frac{\partial g(t_2, \mathbf{p}^0)}{\partial p_1} & \frac{\partial g(t_2, \mathbf{p}^0)}{\partial p_2} & \dots & \frac{\partial g(t_2, \mathbf{p}^0)}{\partial p_M} \\ \dots & \dots & \dots & \dots \\ \dots & \dots & \dots & \dots \\ \frac{\partial g(t_N, \mathbf{p}^0)}{\partial p_1} & \frac{\partial g(t_N, \mathbf{p}^0)}{\partial p_2} & \dots & \frac{\partial g(t_N, \mathbf{p}^0)}{\partial p_M} \end{bmatrix} \begin{bmatrix} p_1 - p_1^0 \\ p_2 - p_1^0 \\ \dots \\ p_M - p_M^0 \end{bmatrix} + \begin{bmatrix} v_1 \\ v_2 \\ v_3 \\ \dots \\ v_N \end{bmatrix} \quad (8.108)$$

and thus:

$$\Delta \mathbf{z} = \mathbf{S} \Delta \mathbf{p} + \mathbf{v} \quad (8.109)$$

with obvious definition of  $\Delta \mathbf{z}$ ,  $\mathbf{S}$  and  $\Delta \mathbf{p}$  from (8.109).

Now since  $\Delta \mathbf{z}$  ( $\mathbf{p}^0$  is given,  $\mathbf{z}$  is measured) and  $\mathbf{S}$  can be computed, one can use WLS to estimate  $\Delta \mathbf{p}$  with the linear machinery:

$$\Delta \hat{\mathbf{p}} = (\mathbf{S}^T \boldsymbol{\Sigma}_v^{-1} \mathbf{S})^{-1} \mathbf{S}^T \boldsymbol{\Sigma}_v^{-1} \Delta \mathbf{z} \quad (8.110)$$

Hence, a new estimate of  $\mathbf{p}$  can be obtained as:

$$\mathbf{p}^1 = \mathbf{p}^0 + \Delta \hat{\mathbf{p}} \quad (8.111)$$



Now, with  $\mathbf{p}^1$ , which is by definition a better estimate than  $\mathbf{p}^0$ , the process can restart: the model is linearized around  $\mathbf{p}^1$ , a new estimate  $\mathbf{p}^2$  is obtained and so on until the cost function stops decreasing significantly, e.g. when two consecutive values of  $\text{WRSS}(\mathbf{p})$  are within a prescribed tolerance.

Once  $\Delta\hat{\mathbf{p}}$  has been obtained, by paralleling the general linear model case discussed in section 8.4.4, one can obtain the covariance of the parameter estimates as:

$$\Sigma_{\hat{\mathbf{p}}} \cong (\mathbf{S}^T \Sigma_{\mathbf{v}}^{-1} \mathbf{S})^{-1} = \Sigma_{\hat{\mathbf{p}}} \quad (8.112)$$

with:

$$\mathbf{S} = \begin{bmatrix} \frac{\partial g(t_1, \hat{\mathbf{p}})}{\partial \mathbf{p}_1} & \frac{\partial g(t_1, \hat{\mathbf{p}})}{\partial \mathbf{p}_2} & \dots & \frac{\partial g(t_1, \hat{\mathbf{p}})}{\partial \mathbf{p}_M} \\ \frac{\partial g(t_2, \hat{\mathbf{p}})}{\partial \mathbf{p}_1} & \frac{\partial g(t_2, \hat{\mathbf{p}})}{\partial \mathbf{p}_2} & \dots & \frac{\partial g(t_2, \hat{\mathbf{p}})}{\partial \mathbf{p}_M} \\ \dots & \dots & \dots & \dots \\ \dots & \dots & \dots & \dots \\ \dots & \dots & \dots & \dots \\ \frac{\partial g(t_N, \hat{\mathbf{p}})}{\partial \mathbf{p}_1} & \frac{\partial g(t_N, \hat{\mathbf{p}})}{\partial \mathbf{p}_2} & \dots & \frac{\partial g(t_N, \hat{\mathbf{p}})}{\partial \mathbf{p}_M} \end{bmatrix} \quad (8.113)$$

Residuals and weighted residuals are defined as for the linear case in section 8.4.4 (equations 8.60 and 8.61) with model prediction provided by  $\mathbf{G}(\hat{\mathbf{p}})$ .

### 8.5.3 Algorithms

The steps of nonlinear least squares estimation have been illustrated using the Gauss-Newton iterative scheme. This outlines the principles of that class of algorithms which requires the computation of derivatives contained in matrix  $\mathbf{S}$ . This is usually done numerically, e.g. using central difference methods, albeit other strategies are also available, e.g. the sensitivity system (Cobelli *et al.*, 2001; Chapter 10). This class is referred to as gradient-type (derivative) algorithms. Numerically refined and efficient algorithms, e.g. the Levenberg-Marquardt technique, based on the Gauss-Newton principle, are available and are implemented in many software tools.

Another category of algorithms for minimizing WRSS which has been applied in physiological model parameter estimation is one that does not require the computation of the derivatives. These algorithms are known as direct search methods, and both deterministic and random search algorithms are available and implemented in software tools. An efficient deterministic direct search algorithm is the simplex method. It is worth emphasizing that with a direct search method, the computation of the derivatives is not required. Albeit that a direct comparison of gradient versus direct search methods is difficult and may be problem dependent, available experience in physiological model parameter estimation tends to favor the gradient type methods.

**Table 8.2** Test data with two descriptions of measurement error

$t_i$	$z_i$	$\text{Var}(v_i) = 0.0025$ $w_i$	$\text{Var}(v_i) = (0.1 \cdot z_i)^2$ $w_i$
15	0.856	400	136
30	0.797	400	157
60	0.538	400	345
120	0.318	400	989
240	0.133	400	5653
360	0.069	400	21003

**Table 8.3** Estimation results with two weighting schemes

	Constant Variance $\text{Var}(v_i) = 0.0025$	Constant FSD $\text{Var}(v_i) = (0.1 \cdot z_i)^2$
$\alpha$	0.00923	0.00808
$\text{Var}(\alpha)$	$0.593 \times 10^{-6}$	$0.576 \times 10^{-7}$
$\text{SD}(\alpha)$	$0.77 \times 10^{-3}$	$0.24 \times 10^{-3}$
FSD( $\alpha$ )	8%	3%
WRSS	1.94	11.0


### 8.5.4 An Example

Consider next the data given in Table 8.2 and assume that a mono-exponential function is to be fitted to the data,  $y(t) = Ae^{-\alpha t}$ , i.e. both  $A$  and  $\alpha$  need to be estimated from the data. Consider two situations for the variance of measurement error. In the first there is a constant standard deviation of 0.05 assigned to each datum, while in the second a constant fractional standard deviation equal to 10% is assigned to each datum. The weights are calculated as  $w_i = 1/\sigma^2(t_i)$ . The two situations are summarized in Table 8.3.

When the function  $y(t) = Ae^{-\alpha t}$  is fitted to these data using the two weighting schemes, estimates of  $A$ ,  $\alpha$ ,  $\text{SD}(A)$  and  $\text{SD}(\alpha)$  are obtained. Table 8.3 and Figure 8.8 summarize the results. The estimates of  $A$  and  $\alpha$  and their precision clearly depend upon the weighting scheme. This observation underlines the importance of having a good knowledge of the error structure in the data.

## 8.6 TESTS FOR MODEL ORDER

Up to this point, only the problem of testing whether or not a specific model is an appropriate description of a set of data has been examined. Consider now the case where different candidate models are available, and the problem is to select the



**Figure 8.8** Upper panel: A plot of a function  $y(t) = Ae^{-at}$  for the case of constant variance (dashed line) and constant FSD (solid line). Lower panel: A plot of the weighted residuals (adapted from Cobelli *et al.*, 2001).

model that provides the best description of the data. For example, when performing multiexponential modeling of a decay curve:

$$y(t) = \sum_{i=1}^n A_i e^{-\lambda_i t} \quad (8.114)$$

the model order, that is the number  $n$  of exponentials, is not known *a priori*. A mono-, bi- and tri-exponential model are usually fitted to the data, and the results of parameter estimation evaluated so as to select the optimum order, i.e. the ‘best’ value for  $n$ .

Relying solely upon WRSS and an examination of the weighted residuals to determine the optimum model order is not appropriate since, as the model order increases, WRSS will decrease. For example, in dealing with a tracer decay curve following a bolus injection, each additional exponential term added to the sum of exponentials will decrease WRSS. Similarly, the pattern of residuals will become more random. However, each time an exponential term is added, two parameters are added (a coefficient and an exponential), and the degrees of freedom are decreased by two. Thus intuitively, when comparing different model structures, both WRSS and the degrees of freedom should be evaluated. This is in order to check whether or not the reduction of WRSS truly reflects a more accurate representation of the data, or whether it is merely the result of the increase in the number of parameters. Hence additional tests are required.

The two tests which are frequently used to compare model structures are the F-test and tests based on the principle of parsimony. We briefly describe below only the latter and refer the reader for illustration of the F-test to Cobelli *et al.* (2001; Chapter 8).

The most commonly employed tests which implement the principle of parsimony, i.e. choose the model which is best able to fit the data with the minimum number of parameters, are the Akaike information criterion (AIC) (Akaike, 1974) and the Schwartz criterion (SC) (Schwartz, 1978). More than two models can be compared and the model which has the smallest criterion value is chosen as the best.

These criteria have been derived for linear dynamic models in a maximum likelihood estimation context, the principles of which are discussed in the next section 8.7. However, if one assumes that errors in the data are uncorrelated and Gaussian, then the criteria can also be computed for WLS and are:


$$\text{AIC} = \text{WRSS} + 2P \quad (8.115)$$

$$\text{SC} = \text{WRSS} + P \ln N \quad (8.116)$$

where  $P$  is the number of parameters in the model and  $N$  are the number of data. While having different derivations, AIC and SC are similar as they are made up of a goodness-of-fit measure plus a penalty function proportional to the number of parameters  $P$  in the model. Note that in SC,  $P$  is weighted  $\ln(N)$ , i.e. with large  $N$ , this may become important.

### *An Example*

To illustrate the use of the criteria based on the parsimony principle let us consider a two- and a three-exponential model as candidates to describe a set of data. Model predictions against data and weighted residuals are shown in Figure 8.9. Parameter estimates with their precision and WRSS values of the two models are shown in Table 8.4. As expected from theory, the value of WRSS and residuals of the three are lower than those of the two-exponential model, while the parameter estimates of the two are more precisely estimated than those of the three-exponential model. Which is the model to adopt? The principle of parsimony tests comes in to play and



**Figure 8.9** Left panel: Two-exponential model fit of the data and weighted residuals. Right panel: Three-exponential model fit of the data and weighted residuals (adapted from Sparacino *et al.*, 2000).

**Table 8.4** Model order choice based upon the principle of parsimony

	$A_1$ (ml) <sup>-1</sup>	$A_2$ (ml) <sup>-1</sup>	$A_3$ (ml) <sup>-1</sup>	$\alpha_1$ (min) <sup>-1</sup>	$\alpha_2$ (min) <sup>-1</sup>	$\alpha_3$ (min) <sup>-1</sup>	WRSS	AIC	SC
2 Exponentials	$1.79 \times 10^{-4}$ (7.2)	$0.90 \times 10^{-4}$ (4.8)	–	0.141 (9.2)	0.025 (2.5)	–	61	69	75
3 Exponentials	$1.29 \times 10^{-4}$ (39)	$0.88 \times 10^{-4}$ (66)	$0.81 \times 10^{-4}$ (9)	0.253 (49)	0.085 (40)	0.024 (3)	40	52	60

in Table 8.4 AIC and SC values are shown: the more parsimonious model is the three-exponential one (lower AIC and SC).

## 8.7 MAXIMUM LIKELIHOOD ESTIMATION

The least squares approach to estimation requires comparatively little *a priori* knowledge. Apart from having the model and the data, all that is required for full probabilistic treatment is information regarding the measurement errors; that is, the noise model. In contrast, a maximum likelihood (ML) estimation has additional requirements of *a priori* knowledge. Not only is a noise model required, but also a probability density function, defining the generation of the experimental data. ML estimation makes use of this additional information so as to maximize the probability that the parameter estimates achieved would enable the actual experimental data to be re-created.

Let us consider the model of (8.98):

$$\mathbf{z} = \mathbf{y} + \mathbf{v} = \mathbf{G}(\mathbf{p}) + \mathbf{v} \quad (8.117)$$

and assume the probability density function of  $\mathbf{v}$ ,  $f_{\mathbf{v}}(\mathbf{v})$  is known. Since  $\mathbf{v}$  is random,  $\mathbf{z}$  will also be random with probability density function  $f_{\mathbf{z}}(\mathbf{z})$ .

To clarify, let us now consider the case where  $\mathbf{v}$  is independent and normally distributed, i.e.  $\mathbf{v} \in \mathcal{N}(\mathbf{0}, \Sigma_{\mathbf{v}})$  with  $\Sigma_{\mathbf{v}}$  diagonal. Then  $\mathbf{z}$  is also normal:

$$\mathbf{z} \in \mathcal{N}(\mathbf{G}(\mathbf{p}), \Sigma_{\mathbf{v}}) \quad (8.118)$$

and:

$$f_{\mathbf{z}}(\mathbf{z}) = \frac{1}{[(2\pi)^N \det(\Sigma_{\mathbf{v}})]^{1/2}} \exp\left(-\frac{1}{2}[\mathbf{z} - \mathbf{G}(\mathbf{p})]^T \Sigma_{\mathbf{v}}^{-1} [\mathbf{z} - \mathbf{G}(\mathbf{p})]\right) \quad (8.119)$$

It should be noted that  $f_{\mathbf{z}}(\mathbf{z})$  is partially unknown since it depends on  $\mathbf{G}(\mathbf{p})$  which is unknown and also reflects randomness of  $\mathbf{v}$  through its  $f_{\mathbf{v}}(\mathbf{v})$ .

What then is the rationale on which ML estimation is based? Let us consider the random vector  $\mathbf{z}$  of (8.117). Since  $f_{\mathbf{v}}(\mathbf{v})$  is known, for a given value of  $\mathbf{p}$ ,  $f_{\mathbf{z}}(\mathbf{z})$

is completely determined as measurements are also known. In other words, for a generic value of  $\mathbf{p}$ ,  $f_{\mathbf{z}}(\mathbf{z})$  gives the *a priori* probability that the random vector  $\mathbf{z}$  can have as its realization exactly the measurements. This quantity, which is called the likelihood of the measurements, varies with  $\mathbf{p}$  and is denoted by  $L(\mathbf{p})$ . The principle of a ML estimation is to choose the value which maximizes the likelihood of the measurements as an estimate of  $\mathbf{p}$ , i.e. it renders most possible the measurements:

$$\hat{\mathbf{p}}_{\text{ML}} = \underset{\mathbf{p}}{\operatorname{argmax}} L(\mathbf{p}) \quad (8.120)$$

The solution of (8.120) is normally tackled numerically and it is usual for computational reasons to maximize  $\ln L(\mathbf{p})$  instead of  $L(\mathbf{p})$  (see below for an example).

It is of interest to see what  $L(\mathbf{p})$  becomes if  $\mathbf{v}$  is Gaussian. Consider (8.119) and fix  $\mathbf{z}$  to the measurements. Then the likelihood of the measurements as a function of  $\mathbf{p}$  becomes:

$$L(\mathbf{p}) = \frac{1}{[(2\pi)^N \det(\boldsymbol{\Sigma}_{\mathbf{v}})]^{1/2}} \exp\left(-\frac{1}{2}[\mathbf{z} - \mathbf{G}(\mathbf{p})]^T \boldsymbol{\Sigma}_{\mathbf{v}}^{-1} [\mathbf{z} - \mathbf{G}(\mathbf{p})]\right) \quad (8.121)$$

Thus the ML estimate is:

$$\hat{\mathbf{p}}_{\text{ML}} = \underset{\mathbf{p}}{\operatorname{argmax}} \frac{1}{[(2\pi)^N \det(\boldsymbol{\Sigma}_{\mathbf{v}})]^{1/2}} \exp\left(-\frac{1}{2}[\mathbf{z} - \mathbf{G}(\mathbf{p})]^T \boldsymbol{\Sigma}_{\mathbf{v}}^{-1} [\mathbf{z} - \mathbf{G}(\mathbf{p})]\right) \quad (8.122)$$

Since  $e^{-f(x)}$  is monotonically decreasing, the argument which maximizes  $e^{-f(x)}$  is that which minimizes  $f(x)$ , so one has:

$$\hat{\mathbf{p}}_{\text{ML}} = \underset{\mathbf{p}}{\operatorname{argmin}} [\mathbf{z} - \mathbf{G}(\mathbf{p})]^T \boldsymbol{\Sigma}_{\mathbf{v}}^{-1} [\mathbf{z} - \mathbf{G}(\mathbf{p})] \quad (8.123)$$

It is then simple to recognize that (8.122) is the same as (8.104). In other words, for Gaussian and independent measurement errors, the ML and WLS estimates coincide.

The maximum likelihood estimation context allows one to set the precision of parameter estimates within a rigorous framework. Let us define the Fisher information matrix as:

$$\mathbf{F}(\mathbf{p}) = \mathbf{E} \left[ \frac{\partial \ln L(\mathbf{p})}{\partial \mathbf{p}} \frac{\partial \ln L(\mathbf{p})^T}{\partial \mathbf{p}} \right] \quad (8.124)$$

Then, one has from the Cramér-Rao inequality that:

$$\operatorname{cov}(\tilde{\mathbf{p}}) = \operatorname{cov}(\hat{\mathbf{p}}) \geq [\mathbf{F}(\mathbf{p})]_{\mathbf{p}=\hat{\mathbf{p}}}^{-1} \quad (8.125)$$

In other words, there is a limit on the achievable precision of parameter estimates which is given by the inverse of the Fisher information matrix.

What kind of expression do we then have for  $\mathbf{F}(\mathbf{p})$ ? Let us consider the case of Gaussian and independent measurement noise  $\mathbf{v}$ . In this case it is easy to show that:

$$[\mathbf{F}(\mathbf{p})]_{ij} = \sum_{i=1}^N \frac{1}{\sigma_i^2} \frac{\partial g(\mathbf{p}, t_i)}{\partial \mathbf{p}_i} \frac{\partial g(\mathbf{p}, t_i)}{\partial \mathbf{p}_j} \quad (8.126)$$

and thus in matrix form:

$$\mathbf{F}(\mathbf{p})|_{\mathbf{p}=\hat{\mathbf{p}}} = \mathbf{S}^T \boldsymbol{\Sigma}_{\mathbf{v}}^{-1} \mathbf{S} \quad (8.127)$$

with:

$$\mathbf{S} = \begin{bmatrix} \left. \frac{\partial g(t_1, \mathbf{p})}{\partial \mathbf{p}_1} \right|_{\mathbf{p}=\hat{\mathbf{p}}} & \left. \frac{\partial g(t_1, \mathbf{p})}{\partial \mathbf{p}_2} \right|_{\mathbf{p}=\hat{\mathbf{p}}} & \cdots & \left. \frac{\partial g(t_1, \mathbf{p})}{\partial \mathbf{p}_M} \right|_{\mathbf{p}=\hat{\mathbf{p}}} \\ \left. \frac{\partial g(t_2, \mathbf{p})}{\partial \mathbf{p}_1} \right|_{\mathbf{p}=\hat{\mathbf{p}}} & \left. \frac{\partial g(t_2, \mathbf{p})}{\partial \mathbf{p}_2} \right|_{\mathbf{p}=\hat{\mathbf{p}}} & \cdots & \left. \frac{\partial g(t_2, \mathbf{p})}{\partial \mathbf{p}_M} \right|_{\mathbf{p}=\hat{\mathbf{p}}} \\ \cdots & \cdots & \cdots & \cdots \\ \cdots & \cdots & \cdots & \cdots \\ \cdots & \cdots & \cdots & \cdots \\ \left. \frac{\partial g(t_N, \mathbf{p})}{\partial \mathbf{p}_1} \right|_{\mathbf{p}=\hat{\mathbf{p}}} & \left. \frac{\partial g(t_N, \mathbf{p})}{\partial \mathbf{p}_2} \right|_{\mathbf{p}=\hat{\mathbf{p}}} & \cdots & \left. \frac{\partial g(t_N, \mathbf{p})}{\partial \mathbf{p}_M} \right|_{\mathbf{p}=\hat{\mathbf{p}}} \end{bmatrix} \quad (8.128)$$

As a result one has that:

$$\text{cov}(\tilde{\mathbf{p}}) = \text{cov}(\hat{\mathbf{p}}) \geq (\mathbf{S}^T \boldsymbol{\Sigma}_{\mathbf{v}}^{-1} \mathbf{S})^{-1} \quad (8.129)$$


Thus, approximating the covariance matrix of parameter estimates with  $(\mathbf{S}^T \boldsymbol{\Sigma}_{\mathbf{v}} \mathbf{S})^{-1}$ , as in WLS, underestimates the effective uncertainty of the parameter estimates.

The ML estimator has important asymptotic (i.e. as  $N \rightarrow \infty$ ) properties for the case of independent and Gaussian measurement error. In particular it is unbiased, normal and efficient, i.e. the equality holds in (8.125) and (8.129). Given the equivalence of ML and WLS for independent and Gaussian measurement error, these properties also carry over to WLS. The above are asymptotic properties; in practice the number of measurements is limited and one has to perform Monte Carlo simulation to assess the reliability of the estimator.

## 8.8 BAYESIAN ESTIMATION

So far we have discussed two methods – nonlinear least squares and maximum likelihood – of the so-called Fisherian approach to parameter estimation. This means that only the data  $\mathbf{z}$  of (8.117) are supplied to the estimator, together with the noise characteristics, in order to estimate the unknown model parameters  $\mathbf{p}$  (Figure 8.10,





**Figure 8.10** Comparison of the requirements for weighted least squares, maximum likelihood and Bayesian estimation.

upper and middle panels). Here we briefly discuss the Bayesian approach to parameter estimation which takes into account not only the data  $\mathbf{z}$ , but also some *a priori* information available on the unknown parameter vector  $\mathbf{p}$ .

A Bayesian estimation assumes that the *a priori* probability distribution of  $\mathbf{p}$ ,  $f_{\mathbf{p}}(\mathbf{p})$ , is available (Figure 8.10, lower panel). This knowledge is independent of the data. The basic idea is to exploit the actual data to refine our *a priori* knowledge and obtain the *a posteriori* probability distribution of  $\mathbf{p}$ , i.e. the probability distribution of  $\mathbf{p}$  given the data,  $f_{\mathbf{p}|\mathbf{z}}(\mathbf{p}|\mathbf{z})$ . How can we obtain  $f_{\mathbf{p}|\mathbf{z}}(\mathbf{p}|\mathbf{z})$ ? Since the model  $\mathbf{G}(\mathbf{p})$  is known (8.117), as is the probability distribution of the noise vector  $\mathbf{v}$ ,  $f_{\mathbf{v}}(\mathbf{v})$ , we can calculate the probability distribution of the data  $\mathbf{z}$  as a function of the parameters  $\mathbf{p}$ , i.e. the likelihood function,  $f_{\mathbf{z}|\mathbf{p}}(\mathbf{z}|\mathbf{p})$ . Now, since we know  $f_{\mathbf{p}}(\mathbf{p})$  and  $f_{\mathbf{z}|\mathbf{p}}(\mathbf{z}|\mathbf{p})$ , Bayes' theorem can be used to obtain  $f_{\mathbf{p}|\mathbf{z}}(\mathbf{p})$ :

$$f_{\mathbf{p}|\mathbf{z}}(\mathbf{p}|\mathbf{z}) = \frac{f_{\mathbf{z}|\mathbf{p}}(\mathbf{z}|\mathbf{p})f_{\mathbf{p}}(\mathbf{p})}{f_{\mathbf{z}}(\mathbf{z})} = \frac{f_{\mathbf{z}|\mathbf{p}}(\mathbf{z}|\mathbf{p})f_{\mathbf{p}}(\mathbf{p})}{\int f_{\mathbf{z}|\mathbf{p}}(\mathbf{z}|\mathbf{p})f_{\mathbf{p}}(\mathbf{p})d\mathbf{p}} \quad (8.130)$$

Once  $f_{\mathbf{p}|\mathbf{z}}(\mathbf{p}|\mathbf{z})$  has been obtained, several point estimators can be defined. Two that are widely used are Maximum A Posteriori (MAP) and Mean Square (MS) estimates which are given respectively, by:

$$\hat{\mathbf{p}}_{\text{MAP}} = \underset{\mathbf{p}}{\operatorname{argmax}} f_{\mathbf{p}|\mathbf{z}}(\mathbf{p}|\mathbf{z}) \quad (8.131)$$

and:

$$\hat{\mathbf{p}}_{\text{MS}} = E[\mathbf{p}|\mathbf{z}] = \int \mathbf{p}f_{\mathbf{p}|\mathbf{z}}(\mathbf{p}|\mathbf{z}) \quad (8.132)$$

In general, an analytic expression for  $f_{\mathbf{p}|\mathbf{z}}$  is either not available or else it is simply intractable. Hence one has to resort to sophisticated numerical simulation techniques

known as Markov chain Monte Carlo (Gilks *et al.*, 1995). The description of these techniques is outside the scope of this book but we refer the interested reader to Pillonetto *et al.* (2002; 2006) for an appreciation of these techniques in relation to biomedical modeling.

The expression for  $f_{\mathbf{p}|\mathbf{z}}(\mathbf{p}|\mathbf{z})$  in (8.130) is simplified considerably if specific assumptions regarding the distributions of  $\mathbf{v}$ ,  $f_{\mathbf{v}}(\mathbf{v})$ , and  $\mathbf{p}$ ,  $f_{\mathbf{p}}(\mathbf{p})$ , are made. For instance, let us assume that both  $\mathbf{v}$  and  $\mathbf{p}$  are independent and normally distributed (8.118). Then we have:

$$f_{\mathbf{p}}(\mathbf{p}) = \frac{1}{[(2\pi)^N \det(\boldsymbol{\Sigma}_{\mathbf{p}})]^{1/2}} \exp\left(-\frac{1}{2}(\mathbf{p} - \boldsymbol{\mu}_{\mathbf{p}})^T \boldsymbol{\Sigma}_{\mathbf{p}}^{-1}(\mathbf{p} - \boldsymbol{\mu}_{\mathbf{p}})\right) \quad (8.133)$$

with  $\boldsymbol{\mu}_{\mathbf{p}}$  and  $\boldsymbol{\Sigma}_{\mathbf{p}}$  as the mean and covariance of  $\mathbf{p}$ , and (see 8.119):

$$f_{\mathbf{z}|\mathbf{p}}(\mathbf{z}|\mathbf{p}) = \frac{1}{[(2\pi)^N \det(\boldsymbol{\Sigma}_{\mathbf{v}})]^{1/2}} \exp\left(-\frac{1}{2}[\mathbf{z} - \mathbf{G}(\mathbf{p})]^T \boldsymbol{\Sigma}_{\mathbf{v}}^{-1}[\mathbf{z} - \mathbf{G}(\mathbf{p})]\right) \quad (8.134)$$

Suppose now that we choose a MAP estimator (8.131). First we note that since the denominator of (8.130) does not depend on  $\mathbf{p}$ , the MAP estimate is given by:

$$\hat{\mathbf{p}}_{\text{MAP}} = \underset{\mathbf{p}}{\operatorname{argmax}} f_{\mathbf{z}|\mathbf{p}}(\mathbf{z}|\mathbf{p}) \cdot f_{\mathbf{p}}(\mathbf{p}) \quad (8.135)$$

with  $f_{\mathbf{z}|\mathbf{p}}(\mathbf{z}|\mathbf{p})$  and  $f_{\mathbf{p}}(\mathbf{p})$  given by (8.134) and (8.133), respectively.

By using a reasoning similar to that used adopted in deriving the ML estimate (8.123), we get:

$$\hat{\mathbf{p}}_{\text{MAP}} = \underset{\mathbf{p}}{\operatorname{argmin}} [\mathbf{z} - \mathbf{G}(\mathbf{p})]^T \boldsymbol{\Sigma}_{\mathbf{v}}^{-1}[\mathbf{z} - \mathbf{G}(\mathbf{p})] + (\mathbf{p} - \boldsymbol{\mu}_{\mathbf{p}})^T \boldsymbol{\Sigma}_{\mathbf{p}}^{-1}(\mathbf{p} - \boldsymbol{\mu}_{\mathbf{p}}) = \underset{\mathbf{p}}{\operatorname{argmin}} \mathbf{J}(\mathbf{p}) \quad (8.136)$$


where the first addendum in the argument is an *a posteriori* information term (the data) and the second an *a priori* one (our expectation on  $\mathbf{p}$ ).

The MAP estimator thus realizes a compromise between *a priori* and *a posteriori* information. For instance, if *a priori* information is ‘poor’, i.e.  $\boldsymbol{\Sigma}_{\mathbf{p}}$  is large, the second term becomes negligible and one has the situation in which the MAP estimate coincides with ML:

$$\hat{\mathbf{p}}_{\text{MAP}} = \underset{\mathbf{p}}{\operatorname{argmin}} [\mathbf{z} - \mathbf{G}(\mathbf{p})]^T \boldsymbol{\Sigma}_{\mathbf{v}}^{-1}[\mathbf{z} - \mathbf{G}(\mathbf{p})] = \hat{\mathbf{p}}_{\text{ML}} \quad (8.137)$$

This is also true in general (above we have made the assumption of normality). In fact, if we consider the definition of the MAP estimate (8.131) and consider a situation of ‘poorer and poorer’ *a priori* information,  $f_{\mathbf{p}}(\mathbf{p})$  will tend to a uniform distribution (Figure 8.11). In other words, it is like not having *a priori* information and the MAP estimate of (8.136) then coincides with the ML estimate of (8.123).

The statistical information characterizing a MAP estimate is similar to that considered in the Fisherian approach; that is, confidence intervals for the parameter



**Figure 8.11** Distribution of  $f_p(\mathbf{p})$  as affected by poorer *a priori* information.

estimates can be derived to assess precision, and parsimony principle criteria for model order selection are available. One that is frequently used is the Generalized Information Criterion (GEN-IC):

$$\text{GEN-IC} = \frac{2M}{N} + \mathbf{J}(\hat{\mathbf{p}}_{\text{MAP}}) \quad (8.138)$$


In general, with respect to ML, MAP estimation worsens the fit (the second term in (8.136) is positive), but precision improves.

As a case in point, we can revisit the example that was considered in section 8.6. The three-exponential model performance can be improved if we have some *a priori* knowledge regarding the parameters. Table 8.5 shows the MAP results for the three-exponential model obtained by assuming that  $\boldsymbol{\mu}_p$  and  $\boldsymbol{\Sigma}_p$  were known from previous population studies. Also shown for comparison are the WLS results (or ML since we assumed measurement errors to be independent and Gaussian) which were already reported in Table 8.4. Precision improves with point estimates remaining very similar. Weighted residuals are shown in Figure 8.12, demonstrating that they are virtually the same as those obtained by WLS/ML estimation.

**Table 8.5** Comparison of ML and MAP estimation

	$A_1$ (ml) <sup>-1</sup>	$A_2$ (ml) <sup>-1</sup>	$A_3$ (ml) <sup>-1</sup>	$\alpha_1$ (min) <sup>-1</sup>	$\alpha_2$ (min) <sup>-1</sup>	$\alpha_3$ (min) <sup>-1</sup>	WRSS
WLS (ML)	$1.29 \times 10^{-4}$ (39)	$0.88 \times 10^{-4}$ (66)	$0.81 \times 10^{-4}$ (9)	0.253 (49)	0.085 (40)	0.024 (3)	40
MAP	$1.51 \times 10^{-4}$ (13)	$0.93 \times 10^{-4}$ (10)	$0.74 \times 10^{-4}$ (7.5)	0.283 (12)	0.074 (11.8)	0.023 (2.9)	48

Examples of situations in which the Bayesian approach is particularly helpful are presented in Chapter 11.



**Figure 8.12** Example of the fitting of data to a three-exponential (3E) model demonstrating the patterns of weighted residuals obtained with ML (left) and MAP (right) estimation.

## 8.9 OPTIMAL EXPERIMENTAL DESIGN

We have now reached the stage where we have a model structure, a description of the measurement error, and the numerical values of our parameters, together with the precision with which they can be estimated. It may now be appropriate to address the issue of optimal experimental design. The rationale here is to act on design variables in order to maximize, according to some criterion, the precision with which the compartmental model parameters can be estimated (DiStefano, 1981; Landaw and DiStefano, 1984). Candidate design variables include the number of test inputs and outputs, the form of test inputs, the number of samples and sampling schedule, and the measurement error. For example, in clinical studies it may be highly

desirable to minimize the experimental effort, say by minimizing the number of blood samples needing to be collected.

The approach is to use the Fisher information matrix  $F$ , which is the inverse of the lower bound of the covariance matrix, as a function of the design variables. Usually the determinant of  $F$  (this is termed D-optimal design) is maximized, which corresponds to minimizing the determinant of the inverse of  $F$ ,  $F^{-1}$ , that is the volume of the asymptotic confidence region for  $\mathbf{p}$ , so as to maximize the precision of the parameter estimates, and hence numerical identifiability.

Let us define the principal variables of the experimental design, considering the scalar case, as follows:

1. The form of the test signal  $u$  (e.g. injection, infusion, or combination of such signals).
2. The duration of the time over which the output variable is measured  $T$ .
3. The number of samples,  $N$ , obtained during  $T$ .
4. The sampling schedule  $SS$ , that is where the samples are located in  $T$  (i.e. the choice of  $t_1, t_2, \dots, t_k, \dots, t_N$ ).
5. The variance of the measurement errors,  $\Sigma_v$ .

The Fisher information matrix can thus be defined as:

$$F = F(u, T, N, SS, \Sigma_v) \quad (8.139)$$

The optimal design of sampling schedules (that is, determining the number and location of the discrete time points at which samples are collected) has received considerable attention, since this is the variable which is generally least constrained by the experimental setting. Theoretical and algorithmic aspects of the problem have been studied, and software is available for both the single- and multi-output cases (DiStefano, 1981; Cobelli *et al.*, 1985; Landaw and DiStefano, 1984). Optimal sampling schedules are usually obtained in an iterative manner. Starting with the model derived from pilot experiments, the program computes optimal sampling schedules for subsequent experimentation.

The D-optimal design for the  $n$ th order multiexponential model usually consists of independent replicates at  $2M$  distinct times, where  $M$  is the number of parameters to estimate. This can be a highly efficient result in terms of resources. In a number of cases these designs can be approximated by rules of thumb, which have become part of our intuition for selecting and modifying optimal designs. Under the error variance model of (8.22), with  $\alpha = 0$  and time interval from  $t_0$  up to  $t_f$ , the D-optimal sampling schedule for the two-parameter mono-exponential model  $y(t) = A_1 e^{\lambda_1 t}$  consists of two times  $t_1^* = t_0$  and:

$$t_2^* = \text{minimum} \left\{ \frac{t_0 + 2}{(\lambda_1(\gamma - 2))}, t_f \right\}.$$

Note that for  $\gamma = 0$  (constant error variance), the spacing between  $t_1^*$  and  $t_2^*$  is  $(-1/\lambda_1)$ , and for  $\gamma = 2$  (constant CV error)  $t_2^*$  is always chosen at the maximum time  $t_f$ . This

latter result is valid, of course, only if the assumption of no constant background constant variance ( $\alpha = 0$ ) still holds at  $t_f$ .

Also note that this design specification is independent of the nominal value for parameter  $A_1$ , in part because the regression model is linear in the  $A_1$  parameter.

The extension of the rules to higher-order multiexponential models is more difficult, but hints are given in Landaw and DiStefano (1984). In general for a single input-single output, linear dynamic model with  $M$  parameters, the D-optimal design consists of  $M$  distinct samples with independent replicates at the  $M$  points. This allows improvement to be made in the precision by a factor  $m$  for the variance and  $\sqrt{m}$  for the CV.

The adoption of optimal sampling schedule design has been shown to enhance the precision of estimated parameters as compared to designs that have been arrived at by intuition or some other means. The approach has also been shown to enhance the cost-effectiveness of a dynamic clinical test by reducing the number of blood samples withdrawn from a patient without significantly reducing the precision with which model parameters have been obtained.

For instance, in Cobelli and Ruggeri (1989), the four parameters of a glucose tracer kinetic model have been estimated in humans with a frequent sampling schedule consisting of 19/35 samples (considered as the reference) and compared with those obtained with an optimal 'population' four sample schedule. In each individual the parameters estimated using the four sample and the 19/35 samples schedule were fairly close: the mean absolute percentage difference from the reference of the four estimated parameters was 18%, 15%, 9% and 4%. The precision of the estimated parameters was obviously lower with the four sample as compared to the reference schedule, but still satisfactory: mean coefficient of variation was for the four parameters 20 vs. 12 (reference), 21 vs. 11, 17 vs. 9 and 4 vs. 3, respectively. This means that with four replicates at the four optimal points, it is possible to achieve a precision virtually identical to that obtained with the full 19/35 sample reference schedule.

## 8.10 SUMMARY

This chapter has focused on the problem of assigning numerical values to the unknown parameters of a structural model, given that relevant experimental data are available for this purpose. The concept of linear and nonlinear parameters has been introduced, followed by a discussion of the basic concepts of regression analysis. This then led on to a consideration of linear and nonlinear least squares estimation. Discussion of maximum likelihood and Bayesian estimation then followed. The chapter concluded with discussion of the related issue of optimal experimental design. Having dealt with structural models in this chapter, Chapter 9 will go on to consider signal estimation in the context of non-parametric models.

## 8.11 EXERCISES AND ASSIGNMENT QUESTIONS

1. Discuss the relative advantages of Weighted Least Squares and Least Squares parameter estimation.

2. Weighted Least Squares parameter estimation for a model that is nonlinear in the parameters is more difficult than for models that are linear in the parameters. Discuss why this is the case.
3. The first criterion with which to judge whether or not a specific system model is a reliable description of the data is the test on residuals. Discuss why residuals should be independent, and why weighted residuals should lie in a  $-1,+1$  wide band.
4. Discuss the relative merits of Least Squares, Maximum Likelihood and Bayesian approaches to parameter estimation in the context of physiological modeling.
5. Discuss the rationale of optimal experiment design and formalize it.

# 9 NON-PARAMETRIC MODELS – SIGNAL ESTIMATION

## Chapter Contents

### 9.1 Introduction

### 9.2 Why is Deconvolution Important?

### 9.3 The Problem

### 9.4 Difficulty of the Deconvolution Problem

### 9.5 The Regularization Method

#### 9.5.1 Fundamentals

#### 9.5.2 Choice of the Regularization Parameter

#### 9.5.3 The Virtual Grid

### 9.6 Summary

### 9.7 Exercises and Assignment Questions

## 9.1 INTRODUCTION

Just as many parameters (the subject of Chapter 8) are not directly measurable *in vivo*, the same is true of many signals that are of interest for the quantitative understanding of physiological systems. Examples include the secretion rate of a gland, the production rate of a substrate, or the rate of appearance of a drug in plasma after an oral administration. Very often, it is only possible to measure the causally-related effects of these signals in the circulation, e.g. the time course of plasma concentrations. Thus, there must be reconstruction of the unknown causes, e.g. hormone secretion rate, from the measured effects, e.g. hormone plasma concentration.

This is referred to as an inverse problem. If the unknown signal is the input of the system, the inverse problem is an input estimation problem (refer back to Figure 4.29),



which in the case of a linear time-invariant system, is called deconvolution. As already anticipated in Chapter 4, section 4.9.2, deconvolution is known to be an ill-posed and ill-conditioned problem and dealing with physiological signals adds to the complexity of the problem. In this chapter we discuss these difficulties in a formal manner and describe a classic non-parametric regularization method to handle these difficulties.

## 9.2 WHY IS DECONVOLUTION IMPORTANT?

One could argue that the measurement of a concentration time series in plasma provides sufficient information on the system of interest, e.g. for understanding its basic mechanisms or for diagnostic and therapeutic purposes. In other words, there would be no need to solve for  $u(t)$  in the integral equation (see (4.29)):


$$c(t) = \int_0^t g(t - \tau)u(\tau) d\tau \quad (9.1)$$

since the samples of  $c(t)$  would do the job. There is no question that concentration time series, i.e. the samples of  $c(t)$ , contain precious information and we discussed in Chapter 4 a number of methods to extract important quantitative information from them. However, these concentration signals also reflect, in addition to the substance secretion/production process of interest, its distribution and metabolism in the organism, i.e. its kinetics. In fact, the kinetics of the substance can play a very important role since they can render the measured plasma concentration signal very different from that of the signal we are interested in, i.e. the secretion/production flux, with obvious consequences on inference from data analysis.

Let us illustrate this aspect with the simulated example of Figure 9.1. The input  $u(t)$  is common to two systems, one characterized by a ‘fast’ impulse response,  $g(t) = e^{-\alpha t}$  with  $\alpha = 12$  (left panels), and the other by a ‘slow’ one, i.e.  $g(t) = e^{-\alpha t}$  with  $\alpha = 2$  (right panels). This makes the two outputs  $c(t)$  calculated by convolution from  $u(t)$  and  $g(t)$  very different (central panels, continuous lines): the ‘slow’ system shows a second peak higher than the first one, while the true input shows the opposite. The situation is further worsened if we consider discrete sampling and measurement noise (central panels, open circles). The investigator only ‘sees’ the measured time series redrawn and interpolated in the bottom panels: the ‘fast’ system shows the two original peaks while the ‘slow’ system only shows a single bell-shaped peak. The lesson of the simulated example shown in Figure 9.1 is pretty clear: there is the need to remove the distortion introduced by the kinetics of the substance by estimating the input.

## 9.3 THE PROBLEM

We solve (9.1) for the unknown input,  $u(t)$ , from the knowledge of the output of the system,  $c(t)$ , and the impulse response of the system,  $g(t)$ . In real world problems, only a finite number of output samples can be measured and the impulse response



**Figure 9.1** Influence of substance kinetics on concentration time series. Left and right panels describe a ‘fast’ and a ‘slow’ system, respectively. From top to bottom panels: impulse response, input, continuous output (continuous line) and noisy samples (open circles) and measurement time series (open circles, interpolation also shown) are shown, respectively (adapted from Sparacino *et al.*, 2004).

$g(t)$  is a model (often a sum of exponentials) either identified through a specific input-output experiment or obtained from population studies.

In (9.1) it is implicitly assumed that  $u(t)$  is causal, i.e.  $u(t) = 0$  for  $t < 0$ . In several cases, this is not true, as when a basal spontaneous hormone secretion also occurs for  $t < 0$ . There are several ways to approach this problem, see for instance Sparacino *et al.* (2001).

It is worth noting that due to the symmetry of (9.1) with respect to  $g(t)$  and  $u(t)$ , a deconvolution problem also arises whenever the impulse response  $g(t)$  of the system given the input  $u(t)$  and the output  $c(t)$  is estimated. For instance, the transport function of a substance through an organ can be estimated by deconvolution of the inlet and outlet concentrations (Sparacino *et al.*, 1998). Hereafter, we address only the input estimation problem.

A final remark. We shall assume the system to be linear and time invariant. There are situations where this is not the case; i.e. the system is linear time-varying. In such situations the input estimation problem becomes that of solving a Fredholm integral equation of the first kind:

$$c(t) = \int_0^t g(t, \tau)u(\tau) d\tau \quad (9.2)$$

The function  $g(t, \tau)$  is called the kernel of the system and depends on both  $t$  and  $\tau$  and not on their difference as in (9.1). In particular, the function  $g(t, \tau_0)$  describes the time course of the output when the system is forced by a unitary pulse input  $\delta(\tau_0)$  given at time  $\tau_0$ . For instance, the reconstruction of hepatic glucose production after a glucose perturbation can be stated as a Fredholm integral equation of the first kind, where the kernel  $g(t, \tau)$  is described by a linear two-compartment model of glucose kinetics with time-varying parameters (Caumo and Cobelli, 1993; Vicini *et al.*, 1999). In the literature, the solution of the Fredholm integral equation of the first kind is usually also called (albeit improperly) deconvolution.

## 9.4 DIFFICULTY OF THE DECONVOLUTION PROBLEM

In the mathematics/physics/engineering literature, deconvolution is known to be difficult because such problems tend to be ill-posed and ill-conditioned. Here, we discuss these ‘analytical’ difficulties of input estimation by using a classic example of the literature (Hunt, 1971), hereafter referred to as the *Hunt simulated problem*. Consider the input given by:

$$u(t) = e^{-[(t-400/75)]^2} + e^{-[(t-600/75)]^2}, \quad 0 \leq t \leq 1025 \quad (9.3)$$

and the impulse response of the system given by:

$$g(t) = \begin{cases} 1, & t \leq 250 \\ 0, & t > 250 \end{cases} \quad (9.4)$$

These functions do not necessarily have a physiological counterpart. Knowing  $u(t)$  and  $g(t)$ ,  $c(t)$  can be obtained. Assume that  $N$  samples of  $c(t)$ ,  $\{c_k\}$  where  $c_k = c(t_k)$ , are measured without error on the uniform sampling grid  $\Omega_s = \{kT\}$ ,  $k = 1, \dots, N$ , with  $T = 25$  and  $N = 41$ . The input  $u(t)$ , the impulse response  $g(t)$  and the output  $c(t)$  together with the samples  $\{c_k\}$  are shown in Figure 9.2 upper panel: left and right; middle: right, respectively.

The problem of reconstructing the continuous-time function  $u(t)$  from the time series  $\{c_k\}$  can be shown not to result in a unique solution (Bertero, 1989). This will be illustrated below by making reference to the least squares deconvolution technique. Thus the problem has, in addition to the true solution, others such as the staircase function (Figure 9.2, middle panel, left), the convolution of which with the impulse response  $g(t)$  perfectly describes the output data  $\{c_k\}$ . More precisely, there is an infinite number of continuous-time functions that, once convoluted with the impulse response, perfectly describe the sampled data. Therefore, the deconvolution problem is an *ill-posed* problem.

To tackle ill-posedness, any deconvolution approach must in some way restrict the field of the functions among which the solution of the problem is sought. For instance, in so-called *discrete deconvolution* the signal  $u(t)$  is assumed to be a piecewise constant within each interval of the sampling grid  $\Omega_s = [t_1, t_2, \dots, t_N]$ , i.e.  $u(t) = u_i$  for  $t_{i-1} \leq t \leq t_i$ ,  $i = 1, 2, \dots, N$ , where  $t_0 = 0$ . From (9.1) it follows that:

$$c(t_k) = \int_0^{t_k} g(t_k - \tau) \cdot u(\tau) \cdot d\tau = \sum_{i=1}^k u_i \cdot \int_{t_{i-1}}^{t_i} g(t_k - \tau) \cdot d\tau \quad (9.5)$$

One may also think of  $u_i$  as being the mean level of  $u(t)$  during the  $i$ -th sampling interval. By letting:

$$g_{k-i} = \int_{t_{i-1}}^{t_i} g(t - \tau) \cdot d\tau \quad (9.6)$$

it follows that:

$$c_k = c(t_k) = \sum_{i=1}^k u_i \cdot g_{k-i} \quad (9.7)$$


So that the first terms are:

$$c_1 = g_0 \cdot u_1 \quad (9.8)$$

$$c_2 = g_0 \cdot u_2 + g_1 \cdot u_1 \quad (9.9)$$

$$c_3 = g_0 \cdot u_3 + g_1 \cdot u_2 + g_2 \cdot u_1 \quad (9.10)$$

·  
·  
·



**Figure 9.2** The Hunt simulated problem. Upper panels: True input (left) and impulsive response (right). Middle panels: Ill-posedness. The staircase function (left, thick line) is a solution of the problem with error-free data like the true input (left, thin line), i.e. it perfectly describes the sampled data (right, open circles,  $N = 41$ ). The true continuous output is also shown (right, continuous line). Lower panels: Ill-conditioning. Solution provided by LS deconvolution vs true input (left, thick vs thin line) from the noisy ( $SD = 3$ ) sampled data (right, open circles). Also shown is reconvolution (right, continuous line) (adapted from Sparacino *et al.*, 2004).

Adopting a matrix notation:

$$\mathbf{c} = \mathbf{G}\mathbf{u} \quad (9.11)$$


where  $\mathbf{c} = [c_1, c_2, \dots, c_N]^T$  is the  $N$ -dimensional vector of sampled output,  $\mathbf{u} = [u_1, u_2, \dots, u_N]^T$ , and  $\mathbf{G}$  is an  $N \times N$  lower triangular (Toeplitz) matrix:

$$\mathbf{G} = \begin{bmatrix} g_0 & 0 & 0 & 0 & 0 \\ g_1 & g_0 & 0 & 0 & 0 \\ g_2 & g_1 & g_0 & 0 & 0 \\ \dots & \dots & \dots & \dots & \dots \\ g_N & \dots & g_2 & g_1 & g_0 \end{bmatrix} \quad (9.12)$$

Since  $\mathbf{G}$  is invertible, (9.11) provides a unique solution:

$$\hat{\mathbf{u}} = \mathbf{G}^{-1}\mathbf{c} \quad (9.13)$$

For the Hunt simulated problem, this solution is displayed in Figure 9.2, middle panel: left. It should be noted that, given the ill-posed nature of the problem, this profile is only one possible solution of the deconvolution problem with noise-free data. Once convoluted with  $g(t)$ , the staircase function perfectly describes the output samples just as the true input, providing an accurate approximation, apart from the staircase approximation.



**Figure 9.3** Output samples and measurement error.

Equation (9.11) addresses the noise-free situation. However, output samples are usually affected by measurement error (Figure 9.3), and this dramatically enhances the difficulty of the deconvolution problem. Let  $z_k$  denote the  $k$ -th measurement:

$$z_k = c_k + v_k \quad k = 1, 2, \dots, N \quad (9.14)$$

where  $v_k$  is the error. Thus, in vector notation:

$$\mathbf{z} = \mathbf{G} \cdot \mathbf{u} + \mathbf{v} \quad (9.15)$$

where  $\mathbf{z} = [z_1, z_2, \dots, z_N]^T$  and  $\mathbf{v} = [v_1, v_2, \dots, v_N]^T$ . Let us assume  $\mathbf{v}$  to be of zero mean and independent with covariance matrix  $\Sigma_v$  given by (8.50). The simplest estimate of  $\mathbf{u}$  from data  $\mathbf{z}$  is achieved by resorting to least squares parameter estimation, i.e. to solve the LS problem:

$$\min_{\mathbf{u}} (\mathbf{z} - \mathbf{G} \cdot \mathbf{u})^T \Sigma_v^{-1} (\mathbf{z} - \mathbf{G} \cdot \mathbf{u}) \quad (9.16)$$

The solution of (9.16) is (see Chapter 8, (8.59)):

$$\hat{\mathbf{u}}_{LS} = (\mathbf{G}^T \Sigma_v^{-1} \mathbf{G})^{-1} \mathbf{G}^T \Sigma_v^{-1} \mathbf{z} = \mathbf{G}^{-1} (\mathbf{G}^T \Sigma_v^{-1})^{-1} \mathbf{G}^T \Sigma_v^{-1} \mathbf{z} = \mathbf{G}^{-1} \mathbf{z} \quad (9.17)$$

since  $\mathbf{G}$  is square and invertible.

In this case reconvolution, i.e. the prediction of the output  $z(t)$  in (9.1) by using  $\hat{\mathbf{u}}_{LS}(t)$ :


$$z(t) = \int_0^t g(t - \tau) \cdot \hat{\mathbf{u}}_{LS}(\tau) \cdot d\tau \quad (9.18)$$

describes perfectly the sampled data, i.e. the residual vector  $\mathbf{r} = \mathbf{z} - \mathbf{G} \hat{\mathbf{u}}_{LS}$  is identically zero.

The presence of noise in the measurement vector  $\mathbf{z}$  (9.15) has a dramatic effect on the quality of the estimate. In Figure 9.2 (lower panel: right) Gaussian noise (standard deviation  $SD = 3$ ) was added to the data of the Hunt simulated problem and LS deconvolution was performed (Figure 9.2, lower panel: left). Note that wide, spurious, and unrealistic oscillations contaminate the estimated input, which also takes on negative values. The reason for this deterioration is that deconvolution is not only ill-posed but is also an ill-conditioned problem. Small errors in the observed data can be amplified, thus yielding much larger errors in the estimates.

It could be hypothesized that increasing the number of samples would be beneficial to the solution of the problem. On the contrary, both theory and practice show that increasing the sampling rate worsens the ill-conditioning. In addition, the ‘slower’ the system (i.e. the smoother the impulse response), the worse the ill-conditioning for the same sampling frequency. This is well-exemplified in Figure 9.4 again on the Hunt simulated problem. For the sake of clarity, we report in the top panels the lower panels of Figure 9.2, i.e. those corresponding to a sampling period of  $T = 25$ . The middle panels refer to the same impulsive response and measurement error ( $SD = 3$ ) of the top panels, but the sampling period is now  $T = 10$  (vs 25). The lower panels refer to a ‘slower’ system ( $g(t)$  lasts 400 instead of 250) with the original sampling period ( $T = 25$ ) and measurement error ( $SD = 3$ ). This means, for example, that the longer the hormone half-life and the higher the sampling rate, the more difficult the reconstruction of the hormone secretion rate by deconvolution.

The conceptual difficulties described above made the deconvolution problem a classic of the engineering/mathematics/physics literature. Unfortunately, dealing with physiological signals adds to the complexity of the problem. For instance, parsimonious sampling schemes are needed to cope with technical and budget limitations as well as patient comfort. Consequently, the data are often collected with infrequent and non-uniform sampling schedules. Among other things, non-uniform sampling hinders the possible use of frequency domain techniques such as Wiener filtering. Furthermore, physiological inputs are often intrinsically non-negative (e.g. hormone secretion or substrate production rate). Thus, negative input estimates due to ill-conditioning are physiologically implausible. Finally, physiological systems are sometimes time-varying, e.g. the glucose-insulin system during a glucose perturbation.



**Figure 9.4** The Hunt simulated problem. Effect of sampling frequency and system dynamics. Upper panels: Lower panels of Figure 9.2 are reported for sake of comparison. Middle panels: Effect of an increased sampling frequency. LS deconvolution vs true input (left, thick vs thin line) from noisy ( $SD = 3$ ) samples (right, open circles,  $N = 102$ ). Also shown is reconvolution (right, continuous line). Lower panels: Effect of a 'slower' dynamics. LS deconvolution vs true input (left, thick vs thin line) from noisy ( $SD = 3$ ) samples (right, open circles,  $N = 41$ ). Also shown is reconvolution (right, continuous line) (adapted from Sparacino *et al.*, 2004).



Least square deconvolution is appealingly simple but weak because it is too sensitive to ill-conditioning. In the literature many methods have been developed to circumvent ill-conditioning. Broadly speaking, these methods can be divided into two categories. The first, named *parametric deconvolution*, assumes the analytical expression of the input to be known except for a small number of parameters, so that the deconvolution problem becomes one of parameter estimation. A second, often referred as *non-parametric deconvolution*, does not require an analytical form of the input to be postulated. The best known non-parametric approach is the regularization method. A deterministic version of this will be described in detail in the next section.

## 9.5 THE REGULARIZATION METHOD

### 9.5.1 Fundamentals

The regularization method is a non-parametric approach (Philips, 1962; Tikhonov, 1963). The idea of the method is to identify a solution that provides not a perfect fit to the data (like LS deconvolution) but rather a good data fit and one that simultaneously enjoys a certain degree of ‘smoothness’. This is done by solving the optimization problem:

$$\min_{\mathbf{u}} (\mathbf{z} - \mathbf{G} \cdot \mathbf{u})^T \boldsymbol{\Sigma}_v^{-1} (\mathbf{z} - \mathbf{G} \cdot \mathbf{u}) + \gamma \mathbf{u}^T \mathbf{F}^T \mathbf{F} \mathbf{u} \quad (9.19)$$

where  $\boldsymbol{\Sigma}_v$  is the covariance matrix of the measurement error,  $\mathbf{F}$  is a  $N \times N$  penalty matrix (see below) and  $\gamma$  is a real non-negative parameter (see below).

The problem posed in (9.19) is quadratic and its solution is:

$$\hat{\mathbf{u}} = (\mathbf{G}^T \boldsymbol{\Sigma}_v^{-1} \mathbf{G} + \gamma \mathbf{F}^T \mathbf{F})^{-1} \mathbf{G}^T \boldsymbol{\Sigma}_v^{-1} \mathbf{z} \quad (9.20)$$

which depends linearly on the vector data  $\mathbf{z}$ .

Note that, if  $\gamma = 0$ , (9.19) and (9.20) coincide with (9.16) and (9.17), respectively, and the LS solution is obtained. When  $\gamma > 0$ , the cost function (9.19) is made up of two terms. The first one penalizes the distance, weighted by the inverse of  $\boldsymbol{\Sigma}_v$ , between the model prediction  $\mathbf{G}\mathbf{u}$  (the reconversion vector) and the data. The second contribution  $\mathbf{u}^T \mathbf{F}^T \mathbf{F} \mathbf{u}$ , is a term that penalizes the ‘roughness’ of the solution. The standard choice is to penalize the energy of the  $m$ -th order time derivative, with  $m$  being an integer parameter. Usually the energy of the first or second derivatives is considered. How is  $\mathbf{F}$  built in order to achieve this? Let us consider the case of uniform sampling (in what follows we shall remove this assumption).  $\mathbf{F}$  is built so that  $\mathbf{F}\mathbf{u}$  gives the  $m$ -th differences of  $\mathbf{u}$  ( $m = 1, 2, \dots$ ), i.e. one has:

$$\mathbf{F} = \mathbf{D}^m \quad (9.21)$$

$$\mathbf{D} = \begin{bmatrix} 1 & 0 & 0 & \dots & 0 \\ -1 & 1 & 0 & \dots & 0 \\ 0 & -1 & 1 & \dots & 0 \\ \dots & \dots & \dots & \dots & \dots \\ 0 & \dots & \dots & -1 & 1 \end{bmatrix} \quad (9.22)$$

As an illustration let us consider the case where the energy of the first derivatives is penalized, i.e.  $m = 1$ . In this case:

$$\mathbf{F} = \begin{bmatrix} 1 & 0 & 0 & \dots & 0 \\ -1 & 1 & 0 & \dots & 0 \\ 0 & -1 & 1 & \dots & 0 \\ \dots & \dots & \dots & \dots & \dots \\ 0 & \dots & \dots & -1 & 1 \end{bmatrix} \quad (9.23)$$

and thus  $\mathbf{F}\mathbf{u}$  with  $\mathbf{F} = \mathbf{D}$  gives the first differences of  $\mathbf{u}$ :

$$\mathbf{D}\mathbf{u} = \begin{bmatrix} 1 & 0 & 0 & \dots & 0 \\ -1 & 1 & 0 & \dots & 0 \\ 0 & -1 & 1 & \dots & 0 \\ \dots & \dots & \dots & \dots & \dots \\ 0 & \dots & \dots & -1 & 1 \end{bmatrix} \begin{bmatrix} u_1 \\ u_2 \\ u_3 \\ \dots \\ u_N \end{bmatrix} = \begin{bmatrix} u_1 \\ u_2 - u_1 \\ u_3 - u_2 \\ \dots \\ u_N - u_{N-1} \end{bmatrix} \quad (9.24)$$

If the energy of the second derivatives is penalized, i.e.  $m = 2$ , one has:

$$\mathbf{F} = \begin{bmatrix} 1 & 0 & 0 & \dots & 0 \\ -2 & 1 & 0 & \dots & 0 \\ 1 & -2 & 1 & \dots & 0 \\ \dots & 1 & -2 & \dots & 0 \\ \dots & \dots & \dots & \dots & \dots \\ 0 & \dots & 1 & -2 & 1 \end{bmatrix} \quad (9.25)$$

and thus  $\mathbf{F}\mathbf{u}$  with  $\mathbf{F} = \mathbf{D}^2$  gives the second differences of  $\mathbf{u}$ :

$$\mathbf{D}^2\mathbf{u} = \mathbf{D}(\mathbf{D}\mathbf{u}) = \begin{bmatrix} 1 & 0 & 0 & \dots & 0 \\ -1 & 1 & 0 & \dots & 0 \\ 0 & -1 & 1 & \dots & 0 \\ \dots & \dots & \dots & \dots & \dots \\ 0 & \dots & \dots & -1 & 1 \end{bmatrix} \begin{bmatrix} u_1 \\ u_2 - u_1 \\ u_3 - u_2 \\ \dots \\ u_N - u_{N-1} \end{bmatrix} = \begin{bmatrix} u_1 \\ u_2 - 2u_1 \\ u_3 - 2u_2 + u_1 \\ \dots \\ u_N - 2u_{N-1} + u_{N-2} \end{bmatrix} \quad (9.26)$$

The relative weight given to data and solution regularity is governed by the so-called *regularization parameter*  $\gamma$ . By increasing  $\gamma$ , the cost of roughness increases and the data match becomes relatively less important. Conversely, by decreasing the value of  $\gamma$  the cost of roughness is lowered, and the fidelity to the data becomes relatively more important. The choice of regularization parameter is a crucial problem: too large values of  $\gamma$  will lead to very smooth estimates of  $\hat{\mathbf{u}}$  that may not be able to explain

the data (over-smoothing), while too small values of  $\gamma$  will lead to ill-conditioned solutions of  $\hat{\mathbf{u}}$  that accurately fit the data but exhibit spurious oscillations due to their sensitivity to noise (for  $\gamma \rightarrow 0$  the LS solution is approached).

The importance of the choice of  $\gamma$  is demonstrated by the profiles reported in Figure 9.5 (left panels) for the Hunt simulated problem (right panels display how well the estimated input, once convoluted with the impulse response, matches the data). Too small a value of  $\gamma$  produces an input estimate  $\hat{\mathbf{u}}$  which suffers from noise amplification due to ill-conditioning (under-smoothing) while too high a value produces an estimate of  $\hat{\mathbf{u}}$  that is too regular and hence is not able to explain the data (over-smoothing).

### 9.5.2 Choice of the Regularization Parameter

In the literature, several criteria have been proposed for the choice of the regularization parameter  $\gamma$  such as: discrepancy; cross-validation and generalized cross-validation; unbiased risk; minimum risk; and L-curve (see Sparacino *et al.*, 2001 for references). Below we only describe the popular discrepancy criterion (Twomey, 1965) which suggests the following. Let us compare the residual vector:

$$\mathbf{r} = \mathbf{z} - \mathbf{G}\hat{\mathbf{u}} \quad (9.27)$$

where  $\mathbf{r}$  depends on  $\gamma$ .

Since from (9.15) one has:

$$\mathbf{v} = \mathbf{z} - \mathbf{G}\mathbf{u} \quad (9.28)$$

the residual vector  $\mathbf{r}$  can be thought of as an estimate of the measurement error vector  $\mathbf{v}$ , i.e.

$$\hat{\mathbf{v}} = \mathbf{r} \quad (9.29)$$


Thus it is ‘logical’ to expect that:

$$\mathbf{r}^T \mathbf{r} \cong E[\mathbf{v}^T \mathbf{v}] \quad (9.30)$$


Since  $\mathbf{r}^T \mathbf{r}$  depends on  $\gamma$ , one has to adjust  $\gamma$  iteratively until:

$$\sum_{i=1}^N r_i^2 \cong \text{trace}(\Sigma_v) = \sum_{i=1}^N \sigma_i^2 \quad (9.31)$$


Examples of the use of the Phillips-Tikhonov regularization method with the discrepancy criterion are shown in Figures 9.6–9.8 (left panels). In Figure 9.6, results of the Hunt simulation problem are shown which are definitely better than those of Figure 9.5 where the regularization parameter  $\gamma$  was chosen empirically. Figures 9.7 and 9.8 are two physiological case studies on insulin and LH oscillations, respectively.




**Figure 9.5** The Hunt simulated problem. Upper panels: Regularized deconvolution vs true input (left, thick vs thin line) obtained with too small a value of the regularization parameter ( $\gamma = 5$ ) from the noisy data (right, open circles). Also shown is reconvolution (right, continuous line). Lower panels: Regularized deconvolution vs true input (left, thick vs thin line) obtained with too large a value of the regularization parameter ( $\gamma = 400$ ) from the noisy data (right, open circles). Also shown is reconvolution (right, continuous line) (adapted from Sparacino *et al.*, 2004).



**Figure 9.6** The Hunt simulated problem. Left panels: Regularized deconvolution vs true input (upper, thick vs thin line) obtained with the value of the regularization parameter determined by the discrepancy criterion ( $\gamma = 105$ ) from the noisy samples (lower, open circles). Also shown is reconvolution (lower, continuous line). Right: Same as left by employing the virtual grid ( $\gamma = 1237455$ ).



**Figure 9.7** Insulin oscillation case study. Left: Regularized deconvolution obtained with a value of the regularization parameter determined by the discrepancy criterion ( $\gamma = 0.0015$ ) from the noisy samples (lower, open circles). Also shown is reconvolution (lower, continuous line). Right: Same as left by employing the virtual grid ( $\gamma = 0.588$ ).



**Figure 9.8** Luteinizing hormone (LH) oscillation case study. Left: Regularized deconvolution obtained with a value of the regularization parameter determined by the discrepancy criterion ( $\gamma = 130$ ) from the noisy samples (bottom, open circles). Also shown is reconvolution (lower panel, continuous line). Right: Same as left by employing the virtual grid ( $\gamma = 776$ ).

### 9.5.3 The Virtual Grid

Physiological signals are often sampled at a low and often non-uniform rate. The regularization method is based on the discrete model, (9.7), which was derived assuming that the unknown input is constant during each sampling interval, no matter how long. In the infrequent sampling case, this results in a poor approximation of the signal. For instance, consider the problem of estimating insulin secretion rate from an intravenous glucose tolerance test (IVGTT). Figure 9.9 (left, upper panel) shows the secretion profile obtained by deconvolution from plasma C-peptide data (left, bottom panel) using the C-peptide impulse response. Due to the infrequent sampling, the staircase approximation is hardly acceptable. The roughness of the staircase approximation can also be appreciated by examining the deconvoluted profiles obtained for the Hunt simulated problem, in both the ideal (Figure 9.2, middle panel, left) and noisy case (Figure 9.2, bottom panel, left and Figure 9.5, left panels).

Such an unsatisfactory performance is due to the fact that the number of components of the unknown vector  $\mathbf{u}$  is assumed to be equal to the number  $N$  of measurements. To remove this assumption, a different discretization grid can be used for the input and the output. Let  $\Omega_S$  be the (experimental) sampling grid and  $\Omega_V = \{T_1, T_2, \dots, T_k, \dots, T_V\}$  a finer ( $V \gg N$ ) grid (possibly uniform) over which the unknown input  $u(t)$  is described as a piecewise constant function.  $\Omega_V$  must contain  $\Omega_S$  but, apart from this, it is arbitrary and has no experimental counterpart. For this reason,  $\Omega_V$  is called a *virtual grid*. Let  $c_V(T_k)$  denote the (noise-free) output at the virtual sampling times  $T_k$ . Assuming that  $u(t)$  is piecewise constant within each time interval of the virtual grid, it follows that:

$$c_V(T_k) = \int_0^{T_k} g(T_k - \tau) u(\tau) d\tau = \sum_{i=1}^k u_i \int_{T_{i-1}}^{T_i} g(T_k - \tau) d\tau \quad (9.32)$$

where  $T_0 = 0$ . Adopting the usual matrix notation one has:

$$c_V = G_V \mathbf{u} \quad (9.33)$$


where  $V$  stands for ‘virtual’,  $c_V$  and  $\mathbf{u}$  are  $V$ -dimensional vectors obtained by sampling  $c(t)$  and  $u(t)$  on the virtual grid, and  $G_V$  is a  $V \times V$  lower-triangular matrix. Times belonging to the virtual grid  $\Omega_V$  have no counterpart in the sampled output data. We can regard them as (virtually) missing data.

Let us denote by  $\mathbf{G}$  the  $N \times V$  matrix obtained by removing from  $G_V$  those rows which do not correspond to sampled output data. The measurement vector is thus:

$$\mathbf{z} = \mathbf{G}\mathbf{u} + \mathbf{v} \quad (9.34)$$

where  $\mathbf{v}$  is the  $N$ -dimensional vector of the measurement error,  $\mathbf{u}$  is the  $V$ -dimensional vector of the input discretized over the virtual grid. If  $\Omega_V$  is uniform (note that a uniform  $\Omega_V$  can always be chosen),  $\mathbf{G}$  has a near-to-Toeplitz structure, meaning that it misses some of the rows of the Toeplitz matrix  $G_V$ .





**Figure 9.9** IVGTT insulin secretion case study. Left: Regularized deconvolution obtained with a value of the regularization parameter determined by the discrepancy criterion ( $\gamma = 0.0012$ ) from the noisy samples (lower panel, open circles). Also shown is reconversion (lower panel, continuous line). Right: Same as left by employing the virtual grid ( $\gamma = 0.25$ ) (adapted from Sparacino *et al.*, 2001).

The estimate  $\hat{\mathbf{u}}$  is given by (9.20), where  $\mathbf{G}$  and  $\mathbf{u}$  are those of (9.34) and  $\mathbf{F}$  has magnitude of  $V \times V$ . In fact, in (9.20) the matrix  $(\mathbf{G}^T \Sigma_V^{-1} \mathbf{G} + \gamma \mathbf{F}^T \mathbf{F})$  is invertible because it is the sum of  $\mathbf{G}^T \Sigma_V^{-1} \mathbf{G}$  (semi-definite positive) and  $\mathbf{F}^T \mathbf{F}$  (positive). Provided that  $\Omega_V$  has a fine time detail (in other words the time points are not widely spaced), this method yields a stepwise estimate that is virtually indistinguishable from a continuous profile.

To clarify the mechanics of the virtual grid rationale an illustrative example can help. Let us consider a non-uniform and infrequent sampling grid (5 samples, time is arbitrary):

$$\underline{1 \quad ? \quad 3 \quad ? \quad ? \quad 6 \quad ? \quad ? \quad ? \quad 10 \quad ? \quad ? \quad ? \quad ? \quad 15}$$

and define a virtual grid as:

$$\underline{1 \quad 2 \quad 3 \quad 4 \quad 5 \quad 6 \quad 7 \quad 8 \quad 9 \quad 10 \quad 11 \quad 12 \quad 13 \quad 14 \quad 15}$$

then one has:

$$\begin{bmatrix} c(1) \\ c(3) \\ c(6) \\ c(10) \\ c(15) \end{bmatrix} = \begin{bmatrix} g_0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 \\ g_2 & g_1 & g_0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 \\ g_5 & g_4 & g_3 & \dots & g_0 & 0 & 0 & 0 & 0 & 0 \\ g_9 & g_8 & g_7 & \dots & \dots & \dots & g_0 & 0 & 0 & 0 \\ g_{14} & g_{13} & g_{12} & \dots & \dots & \dots & \dots & g_1 & g_0 & 0 \end{bmatrix} \begin{bmatrix} u_1 \\ u_2 \\ u_3 \\ u_4 \\ \dots \\ \dots \\ u_{15} \end{bmatrix} \tag{9.35}$$

If all samples of the virtual grid are available, then we have:

$$\begin{bmatrix} c(1) \\ c(2) \\ c(3) \\ c(4) \\ \dots \\ \dots \\ c(14) \\ c(15) \end{bmatrix} = \begin{bmatrix} g_0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 \\ g_1 & g_0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 \\ g_2 & g_1 & g_0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 \\ g_3 & g_2 & g_1 & g_0 & 0 & 0 & 0 & 0 & 0 & 0 \\ \dots & & & \dots & \dots & \dots & & & & \\ \dots & & & & & & & & & \\ g_{13} & g_{12} & \dots & \dots & \dots & \dots & g_1 & g_0 & 0 & 0 \\ g_{14} & g_{13} & g_{12} & \dots & \dots & \dots & \dots & g_1 & g_0 & 0 \end{bmatrix} \begin{bmatrix} u_1 \\ u_2 \\ u_3 \\ u_4 \\ \dots \\ \dots \\ u_{15} \end{bmatrix} \tag{9.36}$$

We can now remove those rows that do not correspond to the sampled output data and have:

$$\begin{bmatrix} c(1) \\ \cancel{c(2)} \\ c(3) \\ c(4) \\ \dots \\ \dots \\ \cancel{c(14)} \\ c(15) \end{bmatrix} = \begin{bmatrix} g_0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 \\ \cancel{g_1} & \cancel{g_0} & \cancel{0} & \cancel{0} & \cancel{0} & \cancel{0} & \cancel{0} & \cancel{0} & \cancel{0} & \cancel{0} \\ g_2 & g_1 & g_0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 \\ g_3 & g_2 & g_1 & g_0 & 0 & 0 & 0 & 0 & 0 & 0 \\ \dots & & & \dots & \dots & \dots & & & & \\ \dots & & & & & & & & & \\ \cancel{g_{13}} & \cancel{g_{12}} & \dots & \dots & \dots & \dots & \cancel{g_1} & \cancel{g_0} & \cancel{0} & \cancel{0} \\ g_{14} & g_{13} & g_{12} & \dots & \dots & \dots & \dots & g_1 & g_0 & 0 \end{bmatrix} \begin{bmatrix} u_1 \\ u_2 \\ u_3 \\ u_4 \\ \dots \\ \dots \\ u_{15} \end{bmatrix} \tag{9.37}$$

and thus:

$$\begin{bmatrix} c(1) \\ c(3) \\ c(6) \\ c(10) \\ c(15) \end{bmatrix} = \begin{bmatrix} g_0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 \\ g_2 & g_1 & g_0 & 0 & 0 & 0 & 0 & 0 & 0 \\ g_5 & g_4 & g_3 & \dots & g_0 & 0 & 0 & 0 & 0 \\ g_9 & g_8 & g_7 & \dots & \dots & \dots & g_0 & 0 & 0 \\ g_{14} & g_{13} & g_{12} & \dots & \dots & \dots & \dots & g_1 & g_0 \end{bmatrix} \begin{bmatrix} u_1 \\ u_2 \\ u_3 \\ u_4 \\ \dots \\ \dots \\ \dots \\ u_{15} \end{bmatrix} \quad (9.38)$$

In matrix notation:

$$\begin{array}{c} \boxed{\mathbf{z}} \\ 5 \times 1 \end{array} = \begin{array}{c} \boxed{\mathbf{G}} \\ 5 \times 15 \end{array} \begin{array}{c} \boxed{\mathbf{u}} \\ 15 \times 1 \end{array} + \begin{array}{c} \boxed{\mathbf{v}} \\ 5 \times 1 \end{array}$$

Results obtained with a one-minute virtual grid and employing the discrepancy criterion are shown in Figures 9.6–9.9 (right panels), where the corresponding, already discussed, estimates obtained with the sampling grid are shown on the left panels. The estimates are able to describe both the true continuous-time input of the Hunt simulated problem (Figure 9.6) and the physiological case studies data (Figures 9.7–9.9) much better than staircase functions.

## 9.6 SUMMARY

In this chapter we have discussed the importance, and also the difficulties, of the deconvolution problem for estimating an unknown input, e.g. the secretion rate of a gland or a substrate production rate of an organ. We have presented in detail a regularization method which can cope with most of the difficulties. However, one can do much better. For instance, as concerns the choice of the regularization parameter, albeit the discrepancy criterion has an intuitive rationale, it has no solid theoretical foundation. In particular, it can be shown to be at risk of oversmoothing, i.e. it provides too high a value of  $\gamma$  (De Nicolao *et al.*, 1997). Another shortcoming is the impossibility, within the deterministic context of the regularization method as presented, of obtaining the confidence intervals of the reconstructed input. This is a very important point, since deconvolution provides an indirect way of measuring a non-accessible variable. Hence, it is important to assess the reliability of such a measurement. In physiological systems analysis, confidence limits are particularly

useful when one has to make inferences, such as choosing a threshold for detecting the number of pulses present in a hormone secretory pulsatile profile or deciding if a secretory profile is a pathological one. Another drawback is that sometimes, albeit the input  $u(t)$  is known to be intrinsically non-negative, e.g. hormone secretion rates and drug absorption rates, due to the measurement errors and impulse response model mismatch, the solution provided may take on negative values.

All of the above aspects can be handled by more sophisticated approaches. For instance, by setting the deconvolution problem within a stochastic embedding (De Nicolao *et al.*, 1997; Sparacino *et al.*, 2001), we can derive a statistically-based choice of the regularization parameter, improving on the discrepancy criterion and putting statistically-based confidence limits on the reconstructed input. Also, non-negativity constraints can be handled by considering constrained deconvolution (De Nicolao *et al.*, 1997; Sparacino *et al.*, 2001; Pillonetto *et al.*, 2002a). Finally, it is worth mentioning that a user-friendly software tool, WINSTODEC (Sparacino *et al.*, 2002) is available, which implements both the deterministic version of the regularization method described in this chapter as well as its stochastic embedding.

## 9.7 EXERCISES AND ASSIGNMENT QUESTIONS

1. Hormonal concentration time series reflect both secretion by the gland and its distribution and metabolism in the body. Discuss why deconvolution is important if the study goal is to reconstruct the secretion rate of the gland.
2. Discuss the difficulties of the deconvolution problem in general and the additional complexity involved when dealing with physiological signals.
3. Least Squares deconvolution generally performs poorly when attempting to reconstruct the unknown input. Discuss why this is the case.
4. Discuss the rationale of the regularization method.
5. The regularization method guarantees a certain degree of smoothness of the reconstructed input. Discuss how this is achieved.

*This page intentionally left blank*

# 10 MODEL VALIDATION

## Chapter Contents

### 10.1 Introduction

### 10.2 Model Validation and the Domain of Validity

10.2.1 Validation During Model Formulation

10.2.2 Validation of the Completed Model

### 10.3 Validation Strategies

10.3.1 Validation of a Single Model – Basic Approach

10.3.2 Validation of a Single Model – Additional Quantitative Tools for Numerically Identified Models

10.3.3 Validation of Competing Models

### 10.4 Good Practice in Good Modeling

### 10.5 Summary

### 10.6 Exercises and Assignment Questions

## 10.1 INTRODUCTION

‘Model validation’ involves assessing the extent to which a model is well-founded and tractable, while fulfilling the purpose for which it was formulated (valid – from the Latin *validus*, ‘strong, vigorous’). This assumes that, in a Popperian\* sense, it can be tested. Clearly, no model can have absolute, unbounded validity given that, by definition, a model is an approximation of reality. When dealing with a set of competing, candidate models, the validation process involves determining which of them is best in relation to its intended purpose. A valid model is one that has successfully passed through the validation process.

The aim of this chapter is to consider the nature of model validity and provide a framework, with associated methods, for the model validation process. First, we consider model validation and the domain of validity of models. This is followed by

---

\* General attitude and practice of critical rationalism – Karl Popper.

an examination of validation strategies; this involves considering both the validation of a single model as well as the situation in which there is a need to choose amongst a number of competing models. The chapter concludes with some thoughts on what constitutes good practice in the overall context of good modeling methodology.

## 10.2 MODEL VALIDATION AND THE DOMAIN OF VALIDITY

Validation is integral to the overall modeling process. It is an activity which needs to be performed both during model building, and upon completion of the model. Let us consider each of these in turn.

### 10.2.1 Validation During Model Formulation

As already explained, model validation involves assessing the model in order to check that it is well-founded and fulfils the purpose for which it was intended. Validation is something that needs to be considered all the way through the modeling process. It begins when specifying the purpose of the modeling activity and continues right on to the completed model as discussed below.

Here we wish to consider the validation process as it should be applied during the formulation of the model. First of all we need to think very carefully about the purpose of the model. This needs to be specified very precisely and clearly. Validation involves assessing the goodness or the worth of the model in relation to its intended purpose. If this purpose has not been clearly defined, then it will not be possible to make the required judgment as to whether the model is fit for its purpose.

The building of a model normally proceeds by postulating a conceptual model and then proceeding to a mathematical realization of this conceptual form. In putting up a conceptual framework, care needs to be taken to ensure that all the relevant physical and chemical concepts are properly described. This is important when it comes to producing the mathematical realization. For example, it might be assumed that the flow of air in a portion of the respiratory system is to be considered, conceptually, as including a turbulent component. This means that the mathematics used to describe that flow must be appropriate as a description of the process of turbulent flow. More generally, the particular mathematical formulation adopted must be consistent with the physics, chemistry and physiology that are relevant to the situation being modeled.


As was discussed in Chapter 5, different degrees of assumption can be built into the model. In reality, most physiological systems exhibit the complexities of nonlinearity, distributed phenomena, stochasticity, etc. Yet, in appropriate circumstances, it may be acceptable (in relation to the intended purpose) to adopt a linear, time-invariant, deterministic, lumped parameter model. Such simplifications imply assumptions being made, and it is essential to be sure that such assumptions are valid. This is a key component of the validation process during the formulation of a model. For example, is an assumption of laminar air flow in the portion of the respiratory system being modeled valid? Is the perturbation being modeled in relation to

an oral glucose tolerance test sufficiently small that it is valid to adopt a linear model of glucose metabolism?

Not only should the mathematical model be consistent with the relevant physical and chemical principles and laws that are being represented, but the model should also be consistent in other ways. It is important to ensure that the proposed set of differential equations, say representing some of the dynamics of lipid metabolism, is compatible with a feasible steady state. To carry out this check, the derivative terms in all the differential equations of the model are set equal to zero. Solving what is now a set of algebraic equations gives the values of all the variables that correspond to that steady state. If the equations had been compiled in an inconsistent manner, it might be found that one or more of the variables had an infinite or zero value in the steady state, clearly providing evidence of model invalidity.

### 10.2.2 Validation of the Completed Model

The essence of the validation process once the model is complete is shown in Figure 10.1. In other words, by this stage all of the previously unknown parameters will have been estimated.



**Figure 10.1** Validating the complete model.

It is important to stress that, in examining the validity of the complete model, the process is dependent on model purpose. In other words, the task is problem-specific. Validity is a multidimensional concept reflecting model purpose, current theories, and experimental data relating to the particular physiological system of interest, together with other relevant knowledge. Thus, as new theories are developed and additional data become available, the requirements for a model to be deemed valid can change although its validity is still assessed in terms of the same criteria.



In general, for a model to be valid it will need to satisfy one or more of the criteria of: empirical, theoretical, pragmatic and heuristic validity.

### **Empirical**

Empirical validity is assessed by examining how well the model corresponds to available data.

### **Theoretical**

Theoretical validity, on the other hand, is concerned with ensuring that the model is consistent with accepted physiological theories.

### **Pragmatic**

Pragmatic validity particularly comes into play in the context of a model that is to be used to support clinical decision making. For instance, consider the case of a model being used to predict the way in which a patient would respond to a change in therapy as evidenced by a change in blood glucose concentration or blood pressure. For the model to be useful, it needs to be able to predict patient response with sufficient accuracy for the predictions to be clinically useful. A model which was sufficiently accurate in its predictions would be deemed to be pragmatically valid.

### **Heuristic**

Heuristic validity is important when a model is to be used to test physiological hypotheses. For instance, if a model is to be used to explore competing hypotheses as to the type of sensors involved in providing information for the short-term regulation of cardiovascular dynamics, the model would include representations of the various types of sensor being considered if it was to be used in such hypothesis testing. So a test of heuristic validity in this connection would be an examination of the inclusion of such sensor representations.

Clearly which of the above validity criteria are relevant in any particular case is dependent on the intended purpose of the modeling. In other words, the issue is very much problem-specific. This again emphasizes the fact that we are dealing in a particular instance with a specific domain of validity. We are seeking a model that is good enough in relation to its domain of validity. However, in some cases a model may be valid for some situations that lie outside the original domain of validity. This adds to the credibility of the model. That means that a model that has a wider domain of validity than a competitor would be regarded as a more credible model, if all other considerations were equal.

## 10.3 VALIDATION STRATEGIES

### 10.3.1 Validation of a Single Model – Basic Approach

The strategy to be adopted in the validation of a single model has as its essence a comparison of the behavior of the model with that of the physiological system being considered. This will involve assessing any mismatch between the system output, as evidenced principally by experimental data, and the model output. In addition, the model should be checked for plausibility of behavior.

Examining system and model responses has two ingredients. The first involves comparison of overall patterns of response. The second focuses on particular features of response.

#### Overall patterns of response

In terms of overall patterns of response, the usual measure is the goodness of fit of the model response to the response of the physiological system as evidenced by the data collected from input/output experiments. So typically we are examining the residual sum of squares,  $SS_R$ , corresponding to the final parameter estimates of the model,  $\mathbf{p}$ . This is the expression, as shown in (10.1) that we wish to make as small as possible, or at least not greater than some agreed threshold value. In other words, we are seeking to ensure that the model response must fit the experimental test data with sufficient accuracy.

$$SS_R = \sum_{i=1}^N \left( \frac{1}{\sigma^2(t_i)} \right) [z(t_i) - y(t_i, \mathbf{p})]^2 \quad (10.1)$$

In (10.1),  $z(t_i)$  is the measured experimental value of the output variable of the physiological system made at time  $t_i$ ,  $\sigma$  is the standard deviation of that measurement,  $y(t_i)$  is the value of the corresponding model output variable for time  $t_i$ , and  $\mathbf{p}$  is the vector of parameter estimates.

#### Features of response

In assessing the validity of a model, it may be useful to examine the occurrence of certain patterns of features to be observed in the dynamic behavior produced by the model. In essence, we are asking the question as to whether or not certain response features which are to be seen in experimental data are reproduced by the model.

In many physiological systems, the normal or abnormal response is characterized by the presence or absence of such features. Therefore, a qualitative assessment of the occurrence or non-occurrence of features can be an important ingredient of the validation process. Such features, which can be said to represent a subset of the information contained in the available data may be simple or complex. Simple features might include the rise or fall of a particular variable following the application of a

particular physiological stimulus. More complex features might include the occurrence and specific timing of a peak value of a variable, a biphasic response pattern, or particular patterns of oscillatory behavior. The model must be capable of reproducing such qualitative features if it is to be deemed valid.

As well as undertaking such a qualitative analysis, it may be useful to quantify the occurrence of such distinctive features. Typically this will involve setting up an appropriate measure of ‘distance’ between the features as predicted by the model and those exhibited in available experimental test data. The setting up of such quantitative measures of features such as ‘distance’ can be regarded as a form of error function that should be reduced to an adequate level if a model is to be valid.

For instance, suppose  $\mathbf{x}_D$  is a vector of quantitative features in the data and  $\mathbf{x}_M$  is the vector of the corresponding model features. The distance between  $\mathbf{x}_M$  and  $\mathbf{x}_D$  in feature space can be used to provide a measure of the error of fit between model and data. Let us define a ‘figure of merit’ or measure of model adequacy  $F$  in terms of the error between the data features  $x_D(k)$  and the model features  $x_M(k)$ ,  $k = 1, \dots, N$ :

$$F = \frac{1}{\left(1 + \left(\frac{1}{N}\right) \sum_{k=1}^N \omega_k \delta_k\right)}, \quad F \in [0, 1] \quad (10.2)$$

where:

$$\delta_k = \left| \frac{(x_M(k) - x_D(k))}{x_D(k)} \right| \quad (10.3)$$

and  $\omega_k$  are weighting factors ( $\omega_k \in [0, 1]$ ).  $\delta_k$  is the fractional error of the  $k$ th model feature. If there is no error,  $F = 1$ , whereas an average error of  $\pm 50\%$  between model and data gives  $F = 0.67$ .

A figure of merit such as this thus provides an indicator of how closely important features of dynamic response in the physiological system are mimicked by those in the model. As well as being a useful tool in the validation of a single model, this measure can also be very helpful when deciding between two or more competing models as discussed below. An assessment of such quantitative measures of features may equally enable deficiencies in the individual model to be revealed, requiring a return to model formulation.

### 10.3.2 Validation of a Single Model – Additional Quantitative Tools for Numerically Identified Models

In the case of validating a complete, single model, a number of other quantitative tools are available. Let us consider the case where parameters have been estimated using the methods that were described in Chapter 8. These tools enable us to investigate the precision of the estimated parameters, the residuals of the mismatch between model and data, and the plausibility of the parameter estimates for the situation in which the parameters should have some explicit correspondence to physiological concepts.

### Parameter precision

An important test of model validity involves assessing the precision of the parameters that have been estimated. In general terms, this can be achieved by determining the covariance matrix of the parameter estimates,  $V(\hat{\mathbf{p}})$ . In the case of nonlinear least squares estimation as considered in Chapter 8, the diagonal elements  $v_{ii}(\hat{\mathbf{p}})$  of  $V(\hat{\mathbf{p}})$ , provide the variances of the parameter estimates. Hence, the precision with which the parameter  $p_i$  can be estimated may be expressed in terms of the standard deviation by:

$$\hat{p}_i \pm \sqrt{v_{ii}(\hat{\mathbf{p}})} \quad (10.4)$$

Very often in judging parameter precision (*a posteriori* identifiability) a percentage measure is employed. This is the coefficient of variation (CV) or fractional standard deviation (FSD):

$$CV(\hat{p}_i) = \text{FSD}(\hat{p}_i) = \left( \frac{\sqrt{v_{ii}(\hat{\mathbf{p}})}}{\hat{p}_i} \right) \times 100 \quad (10.5)$$

### Residuals of the mismatch between model and data

As indicated above, for the model to be deemed valid, there must be an adequately good fit of the model to the data that will have been assessed through the residual sum of squares. Following on from this should be an investigation of the statistics of the residual errors of this fitting process.

For example, it may have been assumed *a priori* that the measurement noise is white, Gaussian and of zero mean. The residual errors of the fitting process must thus be examined for bias, normality and whiteness, wherever possible using appropriate statistical tests. For instance, whiteness can be examined by the use of correlation techniques and normality by the application of a  $\chi^2$  test. If, however, the data are small in number, empirical visual methods may need to be adopted in examining the residuals. This would typically involve plotting them against time in order to detect possible inconsistencies; for example, outliers or systematic deviations between experimental data and predicted model response.

### Parameter plausibility

After assessing these other quantitative methods, we can finally turn to examining the plausibility of the parameters in particular, as well as the plausibility of the model overall. If the estimated parameters of a model correspond to some specific physical or physiological properties, then those parameter estimates must accord with the known values of such properties. In other words, if estimated parameters of a model take on values that are absurd (e.g. fractional transfer rate constants in a metabolic system or compliance of a blood vessel in the circulatory system lying outside the physiologically feasible range), the model must be deemed invalid and is rejected.

In the case of a model that is identifiable, but not uniquely so (i.e. there are two possible values for one or more of the parameters), this criterion may enable one to be selected on the grounds that it is plausible whereas the other one is not.

In addition to the specific issues of parameter plausibility just examined, other features of model plausibility may be used in assessing validity. For instance, wherever possible, the validity of the model should be tested against data independent of those used in the fitting process, but obtained from other tests that are nevertheless within the chosen domain of validity. For example, in the context of a metabolic system, the model may enable values to be estimated for parameters such as volume of distribution and clearance rate; parameters not directly estimated in the identification process. The values estimated for such parameters from the model should then be compared with the corresponding parameter values obtained from independent experiments. Such parameters can be used in assessing the validity of the model under consideration.

In addition to the criteria already cited, wherever possible the validity of the model should be tested against data independent of those used in the fitting process, but obtained from other tests that are nevertheless within the chosen domain of validity. For example, a model of a metabolic system may enable values to be estimated for parameters such as volume of distribution and clearance rate: parameters not directly estimated in the identification process. The values estimated for such parameters should then be compared with the corresponding parameter values obtained from independent experiments. Such parameters can be used in assessing the validity of the individual model. Another useful test is to examine the prediction provided by the model of variables other than those measured in the available input/output identification experiments. Again, such predictions may support or refute a specific model.

Finally, there is the need to consider the extent to which the model is compatible with current physiological knowledge.

### 10.3.3 Validation of Competing Models

#### Goodness of fit

If there is a set of two or more candidate models, comparisons between them of their ability to fit the available data as one measure of model validity should be made. In this way the best model, in terms of goodness of fit, may be selected. However, the improvement in predictability of the data by one model over a competing model should not be obtained purely as a result of an increase in the number of parameters. It must truly reflect a more accurate representation of data corrected for the increase in the degrees of freedom in fitting. This is sometimes referred to as the *principle of parsimony*.

In the case of linear dynamic models, the Akaike information criterion takes into account both goodness of fit and number of parameters when comparing models (Akaike, 1974). This criterion, AIC, is given by:

$$\text{AIC} = N \ln \text{SS}_R + 2P \quad (10.6)$$

where  $N$  is the number of data points,  $P$  is the number of parameters, and  $\text{SS}_R$  is the residual sum of squares defined in (10.1) as:

$$\text{SS}_R = \sum_{i=1}^N \left( \frac{1}{\sigma^2(t_i)} \right) [z(t_i) - y(t_i, \mathbf{p})]^2 \quad (10.7)$$

### Features of response

The role of feature comparison has already been discussed above in the context of a single model. However, this aspect of testing for model validity can also play an important role in the situation in which a choice amongst two or more competing models is sought. The figure of merit,  $F$ , such as that defined in (10.2), can be very useful as an objective measure for deciding among competing models, enabling one or more to be rejected without having to proceed further in the validation process.

### Model plausibility

The considerations of plausibility, described above in relation to a single model, are equally applicable when choosing the best out of a number of candidate models. Examination of the plausibility of the parameter estimates achieved should help when choosing the most appropriate model.

Having examined the plausibility of the parameters of the competing models, other aspects of plausibility should be investigated, as for the case above when considering the validity of just a single model. So again this involves exploring the plausibility of other features such as structure, parameters and behavior, as well as overall physiological plausibility compatible with current physiological knowledge.

## 10.4 GOOD PRACTICE IN GOOD MODELING


Let us conclude this chapter by offering a few remarks that should be helpful in ensuring good practice. First of all, remain critical of your model. Do not love it too much! Remember that, by definition, a model is an approximation of reality. As such, it cannot be perfect. So always be prepared to take account of new facts and observations with a view to including them in your model.

A good model, in a Popperian sense, is one that is clearly falsifiable and therefore is capable of bringing about its own downfall. In other words, it should be possible to devise critical experiments to perform on the model which will provide a rigorous test of its validity and provide clues as to where improvement is needed.

It should also be remembered that in situations of complexity, it might be appropriate to think in terms of a suite of models, where each would have its own distinct domain of validity. It is then a case of choosing which is most appropriate for the specific context. This may reflect the particular level in the physiological hierarchy that is being represented and the time scale of interest in relation to dynamic response, for instance short-term or long-term. For example, the model chosen to examine breath-by-breath control in the human respiratory system is likely to be significantly different, both in terms of structure and parameters, from that needed to investigate day-by-day changes in the asthmatic patient.

In summary, we have examined what is required in order to produce a model that can be deemed to be valid. This requires the adoption of good modeling methodology, with its ingredients that have been discussed in detail in this book. What should

be clear, as captured in Figure 10.2, is that a successful outcome to the modeling process is critically dependent on both the quality of the model and the quality of the experimental data. Neither by itself is sufficient. We hope that by explaining good methodology, and demonstrating its application in a variety of physiological settings, we have given you the confidence to embark on this fascinating and important arena of scientific endeavor.



**Figure 10.2** The garbage paradigm.

Now that we have established a framework for considering the validity of one or more models, the final chapter will look at a number of case studies to demonstrate how these methods and techniques can be applied in practice.

## 10.5 SUMMARY

This chapter has provided an overview of the process of model validation. It has been shown to be a process that pervades the whole modeling process, from initial thinking about model purpose through to consideration of the worth or value of the completed model. Strategies for validation have been outlined, both for the case of a single model and also for the situation in which one is seeking to judge between competing models. Suggestions have also been offered as to what constitutes good modeling practice. The final chapter of the book will put these concepts and methods into practice, offering a number of detailed case studies of model validation in action.

## 10.6 EXERCISES AND ASSIGNMENT QUESTIONS

1. Describe how the process of model validation is influenced by the purpose for which a physiological model is intended.

- 2.** Discuss how issues of validation need to be considered during the process of formulating a mathematical model of a physiological system.
- 3.** Give an account of the criteria that can be used to assess the validity of a single model, where the model might be developed for use in the context of (a) physiological research, or (b) clinical decision support.
- 4.** Two competing models have been developed as possible representations of the dynamic processes with a particular area of human metabolism. Indicate ways by means of which it might be possible to judge which model is the more appropriate.



*This page intentionally left blank*

# 11 CASE STUDIES

## Chapter Contents

- 11.1 Case Study 1: A Sum of Exponentials Tracer Disappearance Model**
- 11.2 Case Study 2: Blood Flow Modeling**
- 11.3 Case Study 3: Cerebral Glucose Modeling**
- 11.4 Case Study 4: Models of the Ligand-Receptor System**
- 11.5 Case Study 5: A Simulation Model of the Glucose-Insulin System**
  - 11.5.1 Model Formulation
  - 11.5.2 Results
- 11.6 Case Study 6: A Model of Insulin Control**
- 11.7 Case Study 7: Illustrations of Bayesian Estimation**
- 11.8 Postscript**

The previous chapters have outlined concepts, methods and techniques relevant to the development of mathematical models of physiological systems. This final chapter now presents a number of case studies which will demonstrate how such approaches have been applied in tackling a number of real physiological and medical situations. Taken together, these case studies cover the application of a wide range of modeling methods and techniques.

## 11.1 CASE STUDY 1: A SUM OF EXPONENTIALS TRACER DISAPPEARANCE MODEL

As a first case study let us consider a set of data that have been collected during a tracer experiment. These data represent the time course of radioactive glucose tracer concentration following an injection of tracer at time zero. The data, which were collected from a normal subject, are depicted in Table 11.1 where the plasma measurements are dpm/ml and the measurement times are minutes following the injection.

**Table 11.1** Plasma data from a tracer experiment (adapted from Cobelli *et al.*, 2000)

Time	Plasma	Time	Plasma		
2	3993.50	99.87	28	2252.00	65.04
4	3316.50	86.33	31	2169.50	63.39
5	3409.50	88.19	34	2128.50	62.57
6	3177.50	83.55	37	2085.00	61.70
7	3218.50	84.37	40	2004.00	60.08
8	3145.00	82.90	50	1879.00	57.58
9	3105.00	82.10	60	1670.00	53.40
10	3117.00	82.34	70	1416.50	48.33
11	2984.50	79.69	80	1333.50	46.67
13	2890.00	77.80	90	1152.00	43.04
14	2692.00	73.84	100	1080.50	41.61
15	2603.00	72.06	110	1043.00	40.86
17	2533.50	70.67	120	883.50	37.67
19	2536.00	70.72	130	832.50	36.65
21	2545.50	70.91	140	776.00	35.52
23	2374.00	67.48	150	707.00	34.14
25	2379.00	67.58			

From a modeling perspective, our aim is to fit these data to a set of exponential terms. The number of exponentials required to fit the data would give us a clue as to how many compartments would be needed should we wish to model our physiological system explicitly in terms of a number of interconnected compartments.

In order to select the order of the multiexponential model which is best able to describe these data, one, two and three-exponential models can be considered as represented by equations (11.1)–(11.3):

$$y(t) = A_1 e^{-\alpha_1 \cdot t} \quad (11.1)$$

$$y(t) = A_1 e^{-\alpha_1 \cdot t} + A_2 e^{-\alpha_2 \cdot t} \quad (11.2)$$

$$y(t) = A_1 e^{-\alpha_1 \cdot t} + A_2 e^{-\alpha_2 \cdot t} + A_3 e^{-\alpha_3 \cdot t} \quad (11.3)$$


It is assumed that the measurement error is additive:

$$z_i = y_i + v_i \quad (11.4)$$

where the errors  $v_i$  are assumed to be independent, Gaussian with a mean of zero, and having an experimentally-determined standard deviation of:

$$SD(v_i) = 0.02 \cdot z_i + 20 \quad (11.5)$$

These values are shown associated with each datum in Table 11.1. The three models are to be fitted to the data by applying weighted nonlinear regression, as discussed in Chapter 8, with the weights chosen equal to the inverse of the variance. The plots of the data and the model predictions, together with the corresponding weighted residuals, are shown in Figure 11.1. The model parameters, that is to say the coefficients of



**Figure 11.1** The best fit of the data given in Table 11.1 to a single, a two and three-exponential models, together with a plot of the weighted residuals for each case. The exponential coefficients and rate constants (eigen values) for each model are given in Table 11.2.

**Table 11.2** One, two, three-exponential model parameter estimates (see text for explanation)

	One exponential	Two exponentials	Three exponentials
$A_1$	3288 (1%)	1202 (10%)	724866 (535789%)
$\alpha_1$	0.0111 (1%)	0.1383 (17%)	4.5540 (7131%)
$A_2$		2950 (2%)	1195 (14%)
$\alpha_2$		0.0098 (3%)	0.1290 (14%)
$A_3$			2925 (2%)
$\alpha_3$			0.0097 (3%)
AIC	171.10	40.98	
SC	174.09	46.97	

the exponential terms and their corresponding rate constants (eigenvalues), are given in Table 11.2.

On examination of the parameter values presented in Table 11.2, it can be observed that all those corresponding to the one and two-exponential models can be estimated with acceptable precision. However, some of the parameters of the three-exponential model are very uncertain. This means that the three-exponential model cannot be resolved with precision from the data.

This arises from the fact that the first exponential is so rapid,  $\alpha_1 = 4.6 \text{ min}^{-1}$ , that it has practically vanished by the time of the first available datum at 2 minutes. The other two exponential terms have values similar to those obtained for the two-exponential model. In addition, the final estimates of  $A_1$  and  $\alpha_1$  are also dependent upon the initial estimates; that is, starting from different initial points in parameter space, the nonlinear regression procedure yields different final estimates while producing similar values of the weighted residual sum of squares (WRSS). Therefore, the three-exponential model is not numerically identifiable, and hence can be rejected at this stage.


The next step is to compare the fit of the one and two-exponential models. It can be seen by inspection that the residuals of the one-exponential model are not random because the plot reveals long runs of consecutive residuals of the same sign. This can also be tested more formally using the statistical runs test. For details, see Cobelli *et al.* (2000).

Most residuals for the two-exponential model lie between  $-1$  and  $1$ . This indicates that they are compatible with the assumptions made regarding the variance of the measurement error. On the other hand, only a few of the residuals of the one-exponential model fall in this range. To test formally if the weighted residuals have unit variance, as expected if the model and/or assumptions on the variance of the measurement error are correct, the  $X^2$ -test can be applied. Again, details can be found in Cobelli *et al.* (2000).

Applying the Akaike criterion (AIC) and the Schwarz criterion (SC) (refer to (8.115) and (8.116)), Table 11.2 shows that the two-exponential model reduces the WRSS significantly when compared with the one-exponential model. Applying an F test reveals similar results (see Cobelli *et al.*, 2000).

## 11.2 CASE STUDY 2: BLOOD FLOW MODELING

This next case study demonstrates how the classic model of Kety and Schmidt (1948) can be used to measure blood flow, making use of experimental data obtained from Positron Emission Tomography (PET) functional imaging. These data are measures of radioactivity concentration in the blood over time following injection of an appropriate radioactive tracer substance. The basic model used is shown in Figure 11.2.



**Figure 11.2** Blood flow model incorporating a single-tissue compartment.

The model equation is:

$$\frac{dC_t(t)}{dt} = K_1 C_p(t) - k_2 C_t(t) \quad C_t(0) = 0 \quad (11.6)$$

where  $C_t$  is the tracer concentration in tissue, and  $C_p$  is the tracer concentration in arterial plasma.  $K_1$  and  $k_2$  (adopting the nomenclature used in PET modeling) are two first-order kinetic rate constants. The tracer concentrations are often measured in units of  $\mu\text{Ci/ml}$  or in  $\text{kBq/ml}$  and the acquisition time in minutes. Consequently,  $K_1$  has units of  $\text{ml}_{\text{plasma}}/\text{ml}_{\text{tissue}}/\text{min}$  or, in abbreviated form,  $\text{ml/ml/min}$  or  $\text{ml}/100 \text{ g/min}$  and  $k_2$  has units of  $\text{min}^{-1}$ .

At any time following the introduction of the PET tracer, the total concentration of radioactivity measured by a PET scanner,  $C(t)$ , is the sum of the tissue activity in a region of interest (ROI), or in a voxel, and a certain fraction of blood tracer concentration:

$$C(t) = (1 - V_b) \cdot C_t(t) + V_b \cdot C_b(t) \quad (11.7)$$

where  $V_b$  is the fraction of the measured volume occupied by blood and  $C_b$  the tracer concentration in the whole blood. The three model parameters are *a priori* uniquely identifiable and can be estimated by weighted nonlinear least squares.

In PET neuroimaging, because blood volumes in the human brain are small, typically constituting only 5% of the total blood volume, the blood volume term is often omitted. Adopting this simplified model structure, together with experimental data obtained following the injection of freely diffusible [ $^{15}\text{O}$ ]H $_2\text{O}$  PET tracer, blood flow can be quantified making use of the assumptions:

$$K_1 = F \quad (11.8)$$

$$k_2 = \frac{F}{\lambda} \quad (11.9)$$

where  $F$  is the rate of blood flow per unit mass of tissue and  $\lambda$  is the tissue–blood partition coefficient. The partition coefficient was originally defined as the ratio of the tissue to venous blood concentration. In PET studies the partition coefficient refers to the concentration ratio between a tissue compartment and arterial plasma at equilibrium, i.e.  $\lambda = C_t/C_p|_{\text{equilibrium}} = K_1/k_2$  which is more correctly termed volume of distribution, generally represented by  $V_d$ . However, traditionally in [ $^{15}\text{O}$ ]H $_2\text{O}$  PET quantification, the ratio  $\lambda = K_1/k_2$  is named partition coefficient.


### 11.3 CASE STUDY 3: CEREBRAL GLUCOSE MODELING

Experimental data obtained by PET functional imaging can also be used in order to study glucose metabolism in the brain. In this case a two-compartment model is adopted as shown in Figure 11.3.

This two-compartment model proposed by Sokoloff and colleagues (1977) was originally developed for autoradiographic studies in the brain, but has subsequently been used for PET studies of glucose utilization with [ $^{18}\text{F}$ ]fluorodeoxyglucose, [ $^{18}\text{F}$ ]FDG. [ $^{18}\text{F}$ ]FDG is an analog of glucose that crosses the blood–brain barrier by a saturable carrier-mediated transport process and competes with glucose for the same carrier. Once in the tissue, [ $^{18}\text{F}$ ]FDG, like the glucose, can either be transported back to plasma or can be phosphorylated. In the model,  $C_p$  is [ $^{18}\text{F}$ ]FDG plasma arterial concentration,  $C_e$  is [ $^{18}\text{F}$ ]FDG cerebral tissue concentration, and  $C_m$  is [ $^{18}\text{F}$ ]FDG-6-P cerebral concentration in tissue.  $K_1$  [ml/100 g/min or ml/ml/min] and  $k_2$  ( $\text{min}^{-1}$ ) are the rate constants of [ $^{18}\text{F}$ ]FDG forward and reverse transcapillary membrane transport, respectively, and  $k_3$  ( $\text{min}^{-1}$ ) is the rate constant of [ $^{18}\text{F}$ ]FDG phosphorylation.

The model equations are:

$$\frac{dC_e(t)}{dt} = K_1 C_p(t) - (k_2 + k_3) C_e(t) \quad C_e(0) = 0 \quad (11.10)$$



**Figure 11.3** Cerebral [ $^{18}\text{F}$ ]FDG model incorporating two-tissue compartments.

and

$$\frac{dC_m(t)}{dt} = k_3 C_m(t) \quad C_m(0) = 0 \quad (11.11)$$

The total concentration of radioactivity measured by a PET scanner,  $C(t)$ , is the sum of the tissue activity in a ROI, or in a voxel, and a certain fraction of blood tracer concentration:

$$C(t) = (1 - V_b) \cdot (C_e(t) + C_m(t)) + V_b \cdot C_b(t) \quad (11.12)$$

where  $V_b$  is the fraction of the measured volume occupied by blood, and  $C_b$  is the tracer concentration in whole blood. All four parameters,  $[K_1, k_2, k_3, V_b]$  are *a priori* uniquely identifiable. It should be noted that the model parameters reflect [ $^{18}\text{F}$ ]FDG kinetics and not those of glucose. However, from [ $^{18}\text{F}$ ]FDG parameter estimates it is possible to also derive the cerebral metabolic rate of glucose utilization,  $\text{CMR}_{\text{glu}}$  from:

$$\text{CMR}_{\text{glu}} = \frac{K_1 k_3}{k_2 + k_3} \frac{C_p^{\text{glu}}}{\text{LC}} \quad (11.13)$$

where  $C_p^{\text{glu}}$  is the arterial plasma glucose concentration (mg/dl). LC is a lumped constant (unitless) that describes the relationship between the glucose analog [ $^{18}\text{F}$ ]FDG and glucose itself. LC is given by:

$$\text{LC} = \frac{E^{\text{FDG}}}{E^{\text{GLU}}} \quad (11.14)$$




where  $E^{FDG}$  and  $E^{GLU}$  are, respectively, the extraction of [ $^{18}F$ ]FDG and glucose. The value of LC for the human brain under normal physiological conditions is in the region of 0.85 (Graham *et al.*, 2002). From the model parameter estimates obtained, it is also possible to derive the distribution volume for the  $C_e$  compartment as:

$$V_d = \frac{K_1}{k_2 + k_3} \left( \frac{\text{ml}}{100 \text{ g}} \right) \text{ or } \left( \frac{\text{ml}}{\text{ml}} \right) \quad (11.15)$$

## 11.4 CASE STUDY 4: MODELS OF THE LIGAND-RECEPTOR SYSTEM

Advances in PET imaging also make it possible to study receptor density and radioligand affinity in the brain and in the myocardium. Quantification of the ligand-receptor system is of fundamental importance not only in understanding how the brain works, e.g. how it performs the various commands and reacts to stimuli, but also in the investigation of the pathogenesis of important diseases such as Alzheimer's and Parkinson's. In recent years PET has become an increasingly used tool to quantify important parameters such as the receptor density and the binding affinity of radioligands. A number of models have been proposed for specific ligand-receptor interactions, including those of Mintun *et al.* (1984) which will be discussed below.

The most widely adopted model in this context is one that incorporates two tissue compartments as shown in Figure 11.4.




**Figure 11.4** Model incorporating two tissue compartments.

In this model  $C_p$  is the plasma arterial plasma concentration corrected for metabolites,  $C_{f+ns}$  is the free and the non-specifically bound tissue concentration of the PET

ligand, and  $C_s$  is the tissue concentration of specifically bound ligand. The parameters  $K_1$  ( $\text{ml ml}^{-1}\text{min}^{-1}$ ) and  $k_2$  ( $\text{min}^{-1}$ ) represent rate constants for the ligand transfer from plasma to tissue and vice-versa, while  $k_3$  ( $\text{min}^{-1}$ ) represents the transfer of tracer to the specifically bound compartment and  $k_4$  ( $\text{min}^{-1}$ ) relates to the return from the specifically bound compartment to the free and non-specifically bound compartment.

Whilst the two-tissue compartment model is the one that is most widely employed, it is in fact a simplification of the true tissue distribution space which should be more realistically represented by three compartments. This structure is depicted in Figure 11.5.



**Figure 11.5** Model incorporating three-tissue compartments.

In this model,  $C_p$  is the arterial plasma concentration corrected for metabolites,  $C_f$  is the concentration of free ligand,  $C_{ns}$  is the concentration of non-specifically bound ligand, and  $C_s$  is the concentration of specifically bound ligand. The model equations are thus:

$$\frac{C_f(t)}{dt} = K_1 C_p(t) - (k_2 + k_3 + k_5)C_f(t) + k_4 C_s(t) + k_6 C_{ns}(t) \quad (11.16)$$

$$\frac{C_s(t)}{dt} = k_3 C_f(t) - k_4 C_s(t) \quad (11.17)$$

$$\frac{C_{ns}(t)}{dt} = k_5 C_f(t) - k_6 C_{ns}(t) \quad (11.18)$$

with initial conditions  $C_f(0) = C_s(0) = C_{ns}(0) = 0$ .  $K_1$  ( $\text{ml/ml/min}$ ) is the rate constant for the transfer from plasma to the free ligand tissue compartment, and  $k_2$ ,  $k_3$ ,  $k_4$ ,

$k_5, k_6$  ( $\text{min}^{-1}$ ) are the rate constants for ligand transfer from tissue to plasma and within the tissue space.

In order to have a better understanding of the physiological meaning of parameters  $k_3$  and  $k_4$ , let us assume that the binding of the ligand to the receptor site can be described by a bimolecular reaction:



where L represents the ligand, R the receptor site, LR the binding product,  $k_{\text{on}}$  is the association rate of the ligand with the receptor sites, and  $k_{\text{off}}$  the dissociation rate of the specifically bound reaction product. In terms of the notation of Figure 11.5,  $C_f$  and  $C_s$  represent L and LR, respectively, hence:

$$\frac{dC_s(t)}{dt} = k_{\text{on}}C_f(t)C_r(t) - k_{\text{off}}C_s(t) \quad (11.20)$$

where  $C_r$  denotes the concentration of receptors. If  $B_{\text{max}}$  is the total number of available reactions sites, then:

$$B_{\text{max}} = C_s + C_r \quad (11.21)$$

and, if the ligand is present in tracer concentration, then the concentration  $C_s$  is negligible and thus:

$$B_{\text{max}} \approx C_r \quad (11.22)$$

Hence (11.20) becomes:

$$\frac{dC_s(t)}{dt} = k_{\text{on}}B_{\text{max}}C_f(t) - k_{\text{off}}C_s(t) = k_3C_f(t) - k_4C_s(t) \quad (11.23)$$

with  $k_3 = k_{\text{on}}B_{\text{max}}$  and  $k_4 = k_{\text{off}}$ .

Another important parameter is the equilibrium binding constant  $K_d$  which is defined with the ligand-receptor reaction in steady state as:

$$K_d = \frac{C_s}{C_r C_f} = \frac{k_{\text{on}}}{k_{\text{off}}} \quad (11.24)$$

The PET measurement is the result of the tracer present in the tissue and of that present in the blood of the ROI. Consequently the measurement equation for the three-tissue compartment model is:

$$C(t) = (1 - V_b)(C_f(t) + C_{\text{ns}}(t) + C_s(t)) + V_b C_b(t) \quad (11.25)$$

where  $C_b$  is whole blood tracer concentration including metabolites and  $V_b$  is the fraction of the measured volume occupied by blood. However, the three-tissue model

is *a priori* only nonuniquely identifiable, allowing two solutions for each parameter. To ensure unique identifiability, it is usually assumed that the exchange rates between the free tissue and nonspecific binding pools are sufficiently rapid (compared with the other rates of the model) so that the three-tissue compartment model reduces to the two-tissue model, where  $C_{f+ns}(t) = C_f(t) + C_{ns}(t)$  is the free and nonspecific binding tracer concentration. It is for this reason that the two-tissue compartment model is the most widely adopted in studies designed to quantify receptor binding. The model equations for the two-tissue compartment model are:

$$\begin{aligned} \frac{C_{f+ns}(t)}{dt} &= k_1 C_p(t) - (k_2 + k_3) C_{f+ns}(t) + k_4 C_s(t) \\ \frac{C_s(t)}{dt} &= k_3 C_{f+ns}(t) - k_4 C_s(t) \end{aligned} \quad (11.26)-(11.27)$$

with initial conditions  $C_{f+ns}(0) = C_s(0) = 0$  and with:

$$k_3 = k_{on} B_{max} f \quad (11.28)$$

where  $f$  is given by:

$$f \equiv \frac{C_f}{C_{f+ns}} = \frac{C_f}{C_f + C_{ns}} = \frac{C_f}{C_f \left(1 + \frac{C_{ns}}{C_f}\right)} = \frac{1}{1 + \frac{k_5}{k_6}} \quad (11.29)$$

The measurement equation thus becomes:

$$C(t) = (1 - V_b)(C_{f+ns}(t) + C_s(t)) + V_b C_b(t) \quad (11.30)$$

The model is now *a priori* uniquely identifiable. Moreover, in addition to  $k_1, k_2, k_3, k_4, V_b$  it is also possible to estimate the binding potential, BP:

$$BP = f \cdot \frac{B_{max}}{K_d} = \frac{k_3}{k_4} \quad (11.31)$$

and the distribution volumes:

$$V_{d-C_{f+ns}} = \left. \frac{C_{f+ns}}{C_p} \right|_{equilibrium} = \frac{K_1}{k_2} \quad (11.32)$$

$$V_{d-C_s} = \left. \frac{C_s}{C_p} \right|_{equilibrium} = \frac{K_1 k_3}{k_2 k_4} \quad (11.33)$$

$$V_d = \left. \frac{C_s + C_{f+ns}}{C_p} \right|_{equilibrium} = \frac{K_1}{k_2} + \frac{K_1 k_3}{k_2 k_4} = \frac{K_1}{k_2} \left(1 + \frac{k_3}{k_4}\right) \quad (11.34)$$

## 11.5 CASE STUDY 5: A SIMULATION MODEL OF THE GLUCOSE-INSULIN SYSTEM

This case study describes a model of the glucose-insulin control system that is to be used to examine dynamic effects both during meals and in normal daily life. Such a model is useful for testing glucose sensors, algorithms for the infusion of insulin and, more generally, decision support systems for diabetes. This simulation model enables computer-based experiments to be performed which would be too difficult, too dangerous or unethical to perform in real life.

One of the key factors for success in any modeling study is the availability of experimental data. In this case data were available from 204 normal subjects who received a triple tracer, mixed meal. The resultant data allowed estimates to be made for a number of glucose and insulin fluxes as well as measures of glucose and insulin concentration. Figure 11.6 depicts the mean  $\pm 1$  SD values over a time course of seven hours.

### 11.5.1 Model Formulation


The basic structure of the glucose-insulin control system is shown in Figure 11.7. This depicts the uptake of the ingested glucose via the gastro-intestinal tract, the distribution of glucose in the liver and in muscle and adipose tissue, together with the various regulating mechanisms. However, on the basis of experimental data that are limited to measures of glucose and insulin concentrations, it would not be possible to identify the parameters of a mathematical model that encompassed the full complexity of the system as shown. For instance, a good model representation of the plasma glucose and insulin concentrations would be compatible with a wide range of descriptions of endogenous glucose production by the liver, its rate of appearance in the plasma from the gut and its rate of utilization.

Fortunately, an approach can be adopted which is based on developing structural models corresponding to each unit process. Reliable parametric models can be formulated in this way. For example, in order to model the rate of glucose utilization, we can make use of our knowledge of endogenous glucose production, glucose rate of appearance and insulin concentration as known inputs, and as model outputs glucose utilization and plasma glucose concentration.

#### Glucose subsystem

The two-compartment model used to describe glucose kinetics is shown in the upper panel of Figure 11.8 (Vicini *et al.*, 1997). The model equations are:

$$\begin{cases} \dot{G}_p(t) = EGP(t) + Ra(t) - U_{ii}(t) - E(t) \\ \quad - k_1 \cdot G_p(t) + k_2 \cdot G_t(t) & G_p(0) = G_{pb} & (11.35) \\ \dot{G}_t(t) = -U_{id}(t) + k_1 \cdot G_p(t) - k_2 \cdot G_t(t) & G_t(0) = G_{tb} & (11.36) \\ G(t) = \frac{G_p}{V_G} & G(0) = G_b & (11.37) \end{cases}$$




**Figure 11.6** Glucose and insulin database corresponding to 204 normal subjects (adapted from Dalla Man *et al.*, 2006).

where  $G_p$  and  $G_t$  (mg/kg) are glucose masses in plasma and rapidly-equilibrating tissues, and in slowly-equilibrating tissues, respectively,  $G$  (mg/dl) plasma glucose concentration, with the suffix  $b$  denoting the basal state. EGP is the endogenous glucose production (mg/kg/min),  $R_a$  is the glucose rate of appearance in plasma (mg/kg/min),  $E$  is renal excretion (mg/kg/min), and  $U_{ii}$  and  $U_{id}$  are the insulin-independent and dependent glucose utilizations, respectively (mg/kg/min).  $V_G$  is the distribution volume of glucose (dl/kg), and  $k_1$  and  $k_2$  ( $\text{min}^{-1}$ ) are rate parameters.

In the basal steady-state endogenous production,  $EGP_b$ , equals glucose disappearance, i.e. the sum of glucose utilization and renal excretion (which is zero in the normal subject),  $U_b + E_b$ .

$$EGP_b = U_b + E_b \quad (11.38)$$



**Figure 11.7** Basic structure of the glucose-insulin control system.


Parameter values of  $V_G$ ,  $k_1$ ,  $k_2$  are reported in Table 11.3 (Glucose Kinetics) for both the normal and the type 2 diabetic subject.

### Insulin subsystem

The lower panel of Figure 11.8 depicts the two-compartment model used to describe insulin kinetics (Ferrannini and Cobelli, 1987). The model equations are:

$$\begin{cases} \dot{I}_l(t) = -(m_1 + m_3(t)) \cdot I_l(t) + m_2 I_p(t) + S(t) & I_l(0) = I_{lb} & (11.39) \\ \dot{I}_p(t) = -(m_2 + m_4) \cdot I_p(t) + m_1 \cdot I_l(t) & I_p(0) = I_{pb} & (11.40) \\ I(t) = \frac{I_p}{V_I} & I(0) = I_b & (11.41) \end{cases}$$

where  $I_p$  and  $I_l$  (pmol/kg) are insulin masses in plasma and in liver respectively,  $I$  (pmol/l) is plasma insulin concentration, with the suffix b denoting basal state.  $S$  is insulin secretion (pmol/kg/min),  $V_I$  is the distribution volume of insulin (l/kg), and  $m_1$ ,  $m_2$ ,  $m_4$  ( $\text{min}^{-1}$ ) are rate parameters. Degradation,  $D$ , occurs both in the liver and in the periphery. Peripheral degradation has been assumed to be linear ( $m_4$ ).



**Figure 11.8** Glucose (upper panel) and insulin (lower panel) subsystem models (adapted from Vicini *et al.*, 1997 and Ferrannini and Cobelli, 1987).

Hepatic extraction of insulin, HE, is defined as the insulin flux which leaves the liver irreversibly divided by the total insulin flux leaving the liver. Thus, we get:

$$m_3(t) = \frac{HE(t) \cdot m_1}{1 - HE(t)} \tag{11.42}$$

Experimental evidence suggests that the time course of HE is related to the secretion of insulin, S in the following equation:

$$HE(t) = -m_5 \cdot S(t) + m_6 \quad HE(0) = HE_b \tag{11.43}$$

In the basal steady state we have:

$$m_6 = m_5 \cdot S_b + HE_b \tag{11.44}$$

$$m_3(0) = \frac{HE_b \cdot m_1}{1 - HE_b} \tag{11.45}$$

$$S_b = m_3(0) \cdot I_{1b} + m_4 \cdot I_{pb} = D_b \tag{11.46}$$

with  $S_b$  and  $D_b$  being basal secretion and degradation, respectively.



**Table 11.3**

Process	Parameter	Normal value	Type 2 diabetic value	Unit
Glucose kinetics	$V_G$	1.88	1.49	dl/kg
	$k_1$	0.065	0.042	min <sup>-1</sup>
	$k_2$	0.079	0.071	min <sup>-1</sup>
Insulin kinetics	$V_I$	0.05	0.04	l/kg
	$m_1$	0.190	0.239	min <sup>-1</sup>
	$m_2$	0.484	0.302	min <sup>-1</sup>
	$m_4$	0.194	0.477	min <sup>-1</sup>
	$m_5$	0.0304	0.0690	min · kg/pmol
	$m_6$	0.6471	0.8778	dimensionless
	$HE_b$	0.6	0.6	dimensionless
Rate of appearance	$k_{max}$	0.0558	0.0465	min <sup>-1</sup>
	$k_{min}$	0.0080	0.0076	min <sup>-1</sup>
	$k_{abs}$	0.057	0.023	min <sup>-1</sup>
	$k_{gri}$	0.0558	0.0465	min <sup>-1</sup>
	$f$	0.90	0.90	dimensionless
	$a$	0.00013	0.00006	mg <sup>-1</sup>
	$b$	0.82	0.68	dimensionless
	$c$	0.00236	0.00023	mg <sup>-1</sup>
Endogenous production	$d$	0.010	0.09	dimensionless
	$k_{p1}$	2.70	3.09	mg/kg/min
	$k_{p2}$	0.0021	0.0007	min <sup>-1</sup>
	$k_{p3}$	0.009	0.005	mg/kg/min per pmol/l
	$k_{p4}$	0.0618	0.0786	mg/kg/min per pmol/kg
Utilization	$k_i$	0.0079	0.0066	min <sup>-1</sup>
	$F_{ens}$	1	1	mg/kg/min
	$V_{m0}$	2.50	4.65	mg/kg/min
	$V_{mx}$	0.047	0.034	mg/kg/min per pmol/l
	$K_{m0}$	225.59	466.21	mg/kg
Secretion	$p_{2U}$	0.0331	0.0840	min <sup>-1</sup>
	$K$	2.28	1.38	pmol/kg per (mg/dl)
	$\alpha$	0.050	0.014	min <sup>-1</sup>
	$\beta$	0.11	0.05	pmol/kg/min per (mg/dl)
Renal excretion	$\gamma$	0.5	0.5	min <sup>-1</sup>
	$k_{e1}$	0.0005	0.0007	min <sup>-1</sup>
	$k_{e2}$	339	269	mg/kg

Moreover, given that the liver is responsible for 60% of insulin clearance in the steady state, one has:

$$m_2 = \left( \frac{S_b}{I_{pb}} - \frac{m_4}{1 - HE_b} \right) \cdot \frac{1 - HE_b}{HE_b} \quad (11.47)$$

and

$$m_4 = \frac{2}{5} \cdot \frac{S_b}{I_{pb}} \cdot (1 - HE_b) \quad (11.48)$$

$HE_b$  was fixed to 0.6, and is reported together with  $V_I$ ,  $m_1$ ,  $m_2$ ,  $m_4$ ,  $m_5$  and  $m_6$  in Table 11.3 (Insulin Kinetics) for both the normal and type 2 diabetic subject.

## Unit process models and identification

The model is divided into the unit processes of the glucose and insulin subsystems: *endogenous glucose production, glucose rate of appearance, glucose utilization, renal excretion and insulin secretion*. The model for each of them was identified from average data with a forcing function strategy; that is to say that some variables, considered to be the input of the unit process, were assumed to be known without error.

### *Endogenous glucose production*

The functional description of EGP in terms of glucose and insulin signals is described in Dalla Man *et al.* (2006); it comprises a direct glucose signal and both delayed and anticipated insulin signals:

$$\text{EGP}(t) = k_{p1} - k_{p2} \cdot G_p(t) - k_{p3} \cdot I_d(t) - k_{p4} \cdot I_{po}(t) \quad \text{EGP}(0) = \text{EGP}_b \quad (11.49)$$

where  $I_{po}$  is the quantity of insulin in the portal vein (pmol/kg),  $I_d$  (pmol/l) is a delayed insulin signal realized with a chain of two compartments:

$$\begin{cases} \dot{I}_1(t) = -k_i \cdot [I_1(t) - I(t)] & I_1(0) = I_b \\ \dot{I}_d(t) = -k_i \cdot [I_d(t) - I_1(t)] & I_d(0) = I_b \end{cases} \quad (11.50)$$

$$(11.51)$$

In terms of the parameters,  $k_{p1}$  (mg/kg/min) is the extrapolated EGP at zero glucose and insulin,  $k_{p2}$  ( $\text{min}^{-1}$ ) liver glucose effectiveness,  $k_{p3}$  (mg/kg/min per pmol/l) the parameter governing amplitude of insulin action on the liver,  $k_{p4}$  (mg/kg/min/(pmol/kg)) the parameter governing amplitude of portal insulin action on the liver, and  $k_i$  ( $\text{min}^{-1}$ ) is rate parameter accounting for delay between insulin signal and insulin action. EGP is also constrained to be non-negative.

In the basal steady state we have:

$$k_{p1} = \text{EGP}_b + k_{p2} \cdot G_{pb} + k_{p3} \cdot I_b + k_{p4} \cdot I_{pob} \quad (11.52)$$

The model of (11.49) was identified by nonlinear least squares using mean EGP data with the forcing function strategy of: mean insulin, portal insulin and glucose concentrations as the model inputs, assumed to be known without error and EGP is the model output. The measurement error of the EGP data was assumed to be independent, with zero mean and unknown constant standard deviation (constant SD assumes relatively more precise values when the signal is higher). A satisfactory model fit was obtained and parameters were estimated with precision for both the normal and type 2 diabetic subject. They are reported in Table 11.3 (Endogenous Glucose Production).

### *Glucose rate of appearance*

The physiological model of glucose intestinal absorption, as proposed in Dalla Man *et al.* (2006), was used to describe the glucose transit through the stomach and

intestine; it assumes that the stomach is represented by two compartments (one for solid and one for the triturated phase), while a single compartment is used to describe the gut:

$$\left\{ \begin{array}{l} Q_{\text{sto}}(t) = Q_{\text{sto1}}(t) + Q_{\text{sto2}}(t) \\ \dot{Q}_{\text{sto1}}(t) = -k_{\text{gri}} \cdot Q_{\text{sto1}}(t) + D \cdot \delta(t) \\ \dot{Q}_{\text{sto2}}(t) = -k_{\text{empt}}(Q_{\text{sto}}) \cdot Q_{\text{sto2}}(t) + k_{\text{gri}} \cdot Q_{\text{sto1}}(t) \\ \dot{Q}_{\text{gut}} = -k_{\text{abs}} \cdot Q_{\text{gut}}(t) + k_{\text{empt}}(Q_{\text{sto}}) \cdot Q_{\text{sto2}}(t) \\ \text{Ra}(t) = \frac{f \cdot k_{\text{abs}} \cdot Q_{\text{gut}}(t)}{\text{BW}} \end{array} \right. \quad \begin{array}{l} Q_{\text{sto}}(0) = 0 \\ Q_{\text{sto1}}(0) = 0 \\ Q_{\text{sto2}}(0) = 0 \\ Q_{\text{gut}}(0) = 0 \\ \text{Ra}(0) = 0 \end{array} \quad \begin{array}{l} (11.53) \\ (11.54) \\ (11.55) \\ (11.56) \\ (11.57) \end{array}$$

where  $Q_{\text{sto}}$  (mg) is quantity of glucose in the stomach (solid,  $Q_{\text{sto1}}$ , and liquid phase,  $Q_{\text{sto2}}$ ),  $Q_{\text{gut}}$  (mg) is the glucose mass in the intestine,  $k_{\text{gri}}$  ( $\text{min}^{-1}$ ) rate of grinding, and  $k_{\text{abs}}$  ( $\text{min}^{-1}$ ) rate constant of intestinal absorption,  $f$  fraction of intestinal absorption which actually appears in plasma.  $D$  (mg) is the quantity of ingested glucose,  $\text{BW}$  (kg) body weight and  $\text{Ra}$  (mg/kg/min) appearance rate of glucose in plasma;  $k_{\text{empt}}(Q_{\text{sto}})$  ( $\text{min}^{-1}$ ) is the rate constant of gastric emptying which is a nonlinear function of  $Q_{\text{sto}}$ :

$$k_{\text{empt}}(Q_{\text{sto}}) = k_{\text{min}} + \frac{k_{\text{max}} - k_{\text{min}}}{2} \cdot \left\{ \tan h[a(Q_{\text{sto}} - b \cdot D)] + \right. \\ \left. - \tan h[c(Q_{\text{sto}} - d \cdot D)] + 2 \right\} \quad (11.58)$$

The model of (11.53)–(11.58) was identified using  $\text{Ra}$  data with the forcing function strategy. A good model fit was achieved. The parameters  $k_{\text{gri}}$ ,  $a$  and  $c$  were fixed as follows:

$$k_{\text{gri}} = k_{\text{max}} \quad (11.59)$$

$$a = \frac{5}{2 \cdot D \cdot (1 - b)} \quad (11.60)$$

$$c = \frac{5}{2 \cdot D \cdot d} \quad (11.61)$$

while the remaining parameters were estimated with precision. They are reported in Table 11.3 (Glucose Rate of Appearance) for both the normal and type 2 diabetic subject.

### Glucose utilization

The model of glucose utilization by body tissues during a meal assumes that glucose utilization is made up of two components: insulin-independent and insulin-dependent.

Insulin-independent utilization takes place in the first compartment, is constant, and represents glucose uptake by the brain and erythrocytes ( $F_{\text{cns}}$ ):

$$U_{\text{ii}}(t) = F_{\text{cns}} \quad (11.62)$$

Insulin-dependent utilization takes place in the remote compartment and depends nonlinearly (Michaelis Menten) upon glucose in the tissues:

$$U_{id}(t) = \frac{V_m(X(t)) \cdot G_t(t)}{K_m(X(t)) + G_t(t)} \quad (11.63)$$

where  $V_m(X(t))$  and  $K_m(X(t))$  are assumed to be linearly dependent upon a remote insulin,  $X(t)$ :

$$V_m(X(t)) = V_{m0} + V_{mx} \cdot X(t) \quad (11.64)$$

$$K_m(X(t)) = K_{m0} + K_{mx} \cdot X(t) \quad (11.65)$$

It should be noted that, when fitting this model to available data,  $K_{mx}$  collapsed to zero, so that  $K_m$  is no longer dependent upon  $X$ .

$X$  (pmol/L) is insulin in the interstitial fluid described by:

$$\dot{X}(t) = -p_{2U} \cdot X(t) + p_{2U}[I(t) - I_b] \quad X(0) = 0 \quad (11.66)$$

where  $I$  is plasma insulin, with the suffix  $b$  denoting basal state, and  $p_{2U}$  ( $\text{min}^{-1}$ ) is a rate constant defining insulin action on peripheral glucose utilization.

Total glucose utilization,  $U$ , is therefore:

$$U(t) = U_{ii}(t) + U_{id}(t) \quad (11.67)$$

In the basal steady state one has:

$$G_{tb} = \frac{F_{cns} - EGP_b + k_1 \cdot G_{pb}}{k_2} \quad (11.68)$$

and:

$$U_b = EGP_b = F_{cns} + \frac{V_{m0} \cdot G_{tb}}{K_{m0} + G_{tb}} \quad (11.69)$$

from which:

$$V_{m0} = \frac{(EGP_b - F_{cns}) \cdot (K_{m0} + G_{tb})}{G_{tb}} \quad (11.70)$$

This model and that of (11.35)–(11.37) were simultaneously identified using  $U$  and  $G$  data with the forcing function strategy (Figure 11.8, bottom left panel). A good model fit was achieved and the parameters were estimated with precision and are reported in Table 11.3 (Glucose Utilization) for both the normal and type 2 diabetic subject.

### *Insulin secretion*

The model used to describe pancreatic insulin secretion is:

$$S(t) = \gamma \cdot I_{po}(t) \quad (11.71)$$

$$\dot{I}_{po}(t) = -\gamma \cdot I_{po}(t) + S_{po}(t) \quad I_{po}(0) = I_{pob} \quad (11.72)$$

$$S_{po}(t) = \begin{cases} Y(t) + K \cdot \dot{G}(t) + S_b & \text{for } \dot{G} > 0 \\ Y(t) + S_b & \text{for } \dot{G} \leq 0 \end{cases} \quad (11.73)$$

and

$$\dot{Y}(t) = \begin{cases} -\alpha \cdot [Y(t) - \beta \cdot (G(t) - h)] & \text{if } \beta \cdot (G(t) - h) \geq -S_b \\ -\alpha \cdot Y(t) - \alpha \cdot S_b & \text{if } \beta \cdot (G(t) - h) < -S_b \end{cases}; \quad Y(0) = 0 \quad (11.74)$$

where  $\gamma$  ( $\text{min}^{-1}$ ) is the transfer rate constant between portal vein and liver.  $K$  ( $\text{pmol/kg}$  per  $\text{mg/dl}$ ) is the pancreatic responsivity to glucose rate of change,  $\alpha$  ( $\text{min}^{-1}$ ) is the delay between glucose signal and insulin secretion,  $\beta$  ( $\text{pmol/kg/min}$  per  $\text{mg/dl}$ ) is the pancreatic responsivity to glucose, and  $h$  ( $\text{mg/dl}$ ) is the threshold level of glucose above which the  $\beta$ -cells initiate the production of new insulin ( $h$  has been set to the basal glucose concentration  $G_b$  to guarantee system steady state in basal condition).

This model and that of (11.39)–(11.41) were simultaneously identified using  $S$  and  $I$  data with the forcing function strategy. A good model fit was achieved and the parameters were estimated with precision and are reported in Table 11.3 (Insulin Secretion) for both the normal and type 2 diabetic subject.

#### *Glucose renal excretion*

Glucose excretion by the kidney occurs if plasma glucose exceeds a certain threshold and can be modeled by a linear relationship with plasma glucose:


$$E(t) = \begin{cases} k_{e1} \cdot [G_p(t) - k_{e2}] & \text{if } G_p(t) > k_{e2} \\ 0 & \text{if } G_p(t) \leq k_{e2} \end{cases} \quad (11.75)$$

where  $k_{e1}$  ( $\text{min}^{-1}$ ) is glomerular filtration rate and  $k_{e2}$  ( $\text{mg/kg}$ ) is the renal threshold for glucose. The parameters are reported in Table 11.3 (Glucose Renal Excretion).

## 11.5.2 Results

### **Meal in normal subject**


A normal subject receiving a mixed meal was simulated first using parameters reported in Table 11.3 (Normal value). Figure 11.9 shows the predicted glucose and insulin concentrations and glucose/insulin fluxes (continuous line) against  $\pm 1\text{SD}$  confidence limits (gray area, Figure 11.6). The model also enables prediction of the effect of the various control signals on glucose production (Figure 11.10, upper panel), as well as the insulin-independent and dependent components of glucose utilization (Figure 11.10, right panel); in addition, hepatic insulin extraction can be predicted (Figure 11.10, lower panel).



**Figure 11.9** Simulation results following the administration of a meal for both normal (continuous line) and type 2 diabetic subjects (dashed line) (adapted from Dalla Man *et al.*, 2006).

### Meal in type 2 diabetic subject

The model was also numerically identified for the type 2 diabetic subject, although in this case the database was much smaller and involved a triple tracer meal. The model structure that had been proposed for the normal subject turned out to be robust and data were fitted well. In other words the type 2 diabetic subject can be described quantitatively using the same model structure, but with different parameter values (Table 11.3, Type 2 diabetic). In particular, gut absorption,  $k_{abs}$ , was slower than in the normal case; parameters quantifying insulin action, both peripheral,  $V_{mx}$ , and hepatic,  $k_{p3}$ , were lower; hepatic glucose effectiveness,  $k_{p2}$ , was lower; even though the maximum utilization by the tissue at basal insulin,  $V_{m0}$ , was higher, it was




**Figure 11.10** Use of the simulation model to predict the effects of various control signals on endogenous glucose production (upper left panel), glucose utilization (upper right) and hepatic insulin extraction (lower panel) (adapted from Dalla Man *et al.*, 2006).

reached at higher glucose levels,  $K_{m0}$ . Finally, both dynamic,  $K$ , and static beta cell responsivity,  $\beta$ , as well as the rate of response,  $\alpha$ , were lower. This different parametric portrait is reflected in the predictions of the model. It can be seen that there are important derangements in both glucose and insulin concentration as well in glucose and insulin fluxes as compared to the normal situation (Figure 11.9, dashed line).

### Daily life for a normal subject

The model can also be used to simulate the dynamic patterns occurring during the day in the case of a normal subject: 24 h with breakfast at 0800 (45 g), lunch at 12 (70 g) and dinner at 2000 (70 g). Figure 11.11 (continuous line) shows the predictions of concentrations and fluxes in the normal subject during the day.



**Figure 11.11** Model predictions for both the normal subject and the subject with impaired glucose tolerance (adapted from Dalla Man *et al.*, 2006).




## Daily life for a subject with impaired glucose tolerance

Glucose intolerance can also be simulated. In particular, an impairment in insulin sensitivity (with both  $V_{mx}$  and  $k_{p3}$  halved) is considered for the cases both compensated and not by higher beta cell response to glucose. For instance, if the parameters  $V_{mx}$  and  $k_{p3}$  are halved, without a significant increase in beta cell responsivity, glucose concentration exhibits a higher peak and returns to basal level almost two hours later than in the normal subject (Figure 11.11, dashed line).


Conversely, if the parameters  $K$  and  $\beta$  are both doubled, glucose concentration basically does not differ significantly from the normal case. However, plasma insulin concentration is doubled (Figure 11.11, dashed-dotted line). Finally, if  $K$  and  $\beta$  are halved with insulin action remaining normal, glucose concentration peaks at a higher value and returns to its basal level almost three hours later than in the normal subject. However, if  $V_{mx}$  and  $k_{p3}$  are both doubled, glucose concentration remains essentially normal, but plasma insulin concentration is halved (results not shown).

## 11.6 CASE STUDY 6: A MODEL OF INSULIN CONTROL

In pathophysiology it is of the utmost importance to measure quantitatively the control that insulin exerts on glucose metabolism. In fact, insulin stimulates glucose utilization and inhibits glucose production (Figure 11.12) and it is easily appreciated that derangement of these two control features can lead to glucose intolerance and type 2 diabetes. In this case study we discuss a widely adopted model. This is the so-called glucose minimal model that is used to measure insulin action from an intravenous glucose tolerance test (IVGTT) (see Figure 11.13).




**Figure 11.12** The glucose-insulin control system.




**Figure 11.13** Mean experimental data for glucose and insulin for an IVGTT. The data show the mean values and standard deviation.

The feedback nature of the glucose-insulin system poses major difficulties. A closed-loop model must be postulated, thus possible inaccuracies in modeling insulin action and secretion can compensate for each other. To avoid this, the feedback loop can be opened conceptually by partitioning the whole system into two subsystems (Figure 11.14) linked by the measured variables, insulin and glucose concentration. The two subsystems cannot be separately modeled. For the model of insulin action on glucose production and utilization, insulin is the (known) input and glucose the output (Figure 11.15).



**Figure 11.14** Partitioning of the feedback system into glucose and insulin subsystems, linked by plasma measurements.



**Figure 11.15** Model of insulin secretion to be determined using insulin as the input variable and glucose as the output.

Since the whole model is intended for clinical use, another important attribute is its parsimony, in other words the model must be simple; this is to enable all the parameters to be estimated with acceptable precision from the data of an individual subject. At the same time the model must not be simplistic, since it needs to be able to provide a reliable description of the relevant physiological processes. It is in this context that the term *minimal model* was coined (Bergman *et al.*, 1979).

The model is shown in Figure 11.16 and its key features are as follows: (a) glucose kinetics are described by a single-compartment model; (b) glucose inhibition of production and stimulation of utilization are proportional to glucose plasma concentration; and (c) insulin inhibition of glucose production and stimulation of glucose utilization are proportional to insulin concentration in a compartment remote from plasma. Mathematically one has:

$$\begin{aligned} Q(t) &= R_a(Q(t), I'(t)) - R_d(Q(t), I'(t)) + D \cdot \delta(t) & Q(0) &= Q_b \\ &= NHGB(Q(t), I'(t)) - R_d(Q(t), I'(t)) + D \cdot \delta(t) \end{aligned} \quad (11.76)$$


$$I'(t) = -k_3 \cdot I'(t) + k_2 \cdot I(t) \quad I'(0) = I'_b \quad (11.77)$$

$$G(t) = \frac{Q(t)}{V} \quad (11.78)$$


where  $Q$  is the mass of glucose, with  $Q_b$  denoting its basal value;  $D$  is the glucose dose,  $\delta(t)$  is the Dirac function,  $R_a$  is the rate of appearance of glucose in plasma which is equal to  $NHGB$ , the net hepatic glucose balance;  $R_d$  is plasma glucose disappearance rate.  $I'(t)$  is insulin concentration in a compartment remote from plasma, i.e. interstitial fluid and  $I(t)$  is plasma insulin concentration with  $I_b$  denoting its basal value;  $G$  is plasma glucose concentration; and  $V$  is the glucose distribution volume.

The next step is to provide functional descriptions of  $NHGB$  and  $R_d$ . These are displayed graphically in Figure 11.17 and mathematically one has:

$$NHGB(t) = NHGB_0 - [k_5 + k_6 I'(t)]Q(t) \quad (11.79)$$



**Figure 11.16** The glucose minimal model (adapted from Bergman *et al.*, 1979). Continuous lines denote flux of material and dashed lines denote control signals.



**Figure 11.17** Graphical description of net hepatic glucose balance (NHGB) and the rate of appearance of glucose ( $R_d$ ).

where  $NHGB_0$  is net endogenous glucose balance at zero glucose, and:

$$R_d(t) = [k_1 + k_4 I'(t)]Q(t) + R_{d0} \tag{11.80}$$

where  $R_{d0}$  is glucose disappearance rate at zero glucose.

Sigmoidal shaped relationships would be more realistic but one has to remember that during an IVGTT glucose is usually confined in a range, say 90 to 350 mg/dl, so one has to regard these linear relationships as a reasonable approximation in the observed glucose range.

Now, incorporating (11.79) and (11.80) into (11.76) enables us to write:

$$Q(t) = [(k_5 + k_1) - (k_6 + k_4)I'(t)](Q(t) + (NEGB_0 - R_{d0})) \quad Q(0) = Q_b + D \tag{11.81}$$

$$I'(t) = -k_3 \cdot I'(t) + k_2[I(t) - I_b] \quad I'(0) = 0 \tag{11.82}$$

$$G(t) = \frac{Q(t)}{V} \tag{11.83}$$

where the term  $(\text{NHGB}_0 - R_{d_0})$  can be written as  $(k_5 + k_1)Q_b$  by using the steady-state constraint  $Q(t) = 0$ , and the impulse dose has been incorporated into the initial condition.

Unfortunately, the model has too many parameters to be resolved, assuming plasma insulin concentration  $I$  as a known input, from plasma glucose concentration data. By testing *a priori* identifiability with the Taylor series expansion method (the model is nonlinear) of section 7.5 one can show that the model is *a priori* nonidentifiable since all the  $k$  parameters are nonidentifiable (only  $V$  is uniquely identifiable). The uniquely identifiable parametrization of the model is:

$$Q(t) = -[p_1 + X(t)]Q(t) + p_1 Q_b \quad Q(0) = Q_b + D \quad (11.84)$$

$$X(t) = -p_2 X(t) + p_3 [I(t) - I_b] \quad X(0) = 0 \quad (11.85)$$

$$G(t) = \frac{Q(t)}{V} \quad (11.86)$$

This parametrization includes new  $p$  parameters, and a new variable,  $X$ , where these are related to the original parameters as follows:

$$X(t) = (k_4 + k_6)I'(t) \quad (11.87)$$

$$p_1 = k_1 + k_5 \quad (11.88)$$

$$p_2 = k_3 \quad (11.89)$$

$$p_3 = k_2(k_4 + k_6) \quad (11.90)$$

From the uniquely identifiable model parameters  $p_1$ ,  $p_2$ ,  $p_3$  and  $V$ , one can calculate indices of glucose effectiveness,  $S_G$ , and insulin sensitivity,  $S_I$ , as follows.

### Glucose effectiveness

$$\begin{aligned} S_G &= - \left. \frac{\partial \dot{Q}}{\partial Q} \right|_{ss} = -[-(p_1 + X(t))]_{ss} = p_1 + X_b \\ &= p_1 + \frac{p_3}{p_2} \cdot I_b = k_1 + k_5 + \frac{k_2 \cdot (k_4 + k_6)}{k_3} \cdot I_b \end{aligned} \quad (11.91)$$

### Insulin sensitivity

$$S_I = - \left. \frac{\partial^2 \dot{Q}}{\partial Q \cdot \partial I} \right|_{ss} = \left. \frac{\partial [p_1 + X(t)]}{\partial I} \right|_{ss} = \left. \frac{\partial X}{\partial I} \right|_{ss} \quad (11.92)$$

In the steady state:

$$0 = -p_2 \cdot X_{ss} + p_3 \cdot I(t) \quad (11.93)$$

$$X_{ss} = \frac{p_3}{p_2} \cdot I(t) \quad (11.94)$$

and thus:

$$S_I = \left. \frac{\partial X}{\partial I} \right|_{ss} = \frac{p_3}{p_2} = \frac{k_2 \cdot (k_4 + k_6)}{k_3} \quad (11.95)$$

$S_G$  and  $S_I$  reflect both the effect of glucose and insulin on  $R_d$  and NHGP. In fact,  $S_G$  is a function not only of  $k_1$  but also of  $k_5$ , and thus measures the ability of glucose *per se*, at basal insulin, to stimulate  $R_d$  and inhibit NHGP. Similarly,  $S_I$  is a function not only of  $k_2, k_3, k_4$  but also of  $k_6$ , and thus measures the ability of insulin to enhance the glucose *per se* stimulation of  $R_d$  and the glucose *per se* inhibition of NHGP.

The model of (11.84)–(11.86) can be identified for instance by weighted nonlinear least squares assuming that the measurement error is independent, zero mean and with a  $CV = 2\%$ . To favor the single compartment approximation, the first 8–10 min samples are usually neglected. A typical identification result is shown in Figure 11.18.

This model also allows discussion of issues related to model validation. For instance, is the value of  $S_I$  reliable? In fact, there is an alternative, albeit rather invasive and intensive, technique to measure  $S_I$  which is the euglycemic hyperinsulinemic clamp (Figure 11.19). In this case, the feedback loop is opened experimentally by maintaining glucose concentration at basal level in spite of an elevated insulin concentration:

$$S_I = \frac{M}{\Delta I \cdot G_b} \quad (11.96)$$


where  $\Delta I = I_{ss} - I_b$ .

The minimal model  $S_I$  has been validated against the clamp  $S_I$  in numerous studies with correlation ranging from 0.79–0.92.


## 11.7 CASE STUDY 7: ILLUSTRATIONS OF BAYESIAN ESTIMATION

A key step in developing both structural and input/output models of physiological systems is parameter estimation. That is, assigning numerical values to the unknown model parameters from the experimental data. Maximum likelihood (ML) is probably the most used parameter estimation approach, also given its connection, in the Gaussian case, to least squares estimation. A more sophisticated but less adopted approach is maximum *a posteriori* (MAP) estimation.

The major difference between these two approaches lies in the fact that MAP estimation exploits not only the experimental data, but also the *a priori* available statistical information on the unknown parameter vector; for example, its expected value and covariance matrix in the Gaussian case. In other words, while ML is a Fisherian approach (that is to say that experimental data are the only information supplied to the estimator) MAP is a Bayesian approach (that is *a priori* information is used) in addition to the information contained in the data (therefore termed *a posteriori* information), in the determination of the numerical values of the model parameters. Often, the *a priori* information needed to implement Bayesian estimation is available, for instance from population studies.



**Figure 11.18** Upper panel: data (left – glucose; right – insulin) of an individual subject. Lower panel: left – model fit to glucose data; right – weighted residuals.



**Figure 11.19** The glucose clamp technique.



In this case study a comparison will be performed between ML and MAP estimators in the determination of the parameters of a sum of exponentials model which describes the impulse response of C-peptide (CP), using the results obtained by Sparacino *et al.* (2000).

CP is a peptide co-secreted with insulin on an equimolar basis, but is not extracted by the liver and exhibits linear kinetics over a large range of concentrations. Therefore, CP plays a key role in quantitative studies of the insulin system, since its impulse response (but not that of insulin) allows the reconstruction of pre-hepatic  $\beta$ -cell insulin secretion rate by deconvolution.

In particular, it will be shown that, when *a priori* information on the unknown model parameters is available, Bayesian estimation can be of particular interest since it can significantly improve the precision of parameter estimates with respect to Fisher estimation. This enables more complex models to be adopted than would be the case with a Fisherian approach. Moreover, it also enables a model to work in a data-poor situation, for instance with reduced sampling schedules and large errors in the measurements that constitute the data.

## Database

In 14 normal humans, a bolus of biosynthetic CP was administered intravenously. Blood samples were collected at 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 14, 17, 20, 25, 30, 35, 40, 45, 50, 55, 60, 70, 80, 90, 100, 110, 120, 140, 160 and 180 minutes following the bolus administration and CP plasma concentration was measured. The measurement noise was assumed Gaussian and independent, i.e. the covariance matrix  $\Sigma_v$  was diagonal, with zero mean, and with constant CV equal to 5%. A representative decay curve (subject # 1) is shown in Figure 11.21 (top panels, open bullets).

## The two-exponential model: ML vs. MAP

The unknown vector is  $\mathbf{p} = [A_1, A_2, \alpha_1, \alpha_2]^T$ . Table 11.4 shows the estimates obtained by ML and MAP together with their precision. These values of  $\boldsymbol{\mu}$  and  $\Sigma_p$  needed for MAP estimation have been obtained from

$$\boldsymbol{\mu} = \frac{1}{M} \sum_{i=1}^M \mathbf{p}^{(i)} \quad (11.97)$$


$$\Omega = \frac{1}{M-1} \sum_{i=1}^M (\mathbf{p}^{(i)} - \boldsymbol{\mu})(\mathbf{p}^{(i)} - \boldsymbol{\mu})^T \quad (11.98)$$

where  $\mathbf{p}^{(i)}$  is the parameter vector of the  $i$ -th subject of the population. First, individual ML estimates of the parameters of the CP impulse response model are obtained for the 14 subjects. Then,  $\boldsymbol{\mu}$  and  $\Sigma_p$  are calculated from these estimates by applying (11.97) and (11.98).

**Table 11.4** Parameter estimates of the two-exponential (2E) model with their precision (expressed as percentage CV, in parenthesis) obtained by maximum likelihood (ML) and maximum *a posteriori* (MAP) estimation (the amplitudes of the exponentials are divided by the bolus dose). WRSS is the weighted residuals sum of squares (adapted from Sparacino *et al.*, 2000)

		$A_1 \times 10^{-4}$ ml <sup>-1</sup>	$A_2 \times 10^{-4}$ ml <sup>-1</sup>	$\alpha_1$ min <sup>-1</sup>	$\alpha_2$ min <sup>-1</sup>	WRSS
# 1	ML	1.894 (4.7)	0.5564 (4.6)	0.1443 (5.6)	0.0262 (2.2)	55.56
	MAP	1.896 (4.3)	0.5518 (4.3)	0.1436 (5.0)	0.0261 (2.1)	55.58
# 2	ML	1.996 (4.7)	0.5612 (4.4)	0.1470 (5.5)	0.0251 (2.3)	43.88
	MAP	1.991 (4.3)	0.5585 (4.2)	0.1461 (5.0)	0.0250 (2.2)	43.88
# 3	ML	1.908 (4.5)	0.6444 (4.0)	0.1256 (5.9)	0.0204 (2.1)	76.67
	MAP	1.956 (4.4)	0.6634 (3.6)	0.1328 (5.4)	0.0206 (1.9)	77.23
# 4	ML	2.210 (5.2)	0.6747 (3.7)	0.1625 (5.8)	0.0240 (1.9)	47.99
	MAP	2.167 (4.7)	0.6662 (3.6)	0.1579 (5.1)	0.0239 (1.9)	48.17
# 5	ML	1.913 (6.3)	0.7551 (3.0)	0.1750 (6.9)	0.0196 (1.8)	77.91
	MAP	1.875 (5.4)	0.7489 (2.9)	0.1692 (5.7)	0.0195 (1.7)	78.05
# 6	ML	1.443 (5.8)	0.5222 (4.0)	0.1691 (6.7)	0.0257 (2.2)	89.15
	MAP	1.413 (5.1)	0.5058 (3.8)	0.1595 (5.6)	0.0253 (2.1)	89.44
# 7	ML	1.777 (5.7)	0.8846 (4.1)	0.1353 (7.7)	0.0245 (2.0)	45.15
	MAP	1.842 (5.2)	0.8856 (3.7)	0.1407 (6.5)	0.0244 (1.8)	45.61
# 8	ML	2.444 (5.4)	0.8595 (3.3)	0.1552 (6.1)	0.0222 (1.7)	59.75
	MAP	2.410 (4.8)	0.8555 (3.2)	0.1529 (5.3)	0.0222 (1.7)	59.88
# 9	ML	2.309 (3.8)	0.6049 (5.7)	0.1186 (5.1)	0.0273 (2.4)	96.37
	MAP	2.313 (3.6)	0.6032 (5.3)	0.1191 (4.7)	0.0272 (2.3)	96.47
# 10	ML	2.271 (4.3)	0.4515 (3.8)	0.1555 (4.5)	0.0220 (2.1)	128.85
	MAP	2.229 (4.0)	0.4506 (3.7)	0.1527 (4.1)	0.0220 (2.0)	129.03
# 11	ML	2.605 (5.1)	0.6719 (3.5)	0.1705 (5.2)	0.0237 (1.8)	39.56
	MAP	2.497 (4.5)	0.6614 (3.4)	0.1625 (4.7)	0.0235 (1.7)	40.29
# 12	ML	2.046 (7.1)	1.037 (3.2)	0.1720 (8.1)	0.0215 (1.8)	70.65
	MAP	2.042 (5.8)	1.023 (2.9)	0.1681 (6.3)	0.0214 (1.7)	70.86
# 13	ML	2.104 (3.7)	0.4548 (4.0)	0.1214 (4.4)	0.0195 (2.1)	130.90
	MAP	2.143 (3.7)	0.4724 (3.7)	0.1273 (4.2)	0.0198 (1.9)	131.49
# 14	ML	1.243 (5.3)	0.4691 (3.9)	0.1431 (6.8)	0.0231 (2.0)	44.44
	MAP	1.265 (4.9)	0.4717 (3.6)	0.1459 (5.9)	0.0232 (1.9)	44.53

The values of ML and MAP estimates are very similar. In all subjects, the weighted residual sum of squares (WRSS) is lower for ML. This should not be surprising since, while the ML estimator only weights the distance of the model predictions from the data, the MAP estimator also weights the distance of the parameters from their



**Figure 11.20** The 2E model identified by ML (left) and MAP (right) estimators from C-peptide concentration samples following the administration of a bolus at  $t=0$  (subject #1). Top: model predictions (continuous line) vs. data (open bullets). Bottom: weighted residuals (adapted from Sparacino *et al.*, 2000).

*a priori* expected values. However, the WRSS difference is very small. Turning to precision of parameter estimates (CV, reported in parentheses), it can be noted that it always improves by using Bayesian estimation. This is again in line with theoretical expectations, given the incorporation of *a priori* knowledge into the algorithm. However, here the improvement is almost undetectable, since the parameters estimated by ML, exploiting only the *a posteriori* information, already have very good precision.

To give a quantitative flavor of the extent of this modest improvement, by averaging the percentage CV of the estimates of  $[A_1, A_2, \alpha_1, \alpha_2]^T$  reported in Table 11.4, the values are  $[5.1, 3.9, 6.0, 2.0]^T$  with ML and  $[4.6, 3.7, 5.2, 1.9]^T$  with MAP. On average, the uncertainty is thus reduced by approximately 10%.


Figure 11.20 shows the model fit and the weighted residuals for the representative subject, obtained by ML and MAP estimation. In agreement with the small gap in WRSS, no significant differences can be detected by inspecting the two fits.

**Table 11.5** Parameter estimates of the three-exponential (3E) model with their precision (expressed as percentage CV, in parenthesis) obtained by ML and MAP (the amplitudes of the exponentials are divided by the bolus dose). WRSS is the weighted residuals sum of squares (adapted from Sparacino *et al.*, 2000)

		$A_1 \times 10^{-4}$ ml <sup>-1</sup>	$A_2 \times 10^{-4}$ ml <sup>-1</sup>	$A_3 \times 10^{-4}$ ml <sup>-1</sup>	$\alpha_1$ min <sup>-1</sup>	$\alpha_2$ min <sup>-1</sup>	$\alpha_3$ min <sup>-1</sup>	WRSS
# 1	ML	1.304 (32.0)	1.093 (47.1)	0.4929 (10.2)	0.2998 (48.2)	0.0998 (26.4)	0.0251 (4.0)	46.83
	MAP	1.525 (12.0)	0.9294 (13.1)	0.4593 (8.2)	0.2799 (13.8)	0.0859 (9.7)	0.0245 (3.5)	47.82
# 2	ML	1.712 (17.2)	0.8711 (37.0)	0.441 (14.9)	0.2659 (28.0)	0.0793 (26.8)	0.0229 (5.6)	29.29
	MAP	1.750 (10.5)	0.8808 (13.3)	0.4217 (10.5)	0.2723 (13.1)	0.0760 (11.2)	0.0225 (4.3)	29.48
# 3	ML	2.266 (13.5)	1.007 (9.0)	0.3597 (20.6)	0.3283 (17.6)	0.0520 (13.8)	0.0161 (8.5)	21.21
	MAP	2.239 (9.3)	0.9495 (8.0)	0.3786 (17.7)	0.3068 (11.4)	0.0522 (12.3)	0.0165 (7.3)	21.89
# 4	ML	2.313 (13.2)	0.9013 (22.1)	0.5118 (12.9)	0.3273 (21.8)	0.0742 (21.3)	0.0216 (4.9)	21.19
	MAP	2.125 (9.6)	0.8745 (12.3)	0.4918 (9.9)	0.2989 (12.1)	0.0706 (11.6)	0.0213 (4.1)	21.91
# 5	ML	2.112 (15.6)	0.7661 (17.6)	0.5657 (11.8)	0.3576 (22.4)	0.0641 (22.1)	0.0173 (5.2)	46.45
	MAP	2.024 (9.8)	0.6872 (12.5)	0.5541 (9.1)	0.3120 (11.8)	0.0591 (13.3)	0.0171 (4.2)	47.14
# 6	ML	1.648 (15.5)	0.6683 (13.7)	0.3332 (18.5)	0.3677 (21.2)	0.0675 (18.8)	0.0215 (7.0)	47.60
	MAP	1.522 (11.2)	0.6474 (10.7)	0.3444 (12.2)	0.3347 (12.0)	0.0695 (12.0)	0.0218 (5.0)	48.44
# 7	ML	1.331 (35.5)	0.8817 (59.3)	0.7765 (12.7)	0.2471 (47.8)	0.0790 (41.1)	0.0233 (4.5)	38.57
	MAP	1.525 (11.9)	0.7974 (16.1)	0.7672 (6.7)	0.2465 (14.8)	0.0743 (11.2)	0.0232 (2.8)	39.08
# 8	ML	2.428 (9.0)	0.9118 (12.8)	0.3980 (47.0)	0.2311 (14.7)	0.0424 (24.0)	0.0170 (15.5)	28.30
	MAP	2.375 (8.5)	0.9143 (10.9)	0.5013 (19.7)	0.2469 (11.8)	0.0498 (15.7)	0.0183 (7.0)	28.92
# 9	ML	1.998 (13.7)	1.280 (18.7)	0.3907 (20.8)	0.2597 (23.5)	0.0695 (16.1)	0.0236 (6.9)	64.54
	MAP	2.047 (10.1)	1.234 (10.2)	0.3908 (17.1)	0.2534 (13.1)	0.0689 (10.9)	0.0235 (5.9)	64.82
# 10	ML	2.494 (7.5)	0.7363 (9.1)	0.1382 (36.6)	0.2490 (10.1)	0.0455 (13.5)	0.0134 (16.9)	51.73
	MAP	2.441 (6.8)	0.7527 (8.8)	0.1574 (27.3)	0.2534 (9.0)	0.0479 (11.8)	0.0142 (12.2)	52.07
# 11	ML	2.598 (9.8)	0.7882 (24.2)	0.4661 (16.7)	0.2673 (16.7)	0.0640 (24.3)	0.0207 (6.0)	12.85
	MAP	2.380 (8.4)	0.8812 (13.1)	0.4561 (11.0)	0.2712 (11.4)	0.0662 (12.0)	0.0205 (4.3)	14.18
# 12	ML	1.876 (20.0)	0.4559 (79.1)	0.9092 (17.4)	0.2186 (29.3)	0.0618 (80.5)	0.0204 (6.1)	66.90
	MAP	1.871 (9.7)	0.5914 (21.5)	0.8633 (6.6)	0.2393 (13.6)	0.0618 (13.2)	0.0200 (3.0)	67.53
# 13	ML	2.457 (7.9)	0.8876 (6.9)	0.1101 (38.7)	0.2458 (10.4)	0.0405 (10.4)	0.0103 (21.8)	11.68
	MAP	2.484 (7.1)	0.9007 (6.8)	0.1528 (26.0)	0.2596 (9.2)	0.0442 (9.5)	0.0123 (12.7)	12.75
# 14	ML	1.100 (19.4)	0.3997 (51.6)	0.3808 (19.6)	0.2104 (26.4)	0.0636 (46.0)	0.0215 (6.7)	37.64
	MAP	1.103 (12.0)	0.5149 (17.6)	0.3915 (7.4)	0.2571 (14.3)	0.0728 (11.5)	0.0216 (3.2)	38.32

### The three-exponential model: ML vs. MAP

The unknown vector is  $\mathbf{p} = [A_1, A_2, A_3, \alpha_1, \alpha_2, \alpha_3]^T$ . The ML and MAP estimates are shown in Table 11.5. The *a priori* information supplied to the MAP estimator, is the same for the two-exponential (2E) model. Again, by looking at Table 11.5, only small differences between the values of the parameters estimated by ML or MAP can be detected. Also, the WRSS of ML estimation is only slightly better than that of that MAP estimation. In contrast with the 2E model, a significant improvement in the precision of the parameter estimates now occurs with MAP in comparison with ML estimation. For instance, for subject #7 the CV of the parameter  $A_2$  is 59.3% with ML estimation, and 16.1% with MAP estimation. By averaging the percentage CV of the estimates of  $[A_1, A_2, A_3, \alpha_1, \alpha_2, \alpha_3]^T$  reported in Table 11.5, the values are  $[16.4, 29.4, 20.8, 24.2, 27.7, 8.4]^T$  with ML and  $[9.7, 12.4, 13.5, 12.2, 11.8, 5.6]^T$  with MAP. On average, the uncertainty is thus reduced by approximately 50%.



**Figure 11.21** 3E model identified by ML (left) and MAP (right) estimators in the same subject of Figure 11.20. Top: model predictions (continuous line) vs. data (open bullets). Bottom: weighted residuals (adapted from Sparacino *et al.*, 2000).

Figure 11.21 shows the model fit and weighted residuals (bottom) obtained by the two estimation techniques. As with the 2E model, no significant differences can be detected by inspection, again given the fact that the WRSS values are very close.

By comparing the results presented in Tables 11.4 and 11.5, it is evident that the improvement in parameter precision obtained by using MAP in place of ML estimation is now much more significant. This can be explained by noting that in MAP estimation a trade-off is established between *a priori* and *a posteriori* information. Thus, the improvement in the precision obtained by MAP estimation is more significant for those parameters related to the fastest eigenvalues ( $A_1$  and  $\alpha_1$  and  $A_2$  and  $\alpha_2$ ) than for those related to the slowest mode ( $A_3$  and  $\alpha_3$ ), since their estimation is based on fewer data (i.e. less *a posteriori* information).

### Two vs. three-exponential model order choice

In each subject (see, for example, Figures 11.20 and 11.21) both the 2E and the 3E models describe the data satisfactorily. The 3E model obviously fits the data better

**Table 11.6** Values of the difference of AIC ( $\Delta$ AIC) and GEN-IC ( $\Delta$ GEN-IC) between the 3E and the 2E models obtained in a ML and MAP estimation context, respectively (a negative value indicates that the 3E model is the most parsimonious) (adapted from Sparacino *et al.*, 2000)

Subject	$\Delta$ AIC	$\Delta$ GEN-IC
# 1	-4.75	-6.80
# 2	-10.56	-13.90
# 3	-51.78	-55.47
# 4	-22.89	-25.77
# 5	-27.63	-31.70
# 6	-37.62	-39.91
# 7	-2.60	-7.12
# 8	-27.57	-30.10
# 9	-27.94	-31.05
# 10	-73.45	-76.67
# 11	22.79	-26.15
# 12	0.27	-2.30
# 13	-116.0	-120.12
# 14	-2.80	-4.95

than the 2E one, especially in the first portion of the experiment (0–20 min), where the 2E model exhibits larger and correlated residuals in contrast with the assumptions on measurement error. As a consequence, the WRSS is significantly lower for the 3E model. For instance, by looking at Tables 11.4 and 11.5 it can be seen that, for the representative subject, WRSS is approximately 55.5 with the 2E model (Figure 11.20) and 47 with the 3E model (Figure 11.21), thus showing a 15% difference. Even greater WRSS differences can be detected in other subjects (e.g. more than 100% for subject #10). However, the 3E parameter estimates always exhibit worse precision, especially those associated to the fastest eigenvalue. Therefore, the question of selecting the better model needs to be addressed.

The AIC and GEN-IC indexes are the tools for resolving this issue. Table 11.6 shows the differences in AIC,  $\Delta$ AIC, and GEN-IC,  $\Delta$ GEN-IC, between the 3E and the 2E models in the 14 subjects. As far as an ML estimation is concerned, for all the subjects with the exception of #12,  $\Delta$ AIC is negative, suggesting that the 3E model is the one of choice. For subject #12 the slightly positive  $\Delta$ AIC value reflects the similar performance of the two models.


As far as MAP is concerned,  $\Delta$ GEN-IC is negative in all subjects. Therefore, in the context of a Bayesian estimation, the superiority of the 3E model is more clear cut than in the deterministic embedding.

### Data-poor situation: ML vs. MAP

To understand the ML vs. MAP situation in a data-poor context, let us consider two simulations which depict such a data-poor situation. In both cases, the response of a 3E system to a CP bolus was simulated using the parameters reported in Table 11.7.


**Table 11.7** True parameters and parameter estimates with precision obtained by ML and MAP estimation from the simulated bolus responses displayed in Figure 11.22 (simulation #1) and Figure 11.23 (simulation #2). WRSS is the weighted residuals sum of squares. E is the estimation error (adapted from Sparacino *et al.*, 2000)

	$A_1 \times 10^{-4}$ $\text{ml}^{-1}$	$A_2 \times 10^{-4}$ $\text{ml}^{-1}$	$A_3 \times 10^{-4}$ $\text{ml}^{-1}$	$\alpha_1$ $\text{min}^{-1}$	$\alpha_2$ $\text{min}^{-1}$	$\alpha_3$ $\text{min}^{-1}$	WRSS	$E \times 10^{-10}$
True	1.304	1.093	0.4929	0.2998	0.0998	0.0251	–	–
Sim # 1 ML	1.632 (38.7)	0.6443 (80.7)	0.3084 (88.4)	0.1997 (63.4)	0.0545 (82.5)	0.0217 (24.5)	21.5	9.979
MAP	1.663 (18.8)	0.9001 (15.9)	0.3830 (19.7)	0.2798 (16.9)	0.0744 (13.7)	0.0229 (7.2)	21.9	0.654
Sim # 2 ML	1.690 (31.4)	0.5522 (108.3)	0.4976 (12.5)	0.2212 (37.7)	0.0772 (57.3)	0.0251 (3.4)	9.6	2.876
MAP	1.530 (12.7)	0.8206 (15.5)	0.4845 (6.4)	0.2738 (14.9)	0.0839 (9.3)	0.0249 (2.0)	10.7	1.493



**Figure 11.22** Simulation #1 for large measurement error situation. The 3E model identified by ML (left) and MAP (right) estimators. Top: model predictions (continuous line) vs. data (open bullets). Bottom: weighted residuals (adapted from Sparacino *et al.*, 2000).

In simulation #1, we created a situation with a ‘normally-frequent’ sampling schedule (the grid was the same as that described in the Database above) and a large measurement error, i.e. a constant CV of 20%. The simulated, noisy data are displayed in Figure 11.22 (open bullets). The ML and MAP estimates are shown in Table 11.7. The differences between the values of the parameters estimated by ML or MAP are now much larger than in Table 11.5 (where a 5% CV measurement error affected the data).



**Figure 11.23** Simulation #2 for the reduced sampling situation. The 3E model is identified by ML (left) and MAP (right) estimators. Top: model predictions (continuous line) vs. data (open bullets). Bottom: weighted residuals (adapted from Sparacino *et al.*, 2000).

Moreover, the values of the model parameters estimated by MAP are much closer to the true ones than those estimated by ML. It is noteworthy that even if the WRSS of the ML estimation is (only slightly) better than that of the MAP estimation, the realization of the impulse response estimation error  $E$  (defined as the integral from zero to infinity of the squared difference between the true and the estimated impulse response) is much lower in the MAP case. As expected, a large improvement in the precision of parameter estimates now occurs with MAP in comparison with the ML estimation. For instance, the CV of parameter  $A_2$  is 88.4% with the ML estimation, and 19.7% with the MAP estimation. On average, the uncertainty is reduced by 75%.

In simulation #2, we create a situation with the same noise as found in the real data,  $CV = 5\%$ , but with a much reduced sampling schedule: 2, 4, 6, 9, 14, 25, 40, 60, 80, 100, 120, 140, 160, 180 min. It is worth noting that this grid is a subset of the ‘rich’ grid, but, although sparse, is frequent enough to make all the three modes of the impulse response resolvable. The ML and MAP results are shown in Table 11.7 and Figure 11.23. Again, the differences between the values of the parameters estimated by ML or MAP are much larger than in Table 11.5 (where a rich sampling grid was used). The values of the model parameters estimated by MAP are, on average, much closer to the true ones than those estimated by ML, and the lowest estimation error  $E$  is obtained using MAP estimation. More importantly,



the improvement in the precision of parameter estimates with MAP in comparison with ML estimation is now really impressive: for instance, the CV of parameter  $A_2$  is 108.3% with ML and 15.5% with MAP estimation. In both simulations the uncertainty of the ML estimates is unacceptable. In contrast, MAP estimation leads to reasonable confidence intervals.

In summary, the general lesson which emerges is that the improvement obtained by a Bayesian estimation with respect to a Fisher estimation is that the more significant the result, the more the *a priori* information supports the *a posteriori* information. The examples that have been discussed here cover three typical situations in which taking into account *a priori* information can be crucial: the model is too complex for being identifiable with satisfactory precision by a Fisherian approach (see real case studies); data are very noisy (i.e. *a posteriori* information is not sufficiently reliable, see simulation #1); and data are few in number (i.e. there is only a small amount of *a posteriori* information, see simulation #2).

## 11.8 POSTSCRIPT

This final chapter with its set of seven case studies has provided illustrations of some of the varied ways in which modeling of physiological systems can be undertaken. Together they cover many of the main ingredients of modeling methodology that have been described in the earlier chapters. As has been emphasized throughout, good modeling methodology is made up of a number of components, including formulation, identification and validation. This text has set out to provide a guide to such modeling methodology. It has essentially been an introductory exploration, but we hope that we have encouraged at least some readers to explore further in this exciting interdisciplinary field of study.

As a final thought, repeating the comment that we make at the end of the first chapter of our more advanced book (Carson *et al.*, 2001), it is important that one should always remain critical of a model and not love it too much! All models are approximations; hence one should always be prepared to include new facts and observations. A good model (in a Popperian sense) is one that is clearly falsifiable and therefore is readily capable of bringing about its own downfall. It should be remembered that in situations of complexity (very much the norm in physiology and medicine), it may be appropriate to think of a set of models, with each having its own, distinct domain of validity. It is then a case of choosing the one that is most appropriate; for instance, for the level of physiological hierarchy that is being represented and the time scale of interest in relation to the dynamic response. As summarized in Figure 10.2, a successful outcome to the modeling process is critically dependent on both the quality of the model and the quality of the experimental data.

# REFERENCES

- Ackerman E, Rosevear JW, McGuckin WF (1964). A mathematical model of the glucose tolerance test. *Physics in Medicine and Biology* 9(2): 203–213.
- Akaike H (1974). A new look at the statistical model identification. *IEEE Transactions on Automatic Control* AC-19: 716–723.
- Atkins GL (1969). *Multicompartment Models for Biological Systems*. London: Methuen.
- Audoly S, D’Angio L, Saccomani MP, Cobelli C (1998). Global identifiability of linear compartmental models. A computer algebra algorithm. *IEEE Transactions on Biomedical Engineering* 45: 36–41.
- Bassingthwaighte JB, Goresky CA (1984). Modeling in the analysis of solute and water exchange in the microvasculature. In: *Handbook of Physiology – The Cardiovascular System. Microcirculation*. Bethesda, MD: American Society of Physiology.
- Bassingthwaighte JB, Chan IS, Wang CY (1992). Computationally efficient algorithms for convection-permeation-diffusion models for blood-tissue exchange. *Annals of Biomedical Engineering* 20: 687–725.
- Bassingthwaighte JF, Ackerman E, Wood E (1996). Applications of the lagged normal density curve as a model for arterial dilution curves. *Circulation Research* 18: 398–415.
- Bates JTH (1991). Deconvolution of tracer and dilution data using the Wiener filter. *IEEE Transactions on Biomedical Engineering* 38: 1262–1266.
- Beal S, Sheiner LB (1979). *NONMEM Users Guide. Part 1*. San Francisco: University of California.
- Beal SL, Sheiner LB (1998). *NONMEM Users Guide*. San Francisco, CA: NONMEM Project Group, University of California.
- Beck JR, Pauker SG (1983). The Markov process in medical prognosis. *Medical Decision Making* 3(4): 419–458.
- Beneken JEW, DeWit B (1967). A physical approach to hemodynamic aspects of the human cardiovascular system. In: *Physical Bases of Circulatory Transport: Regulation and Exchange*, EB Reeve, AC Guyton (eds). Philadelphia, PA: WB Saunders.
- Bequette W (2005). A critical assessment of algorithms and challenges in the development of a closed-loop artificial pancreas. *Diabetes Technology & Therapeutics* 7: 28–47.
- Bergman RN, Ider YZ, Bowden CR, Cobelli C (1979). Quantitative estimation of insulin sensitivity. *American Journal of Physiology* 236: E667–E677.
- Bertero M (1989). Linear inverse problems and ill-posed problems. *Advances in Electronics and Electron Physics* 75: 1–120.
- Bolie VW (1961). Coefficients of normal blood glucose regulation. *Journal of Applied Physiology* 16: 783–788.
- Box GEP, Jenkins GM (1976). *Time Series Analysis, Forecasting and Control (2nd edition)*. San Francisco: Holden-Day.

- Bronikowsky T, Lawson C, Linehan J (1983). Model-free deconvolution techniques for estimation of vascular transport functions. *International Journal of Biomedical Computing* 14: 411–429.
- Bronzino JD (ed) (2000). *The Biomedical Engineering Handbook (2nd edition)*. Boca Raton, FL: CRC Press.
- Bruce E (2000). *Biomedical Signal Processing and Signal Modeling*. New York: Wiley.
- Cage PE, Carson ER, Britton KE (1977). A model of the human renal medulla. *Computers in Biomedical Research* 10: 561–584.
- Carson ER, Cobelli C (eds) (2001). *Modelling Methodology for Physiology and Medicine*. San Diego, CA: Academic Press.
- Carson ER, Cramp DG (eds) (1985). *Computers and Control in Clinical Medicine*. New York: Plenum.
- Carson ER, Cobelli C, Finkelstein L (1983). *The Mathematical Modeling of Metabolic and Endocrine Systems: Model Formulation, Identification and Validation*. New York: John Wiley & Sons.
- Caumo A, Cobelli C (1993). Hepatic glucose production during the labelled IVGTT: estimation by deconvolution with a new minimal model. *American Journal of Physiology* 264: E829–E841.
- Ceresa F, Ghemi F, Martini PF, Martino P, Segre G, Vitelli A (1973). Control of blood glucose in normal and in diabetic subjects. *Diabetes* 17: 570–578.
- Charter MK, Gull SF (1991). Maximum entropy and drug absorption. *Journal of Pharmacokinetics and Biopharmaceutics* 19: 497–520.
- Clifton DK, Aksel S, Bremner WJ, Steiner RA, Soules MR (1988). Statistical evaluation of coincident prolactin and luteinizing hormone pulses during the normal menstrual cycle. *Journal of Clinical Endocrinology and Metabolism* 67: 832–838.
- Clough A, Cui D, Linehan JH, Krenz GS, Dawson CA, Maron MB (1993). Model-free numerical deconvolution of recirculating indicator concentration curves. *Journal of Applied Physiology* 75: 1444–1453.
- Cobelli C, DiStefano III JJ (1980). Parameter and structural identifiability concepts and ambiguities: a critical review and analysis. *American Journal of Physiology* 239: R7–R24.
- Cobelli C, Ruggeri A (1989). Optimal design of sampling schedules for studying glucose kinetics with tracers. *American Journal of Physiology: Endocrinology and Metabolism* 257: E444–E450.
- Cobelli C, Ruggeri A, DiStefano III JJ, Landaw EM (1985). Optimal design of multioutput sampling schedules: software and applications to endocrine-metabolic and pharmacokinetic models. *IEEE Transactions on Biomedical Engineering* 32: 249–256.
- Cobelli C, Mari A, Del Prato S, De Kreutzenberg S, Nosadini R, Jensen I (1987). Reconstructing the rate of appearance of subcutaneous insulin by deconvolution. *American Journal of Physiology* 252: E549–E556.
- Cobelli C, Foster DM, Toffolo G (2000). *Tracer Kinetics in Biomedical Research: From Data to Model*. New York: Kluwer.
- Commenges D, Brendel AJ (1982). A deconvolution program for processing radiotracer dilution curves. *Computer Methods and Programs in Biomedicine* 14: 271–276.
- Crone C, Lassen NA (eds) (1970). *Capillary Permeability: The Transfer of Molecules and Ions Between Capillary Blood and Tissue*. New York: Academic Press.
- Cunningham DJC, Gardner WN (1977). A quantitative description of the pattern of breathing during steady-state CO<sub>2</sub> inhalation in man with special emphasis on expiration. *Journal of Physiology (London)* 272: 613–632.

- Cutler DJ (1978). Numerical deconvolution by least squares: use of polynomials to represent the input function. *Journal of Pharmacokinetics and Biopharmaceutics* 6: 243–263.
- Dalla Man C, Rizza RA, Cobelli C. (2006). A system model of oral glucose absorption: validation on gold standard data. *IEEE Transactions on Biomedical Engineering* 53: 2472–2478.
- Dalla Man C, Rizza RA, Cobelli C. (2007). Meal simulation model of the glucose-insulin system. *IEEE Trans Biomed Eng* 54: 1740–1749.
- De Nicolao G, Liberati D (1993). Linear and nonlinear techniques for the deconvolution of hormone time series. *IEEE Transactions on Biomedical Engineering* BME-40: 440–455.
- De Nicolao G, Liberati D, Sartorio A (1995). Deconvolution of infrequently sampled data for the estimation of growth hormone secretion. *IEEE Transactions on Biomedical Engineering* 42: 678–687.
- De Nicolao G, Sparacino G, Cobelli C (1997). Nonparametric input estimation in physiological systems: problems, methods, case studies. *Automatica* 33: 851–870.
- Deutsch T, Lehmann ED, Carson ER, Roudsari AV, Hopkins KD, Sönksen PH (1994). Time series analysis and control of blood glucose levels in diabetic patients. *Computer Methods and Programs in Biomedicine* 41: 167–182.
- DiStefano III JJ (1981). Optimized blood sampling protocols and sequential design of kinetic experiments. *American Journal of Physiology* 9: R259–R265.
- DiStefano III JJ, Wilson KC, Jang M, Mak PH (1975). Identification of the dynamics of thyroid hormone metabolism. *Automatica* 11: 149–159.
- Dix L, Frazier D, Cooperstein M, Riviere J (1986). Exponential intravenous infusion in toxicological studies: achieving identical serum drug concentration profiles in individuals with altered pharmacokinetic states. *Journal of Pharmaceutical Science* 75: 448–451.
- Enderle J, Blanchard S, Bronzino J (2000). *Introduction to Biomedical Engineering*. San Diego, CA: Academic Press.
- Ferrannini E, Cobelli C (1987). The kinetics of insulin in man. I. General aspects. *Diabetes and Metabolism Review* 3: 335–363.
- Finkelstein L, Carson ER (1985). *Mathematical Modelling of Dynamic Biological Systems (2nd edition)*. Chichester: Wiley.
- Flenley DC, Warren PM (1988). Clinical measurement in respiratory medicine. In: *The Respiratory System, DG Cramp, ER Carson (eds)*. London: Croom Helm, pp. 97–144.
- Flood RL, Carson ER (1993). *Dealing with Complexity: an Introduction to the Theory and Application of Systems Science (2nd edition)*. New York: Plenum.
- Forker EL, Luxon B (1978). Hepatic transport disappearance curves – distributed modeling versus the conventional approach. *American Journal of Physiology* 235: E648–E660.
- Francis GE, Leaning MS (1985). Stochastic model of human granulocyte-macrophage progenitor cell proliferation and differentiation. I. Setting up the model. *Experimental Hematology* 13: 92–98.
- Gatewood LC, Ackerman A, Rosevear JW, Molnar JD (1968a). Tests of a mathematical model of the blood-glucose regulatory system. *Computers and Biomedical Research* 2: 1–14.
- Gatewood LC, Ackerman A, Rosevear JW, Molnar JD (1968b). Simulation studies of blood-glucose regulation: effect of intestinal glucose absorption. *Computers and Biomedical Research* 2: 15–27.
- Gibaldi M, Perrier D (1982). *Pharmacokinetics (2nd edition)*. New York: Marcel Dekker.
- Gilks WR, Richardson S, Spiegelhalter D (eds) (1995). *Markov Chain Monte Carlo in Practice*. London: Chapman and Hall.
- Gillespie W, Veng-Pedersen P (1985). A polyexponential deconvolution method. Evaluation of the “gastrointestinal bioavailability” and mean in vivo dissolution time of some ibuprofen dosage forms. *Journal of Pharmacokinetics and Biopharmaceutics* 13: 289–307.

- Godfrey KR (1983). *Compartmental Models and Their Application*. New York: Academic Press.
- Goresky CA, Bach GG, Nadeau BE (1973). On the uptake of materials by the intact liver. The transport and net removal of galactose. *Journal of Clinical Investigation* 52: 991–998.
- Graham MM, Muzi M, Spence AM, O’Sullivan F, Lewellen TK, Link JM, Krohn KA (2002). The FDG lumped constant in normal human brain. *Journal of Nuclear Medicine* 43: 1157–1166.
- Grodsky GM (1972). A threshold distribution hypothesis for packet storage of insulin and its mathematical modeling. *Journal of Clinical Investigation* 51: 2047–2059.
- Guardabasso V, Genazzani AD, Veldhuis JD, Rodbard D (1991). Objective assessment of concordance of secretory events in two endocrine time series. *Acta Endocrinologica* 124: 208–218.
- Hartman M, Pincus S, Johnson M, Matthews DH, Faunt L, Vance ML, Thorner M, Veldhuis J (1994). Enhanced basal and disorderly growth hormone secretion distinguish acromegalic from normal pulsatile growth hormone release. *Journal of Clinical Investigation* 94: 1277–1288.
- Harvey AC (1989). *Forecasting, Structural Time Series Models and the Kalman Filter*. Cambridge: Cambridge University Press.
- Hodgkin AL, Huxley AF (1952). A quantitative description of membrane current and its application to conduction and excitation in nerve. *Journal of Physiology* 117: 500–544.
- Hovorka R, Chappell MJ, Godfrey KR, Madden FN, Rouse MK, Soons PA (1998). CODE: a deconvolution program implementing a regularization method of deconvolution constrained to non-negative values: description and pilot evaluation. *Biopharmaceutical Drug Disposition* 19: 39–53.
- Hunt BR (1970). The inverse problem of radiography. *Mathematical Biosciences* 8: 161–179.
- Hunt BR (1971). Biased estimation for nonparametric identification of linear systems. *Mathematical Biosciences* 10: 215–237.
- Iga K, Ogawa Y, Yashiki T, Shimamoto T (1986). Estimation of drug absorption rates using a deconvolution method with nonequal sampling times. *Journal of Pharmaceutical Biology* 14: 213–225.
- Jacquez JA (1972). *Compartmental Analysis in Biology and Medicine: Kinetics of Distribution of Tracer-Labeled Materials*. Amsterdam: Elsevier.
- Jacquez JA (1985). *Compartmental Analysis in Biology and Medicine (2nd edition)*. Ann Arbor, MI: University of Michigan Press.
- Jacquez JA (1996). *Compartmental Analysis in Biology and Medicine (3rd edition)*. Ann Arbor, MI: Biomedware.
- Jacquez JA, Simon CP (1993). Qualitative theory of compartmental systems. *SIAM Review* 35: 43–79.
- Janes FR, Carson ER (1971). Modelling biological systems. *IEE Electronics and Power* 17:110–116.
- Kety SS, Schmidt CF (1948). The nitrous oxide method for the quantitative determination of cerebral blood flow in man: theory, procedure, and normal values. *Journal of Clinical Investigation* 27: 476–483.
- Khoo MCK (2000). *Physiological Control Systems*. New York: IEEE Press.
- King RB, Raymond GM, Bassingthwaighte JB (1996). Modeling blood flow heterogeneity. *Annals of Biomedical Engineering* 24: 352–372.
- Knopp TJ, Dobbs WA, Greenleaf JF, Bassingthwaighte JB (1976). Transcoronary intravascular transport functions obtained via a stable deconvolution technique. *Annals of Biomedical Engineering* 4: 44–59.

- Kuikka J, Levin M, Bassingthwaight JB (1986). Multiple tracer dilution estimates of D- and 2-deoxy-D-glucose uptake by the heart. *American Journal of Physiology* 250: H29–H42.
- Landaw EM, DiStefano III JJ (1984). Multiexponential, multicompartmental and noncompartmental modelling. II Data analysis and statistical considerations. *American Journal of Physiology* 246: R665–R677.
- Leaning MS, Pullen HE, Carson ER, Finkelstein L (1983). Modelling a complex biological system: the human cardiovascular system. I. Methodology and model description. *Transactions of the Institute of Measurement and Control* 5: 71–86.
- Linkens DA (ed) (1979). *Biological Systems, Modelling and Control*. Stevenage: Peter Peregrinus Press.
- Marmarelis PZ, Marmarelis VZ (1978). *Analysis of Physiological Systems: the White Noise Approach*. New York: Plenum.
- McIntosh JEA, McIntosh RP (1980). *Mathematical Modelling and Computers in Endocrinology*. Berlin: Springer-Verlag.
- Meneilly GS, Ryan AS, Veldhuis JD, Elahi D (1997). Increased disorderliness of basal insulin release, attenuated insulin secretory burst mass, and reduced ultradian rhythmicity of insulin secretion in older individuals. *Journal of Clinical Endocrinology and Metabolism* 82: 4088–4093.
- Merriam G, Wachter K (1982). Algorithms for the study of episodic hormone secretion. *American Journal of Physiology* 243: E310–E318.
- Milhorn HT (1966). *The Application of Control Theory to Physiological Systems*. Philadelphia, PA: WB Saunders Company.
- Milsum JH (1966). *Biological Control Systems Analysis*. New York: McGraw-Hill.
- Mintun MA, Raichie ME, Martin WR, Herscovitch P (1984). Brain oxygen utilization measured with O-15 radiotracers and positron emission tomography. *Journal of Nuclear Medicine* 25: 177–187.
- Nakai M (1981). Computation of transport function using multiple regression analysis. *American Journal of Physiology* 240: H133–H144.
- Northrop RB (2000). *Endogenous and Exogenous Regulation and Control of Physiological Systems*. Boca Raton, FL: Chapman and Hall/CRC Press.
- O'Meara NM, Sturis J, Blackman JD, Roland DC, Van Cauter E, Polonsky KS (1993a). Analytical problems in detecting rapid insulin secretory pulses in normal humans. *American Journal of Physiology* 264: E231–E238.
- O'Meara NM, Sturis J, Van Cauter E, Polonsky KS (1993b). Lack of control by glucose of ultradian insulin secretory oscillations in impaired glucose tolerance and in non-insulin-dependent diabetes mellitus. *Journal of Clinical Investigation* 92: 262–271.
- Pantaleon AE, Loutseiko M, Steil GM, Rebrin K (2006). Evaluation of the effect of gain on the meal response of an automated closed-loop insulin delivery system. *Diabetes* 55: 1995–2000.
- Phillips DL (1962). A technique for the numerical solution of certain integral equations of the first kind. *Journal of the Association of Computational Machinery* 9: 97–101.
- Pillonetto G, Sparacino G, Cobelli C (2001). Reconstructing insulin secretion rate after a glucose stimulus by an improved stochastic deconvolution method. *IEEE Transactions on Biomedical Engineering* 48: 1352–1354.
- Pillonetto G, Sparacino G, Cobelli C (2002a). Handling non-negativity in deconvolution of physiological signals: a nonlinear stochastic approach. *Annals of Biomedical Engineering* 30: 1077–1087.

- Pillonetto G, Sparacino G, Magni P, Bellazzi R, Cobelli C (2002b). Minimal model  $S(I) = 0$  problem in NDDM subjects: nonzero Bayesian estimates with credible confidence intervals. *American Journal of Physiology: Endocrinology and Metabolism* 282(3): E564–E573.
- Pillonetto G, Caumo A, Sparacino G, Cobelli C (2006). A new dynamic index of insulin sensitivity. *IEEE Transactions on Biomedical Engineering* 53(3): 369–379.
- Pilo A, Ferrannini E, Navalesi R (1977). Measurement of glucose-induced insulin delivery rate in man by deconvolution analysis. *American Journal of Physiology* 233: E500–E508.
- Pincus SM (1991). Approximate entropy as a measure of system complexity. *Proceedings of the National Academy of Sciences USA* 88: 2297–2301.
- Pincus SM, Gevers EF, Robinson IC, Van Den Berg G, Roelfsema F, Hartman ML, Veldhuis JD (1996a). Females secrete growth hormone with more process irregularity than males in both humans and rats. *American Journal of Physiology* 270: E107–115.
- Pincus SM, Mulligan T, Iranmanesh A, Gheorghiu S, Godschalk M, Veldhuis JD (1996b). Older males secrete luteinizing hormone and testosterone more irregularly, and jointly more asynchronously, than younger males. *Proceedings of the National Academy of Sciences USA* 93: 14100–14105.
- Pohjanpalo H (1978). System identifiability based on the power series expansion of the solution. *Mathematical Biosciences* 41: 21–34.
- Polonsky KS, Licinio-Paixao J, Given BD, Pugh W, Rae P, Galloway J, Karrison T, Frank B (1986). Use of biosynthetic human C-peptide in the measurement of insulin secretion rates in normal volunteers and type 1 diabetic patients. *Journal of Clinical Investigation* 51: 98–105.
- Quon MJ, Campfield LA (1991). A mathematical model and computer simulation study of insulin receptor regulation. *Journal of Theoretical Biology* 150(1): 59–72.
- Richards TG, Tindall VR, Young A (1959). A modification of the bromosulphthalein liver function test to predict the dye content of the liver and bile. *Clinical Science* 18: 499–511.
- Riggs DS (1963). *The Mathematical Approach to Physiological Problems*. Baltimore, MD: Williams & Wilkins.
- Rose CP, Goresky CA (1976). Vasomotor control of capillary transit time heterogeneity in the canine coronary circulation. *Circulation Research* 39: 541–554.
- SAAM User Guide (1998). Seattle, WA: University of Washington.
- Saccomani MP, Cobelli C (1992). Qualitative experiment design in physiological system identification. *IEEE Control Systems Magazine* 12: 18–23.
- Saccomani MP, Bonadonna RC, Bier DM, DeFronzo RA, Cobelli C (1996). A model to measure insulin effects on glucose transport and phosphorylation in muscle: a three tracer study. *American Journal of Physiology* 270: E170–E185.
- Sangren WC, Sheppard CW (1953). A mathematical derivation of the exchange of a labeled substance between a liquid flowing in a vessel and an external compartment. *Bulletin of Mathematical Biophysics* 15: 387–394.
- Saratchandran P, Carson ER, Reeve J (1976). An improved mathematical model of human thyroid hormone regulation. *Clinical Endocrinology* 5: 473–483.
- Sarhan NAS, Leaning MS, Saunders KB, Carson ER (1988). Development of a complex model: breathing and its control in man. *Biomedical Measurement, Informatics and Control* 2: 81–100.
- Sartorio A, De Nicolao G, Pizzini G, Liberati D (1997). Nonparametric deconvolution provides an objective assessment of GH responsiveness to GH releasing stimuli in normal subjects. *Clinical Endocrinology* 46: 387–400.
- Schmitz O, Porksen N, Nyholm B, Skjaerbaer PC, Butler PC, Veldhuis JD, Pincus SM (1997). Disorderly and nonstationary insulin secretion in relatives of patients with NIDDM. *American Journal of Physiology* 272: E218–E226.

- Schwartz G (1978). Estimating the dimension of a model. *Annals of Statistics* 6: 461–464.
- Segre G, Turco GL, Vercellone G (1973). Modelling blood glucose and insulin kinetics in normal, diabetic and obese subjects. *Diabetes* 22: 94–103.
- Sheppard CW (1962). *Basic Principles of the Tracer Method*. New York: Wiley.
- Slate JB, Sheppard LC (1982). Automatic control of blood pressure by drug infusion. *IEE Proceedings* 129 (part A): 639–645.
- Sokoloff L, Reivich M, Kennedy C, Des Rosiers MH, Patlak CS, Pettigrew KD, Sakurada O, Shinohara M (1977). The [<sup>14</sup>C] deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat. *Journal of Neurochemistry* 28: 897–916.
- Sparacino G, Cobelli C (1997). Impulse response model in reconstruction of insulin secretion by deconvolution. Role of input design in the identification experiment. *Annals of Biomedical Engineering* 25: 398–416.
- Sparacino G, Cobelli C (1998). Analisi di serie temporali. In *Bioingegneria dei Sistemi Metabolici*, C. Cobelli, R. Bonadonna (eds). Bologna: Patron, pp. 109–136.
- Sparacino G, Bonadonna R, Steinberg H, Baron A, Cobelli C (1998). Estimation of organ transport function from recirculating indicator dilution curves. *Annals of Biomedical Engineering* 26: 128–135.
- Sparacino G, Cobelli C (1996). A stochastic deconvolution method to reconstruct insulin secretion rate after a glucose stimulus. *IEEE Transactions on Biomedical Engineering* 42: 512–529.
- Sparacino G, Vicini P, Bonadonna RC, Marraccini P, Lehtovirta M, Ferrannini E, Cobelli C (1997). Removal of catheter distortion in multiple indicator dilution studies: a deconvolution-based method and case studies on glucose blood-tissue exchange. *Medical and Biological Engineering and Computer* 35: 337–342.
- Sparacino G, Tombolato C, Cobelli C (2000). Maximum likelihood versus maximum *a posteriori* parameter estimation of physiological system models: the C-peptide impulse response case study. *IEEE Transactions on Biomedical Engineering* 47: 801–811.
- Sparacino G, De Nicolao G, Cobelli C (2001). Deconvolution. In *Modelling Methodology for Physiology and Medicine*, E. Carson, C. Cobelli (eds). New York: Academic Press, pp. 45–75.
- Sparacino G, Pillonetto G, Capello M, De Nicolao G, Cobelli C (2002). WINSTODEC: a stochastic deconvolution interactive program for physiological and pharmacokinetic systems. *Computer Methods and Programs in Biomedicine* 67: 67–77.
- Sparacino G, Pillonetto G, De Nicolao G, Cobelli C (2004). Deconvoluzione per l'analisi di segnali fisiologici. In *Metodi Avanzati di Elaborazione di Segnali Biomedici*, S. Cerutti, C. Marchesi (eds). Bologna: Patron, pp. 163–188.
- Stapleton DD, Moffett TC, Baskin DG, Bassingthwaight JB (1995). Autoradiographic assessment of blood flow heterogeneity in the hamster heart. *Microcirculation* 2: 277–282.
- Stark L, Sherman P (1957). A servo-analytical study of consensual pupil light reflex to light. *Journal of Neurophysiology* 20: 17–26.
- Sturis J, Polonsky K, Shapiro T, Blackman JD, O'Meara N, Van Cauter E (1992). Abnormalities in the ultradian oscillations of insulin secretion and glucose levels in Type 2 diabetic patients. *Diabetologia* 35: 681–689.
- Sturis J, Van Cauter E, Blackman JD, Polonsky KS (1991). Entrainment of pulsatile insulin secretion by oscillatory glucose infusion. *Journal of Clinical Investigation* 87: 439–445.
- Swanson GD, Belville JW (1974). Hypoxic hypercapnic interactions in human respiratory control. *Journal of Applied Physiology* 36: 480–487.



- Talbot SA and Gessner U (1973). *Systems Physiology*. New York: Wiley.
- Tett SE, Cutle D, Day R (1992). Bioavailability of hydroxychloroquine tablets assessed with deconvolution techniques. *Journal of Pharmaceutical Science* 81: 155–159.
- Tikhonov AN (1963). Solution of incorrectly formulated problems and the regularization method. *Soviet Math Dokl* 4: 16–24.
- Toates FM (1975). *Control Theory in Biology and Experimental Psychology*. London: Hutchinson.
- Twomey S (1965). The application of numerical filtering to the solution of integral equations of the first kind encountered in indirect sensing measurements. *Journal of the Franklin Institute* 279: 95–109.
- Ultrainen T, Nuutila P, Takala T, Vicini P, Ruotsalainen U, Rönnemaa T, Tolvanen T, Raitakari M, Haaparanta M, Kirvalä O, Cobelli C, Yki-Järvinen H (1997). Intact insulin stimulation of skeletal muscle blood flow, its heterogeneity and redistribution but not of glucose uptake in non-insulin dependent diabetes mellitus. *Journal of Clinical Investigation* 100: 777–785.
- Van Cauter E (1988). Estimating false-positive and false-negative errors in analysis of hormone pulsatility. *American Journal of Physiology* 254: E786–E794.
- Van Cauter E (1990). Computer assisted analysis of endocrine rhythms. In: *Computers in Endocrinology: Recent Advances*, G Forti, V Guardabasso, D Rodbard (eds). New York: Raven Press, pp. 59–70.
- Veldhuis JD, Johnson ML (1988). Operating characteristics of the hypothalamo-pituitary-gonadal axis in men: circadian, ultradian and pulsatile release of prolactin and its temporal coupling with luteinizing hormone. *J Clin Endocrinol Metab* 67: 116–123.
- Veldhuis JD, King JC, Urban RJ, Rogol AD, Evans WS, Kolp LA, Johnson ML (1987). Operating characteristics of the male hypothalamo-pituitary-gonadal axis: pulsatile release of testosterone and follicle-stimulating hormone and their temporal coupling with luteinizing hormone. *J Clin Endocrinol Metab* 65: 929–941.
- Veldhuis JD, Carlson ML, Johnson ML (1987). The pituitary gland secretes in bursts: appraising the nature of glandular secretory impulses by simultaneous multiple-parameter deconvolution of plasma hormone concentration. *Proceedings of the National Academy of Sciences USA* 4: 7686–7690.
- Verotta D (1996). Concepts, properties and applications of linear systems to describe the distribution, identify input, and control endogenous substances and drugs in biological systems. *Critical Reviews in Bioengineering* 24: 73–139.
- Vicini P (2001). Blood-tissue exchange modelling. In: *Modelling Methodology for Physiology and Medicine*, ER Carson, C Cobelli (eds). San Diego: Academic Press, pp. 373–401.
- Vicini P, Caumo A, Cobelli C (1997). The hot IVGTT two-compartment minimal model: indexes of glucose effectiveness and insulin sensitivity. *American Journal of Physiology* 273: E1024–E1032.
- Vicini P, Bonadonna RC, Ultrianen T, Nuutila P, Raitakari M, Yki-Järvinen H, Cobelli C (1997). Estimation of blood flow heterogeneity distribution in human skeletal muscle from positron emission tomography. *Annals of Biomedical Engineering* 25: 906–910.
- Vicini P, Bonadonna RC, Lehtovirta M, Groop L, Cobelli C (1998). Estimation of blood flow heterogeneity in human skeletal muscle using intravascular tracer data: importance for modeling transcapillary exchange. *Annals of Biomedical Engineering* 26: 764–774.
- Vicini P, Zachwieja JJ, Yarasheski KE, Bier DM, Caumo A, Cobelli C (1999). Glucose production during an IVGTT by deconvolution: validation with the tracer-to-tracee clamp technique. *American Journal of Physiology* 276: E285–E294.

- Walter E, Pronzato L (1997). *Identification of Parametric Models from Experimental Data*. Berlin: Springer.
- Westwick DT, Kearney RE (2003). *Identification of Nonlinear Physiological Systems*. New York: IEEE Press.
- Whiting B, Kelman A, Struthers AD (1984). Prediction of response to theophylline in chronic bronchitis. *British Journal of Clinical Pharmacology* 17: 1–8.
- Yates FE (1978). Complexity and the limits to knowledge. *American Journal of Physiology* 4: R201–R204.
- Young P (1984). *Recursive Estimation and Time-Series Analysis: an Introduction*. Berlin: Springer.

*This page intentionally left blank*

# INDEX

## A

- Abstraction, 29
- Action potential model:
  - electrical model of the cell membrane, 110–112
  - Hodgkin-Huxley model, 112–115
  - potassium conductance, 116
  - sodium conductance, 116–119
- ApEn index, 50, 57
- Approximate entropy, 50–52
- Asymmetric systems, 9
- Auto-correlation coefficient, 39
- Autoregressive integrated moving average (ARIMA) model, 42, 59

## B

- Baroreceptors, 122–124
- Bayesian estimation, 227–231
- Bayesian probability theory, 54
- Biological rhythm, of humans, 38
- Birth rate and feedback, 12
- Black box models, 36
- Blood-tissue exchange model:
  - capillary-interstitial fluid, 95–97
  - capillary-interstitial fluid-cell, 97
  - single-capillary, 93–95
  - whole-organ, 97–101
- Bode diagram, 62–63
- Bronchodilator response, prediction of, 54–56

## C

- Capillary-interstitial-cell model, of equation, 101
- Capillary-interstitial fluid-cell, 97 model, 97

- Capillary-interstitial fluid model, 95–97
- Cardiac modeling, 145–150
- Cardiac timing events, 147
- Case studies:
  - blood flow modeling, 273–274
  - cerebral glucose modeling, 274–276
  - illustrations of Bayesian estimation, 297–308
  - model of insulin control, 292–297
  - models of ligand-receptor system, 276–279
  - simulation model of glucose-insulin system, 280–292
  - sum of exponentials tracer disappearance model, 269–272
- Causally related variables, data modeling:
  - hormone/hormone and substrate/hormone series, 56–58
  - response of urine sodium, 58–61
- Cayley Hamilton theorem, 185
- Cellular modeling, 150–154
- Chemical changes, in physiological systems, 15–16
- Chemical control, of breathing:
  - controlled system, 141–143
  - expiration, 144
  - expiratory time controller, 145
  - inspiration, 143
  - inspiratory flow controller, 144
  - inspiratory time controller, 144
- Closed-loop feedback system, 113
- Closed-loop insulin delivery system, 63–64
- CNS control of heart rate, 124–125
- Compartmental models, 125–133
- Complexity, of a system, 9–10

Computer simulation, 33  
 Conservation equation, of enzymes, 121  
 Continuity equation, 80  
 Continuous signals, 37  
 Convolution integral, 69–70, 82  
 Convolution operator, 95  
 Correlograms, of time series, 39–40, 42  
 Coupled oscillator model, 44  
 C-peptide impulse response, 46, 251  
 Cross-ApEn, defined, 58

## D

Data-driven models, 27  
 Data modeling:  
   approaches, 36–38  
   background, 36  
   basis of, 36  
   of causally related variables  
     hormone/hormone and  
       substrate/hormone series, 56–58  
     response of urine sodium, 58–61  
   for impulse response  
     convolution integral, 69–70  
     estimates, 67–69  
     reconstructing the input, 70–74  
   for input/output control  
     control of blood glucose by insulin,  
       63–66  
     control of blood pressure by sodium  
       nitroprusside, 66–67  
     pupil control, 62–63  
   a single variable in response to  
     perturbation  
       glucose home monitoring data,  
         53–54  
       response to drug therapy, 54–56  
   a single variable occurring spontaneously  
     gastro-intestinal rhythms, 43–45  
     hormonal time series, 45–52  
     temperature, 38–41  
     urine potassium, 41–43  
 Death rate and feedback, 12  
 Deconvolution, 70  
   challenges, 238–244  
   importance, 236  
   and real world problems, 236–238  
 Derivative feedback, 13  
 Discrete-time noisy output measurements,  
   196

Distributed modeling:  
   blood-tissue exchange:  
     capillary-interstitial fluid-cell model, 97  
     capillary-interstitial fluid model, 95–97  
     single-capillary model, 93–95  
     whole-organ model, 97–101  
   hepatic removal of materials, 101–105  
   overview, 90–91  
   renal medulla, 105–109  
 Dual input/five output experiment, 192

## E

Electrical model, of the cell membrane,  
   110–112  
 Enzyme dynamics, 120–122  
 Errors, 164–166  
 Exhaustive summary, 180–181  
 Expiration, 144  
 Expiratory time controller, 145

## F

Feedback:  
   combination of positive and negative,  
     11–12  
   derivative and integral, 13  
   effect on complexity of system, 13  
   inherent, 11  
   negative, 10  
   positive, 10–11  
 Fick's Law, 82–83, 109

## G

Gas exchange, simple linear dynamic  
   modeling, 82–83  
 Gastro-intestinal rhythms, 43–45  
 Glomerular filtration rate (GFR), 107  
 Glucagon, 18  
 Glucose home monitoring data, 53–54  
 Glucose-insulin control system, model of,  
   182–183  
   model formulation:  
     glucose subsystem, 280–282  
     insulin subsystem, 282–284  
     unit process models and identification,  
       285–288  
   results:  
     daily life for a normal subject, 291  
     daily life for a subject with impaired  
       glucose tolerance, 292

- meal in normal subject, 288–289
  - meal in type 2 diabetic subject, 289–291
  - Glucose regulatory system, model of, 87–90
  - Glucose tolerance test, 89
  - Goldman equation, 113
  - Gröbner basis, 184
  - Growth hormone releasing hormone (GHRH) injection, 72
- H**
- Harmonic test signals, 162–163
  - Hepatic removal, of materials, 101–105
  - Hierarchy, of a system, 19–20
  - Hodgkin-Huxley model, 112–120
  - Hormonal action, in a system, 17–19
  - Hormonal time series, 45–52
  - Hormone/hormone and substrate/hormone series, 56–58
  - Hunt simulated problem, 242
- I**
- Identifiability problem, 30
  - Identification, of models:
    - data for:
      - harmonic test signals, 162–163
      - selection of test signals, 160–161
      - transient test signals, 161–162
    - errors, 164–166
    - way forward:
      - parameter estimation, 166–167
      - signal estimation, 167
  - Impulse response, 38
  - Impulse response, data modeling for
    - convolution integral, 69–70
    - estimates, 67–69
    - reconstructing the input, 70–74
  - Inertia torque, 85
  - Inherent feedback, 11
  - Input/output control, data modeling for:
    - control of blood glucose by insulin, 63–66
    - control of blood pressure by sodium nitroprusside, 66–67
    - pupil control, 62–63
  - Inspiration, 143
  - Inspiratory flow controller, 144
  - Inspiratory time controller, 144
  - Insulin action modeling, 135–138
  - Insulin receptor regulation, dynamics of, 133–135
  - Insulin sensitivity, 138
  - Integral feedback, 13
  - Interstitial fluid, 95, 97
  - Interval identifiable, 180
  - Intravenous glucose tolerance test (IVGTT), 135, 251–254
  - Inverse problem, 69
- J**
- Juxtamedullary nephrons (JM), 107
- L**
- Langmuir receptor model, 185–187
  - Langmuir relation, 125
  - Laplace transforms, 175
  - Least square deconvolution, 244
  - Leucine-Kic-bicarbonate model, 188–192
  - Linear compartmental models, 132
  - Linear modeling:
    - Examples:
      - dynamics of swinging human limb, 83–87
      - elimination of a drug from the bloodstream, 81–82
      - glucose homeostasis model, 87–90
      - process of gas exchange, 82–83
      - Windkessel circulatory model, 80–81
  - Linear models, 181–184
  - Linear regression:
    - example, 207–208
    - extension to vector case, 208–212
    - problem, 204–205
    - test on residuals, 205–207
  - Linear regression theory, 197
  - Lumped-distributed model, 105
  - Luteinizing hormone (LH) secretion, in women, 48
- M**
- Markov chains, 155
  - Markov model, 155–156
  - Mathematical model, 24
    - development, 27
  - Maximum likelihood estimation, 54, 225–227
  - Michaelis-Menten equation, 78, 122, 130
  - MINITAB package, 59, 61
  - Model:
    - defined, 23–25
    - in the educational process, 26

- Model: (*Continued*)  
 formulating of, 27–29  
 good modeling methodology, 26  
 identification, 29–30  
 modeling process, 27  
 purpose of modeling, 25–27  
 simulation, 32–33  
 validation, 30–32, *see also* model validation
- Model order, tests for, 221–225
- Model validation:  
 of completed model, 259–260  
 good practice, 265–266  
 during model formulation, 258–259  
 strategies  
   of competing model, 264–265  
   of single model, 261–264
- Monte Carlo simulation strategy, 56
- N**
- N-dimensional vector, 251
- Negative feedback, 10
- Newton's second law of motion, 84
- Nonlinear modeling:  
 action potential model:  
   electrical model of the cell membrane, 110–112  
   Hodgkin-Huxley model, 112–115  
   potassium conductance, 116  
   sodium conductance, 116–119  
 baroreceptors, 122–124  
 chemical control of breathing, 141–145  
 CNS control of heart rate, 124–125  
 compartmental modeling, 125–133  
 dynamics of insulin receptor regulation, 133–135  
 enzyme dynamics, 120–122  
 insulin action modeling, 135–138  
 thyroid hormone regulation, 138–141
- Nonlinear models, 184–187
- Nonlinear regression:  
 algorithms, 220–221  
 example, 221  
 extension to the vector case, 216–220  
 scalar case, 212–216
- Nonlinear systems, 9
- NONMEM program, 56
- Non-parametric deconvolution, 244
- Nuclear magnetic resonance (NMR) spectroscopy, 91
- O**
- Observational parameters, 174, 196
- Observational parameter vector, 180
- Optimal experimental design, 231–233
- P**
- Parametric deconvolution, 244
- Parametric modeling:  
 linear/nonlinear parameter, 197–198  
 regression concepts  
   residual, 199–200  
   residual sum of squares, 200  
   weighted residual sum of squares, 200–201  
   weights and error in the data, 201–203
- Physiological complexity, 9–10
- Physiological modeling:  
 challenges to understanding, 21–22  
 complexity, 9–10  
 control in physiological system:  
   enzymes, 15–17  
   features, 13–15  
   hormones, 17–19  
 feedback:  
   combination of positive and negative, 11–12  
   derivative and integral, 13  
   effect on complexity of system, 13  
   inherent, 11  
   negative, 10  
   positive, 10–11  
 functional and behavioral patterns, 21  
 hierarchy, 19–20  
 ingredients of, 3–4  
 redundancy, 20–21
- Plasma region equation, 96
- Plug flow, 94
- Position emission tomography (PET), 91, 98
- Positive feedback, 10–11
- Potassium activation, 116
- Power series expansion method, 185
- Priori, 29  
 identifiability, 172  
 interval identifiable, 179

- as a model, 180
  - nonidentifiable, 178
  - uniquely or globally identifiable, 174, 180, 187
- Programming language, 33
- Proportional-integral-derivative controller (PID), 64–65
- Pseudorandom binary signal, 66
- Pupil control, model of, 62–63
  
- Q**
- Qualitative experiment design:
  - amino acid model, 188–192
  - fundamentals, 187–188
  
- R**
- Random signal testing, 163–164
- Redundancy, 20–21
- Regression concepts:
  - residual, 199–200
  - residual sum of squares, 200
  - weighted residual sum of squares, 200–201
  - weights and error in the data, 201–203
- Regularization method:
  - choice of parameter, 246–250
  - fundamentals, 244–246
  - virtual grid, 251–254
- Regularization parameter, 245
- Renal medulla, functions of:
  - anatomical structure, 106
  - interstitial compartments, 108–109
  - model assumptions, 106–107
  - principles of the mathematical formulation for the tubular structures, 107–108
  - transmural flux, 109
- Respiratory system mechanics model, 183–184
  
- S**
- Simulation packages, 33
- Single-capillary model, 93–95
- Single variable, data modeling of:
  - occurring spontaneously
    - gastro-intestinal rhythms, 43–45
    - hormonal time series, 45–52
  - temperature, 38–41
  - urine potassium, 41–43
- in response to perturbation:
  - glucose home monitoring data, 53–54
  - response to drug therapy, 54–56
- Sodium activation, 117
- Sodium de-activation, 117
- Spatial heterogeneity, of flow, 97
- Spectral density function, 40
- Spectral representation, 40
- Static models, 76–79
- Stochastic modeling:
  - cellular modeling, 150–154
  - insulin secretion, 154–155
  - Markov model, 155–156
- Stochastic modeling strategy, 37
- Stochastic processes, 150
- Swinging human limb, dynamics of, 83–87
  
- T**
- Taylor series expansion method, 184–187
- Temperature variation, in a woman, 39–41
- Test signals:
  - harmonic, 162–163
  - selection of, 160–161
  - transient, 161–162
- Thyroid hormone regulation, 138–141
- Time series:
  - of cortisol concentration, 46
  - of C-peptide, 47–48, 71
  - of growth hormone (GH) plasma concentration, 50
- Time-varying modeling, 145–150
- Toeplitz matrix, 251
- Transfer function matrix, 181–184
- Transfer function method, 175
- Transfer function model, of pupil control, 63
- Transient test signals, 161–162
- Transport and metabolism of a substance, at the organ level, *see* blood-tissue exchange model
- Two input/four output experiment, 192



**U**

- Ultradian oscillations, 46, 49, 52
- Urine potassium, measurements of the concentration of, 41–43
- Urine sodium response, to water loading, 58–61

**V**

- Van der Pol type dynamics, 44
- Vascular resistance, 77

- V-dimensional vectors, 251
- Virtual grid, 251–254

**W**

- Whole-organ model, 97–101
- Wiener filtering, 242
- Windkessel circulatory model, 80–81